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Abstract
Synthetic methodology is described that permits access to partially modified retro- 
inverso (PMRI) peptides containing the structural motif [Xaaip(NHCO)Gly]n, n ^ 2. Such 
PMRI peptides were expected to be predisposed to (5-sheet formation on the basis of 
molecular modelling studies.
The PMRI dipeptides Boc-Xaaxp(NHCO)Gly-OEt (Xaa = Gly, Val, and Phe) were 
synthesised using a Goldschmidt and Wick type procedure. C- and V-terminal 
deprotections of these PMRI dipeptides were accomplished by saponification and 
acidolysis, respectively.
PMRI dipeptides were coupled to yield Boc-Xaaxp(NHCO)Gly-Xaai|i(NHCO)Gly- 
OEt. EDC / HOSu coupling was the method of choice to yield Boc-Xaaop(NHCO)Gly- 
Xaai|)(NHCO)Gly-OEt (Xaa = Val and Phe). For the synthesis of Boc-Glyi|j(NHCO)Gly- 
Glyiii(NHCO)Gly-OEt, isolation of the active ester and subsequent coupling was 
preferred. Carbonate mixed anhydride couplings were only successful between gem- 
diamino residues and non-malonyl residues. Use of these coupling (and deprotection) 
procedures yielded Boc-Xaa'i|j(NHCO)Gly-Pro-Gly-Xaa'i|)(NHCO)Gly-OEt (Xaa = Gly 
and Val); but failed to furnish Boc-Glyii)(NHCO)Gly-Glyii)(NHCO)Gly-Pro-Gly- 
Gly'i|>(NHCO)Gly-Gly'i|>(NHCO)Gly-OEt. Poor solubility of all PMRI peptides 
containing four or more residues dogged the syntheses and could only be tackled by the 
use of highly polar solvents.
PMRI dipeptides Fmoc-Xaai|)(NHCO)Gly (Xaa = Gly and Val) were obtained 
from the corresponding V-Boc PMRI dipeptides. SPS of PMRI peptides was 
demonstrated using Fmoc-Glyxp(NHCO)Gly, but insolubility prohibited purification of the
p r o d u c t ,  A c - G l  yiKNHCO)Gly-GlyxKNHCO)Gly-Pro-Gly-GlyiKNHCO)Gly- 
GlyiKNHCO)Gly-NH2.
Solubility problems necessitated the use of DMSOd6 as solvent for NMR studies. 
Under these conditions no secondary structure was detected. CD spectra of Boc- 
Glyip(NHCO)Gly-Pro-Gly-Glyi|)(NHCO)Gly-OEt suggested some defined secondary 
structure of the -raGly2-Pro3-Gly4- sequence.
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Brand new you're retro1
3
A Man would do nothing, if he waited until he could do it so 
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A Denotes a figure in the Appendix.
ACE Angiotensin converting enzyme.
Adoc Adamantyloxy carbonyl.
Aib a-Amino-iso-butyric acid.
AMI Austin model 1.
AN Electron-acceptor number.
Bn Benzyl group or benzene.












CNS Central nervous system,
cone Concentrated.




















FAB Fast atom bombardment.









HPLC High performance liquid chromatography.
IBTFA Iodobenzene bis(trifluoroacetate).
IC 50 Median inhibitory concentration,
imid Imidazole.
Kj Inhibition constant.




























































Reverse phase high performance liquid chromatography. 
Structure activity relationship.
Self consistent field molecular orbital.
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SDS Sodium dodecyl sulfate.
SPS Solid phase synthesis.
TBAF Tetrabutylammonium fluoride.
TBDMS tert- Butyldimethylsilyl.




TFA Trifluoroacetic acid or trifluoroacetyl.
TFAA Trifluoroacetic anhydride.
TFE 2,2,2-T rifluoroethanol.
THF T etrahy drofuran.
TLC Thin layer chromatography.
TMEDA N flJP  jV'-T etramethylethylenediamine.




Xaa Unspecified a-amino acid.
Yaa Unspecified a-amino acid.
Z Benzyloxycarbonyl.
Zaa Unspecified a-amino acid.
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Notes On Nomenclature
IUPAC nomenclature and symbolism for peptides and peptide analogues is used.2 
Thus a dash, represents a covalent bond {c.f. figure 4). Conversely a d o t , i s  used 
in this thesis to indicate salt formation. Therefore iV-trifluoroacetylglycine, for example, 
would be represented as TFA-Gly, whereas TFA.Gly would represent glycinium 
trifluoroacetate.
The ip (Greek psi) notation for amide bond surrogates indicates that the amide 
bond between the two residues is replaced by the unit in brackets following the i|), e.g. 






For partially modified retro-inverso (PMRI) pseudopeptides the g / m / r prefix 
system is also used in the literature: gXaa symbolises the gem-diamino alkyl analogue of 
the indicated amino acid residue, mXaa symbolises the malonyl residue corresponding to 
the indicated amino acid residue, and rXaa symbolises the reversed amino acid residue, 
i.e. -COCHRNH- rather than the conventional -NHCHRCO- direction. Thus, -gGly- 
mGly- corresponds to the structure shown in figure 1. This system of nomenclature is 
only used in this thesis to refer to PMRI peptides where the op notation is inappropriate, 
e.g. to refer to isolated residues.
Chemical Abstracts names PMRI pseudopeptides as propanoic acid derivatives. 
Thus, the PMRI pseudodipeptide Phet|j(NHCO)Gly is named (R)-3-[(l-amino-2 - 
phenylethyl)-amino]-3-oxo-propanoic acid. This system of nomenclature rapidly becomes 
cumbersome and is not used in this thesis.
The following terms are used in this thesis with the given meaning.
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"Backbone": a homomeric*, homodetict peptide "backbone" has three 
repeating units, the amide nitrogen, a-carbon, and amide 
carbonyl, see figure 2. R is referred to as the side chain. 
The backbone dihedral angles ((^ipi), describe the 
conformation of the backbone at residue i.3^
R'
H £
Figure 2: Peptide backbone residue i.
"Cycloretro-enantiomer": an isomer of a cyclic compound in which the sequence is
reversed and each residue is inverted.
•  "End group modified 
retro-inverso isomer / 
peptide":




a retro-inverso isomer in which the peptide chain end 
groups are altered to better correspond with those of the 
parent peptide.
a peptide with some of its peptide functional groups 
replaced by other groups, but which retains properties 
analogous to the original peptide.
an isomer of a linear peptide in which some of the peptide 
bonds are reversed and the chirality of the amino acids in 
the reversed section is inverted.
* Consisting of similar monomers, Le. a-amino acids.
t  Consisting of a-amino acid residues solely in eupeptide linkages ( i.e. amide bonds formed between C1 of 
Xaa* and of Yaa*+1).
$ In this thesis the corresponding dihedral angles of both gem-diamino residues and malonyl residues are 
labelled (<j>,ij>), but in other literature the labels (<|>,<j>') and (i|>,i|>') or (<j>i,<t>2) an  ^ respectively, are
used.
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•  "Peptidomimetic": a molecule with some or all peptide functional groups
replaced by other groups, yet which exhibits properties 
analogous to a (or many) peptide(s).
•  "Pseudopeptide": a peptide analogue with a backbone modification.
•  "Retro-inverso peptide": an isomer of a linear peptide in which the direction of the
amino acid sequence is reversed and the chirality of each 
amino acid is inverted.
The following numbering system is used for the residues of PMRI pseudopeptides. 
Residues are numbered from the N-terminus, see figure 3.
This nomenclature is extended, as follows, to refer unambiguously to the component 
atoms of the residues. NHs are numbered as Va^NH (or BocNH, see figure 4), 
V al^N H , etc; side chains and a-carbons are numbered by residue; carbonyls are 
numbered as G ly^CO , Gly2CO, etc: see figure 4.
The terms cis and trans are used in this thesis to describe the configuration of 
amide bonds in accord with their general use in peptide and protein chemistry, i.e. the 
amide bond depicted in figure 1 is described as being in the tram configuration. 
Formally, the amide bond depicted in figure 1 would be described as the s-cis (or Z) form.
•  "Retro-isomer": an isomer (of a peptide) in which the direction of the amino 
acid sequence is reversed.
•  "Surrogate": an unnatural replacement for a natural entity, e.g. 
"CH=CH" is an amide bond surrogate.
Boc-Valip(NHCO)Gly-Pro-Gly-Valqj(NHCO)Gly-OEt 
1 2 3 4 5 6
Figure 3: Residue numbering.
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BocNH 6r Val >NH Gly^CO VaPC^HVal^NH Gly6CO
Figure 4: Atom and functional group labelling illustrated for Boc-Vahp(NHCO)Gly-Pro- 
Gly-VahMNHCO)Gly-OEt, 1.
Chapter One: Introduction
Peptides occur throughout nature in a wide range of roles. They act as 
extracellular messengers, i.e. hormones, neurotransmitters and neuromodulators, in plants 
and animals and thus influence such vital functions as metabolism, immune defence, 
respiration and reproduction. They carry out intracellular functions, e.g. the antioxidant 
and transport tripeptide glutathione. Indeed, they are essential to virtually every 
biochemical process. Peptides are also implicated in the appearance or maintenance of 
various diseases, e.g. the plaques associated with Alzheimer’s disease.4 Peptides find 
other structural applications, e.g. as the cross-links in the peptidoglycan cell walls of 
bacteria; but the structural domain is more properly the realm of polypeptides and 
proteins. More esoteric roles for peptides include mushroom toxins, components of snake 
venoms, and antifreeze in fish.
This broad spectrum of activity has attracted much attention to peptides from 
bioorganic, medicinal and polymer chemists, to name but a few.
1.1 Why Modify?-
The desire to use peptides as pharmaceuticals is the major incentive for 
modification, or tailoring. The pharmacological properties of most peptides preclude their 
use as drugs. The mammalian body presents many barriers to the entry of 
macromolecules and thus peptides fall foul of poor absorption, because they do not readily 
pass across biological membranes; swift metabolism by proteolytic enzymes; and rapid 
excretion through the liver and kidneys.5-7 These barriers result in peptides suffering 
from low bioavailability and short biological half-lives. In addition there is the problem 
of specificity: peptide receptors can be widely distributed in an organism and their 
stimulation results in a variety of desired and undesired effects, especially when the 
peptide is conformationally flexible and hence able to interact with alternative receptors.6
The aim of peptide modification is to determine the structure activity relationships 
of endogenous peptides and to produce analogues which can overcome the barriers and 
problems described above, while retaining selected activity (i.e. specific receptor
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agonists). Conversely, receptor antagonists and enzyme inhibitors are also desirable 
targets attainable through peptide modification.6*8’9
The realisation of these goals is aided by the simultaneous programme of 
discovery and development of peptidomimetics from leads other than the endogenous 
peptides whose action is of interest. Various definitions of peptidomimetics or peptide 
mimetics (the terms are used interchangeably) exist in the literature:
•  Wiley and Rich "Chemical structures designed to convert the information
contained in peptides into small nonpeptide structures."10
•  Giannis and Kolter "A compound that, as a ligand of a receptor, can imitate or
block the biological effect of a peptide at the receptor level."6
•  Moore "A molecule that mimics the biological activity of a peptide but
is no longer peptidic in chemical nature. The term is... 
sometimes used to describe molecules that are no longer 
completely peptidic in nature, such as pseudopeptides... but a 
strict definition is a molecule that no longer contains any 
peptide bonds... and has a molecular weight of less than 700 
Da."11
•  Morgan and Gainor "Structures which serve as appropriate substitutes for peptides
in interactions with receptors and enzymes."12
•  Gante "[A] chemical Trojan horse'... A substance having a secondary
structure as well as other structural features analogous to that of 
the original peptide, which allows it to displace the original 
peptide from receptors or enzymes. As a result the effects of 
the original peptide are inhibited (antagonist, inhibitor) or 
duplicated (agonist)." 8
•  Kemp "Elements which mimic the structure of natural peptide
components."13
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Olson et al. do not offer a formal definition, but their comments are informative:
"The term... 'peptidomimetics* [has been] utilized... to describe compounds discovered 
through a variety of research strategies. Indeed, even compounds identified by random 
screening and subsequently optimized through structural modification have been termed 
peptidomimetics if the initial lead was found in an assay in which the natural ligand is a 
peptide or protein. The field of enzyme inhibitors uses peptide mimetics terminology for 
the replacements of segments of peptide-based substrates and inhibitors... The broad use 
of the term "peptide mimetics" is unavoidable, but the advocates of rational design do not 
favor its use to describe compounds found by screening."14
Veber recently coined the term "peptide limetic" (a contraction of ligand mimetic) to 
distinguish compounds (discovered by screening) so divergent from peptides "that specific 
connections are no longer recognizable" but which exhibit activity in endogenous peptide 
assays, from peptidomimetics more rationally derived.15 This term finds sporadic use in 
the literature, with its own twists of definition. 10
These definitions and comments bring to light the importance of the screening of 
natural products (and other compound collections) in the discovery and development of 
peptidomimetics.6’10’12’16 The natural products (and other compounds) unearthed by 
screening may be peptidic or non-peptidic, and are particularly valuable in the search for 
antagonistic peptidomimetics and enzyme inhibitors.6’10’12’16
The rather broad definition of a peptidomimetic conformed to here is: a molecule 
with some or all peptide functional groups replaced by other groups, yet which exhibits 
properties analogous to a (or many) peptide(s).
Thus, with this definition, a modified peptide may also be described as a 
peptidomimetic, but a peptidomimetic is not necessarily a modified peptide.
There are sources of peptidomimetics other than screening and modification 
starting from an endogenous peptide. The recent ascendance of peptide libraries is 
founded predominantly on their promise of leads for peptidomimetics.17-20 Indeed, 
attention is now also directed upon the development of peptidomimetic libraries, which 
offer further molecular diversity.21-26
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A different approach is that of Greene and co-workers, in which peptidomimetics 
are developed from the complimentarity determining region of monoclonal antibodies 
raised against receptors of interest.27
This antibody approach and Kemp's distinct definition of peptidomimetics, 13 
reveal motives for modification which are less firmly in the medicinal chemistry camp. 
These motives are the study of molecular recognition27 and investigations into protein 
folding.28 The aspiration to an understanding of protein folding inspires much work on 
small molecules {e.g. the studies of Gellman and co-workers29) and modified peptides,28 
which does not sit easily within the more medicinal chemical definitions of 
peptidomimetics, but which ought to be considered in this context [see section 
1.5.3(b)(iii)(2) and (iv)(2)].
1.2 The Range o f Peptide Modifications and Peptidomimetics.-
As might be expected from the variety of definitions, the range of peptidomimetics 
is wide, and different reviewers adopt different modes of classification. Thus 
peptidomimetics may be classified according to origin, 10’12 activity,8’10*11’30 secondary 
structure,31-35 topographical considerations,36 that part of the endogenous peptide which 
is modified,6’8 or which peptide torsion angles are constrained.32 Modification can be 
made at any point in a peptide and modifications can be applied in any combination:37*38 
amino acids can be deleted, or added / replaced (by coded or noncoded alternatives);39 
short-40 or long-range cyclisations41 may be applied, through the side chains or backbone; 
backbone peptide bonds can be replaced with surrogates;38*42 or the backbone may be 
replaced altogether by a novel scaffold,8’16 or alternative backbone [see section 
l,5.3(b)(iii)(2)]. An overview of modifications, and combinations thereof, used in the 
development of therapeutic peptides, is provided by Dutta, in his review of the design of 
peptide-based drugs.43 Rational, general strategies for the use of modifications are under 
development: both Hruby44*45 and Marshall46 have recently published their approaches 
for the use of modifications (with the emphasis on conformationally constrained and 
chimeric, novel amino acids) to produce selective, biologically active, peptide and 
peptidomimetic ligands.
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The subject of this thesis is a particular peptide bond modification, and its 
influence on the conformation of peptides into which it is incorporated. Therefore an 
attempt to tidily classify the world of peptidomimetics is beyond the scope of this 
introduction (the interested reader is referred to the reviews already cited and the annual 
Chemical Society specialist reports47), and further discussion is restricted to peptide bond 
surrogates in general, and the retro-inverso modification in particular.
1.3 Peptide Bond Surrogates.-
Peptide bond surrogates are amide look-alikes used to replace backbone peptide 
bonds. Generally these surrogates are isosteric and / or isoelectronic with the peptide 
bond, and indeed, are often referred to as isosteres. However, the isosteric and / or 
isoelectronic character of the surrogates is not always obvious, nor even necessary for 
biological activity.
Peptide bond surrogates are used to investigate the role and function of backbone 
peptide bonds, and to modify the properties of the parent peptides. In his peptide 
backbone modifications review of 1983,38 Spatola raised these questions of interest (with 
particular reference to peptide hormone analogues):
•  Is there a functional role for the peptide bond itself? Or does the backbone merely 
serve to orient and align the essential side chain residues?
• T o  what extent are the alignment, bond lengths, and stereochemistry of the peptide 
backbone critical for the resulting biological function?
•  How does the modification of the peptide backbone affect the resistance (as measured 
by biological half-lives) toward enzymatic degradation?
• T o  what extent are rigidity and flexibility of peptides manifested in the backbone and 
can these elements be exploited in designing more potent peptide analogues, or 
conversely, peptide antagonists? What are the related consequences of introducing 
peptide backbone modifications in terms of their altered electronic and stereochemical
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properties, hydrophilicity and hydrophobicity, and their effects on adsorption, transport, 
and the ability to penetrate the blood-brain barrier?
Partial answers to these questions emerge. Work covered in Spatola's review, and on 
peptidomimetics in general since then, suggests that in the context of peptide hormone - 
receptor binding, the peptide backbone largely serves to position the essential side 
chains16 (hence the advent of scaffold mimetics8’16 and Hruby's topographical design 
approach44’45). In contrast, with protease inhibitors a non-scissile peptide bond surrogate 
(especially one that can mimic the transition state of amide bond hydrolysis) at the 
substrate cleavage site is a key approach to activity,8’9’38’42 and enzyme - substrate / 
inhibitor binding involves hydrogen bonding to the substrate / inhibitor backbone peptide 
bonds. 16 Well-placed peptide bond surrogates do indeed increase the biological half-lives 
of their parent peptides: nearly all peptide bond surrogates, with the notable exception of 
the ester and thioester surrogates, are more stable to enzymatic hydrolysis than the natural 
peptide bond.38’48 Most peptide bond surrogates do not greatly restrict global peptide 
conformation, but their different influences on the conformational preference of adjoining 
residues, and their capacity to form hydrogen bonded secondary structures, are much 
studied and frequently important. Alterations of electronic properties introduced by 
peptide bond surrogates can significantly affect the transport properties of their parent 
peptides.49’50
Thus the role of peptide bond surrogates is to increase bioavailability and (often 
subtly) to influence the conformation of the parent peptide; and more besides in the case 
of the protease inhibitors.
In addition, those peptide bond surrogates which mimic the transition-state of 
amide bond hydrolysis, or conversely the aminolysis of an amino acid, find use in haptens 
for the generation of catalytic antibodies 51-53 Up until now, success in this field is 
largely restricted to the phosphorus based surrogates (see table l ),51’52 e.g. in haptens 
used to raise antibodies which catalyse peptide bond formation.54' 56
A few comparisons of peptide bond surrogates appear in the literature. In his 
review, Spatola compared peptide bond surrogates with respect to enzyme stability,
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hydrophobicity, conformational influence, e tc ^  Fauchere and Thurieau reviewed the in 
vivo proteolytic degradation of endogenous peptides and the stabilising influence of 
(backbone) modifications used in (potentially) therapeutically useful modified peptides, in 
order to aid rational drug design.48 Fincham et al. compared eleven peptide bond 
surrogates by modelling physiochemical properties (dimensions, volume, lipophilicity and 
hydrogen bonding capability) and biologically in the specific context of two 
cholecystokinin (CCK)-B ligands.57 Most of their analogues displayed lower binding 
affinity than the parent ligands, but no correlation with the modelled properties was 
determined, suggesting that factors such as conformation are more important in this case. 
Nonetheless the study constitutes progress towards a rationale of peptide bond surrogate 
selection.57
Significant surrogates are presented in table 1, with leading references. Other 
surrogates exist, including some which constitute backbone extension, deletion, and 
cyclisation, and others which can only be used at peptide termini.38
Table 1:
Name Symbol Comments
A-Substituted tl>(CONR) R = Me, NH2 or OH: 
conformational implications.58’59
Ester (depsipeptides) 4>(C02) Implications for turn formation: 
conformational study.60
Ketomethylene iKCOCH2) Synthetic methodology for the 
core units:
R1COCH2CHR 2CO 2R3; R1 = 
alkyl, heterocycle or ZNHCHBn; 




x|*CH2NH) Synthesis and conformational 
analysis of a cyclic Arg-Gly-Asp 
(RGD) pseudopeptide.63
Thioamide ip(CSNH) Compatibility with reverse turn: 
conformational study.64
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Phosphinate (n = 1) / 
phosphonate (n = 2) 
(and their esters)
ip[POn+1R(CH2)2-n] R = H; n = 1,2: SPS 
methodologies for the 
incorporation of
Pheil>(P02HCH2)Gly,65,









Synthetic methodology for 
Xaatp(£’-CH=CH)Y aa (R = H)71 
and Alai|>(E-CR=CH)Xaa (R = H 
or Me)72 via S^'-attack of 
organocuprates on y,5-epimino- 
a,p-enoates.
P-Hairpin promoter.73
Fluoroalkene ip(Z-CF=CH) Assessment of binding of 
tripeptide inhibitors to 
thermolysin.74
Carba or dimethylene ip(CH2CH2) Synthesis, conformational study 
and SAR of a substance P NK-1 
agonist.75
Thioether ^(CH2S) Review [including mention of 
sulfoxide variant, ip(CH2SO)].76
Hydroxyethylene i|j[CH(OH)CH2] Synthetic methodology for the 
lactone derivative leading to 
Xaaij) [CH(OH)CH2]Phe, from a - 
amino ketones.77
Dihydroxyethylene ip[CH(OH)CH(OH)] Synthetic methodology for the 
lactone corresponding to PG- 
Leuop[CH(OH)CH(OH)]Ala, 
from V-protected leucinal.78’79
Methyl ene-oxy t|<CH20) Conformational implications.80
Tetrazole ip(CN4) Cis amide bond surrogate: 
synthesis and solution 
conformation of an active, cyclic 
somatostatin analogue.81
25
Cyanomethyleneamino ip[CH(CN)NH] SPS of an NT(8-13) analogue 
with moderate binding 
affinity.82’83
Retrothioamide ip(NHCS) Synthetic methodology for 
Xaai|)(NHCS)Yaa via 
endothionation of 
Xaaip (NHCO) Y aa, and 
subsequent elongation.84
Retroreduced* *i|>(NHCH2) Synthetic methodology for Ac -
PheiKNHCO)PheiKNHCH2)-
(R,S)Val-OR.85
Sulfonamido t xKS02NH) Synthesis of the glutathione 
disulfide analogue,
[Glu1-  i|)(SO 2NH)Cy s-Gly ] 2. 86
Sulfinamido (n = 1) / 
sulfonamido (n = 2)
ip(CHRSOnNH) Synthetic methodology for 
Glyxp(CHRSOnNH)Xaa (R = Me 
or Bn) and
Yaaxli(CH2SOnNH)Zaa via a- and 
P-substituted sulfinyl chlorides 
respectively, and subsequent 
elongation.87’88
Retrosulfonamide i|>(NHS02) Synthesis and crystal structure of 
Boc-Pro-Leutp(NHSO 2)Gly-
n h 2.89
* Retroreduced pseudopeptides are intrinsically unstable unless the surrogate is preceded by a retro amide 
bond.
t Sulfonamido [and sulfinamido, i|>(SONH)] pseudopeptides are intrinsically unstable when preceded by 
-NHCHR- (i.e. when the surrogate is inserted in the peptide backbone) 8637 hencc thc ad\ent of the 
subsequent entries.
1.4 Retro-inverso Pseudopeptides.-
The peptide bond provides the peptide backbone with a "sense of direction". Thus 
peptides and proteins are inherently non-palindromic. The convention for the construction 
of peptide names and sequence representation proceeds from the amino terminus (written 
on the left) to the carboxy terminus (written on the right).2 Therefore the direction of the 
peptide bond is defined as that from the carbonyl carbon atom to the adjoining nitrogen 
atom.
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Hence it is possible to envisage the retro-isomer of a peptide, i.e. an isomer in 
which the direction of the amino acid sequence is reversed;90 see figure 5 (a) and (d) for a 
cyclic example, and figure 6 (a) and (d) for a linear example.
1.4.1 Cyclic peptides.
This concept of retro-isomers was recognised early in the study of the biological 
activity of peptides and was applied to cyclic peptides and cyclic depsipeptides (for an 
overview of this early work see reference 90). Shemyakin, Ovchinnikov and co- 
workers,91’92 and later Wieland and co-workers,93 further recognised that reversal of the 
residue sequence of the enantiomer of a cyclic (depsi)peptide (or conversely, 
enantiomerisation of the retro-isomer) maintains topochemical complimentarity between 
the parent cyclic (depsi)peptide and its isomer.90 The resultant isomer is called a 
cycloretro-enantiomer (or, for the isomer of an all L-cyclopeptide, a retro-all-D- 
cyclopeptide93) and is defined as an isomer of a cyclic compound in which the sequence is 
reversed and each residue is inverted,90 figure 5.
H H
H -N  V R2
O ^ N —N O
H v J I  J * 1 R 1  J, yo r ;  i p  ' NX /
R V  N-H *  o = /  VR2 0 = /  VF
Nv  nV—
H ' "H  H'  X
H R 3  R 3  O R 3  OR 3  H
(a) (b) (c) (d)
Figure 5: Cyclo(-Xaa-Yaa-Zaa-) and some of its cycloisomers; (a) cyclo(-Xaa-Yaa-Zaa-);
(b) the enantiomer, cyclo(-D-Xaa-D-Yaa-D-Zaa-); (c) the cycloretro-enantiomer, cyclo(-D- 
Zaa-D-Yaa-D-Xaa-); and (d) the retro-isomer, cyclo(-Zaa-Yaa-Xaa-); where R1 is the side 
chain of the amino acid Xaa, etc.
It is important to note that: (1) the cycloretro-enantiomer is not the same isomer as the 
enantiomer of a cyclic compound, c.f. figure 5 (c) and (b); and (2) there are (many) other 
cycloisomers of cyclic peptides (see reference 90 for further discussion).
Shemyakin, Ovchinnikov and co-workers synthesised the cycloretro-enantiomer of 
[Gly5,Gly10]gramicidin S, which displayed similar antimicrobial activity to that of the 
parent [Gly5,Gly 10]gramicidin S.91’92*94
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1.4.2 Linear peptides.
The extension of the retro-enantiomer concept to linear peptides was hampered by 
their possession of end groups,90 which are obviously absent in cyclic peptides. Thus 
reversion of sequence and enantiomerisation of a linear peptide produces an isomer 
topochemically complimentary to the parent peptide along the chain length, but with non- 
complimentary end groups: figure 6.90
R1 O R3 R1 O g3
*H3N-\'NYiL'N'Va *H3N'AirNYJS 'Y
O R2 O O R2 O
(a) 2 (b) 3
R1 O R 3 R1 O R3
O R2 O O R2 O
(c) 4 (d) 5
Figure 6: (a) Xaa-Yaa-Zaa, 2; (b) the enantiomer, D-Xaa-D-Yaa-D-Zaa, 3; (c) the retro- 
inverso peptide, D-Zaa-D-Yaa-D-Xaa, 4, obtained from 3 by reversal of sequence, or from 
5 by enantiomerisation; and (d) the retro-isomer, Zaa-Yaa-Xaa, 5.
The term retro-inverso peptides (or retro-inverso pseudopeptides, the "pseudo" being 
tautologous in this context) is used to describe the relationship between peptides 2 and 4, 
(and that between 3 and 5) because 4 is obtained from 2 (and vice versa) by reversal of the 
direction of the amino acid sequence and inversion of each chiral centre.90** The term 
retro-inverso peptide is preferable to retro-enantio peptide in this linear peptide context, 
because the latter implies too much structural equivalence between the parent peptide, 2 
and the isomer, 4.90
Although Shemyakinin and co-workers synthesised an effective retro-inverso 
pepsin inhibitor without complimentary end groups,92 the non-complimentarity of end 
groups (termed the "end group problem") was recognised by the pioneers of the retro-
* Note that for the two coded a-amino acids with chiral CPs, namely threonine and isoleucine, 
enantiomerisation results in topochemical noncomplimentarity with the parent peptide at C P. This is often
ignored in retro-inverso studies, but may be overcome by incorporation the appropriate D-allo-amino acid, 
or by suitable choice of synthetic method for gXaa residues [see section \.S .\(b)(ii)\
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inverse) concept as the probable cause of the inactivity of various retro-inverso peptide 
hormones synthesised by early researchers.90,92,§
(a) End group modification
These set-backs prompted the development of end group modifications, designed 
to improve complimentarity between the parent peptide and its retro-inverso isomer at the 
chain termini. Various modifications were employed with differing degrees of success (as 
judged by the retention of biological activity by the end group modified retro-inverso 
peptides).90’92 Paiva and co-workers synthesised the first biologically active end group 
modified retro-inverso peptide hormones, two angiotensin analogues, which demonstrated 
that the (C2 substituted) malonyl (or malonamyl) residue suggested by Rudinger96 was 











Figure 7: (a) angiotensin and (b) end group modified retro-inverso-[Ala7]-desamino- 
angiotensin.
§ However, the inactivity of those retro-inverso peptide hormones containing proline, e.g. bradykinin, could 
equally well be due to the lack of spatial coincidence between the proline rings of, e.g. bradykinin and retro- 
inverso bradykinin. This topological difference was dubbed the "proline problem", and arises because the 
proline side chain is cyclised onto the proline backbone nitrogen, which changes position with the carbonyl 
carbon in the retro-inverso isomer.90’92’9^
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Hayward and Morley first proposed (and incorporated) the gem-diaminoalkyl 
residue as an amino terminus modification.98 They replaced a pyroglutamyl residue with 
a 5-oxo-2-pyrrolidinylamino residue in a model pseudodipeptide, 48 (see scheme 16)98 
but did not follow up this work. As shown in figure 8 , the incorporation of an amino 
terminal gem-diaminoalkyl residue and a carboxy terminal (C2 substituted) malonyl 
residue results in good structural complimentarity between the parent peptide, 2 , and its 
end group modified retro-inverso isomer, 6 .
(a) 2 (b) 6
Figure 8 : (a) Xaa-Yaa-Zaa, 2; and (b) the end group modified retro-inverso isomer, 
Xaaip(NHCO)Yaai|>(NHCO)Zaa, 6.
Chorev and Goodman took up the retro-inverso concept and, through the general synthetic 
methodology they established, are responsible for the widespread adoption of the gem- 
diaminoalkyl residue as an amino terminus modification.90’99
1.5 Partially Modified Retro-inverso Peptides: the Retro Peptide Bond as a True Peptide 
Bond Surrogate.-
Gem- diaminoalkyl and C2 substituted malonyl residues are not restricted to 
terminal incorporation. When these residues are incorporated within the peptide 
sequence, a new class of peptide isomers are produced. Hayward and Morley first 
introduced this concept,98 but it was Chorev and Goodman who first implemented it and 
who termed the resultant isomers partially modified retro-inverso (PMRI) peptides.90 
Such isomers consist of the parent peptide sequence with two (or more) internal residues 
replaced by gem-diaminoalkyl and C2 substituted malonyl residues, and with the 
intervening amino acids having inverted configuration and reversed sense of direction; i.e. 
an end group modified retro-inverso sequence is incorporated within a peptide sequence: 
figure 9.90’98 [Note that an end group modified retro-inverso isomer, such as that 
depicted in figure 8 (b), is simply a special example of a PMRI peptide with all the amide 
bonds reversed and amino acids inverted. Therefore all subsequent discussion of PMRI
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peptides also applies to this special case]. The application of the gem-diaminoalkyl and 
C2 substituted malonyl residues in this context thus makes the retro peptide bond into a 
true peptide bond surrogate, in that any one peptide bond can be replaced; see figure 9 (d) 
where only the peptide bond between residues 5 and 6 is reversed.
R1 O R 3 O R 5 O
- V v W A V r SO R 2 O R 4 O R 6
(a)
R1 O R3 O R5 O R7 O O RB
^AVrYVVWYSrVO R 2 R4 O R8 O R8 O
(b)
R1 O R 3 O R5 O R7 O R9
O R 2 O R4 R8 O O R8 O(c)
O R5 O O R7 O R 9
FI  ^ H H  ^ H II =;a H IIO R 4 R8 O R 8 O
(d)
Figure 9: (a) The parent peptide and its PMRI isomers, (b) 5 bonds reversed, (c) 2 bonds 
reversed, and (d) 1 bond reversed.5
Chorev and Goodman exhaustively reviewed the field of PMRI peptides in 199369 
and further reviewed developments in enantio-, retro-, and retro-inverso peptides and 
proteins in 1995.70 Therefore subsequent discussion here is largely restricted to PMRI 
peptides, taking pertinent examples from the literature, with special note of material not 
covered by Chorev and Goodman.
1.5.1 Synthetic methodology.
The principal concern of PMRI peptide synthesis is the construction and coupling 
of the gem-diaminoalkyl and C2 substituted malonyl residues, on which this section
5 Figure 9 (b) and (c) are examples of structures that are more conveniently represented using the g I m / r
system of symbols, rather than the system.
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focuses. Assembly of the remainder of the PMRI peptide chain (merely) involves the 
protection and coupling of L- or D-a-amino acids, which is the (by no means trivial) stuff 
of standard peptide chemistry.100*101 As with standard peptide chemistry the 
methodology is readily divided into two categories: that carried out (a) in solution, and (b) 
on a solid support (SPS); there being considerable common ground between the two.
(a) Solution phase methodology 
(i) Gem- diaminoalkyl derivatives
(1) Rearrangements
Most of the pioneering syntheses of gem-diaminoalkyl derivatives for PMRI 
peptides used a rearrangement step to obtain the gem relationship of the amino groups. 
Rearrangements remain the most common methods used for this manipulation. In theory, 
any of the rearrangements depicted in scheme 1 could be employed, but in practice only 
the Curtius and Hofmann rearrangements (in various forms) are utilised in this context.
During all these rearrangements the migrating group (PGNHCHR1 in scheme 1) 
retains its configuration; thus an L-a-amino acid as starting material yields the 
topographically complimentary gem-diaminoalkyl derivative.
The Curtius rearrangement was employed by Chorev, Goodman and co-workers in 
their first preparations of PMRI peptides.90*99*102 Their approach to the gem- 
diaminoalkyl residues, 8 and 9, was based on the Bergmann and Zervas stepwise 
degradation method ("carbobenzoxy degradation”) for polypeptide sequencing: scheme 
2.103 But, rather than degrade the gem-diaminoalkyl derivatives, 8 and 9, to the 
corresponding aldehydes, 10, for identification, Chorev, Goodman and co-workers utilised 
them in their PMRI peptides.90*99’102 As indicated in scheme 2, they applied this 
methodology to both protected peptides, 7(a), leaving the gem-diaminoalkyl group 
attached to the peptide chain [8(a)] and to A-protected amino acids, 7(b), leading to 
isolated, orthogonally protected (when R1 and R3 in scheme 2 are complimentary) gem- 
diaminoalkyl derivatives [8(b) I.90*99*102 This latter synthesis obviously requires an 
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Scheme 1: Rearrangements leading to gem-diamino derivatives, (i) Curtius: A. (ii) 
Hofmann: NaOBr. (iii) Schmidt: HN3. (iv) Lossen: OH", (v) Beckmann: PCI5.
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10
Scheme 2: Carbobenzoxy degradation (R1 = peptide chain and R3 = Bn) via gem- 
diaminoalkyl derivatives, 8(a) and 9(a).
Of course, this approach raises its own questions: (1) how best to synthesise the 
required a-aminoacyl azides, 7? (2) which are the best protecting groups (R1 and CO2R3
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in scheme 2) for the gem-diaminoalkyl derivatives, 8? (3) which is the best coupling 
procedure to employ with the gem-diaminoalkyl derivatives, 9? and (4) is it better to 
synthesise free or peptide bound gem-diaminoalkyl derivatives, i.e. 8 and 9 (a) vs (b)?
Chorev, Goodman and co-workers performed limited comparative studies on the 
use of the Curtius rearrangement, in order to begin to answer these questions.99*104’105 
Since acyl azides have been heavily utilised in peptide chemistry as acylating 
agents100’106 (which probably explains their immediate popularity for PMRI peptide 
synthesis), a number of syntheses of a-aminoacyl azides, 7, exist. 100,106 Chorev and 
Goodman compared two methods of N-formylaminoacyl azide, 14 preparation: 
nitrosylation of an N-formylaminoacyl hydrazide, 13, and formation of a mixed 
anhydride, 12, followed by nucleophilic displacement by sodium azide: scheme 3.104 
Curtius rearrangement of the a-aminoacyl azides, 14, yielded the isocyanates, 15, which 
were trapped with benzyl or tert-butyl alcohol to yield the orthogonally protected gem- 
diaminoalkyl residues, 16, or reacted with a carboxylic acid derivative to yield a PMRI 
peptidic unit, 17, directly (the so-called "Goldschmidt and Wick type reaction", after the 
chemists who employed a closely related procedure for peptide synthesis107’1***).104 
Chorev and Goodman concluded that the mixed anhydride procedure results in better 
yields of the desired gem-diaminoalkyl derivatives, 16, than the nitrosylation method. 104 
However, they did not test the tert-butyl nitrite variant of the nitrosylation method. 
Moutevelis-Minakakis and Photaki109 used this method and obtained yields of 
orthogonally protected gem-diaminoalkyl derivatives comparable with those of Chorev 
and Goodman's nitrosyl chloride method104 (11-45%); therefore, in this context, 





































Scheme 3: Chorev and Goodman's comparative Curtius rearrangements. Yields: 16(a) 
(R2 = Bn), 66 and 77%; 16(b) (R2 = Bul), 37 and 66%; for the NOC1 and NaN3 routes 
respectively (from 11). R3 = R4NHCHBn; (a) R4 = Z, (b) R4 = Boc.104
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The other popular method for the synthesis of a-aminoacyl azides en route to 
PMRI peptides uses the reagent diphenylphosphoryl azide (DPPA).110’111 Reaction of 
DPPA with an A-protected a-amino acid (e.g. 18) or peptide, yields the corresponding 
acyl azide (which is not isolated). Under the usual reaction conditions the intermediate 
acyl azide undergoes the Curtius rearrangement to yield the corresponding isocyanate 
(e.g. 19), which is trapped with an appropriate alcohol (either in situ or added 
subsequently) to furnish the desired gem-diaminoalkyl derivative (e.g. 20): scheme 
4  90,109,112
Scheme 4: An example of the use of DPPA for the synthesis of the protected gem- 
diaminoalkyl derivative, Z-gGlp-Z, 20.90*112
DPPA may be used quite generally for the synthesis of gem-diaminoalkyl derivatives,
Goldschmidt and Wick type reaction is, of course, not possible without ensuring complete 
consumption of the DPPA prior to addition of the second carboxylic acid.
No direct comparison of the DPPA method with other approaches to a-aminoacyl 
azide synthesis has been undertaken, nor have variants of this reagent114 found 
widespread application in PMRI peptide synthesis (but see references 115 and 116).
The literature contains other classical and more modem routes to acyl azides;117- 
120 these have been but little used in PMRI peptide synthesis. The only example of the 
use of TMS-azide to synthesise an acyl azide en route to a PMRI peptide is Fincham et 
al.'s synthesis of CCK-B ligands.57 They synthesised 2-Adoc-Trp-N3 by reaction of the 
amino acid mixed anhydride and TMS-azide. Curtius rearrangement and trapping of the 
isocyanate with p-nitrobenzyl alcohol / DABCO furnished racemic 2-Adoc-(/?,S)gTrp- 
OBn(/?-N02) in 42% yield.57 They offered no explanation for the racemisation.
The criteria against which to judge protecting groups for the gem-diaminoalkyl 
derivatives are, as with any protecting groups, the efficacy of protection [indicated by the
OH DPPA, NEt3 , BnOH, 80°C,
18 19 20
without the need for extraordinary side chain protection. 113 However, a "one-pot"
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prevention of decomposition and si de-reactions (including racemisation)] and their ease of 
incorporation and removal.
Chorev, Goodman and MacDonald studied side reactions during the synthesis of 
protected gem-diaminoalkyl derivatives obtained by the Curtius rearrangement of acetyl, 
Boc or Z-protected phenylalanyl azide, trapping the intermediate isocyanate in situ with 
methanol or benzyl alcohol. 105 They obtained the desired gem-diaminoalkyl derivatives, 
22, plus numerous by-products, in a ratio that depended upon the nature of the 
phenylalanyl azide A-protecting group, and the nature and molar excess of the alcohol.105 
They rationalised the formation of the by-products as shown in scheme 5; the yields are 
shown in table 2.
Table 2:
Isocyanate R1 Alcohol, eq* Product, yieldt / %
22 23 24 25 26
21(a) BnO MeOH, 20 49 9 6 5 1
MeOH, 2 65 nr nr 2 nr
21(b) BulO MeOH, 20 29 44 nr 12 nr
MeOH, 2 45 nr nr 4 nr
BnOH, 10 18 18 nr 20 nr
BnOH, 2 31 nr nr 18 nr
21(c) Me MeOH, 10 78 2 nr nr nr
* They rationalised the increase in the yield of by-products on increasing the molar excess of alcohol (a 
finding contrary to their original expectation) by reasoning that increasing the alcohol content leads to an 
increasingly polar reaction mixture (the solvent being toluene) which relatively favours the heterolytic or 
displacement reactions. A control experiment proved that the desired product, 22(b) (R2 = Me), is stable 
under the reaction conditions. 105
t  Isolated yields relative to starting A-protected phenylalanine.
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Scheme 5: Formation of by-products during the synthesis of bis-protected-1,1-diamino-2 - 
phenylethane, 22, by the addition of alcohol to the isocyanate, 21 (no racemisation was 
observed). The 1-amino-l-alkoxy-2-phenylethane by-product, 23, arises from cyanate 
displacement by the alcohol; whereas the styrene by-product, 24, arises by elimination of 
cyanate. Reaction of displaced cyanate and alcohol produces protected ammonia, 27, 
which adds to the isocyanate, 21, to yield the allophanate by-product, 25. Traces of water 
present in the reaction mixture lead to the formation of the urea by-product, 26.105
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As regards the choice of protecting group for gem-diaminoalkyl derivatives, they 
concluded that acetyl is better than Z, which is better than Boc, on the basis of 
maximisation of product yield and concurrent minimisation of the yield of by-products. 105 
They reasoned that acetyl protection resulted in fewer by-products than carbamate 
protection due to a reduced tendency of isocyanate 21(c) to undergo the heterolytic or 
displacement reactions. 105 Although acetyl is not a practical amino protecting group, they 
argued that it is a suitable model for a peptide chain, and therefore the results they 
obtained suggest that, in answer to question (4) above, it is better to synthesise peptidyl 
gem-diaminoalkyl derivatives. 105
DeBons and Loudon and Moutevelis-Minakakis and Photaki both obtained urea 
by-products, corresponding to 26, in their studies of gem-diaminoalkyl derivative 
synthesis. 109.115 Both argued that the water required for urea formation is generated in 
situ by the dehydration of terf-butanol by the intermediate i s o c y a n a t e . I 0 9 ’ !  15 This 
provides a basis to disfavour tert-butanol as an isocyanate trap. Chorev, Goodman and 
W illson" counselled against Boc deprotection of gem-diaminoalkyl derivatives when 
hydrogenation of a Z group is possible instead, but offered no rationale. Previous work in 
this department on the synthesis of PMRI dipeptides using the Goldschmidt and Wick 
type reaction demonstrated that Boc and Z groups are equally effective as protecting 
groups during the synthesis, but that Boc deprotection by conventional acid hydrolysis 
results in decomposition.84
So, we may conclude from these results that Z is to be favoured over Boc for the 
protection of gem-diaminoalkyl compounds.*
Fmoc and 2-nitrophenylsulfenyl are also acceptable protecting groups for gem- 
diaminoalkyl compounds, and provide additional, orthogonal dimensions;!2! no 
comparison of these with the other protecting groups discussed has been undertaken.
Regarding the coupling of gem-diaminoalkyl derivatives to carboxylic acids 
[question (3) above], no comprehensive comparison of the vast array of available methods
* Loudon and co-workers studied the hydrolysis of gem -diamino alkyl derivatives. Their results, which are 
summarised below [section \.B.\(a)(i)(5)], have similar implications for the choice of gem -diamino alkyl 
derivative protecting groups.
39
has been undertaken (in theory, any peptide coupling procedure100’122 is applicable). Due
to the danger of gem-diaminoalkyl derivative decomposition [see section 1.5.1 (a)(i)(5)\, a 
rapid coupling procedure is essential; however, most peptide coupling procedures 
currently in use meet this requirement. The method used almost exclusively by 
researchers engaged in PMRI peptide synthesis is the A-hydroxybenzotriazole (HOBt) or 
A-hydroxysuccinimide (HOSu) catalysed carbodiimide (usually DCC) procedure 
(however the BOP reagent has also been successfully employed123’124). Although 
catalysed carbodiimide mediated couplings give good results, activated malonates have a 
lower coupling efficiency than normal amino acids.121 Thus yields tend to be lower, and 
reaction times longer than those usually employed.121 In addition, couplings to gem- 
diaminoalkyl derivatives tend to be sluggish per 5 £ . 1 2 1  The reduced coupling efficiency 
of both modified residues is presumably electronic in origin. 125 Therefore, a wise 
strategy for the assembly of a PMRI peptide avoids fragment couplings (i.e. the coupling 
of partial sequences, as opposed to individual residues) to gem-diaminoalkyl derivatives, 
if possible. 121
The only coupling procedure found to be unsatisfactory is the mixed anhydride 
method. Goodman and co-workers discovered that the mixed anhydride coupling of 
monoethyl 2-benzylmalonate, 28, to ammonia, yielded only ethyl /i^-butyl 2- 
benzylmalonate, 30, and none of the expected amide, 29: scheme 6 .121
The Goldschmidt and Wick type reaction obviates the need for such a coupling 
step altogether when the gem-diaminoalkyl group is formed at the peptide carboxy- 
terminus; or reduces the number of necessary couplings from two to one for free gem-
O O
Ph 30
Scheme 6: A failed mixed anhydride coupling.
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diaminoalkyl groups. Chorev and Goodman, in their aforementioned comparison of 
Curtius rearrangements, 104 found that the yield of the Goldschmidt and Wick type 
reaction varied with the carboxylic acid {e.g. R3CC>2H, scheme 3) employed. ^-Protected 
phenylalanine (1.5 eq) gave a reduced yield of the PMRI dipeptide [17(a), 35%; 17(b), 
6%; scheme 3], but malonic acid (3 eq) gave an increased yield of PMRI tripeptide Boc- 
Phe-Alaxp(NHCO)Gly (47%) [changes relative to the corresponding multi-step 
deprotection and coupling procedures: 17(a), 66%; 17(b), 22%; and Boc-Phe- 
Alail? (NHCO)Gly, 11% ].104
The Goldschmidt and Wick type reaction, using a malonate monoester, was 
successfully used in this department to synthesise PMRI dipeptides, which are not readily 
prepared by acylation of mono-protected gem-diaminoalkyl compounds because of their 
tendency to decompose when the protecting group is a carbamate [see section 
l.S.l(a)(i)(5))M>$
Thus the Curtius rearrangement, with suitable precautions, provides ready access 
to gem-diaminoalkyl compounds appropriate for PMRI peptide synthesis and, in 
combination with the Goldschmidt and Wick type reaction is a valuable method for the 
direct synthesis of PMRI peptides.
The Hofmann rearrangement is extensively employed for the synthesis of PMRI 
peptides, exclusively using the mild oxidant iodobenzene bis(trifluoroacetate) 
(IBTFA); 127-129,5 other conditions being too harsh.
IBTFA effects the Hofmann rearrangement on primary amides, under acidic or 
neutral conditions (giving an amine trifluoroacetate salt, 33, and carbon dioxide), but does 
not affect secondary or tertiary amides. 127 Therefore IBTFA may be employed to 
synthesise mono-protected gem-diaminoalkyl derivatives from A-protected a-amino acid
§ However, Verdini and co-workers have developed a non-carbamate nitrogen protecting group, specifically 
to stabilise monoprotected gem -diamino alkyl compounds, in order to synthesise PMRI dipeptides for use in 
SPS;12^ see section l.S.l(b)(ii).
5 IBTFA is also known as phenyl iodosyl bis(trifluoroacetate) (PIFA or PIT), 
[bis(trifluoroacetoxy)iodo]benzene (TIB), phenylbis(trifluoroacetato- O)-iodine and iodoso benzene 1,1- 
bis(trifluoroacetate)!
41
primary amides or peptidyl gem-diaminoalkyl derivatives from peptidyl primary amides
[which Loudon and co-workers hydrolysed to the corresponding aldehyde and a new 
peptidyl amide in their C-terminal sequential degradation process,130 analogous to that of 
Bergmann and Zervas (scheme 2)].121»127»131 However, when the a-amino acid N- 
protecting group is a carbamate, the resultant mono-protected gem-diaminoalkyl 
derivative decomposes under the reaction conditions. 121 Therefore, the requirement to 
favour the synthesis of peptidyl gem-diaminoalkyl derivatives encountered with the 
Curtius rearrangement [in answer to question (4), above] is absolute in the case of the 
IBTFA mediated Hofmann rearrangement.*
The mechanism of the IBTFA mediated Hofmann rearrangement is complex. 
Boutin and Loudon performed a mechanistic study (using hexanamide as substrate),128 
the results of which are in disagreement with the earlier study of Swaminathan and 
Venkatasubramanian.132^  Boutin and Loudon demonstrated that IBTFA forms a dimer, 
31, under the reaction conditions [water / acetonitrile (50:50)]: scheme 7.
It is not clear, however, whether the dimer, 31, or / and the IBTFA monomer is the 
reactive species; scheme 8 shows the mechanism, determined by Boutin and Loudon, with 
the dimer, 31, as the reactive species.128 The rate-determining step is the rearrangement 
of the amide - IBTFA dimer complex, 32.128
* Unless MNP protection is used: see section l.S.l(b)(ii).
t  Although this earlier study investigated the mechanism of action of iodobenzene diacetate, rather than 
IBTFA, with aromatic amide substrates.
F3C CC^  O2CCF 3 
31
Scheme 7: Dimerisation of IBTFA.
IBTFA
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Scheme 8: The mechanism of the IBTFA mediated Hofmann rearrangement. 128
As this mechanism suggests, the reaction proceeds with complete retention of 
configuration of the migrating group. 127,131
The considerations discussed above [question (3)] with respect to coupling 
procedures, also apply to the IBTFA procedure, although no Goldschmidt and Wick type 
reaction is known using IBTFA because the reaction conditions do not permit trapping, 
rather than hydrolysis, of the intermediate isocyanate. However, a conceptually 
analogous, direct synthesis of a PMRI dipeptide unit, 35, is possible by the reaction of 
IBTFA with a malonylaminoacyl amide, 34: scheme 9.69»12i
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,IBTF" '^  tf, hA h
34 35
Scheme 9: Direct synthesis of a PMRI dipeptide unit, 35, using IBTFA. R3 = peptide 
chain or OR4, R4 = alkyl, Bn.
Special considerations are necessary for the synthesis of Gin or Asn containing 
PMRI peptides using IBTFA. The side chains of these amino acids contain primary 
amides, which undergo the Hofmann rearrangement under the action of IBTFA.130 Durr, 
Goodman and Jung circumvented this problem by carrying out the IBTFA mediated 
Hofmann rearrangement on a protected Glu residue, which was subsequently converted to 
the required Gin by treatment with ammonia: scheme 10. 133 Their approach is generally 
applicable for the synthesis of PMRI peptides containing Asn and / or Gin, with 
appropriate protecting group manipulation.
The problems associated with the synthesis of gAsn are not confined to IBTFA. 
Cushman and co-workers were unable to produce satisfactorily protected gAsn from Z- 
Asn via the Curtius rearrangement using either the mixed anhydride or DPPA method of 
acyl azide synthesis.123 They apportioned blame on the side chain amide group of Asn, 
which they therefore "protected” as a nitrile during synthesis: scheme l l .123
The oxidation sensitive amino acids, tyrosine, tryptophan and methionine also 
require special attention if they are to be exposed to IBTFA. Their side chains may be 
effectively protected with Bul, For and as Met(O), respectively.69’121 IBTFA oxidises 
cysteine to cystine and cleaves or oxidises the usual cysteine protecting groups: no way 
around this problem exists, other than strategic assembly. 126
No problems have been reported with any of the other coded amino acid residues,* 
except for one report of terf-butyl ether cleavage and subsequent 2-oxazolidone, 39, 
formation with MNP-Thr(But)-NH2, 38: scheme 12.134
£ However, IBTFA does oxidise free (unprotected) a-amino acids to the corresponding aldehyde (and nitrile 







(i) IBTFA, DMF / H20  (9:1), 3 h
(ii) /V-ethylmorpholine, DMF, 5 min
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-1  % divinylbenzene
H H I Thr-Arg-Ala-Leu-Val
HN
AHoN^NH 36
Scheme 10: Synthesis of the PMRI killer-cell epitope of influenza nucleoprotein, 36.133
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CONHo CN
(i) (a) NEtg, EtOCOCI, acetone, 0°C, 15 m
C 0 2H BocN C 0 2H NaN»JH a  Q°C, «? m --------------f
H ' 3 h, 63% H (ii) BnOH, Bn, reflux, 2.5 h, 27%
CN CONH2
H,Q>, Na9C0o, acetone, A .BocN N7 ■■■2 ■> ■--■ 3 V  RncN NZ
H H H20 , r.t., 24 h, 63% ‘ h h
37
Scheme 11: Synthesis of Boc-gAsn-Z, 37.123
I  n h 2 J B T F A ^  X j * * *
M N pa ^ r
\  . o  
o  y  y►  X .NH
MNPN > T  MNPN > T  M N P N ^ > <
H II H II
0 0 O
38 39
Scheme 12: Acid catalysed deprotection of MNP-Thr(Bul)-NH2, 38, during IBTFA 
treatment.134
The IBTFA mediated Hofmann rearrangement is now the most frequently 
employed method of gem-diaminoalkyl derivative synthesis, with the above mentioned 
provisos. It is certainly the method of choice for the synthesis of peptidyl gem- 
diaminoalkyl derivatives.
(2) The Mannich reaction
Katritzky and co-workers synthesised racemic, mono-protected gem-diaminoalkyl 
compounds, 41, via the Mannich reaction of an amide, aldehyde and benzotriazole (Bt) to 
generate the (isolated) intermediate adduct, 40, and subsequent reaction with ammonia: 
scheme 13.135 Use of A-protected a-amino acid amides as the amide component gave 
peptidyl gem-diaminoalkyl derivatives.135 Although this procedure suffers from the 
drawback of unselectively producing both epimers (at the gem-diamino carbon) of the 
product, 41,§ it has the advantage of expanding the range of gem-diaminoalkyl derivatives
§ Diastereoselectivity in the generation of the intermediate, 40, was observed in some cases when an amino 
acid amide was employed. However, the Bt / NH3 displacement step proceeded with complete 
racemisation, presumably via an S ^ l mechanism. The peptidyl gem-diamino alkyl compounds, 41, were 
readily resolved during purification to provide diastereomerically pure products.135
46
easily accessible beyond those derived from a-amino acids (i.e. variation of R2 is more 
simple here than with a rearrangement method where synthesis of the appropriate a-amino
acid is necessary to produce variation far beyond the 20 coded amino acid side chains).
H




NH3, r.t. I I  J L
N' II ' |  35-100%  ^  R 1  h  N H 2DO40  41
Scheme 13: Mannich reaction leading to gem-diaminoalkyl compounds, 41. In all cases 
small quantities of the benzotriazol-2-yl isomer of the intermediate, 40, were also 
produced. 135
(3) Displacement of sulfur
Bock and co-workers synthesised orthogonally protected a-aminoglycine, 43, 
from a-hydroxy-Z-glycine, 42.136 Amidoalkylation of 2-propanethiol and subsequent 
mercuric ion mediated displacement of sulfur with tert-butyl carbamate yielded racemic 
a-Boc-amino-Z-glycine, 43(a): scheme 14.136
OH SPr1
Z N ....................................................   ' ° H
A ^ O H  PrSH, H ;S 0 4 (cat),




BocNHg (4 e q ) , Hg2*- (1.5 eg)
THF, 65°C, 2 0  h H T
O
43(a)
Scheme 14: Synthesis of orthogonally protected a-aminoglycine, 43.136 Standard 
protection, deprotection and coupling steps facilitated elaboration at either amino 
group. 136
Similarly, Badet and co-workers synthesised a-Boc-amino-Fmoc-glycine, 43(b). 
A Mannich type reaction of a carbamate, 2-propanethiol and glyoxylic acid hydrate, 44, 
furnished the intermediate 45, which yielded racemic a-Boc-amino-Fmoc-glycine, 43(b), 
upon NBS mediated displacement of sulfur: scheme 15.137 Badet and co-workers
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employed a-Boc-amino-Fmoc-glycine, 43(b), to incorporate an a-amino-glycine residue 
into an octapeptide using SPS, although they did not use it to furnish a gem-diamino 
residue in a PMRI peptide. 137
H
O O SPr' NBoc
H - ^ V 0H R ' c A n - V ° H R2° g ? NH^V FmocN'JV OH
II R1OCONH2 H II NBS H IIO O O
4 4  45  43(b)
Scheme 15: Synthesis of orthogonally protected a-aminoglycine; R1 = Bul, R2 = 9-
fluorenylmethyl, or vice versa.137
(4) From nitriles
Hayward and Morley's synthesis of the first gem-diaminoalkyl residue containing 
peptide, 48, started from succinodinitrile, 46 98 They prepared 5-imino-pyrrolidin-2-one, 
47, by cold aqueous hydrolysis of the product from succinodinitrile, 46, and ammonia; 
imino-acylation and subsequent hydrogenation yielded a (separable) mixture of the 
desired pseudodipeptide diastereomers, 48: scheme 16 98
\  \
Ph 48  Ph
Scheme 16: Synthesis of Boc-Phe-(/?,5)gGlp, 48.9s
Though theoretically general, no method based on the reduction of acylamidines, such as 
47, has since found use in PMRI peptide synthesis.
Finally, although not generally applicable to the synthesis of PMRI peptides, 
Puiggalf and Munoz-Guerra's synthesis of nylon 13 {i-c. [Gly'ip(NHCO)Gly]n}, 50, from 
malononitrile, 49, and formaldehyde using Magat's formic acid / sulfuric acid catalysed 
polymerisation, 138 is worthy of note: scheme 17.139
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Scheme 17: Synthesis of nylon 1,3, 50.
The literature contains other methods of gem-diamino derivative synthesis, but the 
resultant derivatives are unsuitable for incorporation into PMRI peptides.
(5) Decomposition
Loudon and co-workers, following on from their work on carboxy-terminal 
peptide degradation mentioned above, studied the mechanism of hydrolysis of mono- 
protected gem-diaminoalkyl compounds, 51.116>5 Under basic conditions the mechanism 
of hydrolysis is as shown in scheme 18, and the observed rates of hydrolysis were in the 
order 51(d) > 51(b) > 51(a), due to imine stabilisation in 51(d) and a better leaving group 










R’^ N H ,
R2
+ H ^ N R 32
H20
R2
A .  + NHR32
Scheme 18: Hydrolysis of gem-diaminoalkyl compounds under basic conditions; (a) R1 = 
Me, R2 = Pr1, R3 = H; (b) R1 = MeOCH2, R2 = Pr1, R3 = H; (c) R 1 = BulO, R2 = Pr', R3 = 
H; and (d) R1 = Me, R2 = Pr>, R3 = Me. 116
Under acidic conditions the mechanism shown in scheme 19 operates, with a possible 
transition state illustrated in figure 10.116
5 This is the only study of the decomposition of gem-diamino alkyl compounds of the variety encountered 
in PMRI peptides. Other researchers have studied the decomposition of gem-diamino alkyl moieties in 
different chemical contexts. 140,141
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Scheme 19: Hydrolysis of gem-diaminoalkyl compounds under acidic conditions; R1, R2 





Figure 10: Possible transition state. 116
The study of gem-diaminoalkyl compound 51(c) was limited due to its instability: under 
acidic conditions it was hydrolysed 9.2 times faster than 51(a) (at 50°C).116 This rate 
acceleration is due to the better leaving group in 51(c) overcoming its lower basicity.116
These mechanisms suggest that gem-diaminoalkyl compounds 51 with R2 = H 
should be more stable.116 The results enable an estimate of 10-50 h for the biological 
half-life of 51(a),116 and reiterate the advantage of synthesising peptidyl rather than 
mono-(carbamate) protected gem-diaminoalkyl derivatives.116
Overall the stability of monoacyl gem-diaminoalkyl compounds is much the same 
at mildly acidic and mildly basic pH, and is greater than one might expect.116 These 
mechanisms explain this stability: under basic conditions the leaving group (an amide 
anion) is poor, whereas under acidic conditions an unfavourable equilibrium must be
overcome 116
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(ii) C2 Substituted malonyl derivatives
Considerations for the coupling and direct incorporation of malonyl derivatives 
were discussed above [section l.S.l(a)(i)(l)]. Here we consider the preparation of C2 
substituted malonyl derivatives appropriate for incorporation into PMRI peptides. The 
derivatives required are substituted at C2 with an amino acid side chain and are mono- 
protected, **.53.
(J) Alkylation and partial hydrolysis ofmalonic acid diesters
This classical method provides access to many appropriate C2 substituted malonyl 
derivatives, e.g. those corresponding to Phe, Lys, Trp, Leu, Ala, His and Met. 108’121 
Deprotonation of malonic acid diesters with sodium ethoxide inhibits dialkylation by most 
electrophiles (because the monoalkyl derivative, e.g. 52, is less acidic than ethanol).142 
Partial saponification of the resultant C2 substituted diesters yields the corresponding 
monoesters: e.g. scheme 20.
HCI.H2N ^  PCI5, CHCI3i HCI.H2N ^  Boc20 , dioxane, H20 ,
°  C a C 0 3 *  °  N a 2C 0 3l 82%
O O
BocHN Diethyl malonate (2 eq),





(i) KOH (1 eq), EtOH, r.t., 2 h




Scheme 20: Synthesis of (/?,5')mLys(Boc)-OEt, 53, for incorporation into PMRI 
somatostatin, by alkylation of diethyl malonate. Overall yield 19%.143
The recent development of the allyl group as a protecting group for the C2 
hydrogen of malonates may facilitate the extension of this method to classically more 
challenging side chains. 144
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(2) Alkylation and hydrolysis o f cyanoacetates
C2 substituted malonamic acids, suitable only for carboxy terminal incorporation, 
may be synthesised by alkylation and hydrolysis of cyanoacetates, e.g. scheme 21, 
however dialkylation is a more serious problem here, due to the substrates' increased 
acidity. 142
J i  ON (a)KI, NaOEt, EtOH, r.t., 15 m J j  CN KOH, B^OH,




Scheme 21: Synthesis of wMet-NH2, 54, for incorporation into end group modified 
bombesin C-terminal nonapeptide. The product, 54, existed in equilibrium with both enol 
tautomers, but this did not prevent subsequent peptide coupling using standard 
methods. 123
(3) From Meldrum's acid
Suitable side chains may be introduced at C5 of Meldrum's acid, 55, by (1) 
reductive alkylation, or (2) a two step process via an alkylidene or a cyclopropyl 
derivative.126.145
Knoevenagel reaction of Meldrum's acid, 55, with aldehydes (or some ketones) 
and reduction by a boron reductant (in situ with borane.dimethylamine complex, 
borane.trimethylamine complex, or sodium cyanoborohydride; subsequently with sodium 
borohydride) yields mono C5 substituted Meldrum's acids, e.g. scheme 22.146-148 
Subsequent alcoholysis yields C2 substituted malonic acid monoesters. Indeed, this 
alcoholysis is sufficiently convenient that Chorev, Goodman and co-workers prepared the 
Meldrum's acid derivative of 2-benzylmalonic acid, 57, in order to obtain the 
corresponding malonic monoester, 59, by ring opening with benzyl alcohol: scheme 
23.149
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Scheme 22: Synthesis of Meldrum's acid derivative 56, corresponding to raLys(TFA), for 
incorporation into PMRI tuftsin.146
pn
59
Scheme 23: Synthesis of monobenzyl 2-benzyl malonate, 59, by alcoholysis of the 
corresponding Meldrum's acid derivative, 58.149
Alternatively, mono C5 substituted Meldrum's acids may be ring opened with 
silylated amines.150 Silylation prevents the amine acting as a base and deprotonating the 
Meldrum's acid derivative at C5.146 Thus the Meldrum's acid derivative remains in the 
keto form appropriate for the ring opening reaction. The reaction mechanism is complex 
and probably involves a cyclic transition state which utilises a vacant silicon 3d- 
orbital.150’151 Verdini and co-workers used this approach to ring open Meldrum's acid 
derivatives with amino acids or mono-protected gem-diaminoalkyl compounds which they
HO
O O
0°C, 10 m, r.t., 1 h, 45%  ^




silylated, in the same pot, with 0,N-bis(trimethylsilyl)acetamide (BSA) .126*146*152’153 
Thus they prepared H2N-D-rThr(But)-mLys(TFA), 63, scheme 24, which they 
subsequently incorporated into PMRI tuftsin. 146
H2
(a) BSA (2 eq), DCM, 
reflux, 6  h ^
Bu*Q







Scheme 24: Synthesis of H2N-D-rThr(But)-mLys(TFA), 63. This was a one-pot reaction 
and the depicted intermediates, 61 and 62, were not isolated or characterised. 146 It is 
distinctly possible that D-Thr(But)-NH2, 60, was bis-silylated under the reaction 
conditions (i.e. as 61 but with a second TMS group on the amide nitrogen).150*152 The 
silylated intermediate 62 was hydrolysed during work-up. Note that CP of -D-Thr- was 
not inverted during this procedure.
Verdini and co-workers also used this method to prepare the PMRI dipeptide 
MM>-Pheip(NHCOX^,S)Tyr(But) , 65, scheme 25, having demonstrated that 
trimethylsilylation does not adversely affect the stability of MNP-gPhe.HCl, 64.126
Dal Pozzo and co-workers, in their synthesis of a PMRI analogue, 67, of the 
growth factor Gly-His-Lys, compared BSA mediated amidative ring opening with 
alcoholysis and subsequent coupling of the Meldrum's acid C5 derivatives 66(a) and 
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Scheme 25: Synthesis of MNP-PheilXNHCOX/^SXTyrCBu1), 65, for use in SPS.126 
Excess BSA was used, and no base was necessary. 126,152,154 Again, the silylated species 
was not isolated or characterised.
Nucleophilic addition to Meldrum's acid Knoevenagel products, 68, permits access 
to C5 derivatives, 69, suitable for elaboration as above: scheme 27.126’!45


























Scheme 26: Alternative routes to Gly-Histy(NHCO)(/?,S)Lys, 67. (i) Boc-Gly-
gHis(Bom), BSA, DCM, reflux, 6 h, then 66(a), r.t., O/N. (ii) TFA, r.t., 20 m, 79%. (iii) 
Thioanisole, TFA, TMSOTf, 0°C, 30 m, 53%. (iv) PhOH, 110°C, 2.5 h + 15 m under 
reduced pressure, 74%. (v) Boc-Gly-gHis(Bom), DCC, HOBt, py, DCM, 0°C, 5 m, r.t., 3 
h, 63%. (vi) NaOH, H20 , MeOH. (vii) Nal, TMSC1, MeCN, 80°C, 6 h, 51%.155





Scheme 28: Synthesis of raXaa precursors via Meldrum's acid C5 cyclopropyl derivative, 
7 0  145,156
(4) Acylation o f text-butyl carboxylates
Acylation of the enolate of a terf-butyl carboxylate, 71, with an alkyl or benzyl 
chloroformate, 72, yields an orthogonally protected, C2 substituted malonate, 73: scheme 
29.69
O' O 0  0
Bu‘O ^W ^R1 + Q-^OR2 ► B u^'^Y ^O R 2
R1
71 72  73
Scheme 29: Synthesis of BuHD-mXaa-OR2, 73. R 1 = suitable amino acid side chain, R2 = 
alkyl or benzyl.
(5) Alkylation o f PMRI dipeptides
Campbell and co-workers found that the yield of Goldschmidt and Wick type 
reactions using C2 substituted monomalonates was lower than when using C2 
unsubstituted monomalonates.84 Thus they introduced the desired side chains ( i.e. the 
malonate C2 substituents) by specific alkylation of the PMRI dipeptides PG- 
Xaai|)(NHCO)Gly-OR2, 74: e.g. scheme 30.84
R1 O O R1 O O
I |  |  (a) KOBu* THF, 0°C A M
H H |
PG-N N 0 R 2  (b) Mel, 0°C to r.t. PG-N N OR2
74
Scheme 30: Alkylation of PMRI dipeptides containing -wzGly- to produce -mAla-; PG = 
Ac, Boc or Z; R1 = amino acid side chain; and R2 = Et or Ph.84’157 Note that this is a 
special case of the alkylation of malonic acid esters, discussed in section l.S.l(a)(iiXl).
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(6) Carboxylation o f glycine
The simplicity of malonate alkylation [(1) and (5) above] is demonstrated by 
Seebach's recent introduction of a malonyl moiety into a peptide in order to facilitate 
specific C-alkylation: e.g. scheme 31.158
PO H
(a) LDA (2 eq), TMEDA (2 eq), V 2
B o c N ^ C 0 2Bn (b) c o F2| 1 0 0 %--------------------"  B o c N j ^ C 0 2Bn
(i) Leu-OMe.HOTs, DCC, HOBt,
NMM, THF, 0 °C to  r.t., 50-70%
(ii) HCI, Et20 ,  95% 0  K1i » BooN
(iii) Boc-Leu, DCC, HOBt, NMM, ° h 
THF, 0°C to r.t., 83%
(iv) (a) Bu*OK (1.3 eq), THF, 0°C,
(b) BnBr, 0°C, 75%________ ^
CO,Me
CO,Bn
( v ) H 2, P d /C , MeOH
Scheme 31: Peptide C-alkylation facilitated by an aminomalonate moiety. 158
’N V ^ I S T  X 0 2Me 
Ph
This method necessitated the synthesis of C2 malonyl derivative 75, which does not, 
however, correspond to a coded amino acid when viewed from the PMRI peptide 
perspective. This approach is conceptually very similar to that described in section
1.5.1 (a)(ii)(4) above.
(7) Configurational lability: C2 fluorinated and bis-alkylated malonyl derivatives
None of the above syntheses of C2 substituted malonyl derivatives are 
stereoselective: all yield both epimers at C2. However, this lack of selectivity is not a 
serious consideration because the C2 malonyl position is configurationally labile during 
synthesis.*69 Many PMRI peptide epimers (at the C2 malonyl position) have been 
separated by RPHPLC and the half-lives for the epimerisation measured.69 The half-lives 
vary from minutes to days, with cyclic PMRI peptides generally displaying greater 
stability.69 Since the epimerisation occurs (with general acid-base catalysis) via a
* C2 substituted malonamic acids are more configurationally stable than C2 substituted malonic acids, *^3 
therefore the configurational stability of malonyl residues increases upon their incorporation into PMRI 
peptides.
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coplanar enol structure, the extra stability of cyclic PMRI peptides can be understood in 
terms of steric hindrance (which blocks the deprotonation) and / or conformational strain 
(which disfavours the coplanar arrangement).69’159 Because the epimers of PMRI 
analogues of peptides often display significantly different biological activities, and, 
indeed, only one can exhibit full topochemical complimentarity with the parent peptide, 
the assignment of configuration is important. Several methods of configurational 
assignment (which utilise RPHPLC retention times, degradation, iH NMR chemical 
shifts, or NOEs) have been developed.69 However, it must be borne in mind that, 
particularly in the case of epimers with short half-lives, separation and assignment may be 
futile, for subsequent epimerisation (the extent of which is difficult to predict) under assay 
conditions is a possibility, leading to blurred bioactivity results.159
Further derivatisation of the C2 malonyl position overcomes the configurational
lability.






Scheme 32: Preparation of 2-Me-mLys(Boc)-OBn, 76.160
They incorporated the racemate into a PMRI growth factor, analogous to 67, and 
separated the diastereomers by HPLC.160 The resultant PMRI growth factor retained 
biological activity.160
Welch and co-workers replaced the labile malonyl C2 proton with fluorine, 
resulting in an optically pure and configurationally stable 2-fluoro-2-benzyl malonyl 
residue which was incorporated into a (proposed) HIV-1 protease inhibitor, 79.161 The 
synthesis was somewhat tortuous: scheme 33; this idea has yet to be adopted by other
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researchers, but may prove to be very useful since a wide range of 3-fluoro p-lactams, 
analogous to 78, are available by stereoselective alkylation or aldol reaction of 77.162
o X XO O
O \— L B
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Me Fv Bn E Bn
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Scheme 33: Synthesis of a PMRI peptide containing a configurationally stable fluoro- 
malonyl residue (-mFPhe-). Ar = /?-methoxy-phenyl. 161>162
(b) Solid phase methodology
SPS of peptides employs a solid, polymeric resin as a special variety of carboxy 
terminal protecting group, to which the growing peptide chain remains attached until the 
end of the synthesis. Each residue is introduced (in amino terminal protected form) using 
some manner of carboxy terminus activation. Following amino terminal deprotection of 
the resin bound (pseudo)peptide, the cycle is repeated. Thus special considerations for 
SPS of PMRI peptides essentially concern the compatibility of the usual solution phase 
methodology with the resin.
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In this section significant examples of PMRI peptide SPS are considered, which 
demonstrate the compatibility (or otherwise) of the solution phase methodology with the 
resin bound conditions, and which introduce new or modified methodology into the SPS 
arena.
(i)IBTFA
Verdini and co-workers performed the first PMRI peptide SPS,163 and have been 
the major contributors to the development of PMRI peptide SPS. Their pioneering 
synthesis of the PMRI substance P analogue, 80, demonstrated the compatibility of 
IBTFA with the solid support (which is also displayed in scheme 10): scheme 34. It is 
noteworthy that the incorporation of malonyl-D-phenylalanine amide [step (ii), scheme 
34] required an unusually long reaction time and resulted in a ca. 20% loss of peptide, 
probably due to Leu-Met diketopiperazine formation.163 This is a symptom of the 
reduced coupling efficiency of malonates, mentioned above [section 1.5.1(a)(i)(l)\. The 
final treatment with MMA was necessary to reverse the effect of IBTFA on -Met-, i.e. to 
reduce methionine sulfoxide back to -Met-.163
Verdini and co-workers used a similar procedure to synthesise the PMRI 
bradykinin potentiating peptide analogue, Glp-Trp-Pro-Arg-Pro-Lys^NHCOXR^Phe- 
Ala-Pro (in 25% yield), which exhibited in vivo activity and enhanced resistance towards 
cleavage by ACE in vitro,164 However, in order to avoid substantial Ala-Pro 
diketopiperizine formation during malonyl coupling, the malonyl residue was 
incorporated as Ala-( R,S)mPhe- D-Lys(Boc)-NH 2-164
61
= \  p





A J k Leu-Met —O
IBTFA, H20 , DMF
TFA.
✓ Ph O/  O 0 / = \  / /




















Scheme 34: SPS of a PMRI substance P analogue, 80.163 Note the direct synthesis of the 
PMRI dipeptide unit using IBTFA (as in scheme 9).
(ii) The MNP group
Although the treatment of a resin bound malonyl-D-amino acid amide with 
IBTFA, described above [section 1.5.1(b)(i)\, is a useful method, it suffers from the 
previously discussed residue specific problems inherent to IBTFA [section 1.5.1 (a )(i)(l)\ 
plus the rather high expense of D-amino acids. It is therefore desirable (and may be 
essential) to avoid treatment of a growing, resin bound peptide chain containing Asn, Gin, 
Met, Cys, Tyr or Trp, with IBTFA if side-reactions and / or extra synthetic manipulations 
are to be avoided. This objective is readily achieved by incorporation of preformed PMRI 
dipeptides, PG-Xaaty(NHCO)Yaa (or the appropriate gem-diaminoalkyl residue
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containing fragment for the synthesis of PMRI peptides with a consecutive sequence of 
reversed bonds).t Therefore, suitably protected PMRI dipeptides are required. 
Difficulties in synthesising carbamate protected PMRI dipeptides are discussed above 
[section l,S.l(a)(i)(l)]. Boc protected PMRI dipeptides are accessible84 and compatible 
with Merrifield SPS, but have not been utilised. Verdini and co-workers found that mono 
Fmoc, trifluoroacetyl or diphenylphosphinoyl-gem-diamino alkanes were insufficiently 
stable to be useful for PMRI dipeptide synthesis.126 They therefore searched for a new 
protecting group and discovered that the (2-methyl-2-o-nitrophenoxy)-propionyl (MNP) 
group is appropriate.126
MNP protected gem-diamino alkanes may be synthesised as shown in scheme 35.
The resultant mono MNP-gem-diamino alkanes are stable for prolonged periods as their 
hydrochlorides, 81.126 When deprotonated they are sufficiently stable to be acylated 
(DCC / HOBt) by mono esters of (C2 substituted) malonic acids, and saponified to furnish 
the desired PMRI dipeptides.126 Alternatively, in situ trimethylsilylation with BSA 





NH3, MeOH (a) IBTFA
(b) cone HQ 1
Scheme 35: Synthesis of MNP-gXaa.HCl, 81.126
t  None of the other methods of gem-diamino alkyl compound synthesis, successful in solution, have been 
tried in SPS, presumably due to excessive synthetic complications.
After incorporation of the MNP-PMRI dipeptide into the resin bound peptide, the 
MNP group is removed by treatment with tin(II) chloride in DMF, conditions compatible 
with Atherton and Sheppard's SPS protocol (using either acid or base labile linkers), 
leaving the resin bound PMRI peptide, 83, ready for further elaboration: scheme 36.
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Scheme 36: Deprotection of MNP-Xaai|)(NHCO)Yaa-R3, 82.126 R3 = resin bound 
peptide chain.
As shown in scheme 12, Verdini and co-workers encountered a problem when they tried 
this approach to MNP-(gThr(But).HCl, 86. However, the desired compound was obtained 
from the acyl azide, 84, using thiophenol to trap the intermediate isocyanate, 85: scheme 
37.134
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Scheme 37: Synthesis of MNP-gThrCBu^.HCl, 86, avoiding 2-oxazolidone, 39, formation 
(c.f. scheme 12).134
This procedure has another advantage over the IBTFA method in that the resultant -gThr- 
derivative, 86, is topochemically equivalent to -Thr- [when -gThr- is obtained from -D- 
Thr-NH2 by the action of IBTFA (c.f. scheme 24) then its CP stereochemistry is non­
equivalent]. The same topochemical considerations favour this procedure for -glle-.69
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MNP-glle- caused a different problem during MNP removal. Verdini and co- 
workers experienced incomplete removal of MNP under their standard deprotection 
conditions, and resultant by-product formation during the SPS of the PMRI NT(8-13) 
analogue, Arg-Arg-Pro-Tyr-Ilex|}(NHCO)(/^S^Leu.165 They ascribed this difficulty to 
steric hindrance from the lie side chain and employed a longer deprotection time to 
minimise (though not eradicate) the problem.165
(iii) Anchorage
When preparing a PMRI peptide with a carboxy terminal malonyl residue by SPS, 
it is necessary to attach ("anchor") the malonyl residue to the solid support (via a linker). 
Therefore an ester linkage (if the target pseudopeptide has a free carboxy terminus) 
between the malonyl residue and the resin must be made. Under these conditions the 
reduced coupling efficiency of malonates [see section l.S.l(a)(i)( 1)] poses a significant 
challenge: Verdini and co-workers obtained yields of less than 15% when anchoring 
MNP-Ilex|)(NHCO)(/?,5)Leu to the Kieselguhr supported hydroxymethyl polyamide resin 
Pepsyn KA (using DCC / HOBt or BOP, with or without DMAP).165 Furthermore, model 
esterifications of MNP-Ile^(NHCO)(R,5)Leu with /?-methoxybenzyl alcohol also gave 
poor yields.165 Their solution to this problem was the in situ generation of the active 
coupling reagent carbonyl bis(V-methylimidazolium) dichloride, 89, from triphosgene, 87, 
and V-methylimidazole, 88, which gave anchorage yields of 50-70%: scheme 38.165 
Subsequent elongation (Fmoc strategy) and cleavage - deprotection yielded the desired, 




MNPN N = Pepsyn  KA
Scheme 38: Anchoring MNP-Ileip(NHCO)(/?,5)Leu using bis(A-methylimidazolium) 
dichloride, 89.165
1.5.2 Biologically active PMRI peptides.
Many biologically relevant PMRI (and end group modified retro-inverso) peptides 
have been synthesised and tested; most are hormone analogues, but there are some 
examples of protease inhibitors and sweeteners. Chorev and Goodman reviewed the 
majority of these examples.69’70 In this section we briefly cover the significant bioactive 
PMRI peptide milestones.
(a) Enkephalin
Chorev, Goodman and co-workers synthesised the first highly bioactive PMRI 
peptides, the enkephalin analogues: Tyr-D-Ala-Gly-Phei|i(NHCO)Leu-NH2 , Tyr-D-Ala- 
Gly-Pheop(NHCO)Met-NH2 , Tyr-D-Ala-Gly-gPhe-D-rLeu-For and Tyr-D-Ala-Gly-gPhe- 
D-rMet-For.102 All four analogues displayed higher activity than Met-enkephalin in an in 
vitro test, and prolonged duration of action (in vitro and in vivo), presumably because the 
modifications protect the pseudopeptides from enzymatic degradation.102 The latter two 
analogues were the more active of the four.102
Further work on PMRI enkephalins has met with more qualified success.69
(b) Protease inhibition
By applying the retro-inverso concept to thiorphan, 90, Roques and co-workers
90, is a highly potent inhibitor of both enkephalinase (K* = 3.5 nM) and a less potent 
inhibitor of ACE (Ki = 140 nM), "retro-thiorphan", 91, inhibits enkephalinase with great 
selectivity [Kj = 6 nM vs IC50 (against ACE) > 10,000 nM].166
Figure 11: Thiorphan, 90 and retro-thiophan, 91.
Retro-thiorphan, 91, and thiorphan, 90, similarly affected analgesia (due to protection of 
endogenous enkephalins) in in vivo studies.166 Crystal structures of (S)-thiorphan, 90, and 
(R)-retro-thiorphan, 91, bound to thermolysin (which shares many active site residues
enzyme (including the hydrogen bonding to the amide linkage).167
Roques and co-workers applied the same approach, and further modifications to 
the zinc metallopeptidase inhibitor kelatorphan, to similar effect. 168>169
(c) Sweeteners
As part of their on-going investigation of the structure - taste relationship of 
peptides and peptidomimetics,170 Goodman and co-workers synthesised the retro-inverso 
peptide sweeteners (based on the Asp-D-Ala-NHR motif), 92 and 93, depicted in figure 
12.171-173
achieved complete differentiation of its inhibitory activity.166 Thus, whereas thiorphan,
90 91
with enkephalinase) show that the two inhibitors utilise very similar interactions with the
“Ofe
92 93
Figure 12: Retro-inverso sweeteners.
These pseudopeptides, 92 and 93, are ca. 800 times sweeter then sucrose.171
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(d) Gastrin antagonism
Martinez and co-workers produced potent gastrin antagonists by partial retro- 
inverso modification of its carboxy terminal tetrapeptide, Trp-Met-Asp-Phe-NH2.174 The 
analogue Boc-Trp-Leu-gAsp-CO(CH2)2Ph displayed in vivo gastrin antagonism (and no 
agonism) with enhanced duration of action.174
(e) CCK
Following on from their work on gastrin, Martinez and co-workers applied the 
PMRI approach to CCK-7 and 8, (Asp-)Tyr(S0 3 ")-Met-Gly-Trp-Met-Asp-Phe-NH2.124 
Roques and co-workers also synthesised PMRI CCK-7 analogues.175 Both groups 
reversed the Met^-Gly29 bond (a major cleavage site), replaced both Met28 and Met31 
with Nle, and used amino terminal Boc protection (the latter two modifications being 
precedented176). All of these PMRI CCK-7 and 8 analogues exhibited affinity to the CNS 
CCK receptor, much lower affinity to the peripheral CCK receptor, and low functional 
potency. Martinez and co-workers' analogue with highest affinity to the CNS receptor, 
Boc-Asp-Tyr(S03_)-Nleip(NHCO)Gly-Trp-Nle-Asp-Phe-NH2, displayed lower affinity 
than B ocfN le^^IC C K ^,124 whereas Roques and co-workers' analogue, Boc-Tyr(S03")- 
Nlexp(NHCO)Gly-Trp-(N-Me)Nle-Asp-Phe-NH2, displayed higher affinity and high 
resistance to proteolysis.175
(f) Tuftsin
Tuftsin, Thr-Lys-Pro-Arg, is degraded in vivo, principally between Thr and Lys, to 
produce tripeptides which inhibit its activity. Therefore Verdini and co-workers 
synthesised the PMRI tuftsin, Thn|>(NHCO)Lys-Pro-Arg, (part of their synthesis is shown 
in scheme 22).146 This PMRI tuftsin displayed prolonged in vitro stability in human 
plasma (less than 2% hydrolysis after 50 m c.f, complete hydrolysis of tuftsin in less than 
8 m).146 It does, however, suffer hydrolysis to H2N-mLys-Pro-Arg [in accordance with 
the usual path of decomposition of ge/n-diaminoalkyl compounds, see section
1.5.1 (a)(i)(5)]ft^
Three types of in vivo test (including oral administration) demonstrated that the 
PMRI tuftsin enhanced immune responses more effectively than tuftsin itself.146
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Subsequent tests have further demonstrated the higher immunostimulatory activity of this 
PMRI tuftsin compared with natural tuftsin.177*178 The enhancement of activity is 
thought to be due to the PMRI tuftsin's resistance to peptidases and the fact that its 
hydrolysis product does not interfere with its activity.146
FAB tandem mass spectrometry revealed that, despite the stability described 
above, the PMRI tuftsin is labile under FAB conditions with the most abundant 
fragmentation processes involving the gem-diamino group.179 Indeed, it is generally the 
case for PMRI peptides that ions formed by fragmentation in the vicinity of the gem- 
diamino residue are particularly abundant, which may be interpreted as indicating lower 
bond strengths in this region.180
(g) The renaissance o f retro-inverso and end group modified retro-inverso peptides
Chorev and Goodman reviewed the recent resurgence of retro-inverso and end 
group modified retro-inverso (i.e. not partially modified retro-inverso) peptides in the 
areas of combinatorial chemistry and immunology,70 where end group modified retro- 
inverso antigens show great promise for the development of vaccines, immunomodulators 
and immunodiagnostics.181
(h) Taking the concept beyond pseudopeptides
We have seen how the PMRI peptide concept developed from end group modified 
retro-inverso and linear retro-inverso peptides, which in turn developed from cyclic retro- 
inverso peptides. The PMRI peptide concept constituted the arrival of the retro-peptide 
bond as a true peptide bond surrogate, which has been widely applied in various 
biologically relevant peptides. The retro concept has recently been applied to amide 
bonds other than those in simple peptides, i.e. in peptide nucleic acids (PNA)182*183 and 
sugar - amino acid links.184
1.5.3 Conformational implications o f partial retro-inverso modification.
(a) The amide bond itself
The retro amide bond obviously scores highly in similarity tests against the natural 
peptide bond,38*69*185 indeed, with some protocols it scores perfectly, due to symmetry.57
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However, in terms of bond dimensions and permitting identical conformers to be 
adopted, the frara-alkene surrogate ['ip(E-CH=CH)] mimics the natural peptide bond 
better than does the retro amide bond.38
(b) The new residues
As discussed in section 1.5, partial retro-inverso modification generates two new 
residues, a gem-diaminoalkyl residue and a C2 substituted malonyl residue. Their 
presence in a PMRI peptide exerts a profound influence upon its conformation, especially 
in their immediate vicinity.
Dauber-Osguthorpe and co-workers carried out a complete search of the 
conformational space available to the gem-diamino and malonyl residues derived by 
partial retro-inverso modification of Ac-Ala-NHMe (i.e. Ac-gAla-Ac and MeNH-mAla- 
NHMe) using a valence force field method. 186 The resultant Ramachandran maps3*187 
(which were similar to the previous results of Stem et a/.188*189) were compared with that 
of the parent residue. 186 For both PMRI residues the Cj regions were destabilised (€7^1, 
or the inverse y-tum, being the lowest energy conformation of Ac-Ala-NHMe), due to the 
proximity of atoms with like charges.186 The gem-diamino residue had its minimum 
energy in an extended conformation, and also local minima in equivalent helical 
conformations containing six-membered hydrogen bonded rings (a arrangement) .186 
The malonyl residue had its minimum energy in equivalent helical conformations (0$ 
arrangement) and low energy regions corresponding to extended conformations. 186 The 
reported crystal structures of appropriate gem-diaminoalkyl and malonyl residues are 
compatible with these results. *
$ Of the gem-diaminoalkyl residues one is in a helical conformation19® and seven are in 0 7 “ ! / extended
conformations.173’191-196 Of the malonyl residues five (all -mGly-) are in helical conformations197-2®® 
and three in the C-fQ / extended region. 199.201,202 por a brief survey of model pseudopeptide crystal
structures (including most PMRI examples) see reference 185.
In all the discussions of Ramachandran maps herein, the following terms are used, rather loosely, to describe 
the given, general regions of the maps:
helical - the lower left and upper right hand quadrants [in the general vicinity of the a-helical conformation, 
ca. ±(60°,60°)];3
extended - the upper left and lower right hand comers;
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From these results were deduced the implications of the incorporation of the 
modified residues into secondary structures, based on the reasoning that "a residue will be 
likely to be part of a secondary structure element if the required conformation corresponds 
to a local minimum of the energy surface of the isolated residue. Conversely, if a specific 
conformation is very unstable for an isolated residue it is not likely to be observed in this 
conformation.”186 Inter-residue interactions were also considered.186
(i) p-turns
Four residues are involved in a p-tum, with a hydrogen bond between the carbonyl 
of residue i and the NH of residue i + 3. The six types of ideal p-tum (types I, II, and III, 
and their mirror images) differ in the (<J>,x|)) angles of residues i + 1 and i + 2.3’187’203’204 
If the first amide bond of a p-tum is reversed, then so must be the third in order to enable 
the i ... i + 3 hydrogen bond to form.186 The compound modelled of this type 
[Aci|i(NHCO)Ala-Ala,i|j(NHCO)NHMe] formed no stable p-turns because the gem- 
diaminoalkyl residue has a very high energy in the conformations necessary for the i + 2 
position.186
Reversal of the second amide bond [model compound Ac-Alaip(NHCO)Ala- 
NHMe] resulted in a PMRI peptide that could form a stable type II p-tum, although an 
extended conformation was more stable.186
These predictions are supported by experimental studies. iH NMR and IR 
spectroscopic studies in solution of ButCO-Ala-Gly-NHPri and its three PMRI analogues 
demonstrated that reversal of the middle amide bond exerts little influence on the 
propensity to form p-tums, in stark contrast to reversal of the other two amide bonds.195 
However, the crystal structure of ButCO-Alax|)(NHCO)Gly-NHPri was "quasi-extended" 
with no intramolecular (only intermolecular) hydrogen bonding, whereas the parent 
peptide adopted a type II P-tum.195 Intermolecular interactions in the crystal are 
presumably responsible for this difference.
For a 9-membered hydrogen bonded ring conformation specific to PMRI peptides 
that resembles a native p-tum see section l,S.3(b)(iv)(2).
P-sheet region - the upper left hand comer, near the protein p-sheet conformation, ca. (-130°,120°)].18^
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(ii) a-helices
An a-helix has a regular hydrogen bond network between the carbonyl of residue i 
and the NH of residue i + 4, with all dipoles aligned.3*187’204 Reversal of one amide bond 
disrupts this hydrogen bond network, and brings two NHs and two carbonyls close 
together, considerably destabilising the helix.186 Reversing every third amide bond 
{model compound: Ac-[4)(NHCO)Ala3]3i|>(NHCO)NHMe} produced a helix with a 
complete hydrogen bond network similar to an a-helix.186 But it was not as stable as a 
native a-helix because the dipole alignment is less favourable and the gem-diaminoalkyl 
residues are not in their lowest energy conformation.186 No experimental studies 
applicable to such systems have been performed.
(iii) fi-sheets
p-Sheets consist of parallel or antiparallel extended peptide chains hydrogen 
bonded to each other.3*187’204 The smallest unit of a p-sheet is not one strand (i.e. one 
extended peptide chain) but two hydrogen bonded strands, since the hydrogen bonds go 
from one strand to another.204 Dauber-Osguthorpe and co-workers used three strands to 
construct model parallel and antiparallel p-sheets and calculated the energy of sheet 
formation with respect to the isolated extended strands [the model antiparallel p-sheets are 
depicted in figure 13]. In common with a-helices, indiscriminate amide bond reversal 
results in disruption of the p-sheet's hydrogen bond network and hence destabilsation. But 
by reversing every second amide bond [model strands: Ac-Alaip(NHCO)Ala- 
Alaij>(NHCO)NHMe and ActKNHCO)Ala-Ala4>(NHCO)Ala-NHMe] fully hydrogen 
bonded parallel and antiparallel p-sheets were constructed.186 Unlike natural p-sheets, 
these modified sheets have all their carbonyls pointing one way, and all their NHs 
pointing the other [see figure 13(b)], which is a similarly favourable arrangement to that 
of a native a-helix and results in strong interstrand attraction.186 Thus, stable parallel and 
antiparallel p-sheets were formed, which each had a significantly more favourable energy 
of formation than the native p-sheets in Dauber-Osguthorpe and co-workers’ study.186
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Figure 13: Model anti-parallel p-sheets: (a) native peptide; and (b) PMRI peptide with 
every second amide bond reversed (retro amide bonds indicated by arrows). Only heavy 
atoms and amide hydrogens shown. Hydrogen bonds indicated by dotted lines.186
(1) An experimental investigation
This project aimed to study the influence of retro-amide bonds on PMRI peptide 
conformation. In particular, we aimed to investigate the effects of systematic, multiple 
reversals in one molecule, and the propensity of the resultant PMRI peptide to form 
secondary structure. Founded on the theoretical study of Dauber-Osguthorpe and co- 
workers (described above),186 this project aimed specifically to investigate the PMRI 
peptide motif with every second amide bond reversed, i.e. lXaaa]>(NHCO)Yaaln with n > 
2. According to Dauber-Osguthorpe and co-workers' study, such PMRI peptides are 
expected to be able to adopt p-sheet type structures I see (iii), above].186
Prior experimental studies applicable to this motif are somewhat limited. El 
Masdouri et al. described the model PMRI peptides BulCO-gVal-COBul and MeNH- 
mVal-NHMe, in their respective crystals, as "hydrogen bonded in such a way as to form a 
parallel p-sheet structure." 196>-01 But the hydrogen bonded structures in both these cases 
are 12-membered rings, rather than the 10-membered rings found in Dauber-Osguthorpe 
and co-workers' model PMRI p-sheets [figure 13(b)], because El Masdouri et a l.'s 
crystallised model peptides do not contain both ge/n-diamino and malonyl residues.
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To the best of our knowledge the only investigation of the stability of these 10- 
membered hydrogen bonded rings formed between gem-diamino and malonyl residues is 
that of Gardner and Gellman,205 described in section 1 £3(b)(iv)(2).
Therefore this project aimed to synthesise and study the conformational behaviour 
of PMRI peptides containing the motif [Xaaxp(NHCO)Yaa]n, n ^  2.§
The one literature example of a PMRI peptide containing this motif is 
Argip(NHCO)(fi^Lys-Aspip(NHCO)(R,S)Wal-Tyr, a biologically active PMRI analogue 
of the immunomodulatory peptide thymopentin 206 However the authors made no 
specific mention of its synthesis or conformation.
For this study it was obviously necessary to make specific choices for residues 
Xaa and Yaa. We chose Yaa = Gly, in order to avoid complications caused by the 
configurational lability of malonyl residues [see section 1.5,l(a)(ii)(7)\ and Xaa = Gly (for 
simplicity) or Ala {the simplest possible side chain, and the residue used in Dauber - 
Osguthorpe and co-workers' modelling study [see section 1.5.3(b), above]}. These 
residue changes, with respect to Dauber-Osguthorpe and co-workers' modelling study, 
will exert some conformational influence. Comparison of previously reported 
experimental results and the modelling studies of both Stern et al. and Aleman and co- 
workers [section 1.5.3(b)(iv)( 1)] allow an estimate of these to be made.
The Ramachandran maps calculated by Stem et al. for the two model compounds 
MeNH-mXaa-NHMe, Xaa = Gly or Ala, are very similar,188 indicating that the presence 
of a side chain little affects the conformational preference of a malonyl residue. However, 
the region of the maps of particular interest in this project, that corresponding to the (5- 
sheet conformation, is that which most differs between the studies of Stem et al. 188 and 
Dauber-Osguthorpe and co-workers.186 In Stem et al.'s study, especially for Xaa = Gly, 
the minima in this region are very shallow and ill defined.188 It is therefore difficult to
§ Throughout this thesis the compounds studied are described as PMRI peptides. In fact the "I" is 
superfluous because they contain no inverted chiral centres, nor any that require inversion in order to 
maintain topochemical complimentarity with a natural peptide. Nevertheless the "I" is retained because the 
absence of such centres means it is not incorrect, and its retention avoids the generation of further 
nomenclature in an already overburdened field.
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deduce the effect of a side chain on the propensity of malonyl residues to adopt a P-sheet 
type conformation. The available crystal structures suggest that the absence of a side 
chain makes an extended conformation less likely: those malonyl residues in extended
conformations in the crystalline state all possess side chains.199’201’202
The Ramachandran maps calculated by Stem et al. for the two model compounds
Ac-gXaa-Ac, Xaa = Gly or Ala, display differences: there are only minima in the 
extended region for Xaa = Ala.188 Therefore the absence of a side chain in a gem- 
diamino residue disfavours an extended conformation with respect to a helical 
conformation. El Masdouri et al.'s crystal structures of B^CO-gVal-COBu1 (extended)196 
and Ac-gGly-Ac (helical)207 support this view.
Therefore of our target motifs, [Xaaip(NHCO)Gly]n (n ^  2), Xaa = Ala is expected 
to be more likely to adopt a p-sheet type structure than Xaa = Gly. Our initial targets 
were the simplest, blocked examples of this motif, i.e. n = 2. We chose Boc and OEt as 
the N- and C- terminal protecting groups respectively. This choice was made in the light 
of the previous success in synthesising PMRI peptides bearing these protecting groups 
(see section 1.5.1) and in order to investigate A-Boc deprotection methods that would 
avoid the previously described decomposition problem [see section l.S.l(a)(i)( 1)].
Thus the initial targets were Boc-Glyii>(NHCO)Gly-Glyii)(NHCO)Gly-OEt, 104, 
and Boc-Alaip(NHCO)Gly-Ala‘»j)(NHCO)Gly-OEt, which were accessible by coupling 
two PMRI dipeptide moieties [route (a), scheme 39] or disconnection to a PMRI tripeptide 
and ultimately a PMRI dipeptide [route (b), scheme 39]. For the PMRI dipeptides we 
planned to use the Goldschmidt and Wick type synthesis, previously developed in this 
department [see section l.S.l(a)(i)(l)].
Route (a) was chosen because it is simpler, more symmetrical and only uses the 
moderate yielding Goldschmidt and Wick type reaction once [for the synthesis of the 
PMRI dipeptide, as opposed to route (b), which necessitates a second Goldschmidt and 










R O O R
n ^ n M n \










A J k A OH
OEt
RX  ^OH
Scheme 39: Retrosynthesis of the target PMRI tetrapeptides (e.g. 104: R = H).
Further targets were planned: PG1 -Xaaty (NHCO)Gly-Xaaxp(NHCO)Gly-Pro-Gly - 
Xaaxp(NHCO)Gly-Xaax|)(NHCO)Gly-PG2 (e.g. 140: Xaa = Gly, PG1 = Boc and PG2 = 
OEt; or 146: Xaa = Gly, PG1 = Ac and PG2 = NH2). These PMRI decapeptides were 
designed to incorporate two of the initial target units linked by a Pro-Gly segment, which 
promotes (type II) p-tum formation.187’203*204’208"210 The resultant PMRI decapeptide 
should therefore be able to turn back on itself and form an intramolecularly hydrogen 
bonded structure analogous to a short length of antiparallel p-sheet, a structure known as a
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P-hairpin.204*211 *5 Thus, unlike the initial target PMRI tetrapeptides (e.g. 104), these 
ultimate target PMRI decapeptides (e.g. 140 and 146) constitute the smallest possible p- 
sheet unit containing our target motif (see schemes 71 and 73 for depictions of folded 140 
and 146 respectively).
A molecular modelling energy minimisation [using DISCOVER (Biosym)] was 
perform ed on Ac-Glyi[KNHCO)Gly-Glyi|)(NHCO)Gly-Pro-Gly-Glyi[>(NHCO)Gly- 
Glyty(NHCO)Gly-NHMe (i.e. a simple, blocked example of the ultimate target PMRI 
decapeptides) and snapshots are depicted in figure 14.213 This study indicated that a 
twisted p-hairpin structure [figure 14(d)] is likely to be more stable than the ideal P- 
hairpin structure [figure 14(a)]: unfavourable interactions between the carbonyls of each 
strand cause twisting, but do not overcome the favourable interstrand hydrogen bonding.
(2) Other p-sheet mimics
Studies of p-sheets using model peptides or peptidomimetics are fewer than those 
of p-tums or a-helices, largely because of the lack of simple models and because 
aggregation frequently causes insurmountable problems.187*212 Nevertheless, some 
successful P-sheet peptidomimetics have been synthesised.32*34*37 Those featuring 
modified backbones are of note here, e.g. Smith, Hirschmann and co-workers' pyrrolinine- 
based mimics,214 which have given rise to HIV-1 protease and renin inhibitors;50*215 
Kemp and co-workers' epindolidione-derived p-sheet templates; t3,28,216 Clardy, 
Schreiber and co-workers' "vinylogous polypeptides" {i.e. containing a [Xaaip(£-CH=CH- 
CONH)Yaa]n motif};217 and Ranganathan and co-workers' range of modified peptides 
containing core units -CO(CH2)nCO- (n = 0, 2... 6, or 8), or NHCOCO, many of which 
form p-sheet type structures:218"221 figure 15.
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Figure 14: Energy m inim isation snapshots of Ac-Glytp(NHCO)Gly-Glyap(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly- 
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Figure 15: Examples of P-sheet peptidomimetics featuring modified backbones, (a) A 
pyrrolinine-based mimic;214 (b) an (epindolidione-derived) templated p-sheet;216 (c) the 
"vinylogous polypeptide" backbone;217 and (d) the "oxalo-retro-peptide" MeO-rLeu- 
COCO-Leu-OMe.219’*
(iv) Other conformational studies o f PMRI peptides
Experimental and modelling studies have been performed on various PMRI 
peptides of biological significance,69«70 but these, not being model PMRI peptides, permit 
few further general conclusions to be drawn.
However two other groups of studies are generally applicable.
(1) Aleman, Puiggali and co-workers: the nylon perspective
As mentioned in section 1.5.1 (a)(i)(4), nylon 1,3 is identical to 
[Glyip(NHCO)Gly] n, 50. Thus there is interest in gem-diamino residues as components of 
nylons l,n; and malonyl residues as components of nylons n,3. Aleman, Puiggali and co- 
workers have carried out many theoretical studies on model compounds containing gem-
* The use of the term "retro" in the context of these modified peptides (that are conceptually similar to 
PMRI peptides) does not conform exactly with the definition provided in the Notes on Nomenclature 
section and used elsewhere in this thesis.
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diamino and malonyl residues, using AMI SCF-MO (i.e. quantum mechanical) 
calculations (supported by ab initio calculations); much of this work is summarised in 
their recent publication, reference 222. In that study, Aleman, Puiggali and co-workers 
built upon their earlier investigations of Me2N-wGly-NMe2,223,224 Me2N-mAla- 
NMe2,225 Me2N-mAib-NMe2,225 and Ac-gGly-Ac226 to parameterise a force field 
suitable for use with gem-diamino and malonyl residues. Their motive for this enterprise 
was the discrepancy between their earlier results and the corresponding force field 
calculations of Dauber-Osguthorpe and co-workers186 and Stem et a /.188 (discussed 
above).
Aleman, Puiggali and co-workers attributed these discrepancies to "deficiencies in 
the force Held parameters, which give a poor description of the conformational properties 
of the excessive attractive interactions, i.e. C = 0 " 'H N , or the excessive repulsive 
interactions, i.e. C = 0 " 0 = =C and NH~HN .”222 But the AMI method is not without 
criticism: Dado and Gellman showed, by comparison with their experimental studies [see 
section l.S3(b)(iv)(2)], that AMI overestimates the strength of intramolecular hydrogen
bonds. 2^ 7
The discrepancies reveal themselves in the computed Ramachandran maps for 
gem-diamino and malonyl residues: though there is overall similarity between the 
different researchers' maps, the minima are in different positions and of different energy.
Specifically, the map of Aleman and Perez for Ac-gGly-Ac only featured minima 
in the helical regions, with merely a saddle point in the p-sheet / extended region.226 ln 
the minimum energy helical conformation, Ac-gGly-Ac formed two intramolecular six- 
membered, hydrogen bonded rings226 [the helical conformations found by Dauber- 
Osguthorpe and co-workers and Stem etal. form one C6 ring: see section 1.5.3(b), above]. 
This conformation changed on inclusion of environmental effects (modelled by the 
introduction of ammonia and formaldehyde in order to mimic intermolecular hydrogen 
bonding), but a helical conformation with the intramolecular hydrogen bonds was 
maintained.226 These results are supported by experimental studies in that Ac-gGly-Ac in 
the crystalline state207 and some nylons 1 ,n228^29 adopt similar helical conformations;
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but no intramolecular hydrogen bonds were detected for Ac-gGly-Ac in solution [see 
section 1.53(b)(iv)(2)] or the solid state.207
Aleman and Perez's maps for MeHN-mGly-NHMe223 and MeHN-D-mAla- 
NHMe225 resemble each other and feature four minima in the helical region [different to 
Stern et al.'s helical conformations but similar to those of Dauber Osguthorpe and co- 
workers, and thus similarly supported by crystal structures: see section 1.53(b), above]. 
The map for MeHN-mGly-NHMe contains no other minima,223 but that for MeHN-D- 
mAla-NHMe has an additional local minimum in a more extended conformation.225 In 
the helical conformations the molecules form a six-membered, hydrogen bonded ring 
[also found by Stem et al. and Dauber Osguthorpe and co-workers: see section 1.53(b), 
above], and detected experimentally by Gellman and co-workers [see section 
1.53(b)(iv)(2)'\. Aleman and Perez found that their predicted minimum energy 
conformation of MeHN-mGly-NHMe is changed by hydration, but remains helical.224
Aleman and Puiggali computed Ramachandran maps for Ac-gAla-Ac and Ac- 
gAib-Ac using the AMI method and found reasonable agreement between them and the 
conformational preferences obtained using their newly parameterised force field 222 The 
map for Ac-gAla-Ac is broadly similar to their map for Ac-gGly-Ac, previously 
calculated (discussed above). However, in addition to helical minimum energy 
conformations, Ac-gAla-Ac was also found to posses semi-extended minima [different 
from those found by Dauber-Osguthorpe and co-workers and Stem et al. for Ac-gAla-Ac: 
see section 1.53(b), above].222 Alem£n and Puiggali further used their force field to 
model nylons 13 and 1,5 and found good correlation with the X-ray data,139’230 i.e. a 
three-fold helical structure with three hydrogen bond directions and the dihedral angles of 
the gem-di ami no residues close to those found for the model compounds; as opposed to 
the more commonly observed (for nylons m,n where m or n are odd) y structure, which 
resembles a protein p-sheet.228’229
Aleman and co-workers have further studied the PMRI peptides Ac- 
Glytji(NHCO)Gly-NHMe,231 and Ac-Gly-Glyip(NHCO)Gly-NHMe,232 as nylon models, 
using AMI and force field methods. Ac-Glyi^(NHCO)Gly-NHMe was found to posses 
helical minima, some resulting in C$ hydrogen bonded rings involving the -mGly2-
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residue carbonyls231 [similar to those found by Dauber-Osguthorpe and co-workers: see 
section 1.5.3(b), above]. When applied to an infinite nylon 1,3 chain model, results 
consistent with previous models of the crystal structure were obtained.231 Only the 
application of an unfavourable symmetry constraint produced minima in an extended / p- 
sheet conformation for Ac-Glyili(NHCO)Gly-NHMe.231 Ac-Gly-Glyi[»(NHCO)Gly- 
NHMe was computed to be rather flexible, but with a strong tendency to fold and adopt 
conformations featuring intramolecular hydrogen bonds.232 An infinite chain model 
produced two low energy conformations: an a-helix [as previously described by Dauber- 
Osguthorpe and co-workers for the corresponding alanine model sequence: see section 
1.5.3(bXn)], and a six-fold helix, stabilised by intra and intermolecular hydrogen bonds 
respectively.232 A model p-sheet structure was of higher energy because of unfavourably 
close contacts between and NH — HN .232
The conformational predictions of Aleman, Puiggali and co-workers of relevance 
to this project may be summarised as indicating that helical structures are always of lower 
energy than extended or p-sheet type structures for the gem-diamino and malonyl residue 
containing model compounds that they studied, irrespective of the nature of the side chain. 
This contrasts with the predictions of Dauber-Osguthorpe and co-workers [see section
1.5.3(b), above]. However, since Aleman, Puiggali and co-workers are primarily 
interested in nylons (i.e. infinite chains) their modelling studies do not provide any 
obvious structures to seek out in our target PMRI peptides, in order to experimentally 
confirm or refute their predictions.
(2) Geliman and co-workers: small molecules
Gellman and co-workers have conducted extensive studies on the conformation 
directing effects of noncovalent interactions, in particular hydrogen bonds, in small 
molecules in order to deduce their impact on biopolymer folding. In the course of these 
studies they have investigated some small molecules containing a malonyl residue, which 
are of interest in the PMRI peptide context.
Gellman and co-workers' results from VT IR and NMR spectroscopy (in 
dichloromethane and acetonitrile) and X-ray crystallography imply that the 9-membered
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hydrogen bonded ring conformation, depicted in figure 16, is intrinsically favourable to 
the N-malonylglycine or alanine unit.29’233-236
Figure 16: The favoured conformation of iV-malonylglycine (R2 = H) or alanine (R2 = 
Me). R 1 = H, Me, or Et; R3 = Me, Bn, 1-adamantyl.
Gellman and co-workers therefore asserted that, "the malonyl-Af-methyl-amino acid 
subunit... represents a potential alternative to the natural dipeptide subunit at residues i + 1 
and i + 2 of a p-tum."234
This folding pattern could possibly be adopted by our ultimate target PMRI 
decapeptides (e.g. 140 and 146), across residues -mGly4-Pro5-Gly6-.
Gellman and co-workers also demonstrated, using VT IR and *H NMR 
spectroscopy, that AWW-trimethylmalonamide adopts a six-membered hydrogen bonded 
ring conformation in dichloromethane solution, and less so in acetonitrile.237 A similar 
hydrogen bonded ring is found in the crystal structures of some malonamide 
derivatives.235 The detection of the hydrogen bond concurs with the predictions of Stem 
et al, Dauber-Osguthorpe and co-workers, and Aleman and Perez [c.f. section 1.53(b), 
above].
Jorgensen and co-workers explained the variations observed among association 
constants for a series of triply hydrogen bonded complexes (pertinent to nucleotide base- 
pairing) by considering the "secondary interactions" among the hydrogen bonded groups, 
i.e. electrostatic interactions between donor and acceptor atoms forced to approach each 
other due to the formation of a primary hydrogen bond.238*239 Moreover they went on to 
predict that secondary interactions would lead to greater stability for the PMRI dipeptide 
dimer depicted in figure 17(b), than for the corresponding glycine dimer, figure 17(a), 
when the hydrogen bonding groups were constrained to be planar.238
Gardner and Gellman published an experimental test (using IR spectroscopy in 
dichloromethane solution) of the latter prediction, after the work described in this thesis
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was completed.205 The model pseudopeptide for their study was Me2N-/nGly- 
Proil>(C02)Gly-gGly-Ac, 94, which should, according to Jorgensen and co-workers’ 
prediction, fold in a (3-hairpin type fashion more readily than the corresponding parent 
depsipeptide, Ac-Gly-Proi|>(C02)Gly-Gly-NMe2. However, Gardner and Gellman found 
that their IR spectroscopy data, while consistent with the two state equilibrium depicted in 
figure 18, yielded indistinguishable equilibrium constants for the parent and PMRI 
depsipeptides (K ~ 0.6, in dichloromethane).205 
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Figure 17: 10-Membered ring hydrogen bonded dimers of (a) blocked glycine, and (b) 




Figure 18: The two state equilibrium found for Me2N-wzGly-Pro,i|)(C02)Gly-gGly-Ac, 94, 
[and Ac-Gly-Proip(C02)Gly-Gly-NMe2, not shown].
Therefore secondary interactions do not increase the p-folding propensity of 94 over that 
of its parent, in this case, probably because intramolecular dipole-dipole repulsions result 
in nonplanarity of the amide groups,205 a situation that cannot arise within the rigid 
heterocyclic systems found in nucleotide bases.
In the course of their study, Gardner and Gellman also demonstrated that Ac-gGly- 
Ac exhibits no intramolecular hydrogen bonding in dichloromethane solution.73 This 
result accords with Dauber-Osguthorpe and co-workers' modelling study, which predicted 
that a six-membered hydrogen bonded ring arrangement of Ac-gAla-Ac is less stable than 
the extended conformation; but it contrasts with the predictions of Aleman and Perez, and
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Stem et al. that such an arrangement is the minimum energy conformation for Ac-gGly- 
Ac [section 1.5.3(b), above].
To the best of our knowledge this study by Gardner and Gellman is the only 
previous investigation of the 10-membered hydrogen bonded rings found in PMRI peptide 
P-sheets [see section 1.5.3(b)(iii)\
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Chapter Two: Results and Discussion
2.1 Synthesis o f Protected PMRI Tetrapeptides, Boc-Xaa NHCO)Gly-Xaa ip(NHCO)Gly -
OEt, 104,122 and 126,
2.1.1 Synthesis ofBoc-Gly ip(NHCO)Gly-Gly NHCO)Gly-OEt, 104.
(a) Synthesis ofBoc-Gly ip( NHCO)Gly-OEt, 99
The approach to Boc-Glyi^(NHCO)Gly-Glyi|>(NHCO)Gly-OEt, 104, was through 
the coupling of two protected Glyi|>(NHCO)Gly moieties. Therefore Boc- 
Gly'iiJ(NHCO)Gly-OEt, 99, was synthesised from Boc-glycine, 95, using the Goldschmidt 
and Wick type procedure previously developed in this department to synthesise PMRI 
dipeptides: scheme 40.84
(a) Bu3 N, EtOCOCI,
„  THF, 0°C, 30  m „  . . / v ^ N a  Tol, 70°C , 1 h
BocN . . .  . ,  I. ’ ------- ► BocN — :-------- :------►
H II (b) NaN3) H20 , h  II
O 0 °C, 1 h O
95 96
O O
/ s ,  HOoCCHoCOoEt (98) J L  J LBocN N ^  -  B o c N ^ N ^ ^ ^ O E t
H 70 C, 45  m H H
97  99 .25-42%
+
O^  X ^B o c N ^ N  — “N ^ "N B oc 
H H H H
100
Scheme 40: Goldschmidt and Wick type synthesis of Boc-Glyi^(NHCO)Gly-OEl. 99.
Boc-glycine, 95, was converted to the acyl azide, 96, via its mixed anhydride, and the acyl 
azide, 96, was extracted from the reaction mixture. It underwent the Curtius 
rearrangement on heating affording the isocyanate, 97, which with monoethyl malonate, 
98 (obtained from benzyl ethyl malonate by hydrogenolysis), gave Boc- 
Glyip(NHCO)Gly-OEt, 99, in 25% yield.
In the light of the yields of 60-75% obtained previously for the PMRI dipeptides, 
R1 -Xaaip(NHCO)Gly-OR2 (R1 = Z, Boc, Ac; R2 = Et, Ph; Xaa = Ala, Val, Phe), using 
this method,84 the yield of 25% for Boc-Glyip(NHCO)Gly-OEt, 99, was disappointing. 
Therefore an investigation of the reaction by-products was performed. TLC analysis 
(mixture E) indicated the presence of much Boc-glycine, 95, (which was not recovered),
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prior to the extraction of the acyl azide, 96: presumably Boc-glycine, 95, was regenerated 
by hydrolysis of the mixed anhydride upon addition of the aqueous sodium azide solution. 
TLC analysis (mixture E) of the crude crystalline product and filtrate indicated that some 
monoethyl malonate, 98, remained unreacted (more being in the filtrate than in the solid). 
The purification of Boc-Glyip(NHCO)Gly-OEt, 99, was therefore difficult, a number of 
recrystallisations being required. Comparison of our results with those of Chorev, 
Goodman and MacDonald [see scheme 5, section l.S.l(a)(i)( 1)] suggested that one of the 
(low yield) isolated by-products was the urea, 100, a fact borne out by experimentation; 
none of the other by-products could be identified.
In order to address these problems, a modified procedure was devised. In the new 
procedure only 1 eq of monoethyl malonate, 98, was used (rather than 1.2 eq in the 
original procedure) and the work-up was altered (see experimental chapter). These 
changes improved the yield to 42%, a fact attributable to greater ease of purification, and 
reduced by-product formation {possibly in accordance with Chorev, Goodman and 
MacDonald's argument relating yield of by-products with reaction mixture polarity [see 
table 2, section 1.5.1(aj(7)(7)]105}.*
(b) N- Terminal deprotection of Boc-Glyip(NHCO)Gly-OEt, 99
(i) Deprotection using hydrogen chloride
Boc-Glyi|>(NHCO)Gly-OEt, 99, was deprotected at its amino terminus using both 
hydrogen chloride and TFA. Initially deprotection using ethanolic hydrogen chloride was 
favoured because the reaction appeared to provide the desired product, 
HCl.Glyip(NHCO)Gly-OEt, 101, as a hygroscopic colourless solid, of reasonable purity, 
in quantitative yield: scheme 41. HCl.Glyi|>(NHCO)Gly-OEt, 101, could be purified, 
albeit with low recovery, by crystallisation: Furthermore, the work-up procedure was 
easier than with TFA deprotection (see experimental chapter).
* Other methods of PMRI dipeptide synthesis were investigated for Boc-Vali|>(NHCO)Gly-OEt, 116(a), see 
section 2.1.2(a).
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Scheme 41: V-Tenninal deprotection of Boc-Glyip(NHCO)Gly-OEt, 99, using ethanolic
hydrogen chloride.
This good result was somewhat surprising given the earlier finding that V-Boc 
deprotection by acid hydrolysis leads to decomposition.84 However, further experiments 
revealed that decomposition did indeed occur. The initial deprotection reactions yielded 
products, the crude !H NMR spectra of which contained a 1:1:1 triplet at 6^ 7.4 (see 
figure A l) which was mistakenly disregarded as due to either a minor impurity or 14N - 
coupling of Gly1NH3+ under the acidic conditions. This signal was absent in the 
NMR spectrum of the crystallised product. Later deprotection reactions (without 
significant procedural change) yielded crude products, the NMR spectra of which 
contained an additional G ly^N H  signal, an additional Gly2CaH2 signal [hidden by the 
water signal in figure Al(a) but visible in figure Al(b)-(d) and figure A2], and a 
broadened Gly1CaH2 signal [figure A 1(a)]. To determine whether this was merely a cis I 
trans phenomenon {i.e. slowly interconverting isomers with cis / tram configurations at 
the amide bond) variable temperature (VT) (figure A 1) and NOESY (figure A2) NMR 
experiments were performed. The NOESY spectrum was consistent with cis i tram 
isomers but coalescence of the suspected isomeric signals was not observed on increasing 
the temperature during the VT experiment. Therefore no firm conclusion can be drawn on 
the presence of amide cis / tram isomers in HCl.Glyi|j(NHCO)Gly-OEt, 101. The 
NOESY spectrum indicated exchange between the Gly1NH3+ signal and the signal at &h 
7.4, and the VT experiment showed strengthening of the 6^ 7.4 signal with increasing 
temperature. This result, reinforced by the universal degeneration of the NMR 
spectrum with increasing temperature (which failed to revert to the original on cooling to 
r.t.), suggested that the 6H 7.4 signal was due to ammonium chloride,240*241 a product of 
HCl.Glyip(NHCO)Gly-OEt, 101, decomposition. Addition of ammonium chloride to the 
NMR sample after the VT experiment and reaccumulation confirmed this assignment. 
Thus we may conclude that HCl.Glytp(NHCO)Gly-OEt, 101, decomposes under the N-
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Boc deprotection conditions, to yield ultimately ammonium chloride, formaldehyde and 
ethyl malonamate, 118, as noted by Loudon and co-workers: see scheme 19, section 
(for 101: R1 = Et02CCH2, R2 = H and R3 = H). Of these decomposition 
products, only ammonium chloride was detected conclusively (during the VT 
experiments); the final VT *H NMR spectrum [figure Al(f)] being insufficiently clear to 
allow unambiguous assignment.
Changing the deprotection medium to 4 M hydrogen chloride in 1,4-dioxane failed 
to alleviate the decomposition problems. Therefore purification by neutralisation of 
HCl.Glyxp(NHCO)Gly-OEt, 101, and extraction was attempted. However, extraction of a 
5% sodium hydrogen carbonate solution of 101 with ether (as recommended Loudon and 
DeBons for the isolation of Boc-gGly115) or ethyl acetate failed to yield any 
Gly xp(NHCO)Gly-OEt.
(ii) Deprotection using TFA
TFA is a simple alternative to hydrogen chloride for iV-Boc removal.242 A recent 
protocol, developed by Douglas and co-workers, was adopted.243 This uses triethylsilane 
(TES) as a carbocation scavenger, which increases the deprotection yield and decreases 
the reaction time.243 Thus, TFA.Glyi^NHCC^Gly-OEt, 102, was obtained from Boc- 
Glyi|>(NHCO)Gly-OEt, 99, as an intractable hygroscopic colourless glassy solid in 86% 
yield, scheme 42.
0 0 O O
^  J L  J L  TFA, TES, DCM, r.t., ^
B o c N T  N ^ ^ X E t  ’ ’ ------------- :--------^  T F A . H 2N ^ N ^ ^ x T ) E t|_| |_| 90 m, 86% £ |-|
99 102
Scheme 42: N-Terminal deprotection of Boc-Glytp(NHCO)Gly-OEt, 99, with TFA / TES.
However, the laborious work-up and intractable nature of TFA.Glyi|>(NHCO)Gly-OEt, 
102, favoured N-Boc deprotection using ethanolic hydrogen chloride until the difficulties 
described above were recognised. Hence HCl.Glyi|>(NHCO)Gly-OEt, 101, rather than 
TFA.Glyi|)(NHCO)Gly-OEt, 102, was used in the majority of the coupling reactions 
requiring Glyip(NHCO)Gly-OEt (see below). However, when these difficulties became 
known, TES was omitted during N-Boc deprotection using TFA, to no adverse effect, and
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the alternative work-up procedure, developed for TFA.Vah|>(NHCO)Gly-OEt, 119, was
furnished TFA.Glyi|)(NHCO)Gly-OEt, 102, in 90% yield [containing only a trace of 
ammonium trifluoroacetate (indicated by *H NMR spectroscopy)].
Therefore, although TV-Boc deprotection of Boc-Glyi|>(NHCO)Gly-OEt, 99, with
of the product.
(iii) NMR exchange effects
During the course of these A-Boc deprotection studies an unexpected NMR 
exchange effect was encountered. NMR spectra of HCl.Glya[)(NHCO)Gly-OEt, 101, 
(and TFA.Glyi|>(NHCO)Gly-OEt, 102) in DMSOd6 showed the expected disappearance of 
the Gly1NH3+ signal (6h 8.4, figure Al) and broadening of the Gly^NH (Sh 9.2) and 
Gly1CaH2 (6h  4.2) signals on D2O exchange. However, samples run in methanold4 
appeared disturbingly simple, containing only the usual signals at 6h 1.2 and 4.1 (<c.f. 
figure A l) and a broad singlet at 6h 4.4! An experiment with Boc-Glyip(NHCO)Gly-OEt, 
99, (to avoid any interference due to decomposition) revealed what was happening: a 
sample of Boc-Glyxp(NHCO)Gly-OEt, 99, in DMSOd6 was left to undergo D2O exchange 
for a few days prior to *H NMR accumulation. The resultant spectrum showed that not 
only the expected BocNH and G ly^N H  were exchanged, but also Gly2CaH2. This 
exchange phenomenon proved useful for signal assignment in some subsequent *H NMR 
spectra.
(c) C-Terminal deprotection o f Boc- Gly ip(NHC O )Gly-OEt, 99
Saponification of Boc-Glyi|i(NHCO)Gly-OEt, 99, gave the free acid, Boc- 
Gly'ip(NHCO)Gly, 103, as a colourless solid in 99% yield: scheme 43.
adopted [see section 2.1.2(b)(ii) and experimental chapter]. These altered conditions
hydrogen chloride is simpler practically and the hydrogen chloride salt, 101, easier to 
handle, deprotection with TFA is to be recommended, for it results in less decomposition
O O O O
NaOH, H2Q, EtOH,.
99 103
Scheme 43: Saponification of Boc-Glyip(NHCO)Gly-OEt, 99.
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(d) Coupling ofBoc-Glyip(NHCO)Gly, 103, and HCl.Glyip(NHCO)Gly-OEt, 101
With the appropriate fragments in hand, the stage was set to couple them to 
produce the PMRI tetrapeptide Boc-Glyip(NHCO)Gly-Glyip(NHCO)Gly-OEt, 104.
(i) Carbodiimide reagent mediated coupling
(1) DCC / HOBt
DCC is a well established peptide coupling reagent, successfully employed in 
PMRI peptide synthesis [see section l.S,l(a)(i)(l)]. Thus Boc-Glyi|)(NHCO)Gly, 103, 
and HCl.Glyi[>(NHCO)Gly-OEt, 101, were coupled using the standard DCC / HOBt 
conditions: scheme 44.242
Scheme 44: DCC / HOBt mediated coupling of Boc-Glyty(NHCO)Gly, 103, and 
HCl.GlyiKNHCO)Gly-OEt, 101.
Following literature work-up 242 only a trace of dicyclohexyl urea (DCU) was isolated. 
The target PMRI tetrapeptide, 104, was found to have precipitated with DCU and was 
therefore filtered off during the work-up. Attempts to separate Boc-Glyi|)(NHCO)Gly- 
Glytp(NHCO)Gly-OEt, 104 and DCU by extraction, washing, or crystallisation merely 
served to demonstrate that they display a similar solubility profile (Le. soluble in DMF 
and DMSO, moderately soluble in methanol and ethanol, and sparingly soluble in many 
other organic solvents). Column chromatography with neutral alumina as the stationary 
phase failed.!- Therefore column chromatography with silica as the stationary phase, 
eluting with chloroform / methanol / acetic acid mixtures (of increasing polarity starting
t  Thin layer chromatographs on silica plates were visualised using ninhydrin dip solution, followed by 
heating. This was less successful on alumina (and various reverse phase silica) plates, where iodine and 
ninhydrin were required, but these still only gave faint spots.
103 101
H H H H 
104
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with 95:3:2) was employed, after a qualitative test showed that this solvent system did not 
deprotect Boc-glycine, 95. Thus Boc-Glyi|>(NHCO)Gly-Glyi|j(NHCO)Gly-OEt, 104, was 
obtained in 41% crude yield (the sample was contaminated with phthalate plasticiser, 
presumably accumulated from the large quantities of solvents used in the various 
purification attempts).
(2) DIPCDI / HOBt
Di -zso-propylcarbodiimide (DIPCDI) is a commercially available carbodiimide 
coupling reagent, the urea by-product [di-zso-propyl urea (DIPU)] of which is more 
soluble in dichloromethane than is DCU.?44 DIPCDI was employed in place of DCC to 
couple Boc-Glyijj(NHCO)Gly, 103, and HCl.Glyip(NHCO)Gly-OEt, 101, (otherwise as 
scheme 44) and produced Boc-Glyi|)(NHCO)Gly-Glyij)(NHCO)Gly-OEt, 104, which 
could be readily purified and was free from DIPU. The precipitated product was collected 
and washed sequentially with THF, dichloromethane and water to provide Boc- 
Glyip(NHCO)Gly-Glyxp(NHCO)Gly-OEt, 104, in 18% yield. The low yield is attributed 
to loss of material during the washings (from which no further product, 104, could be 
recovered), a fair quantity of solvent being required to remove the by-products (DIPU is 
only ca. twice as soluble as DCU in dichloromethane244).
(3)EDC / HOSu
A third class of carbodiimide coupling reagents are water soluble and produce 
water soluble ureas.245’246 l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (EDC)246 is 
a commercially available member of this class (as the hydrochloride salt) and was used, 
with HOSu as auxiliary nucleophile, to couple Boc-Glyip(NHCO)Gly, 103, and 
HCl.Glyi[)(NHCO)Gly-OEt, 101. The change from HOBt to HOSu was made, prompted 
by the previous syntheses, to aid purification of Boc-Glyi[>(NHCO)Gly-Gly'i|)(NHCO)Gly- 
OEt, 104: qualitative experiments indicated that HOSu and 104, are more easily separated 
by column chromatography than HOBt and 104, in addition HOSu is more readily 
removed than HOBt by washing with water.247 So Boc-Glyip(NHCO)Gly, 103, and 
HCl.Glyip(NHCO)Gly-OEt, 101, were coupled using excess EDC.HC1 [the additional half
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equivalent was added after 3 days (slow reactions and / or excess coupling reagent are 
often found in EDC procedures)248-250]: scheme 45.
Scheme 45: EDC / HOSu mediated coupling of Boc-Glyi|>(NHCO)Gly, 103, and 
HCl.Gly4)(NHCO)Gly-OEt, 101.
The product, 104, was obtained in 17% yield after work-up and chromatography. 
Unreacted acid, 103, was identified by TLC, but not recovered. It was unclear whether
So all the available carbodiimide reagent mediated couplings proved 
unsatisfactory, producing the target PMRI tetrapeptide, 104, in low yield after difficult 
isolation and purification procedures.
These experiments did, however, specify criteria for a more successful coupling 
procedure: due to the solubility properties of the target, 104, any procedure using a 
partition between an organic and aqueous phase during isolation is unsuitable. A 
procedure with few by-products would greatly ease product isolation. Although many 
peptide coupling procedures have been developed, few meet these criteria.100’242 An 
ideal coupling procedure would permit isolation of the target, 104, simply by washing out 
impurities from the crude product precipitated during the reaction. These considerations, 
compounded by the generation of HOBt by many of the coupling reagents (e.g. BOP and 
HBTU) ,100 weighed against further investigation of "direct” coupling reagents.
(ii) Mixed anhydride coupling
The mixed anhydride coupling procedure fulfils the above criteria, for the only by­
products are an acid (or carbon dioxide and an alcohol in the case of carbonic anhydrides) 
and the salt of the base employed. 100 However, echoing Goodman and co-workers' earlier
O O O O
103 101
0 0 o  o
EDC.HCl (1.5 eq), HOSu, NEt3 (2 .5eq), 
THF, -5°C, 4  h, r.t., 4  days, 17%
^  BocN 
H
N ^ N  OEt
H H H
104
the difficult work-up caused the low yield or if the reaction was simply inherently low 
yielding.
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result [scheme 6 , section 1.5.1(a)(i)(l)], an attempted ethyl carbonate mixed anhydride 
coupling of Boc-Glyip(NHCO)Gly, 103, and HCl.Glyip(NHCO)Gly-OEt, 101, under 
standard conditions,251 yielded only Boc-Gly'ip(NHCO)Gly-OEt, 99 (65%), not the 
desired product, 104: scheme 46.
O O O O O
^  X X (a) EtOCOCI, NMM, ^  11 A
^ THF.- iyC.5m- B o o N ^ N ^ ^ O ^ O B
103
0 0 0 0
BocN^^N
H H H H
(b) 101, NMM, DMF, 1 0 4  ’ trace
-15°C, 30  m, r.t., 2  h O O
BocN N v  OEt 
H H
99, 65%
Scheme 46: An attempted mixed anhydride synthesis of Boc-Glyi|)(NHCO)Gly-
GlytKNHCO)Gly-OEt, 104.
This result merely served to confirm that carbonate mixed anhydride procedures 
are unsuitable for coupling malonyl residues. None of the other mixed anhydride 
procedures100 were employed in the absence of an explanation for this failure.*
(iii) Formation and coupling o f active esters
The coupling reactions employing carbodiimide reagents and auxiliary 
nucleophiles described above [section 2.1.1(d)(i)] suggested that active esters of PMRI 
dipeptides, formed in situ, are useful acylating species. Thus, the formation and isolation 
of such an active ester, followed by coupling, constitutes a suitable procedure for the 
preparation of Boc-Glyxp(NHCO)Gly-Gly'i|>(NHCO)Gly-OEt, 104, since by-products may 
be removed in both the formation and coupling steps.
* For a discussion of the mechanism of this reaction see section 2A.l(d)(iii)(3). A symmetrical anhydride 
procedure is unfeasible because malonic acids (with a C 2 hydrogen) generally form ketene type, rather than 
conventional dimeric anhydrides, e.g. the dehydration of malonic acid itself yields carbon suboxide 252
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(1) Pentafluorophenol
The pentafluorophenyl active ester Boc-Glyip(NHCO)Gly-OPfp, 105, was 
synthesised using the standard method and readily isolated, largely free from DCU, in 
64% crude yield: scheme 47.242
Scheme 47: DCC mediated synthesis of Boc-Glyi|)(NHCO)Gly-OPfp, 105.
However, the isolated active ester, 105, seemed to be impure, the purity being very 
difficult to assess as the pentafluorophenyl moiety gives rise to no detectable signals in iH
103, and the desired active ester, 105 (ratio undetermined), and TLC suggested that the 
active ester decomposed, further confusing the issue.
Given these difficulties, pentfluorophenol was rejected in favour of other leaving
groups.
(2) HOSu I DCC
Although frequently utilised in situ, HOBt esters are seldom isolated, whereas 
HOSu esters are widely used both in situ and as isolated intermediates.100 HOSu esters 
have been successfully employed in PMRI peptide synthesis.124’174’253 Therefore the 
active ester Boc-Glyx|)(NHCO)Gly-OSu, 106, was prepared using DCC, following a 
standard procedure:242 scheme 48.
O O
103
o  O Fv F
or 13C NMR spectroscopy. The material appeared to be a mixture of the starting material,
DCC, HOSu, THF,
103 106 O
Scheme 48: DCC mediated synthesis of Boc-Gly^(NHCO)Gly-OSu, 106.
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The resultant active ester, 106, (obtained in quantitative crude yield) was reasonably pure,
contaminated only by traces of DCU and unreacted acid, 103 (detected by *H NMR
spectroscopy and m.s.). Purification by crystallisation was possible but gave a low
recovery so the active ester, 106, was employed directly in subsequent coupling reactions.
Coupling of Boc-Glyif>(NHCO)Gly-OSu, 106, and HCl.Glyip(NHCO)Gly-OEt, 101,
under standard conditions,242 produced Boc-Glyili(NHCO)Gly-Glyip(NHCO)Gly-OEt,
104, in 53% yield [over the two steps from Boc-Glyty(NHCO)Gly, 103]: scheme 49.
n o  O O O o
BocN 1° 1 ,N .E y T^ 0 ► B o c N ^ N ^ ^ ^ N ^ N ^ ^ ^ ^ O E tH H r.t., 5 days, 53% H H H H
106 104
Scheme 49: Acylation of HCl.Glyip(NHCO)Gly-OEt, 101, with Boc-Glyip(NHCO)Gly- 
OSu, 106.
Isolation and purification of the product, 104, were achieved, as anticipated, by 
washing the crude precipitate with water, followed by column chromatography.
No improvements on this coupling procedure were found; changing the reaction 
solvent to DMF merely complicated product isolation, resulting in a reduced yield.
(3) Alternative synthesis ofBoc-Gly ip( NHCO )Gly-OSu, 106
An alternative preparation of active esters, developed by Benoiton et al. uses a
mixed anhydride as intermediate, rather than employing DCC.254 However this
procedure failed to give Boc-Glyt|j(NHCO)Gly-OSu, 106; the only isolated product was
Boc-Gly4)(NHCO)Gly-OBui, 107 (in 57% crude yield): scheme 50.
O O  O O O
« (a) Bu'OCOCI, NMM, BBocN N ^  OH ♦ o ^  BocN N 'OBu'H H DCM, r.t., 2 m H H
103
o  o
BocN N ^  OSu 
H H
(b) HOSu (1.5 eq), DCM, 106
NMM (1.5 eq), r.t., 3.5 h q  O
BocN N ^  OBu'
H H
107
Scheme 50: An attempted mixed anhydride synthesis of Boc-Glyij)(NHCO)Gly-OSu, 106.
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This failure provides further evidence, if any was needed, that carbonate mixed 
anhydride procedures are unsuitable for coupling malonyl residues. Indeed, the sole 
application of such procedures is the synthesis of malonate esters. A literature search 
revealed just such an application.255^ In the reaction, after generation of the mixed 
anhydride, 108, deprotonation by base results in elimination of the monoalkyl carbonate, 
110, and the formation of a ketene, 109. These two products then interact and the 
alkoxide residue of 110 is transferred to the ketene, 109, affording the enolate, 111, and 
carbon dioxide. Finally protonation yields the dialkyl malonate, 112: scheme 51.255
O O  O 0 ‘
R i C T ^ T D R 2 * * — R10 " ^ < ^ 0 R 2 + C02
112 111 
Scheme 51: The mechanism of ester formation from malonate / carbonate mixed 
anhydrides, 108.255
This process affords little scope for trapping the mixed anhydride with other nucleophiles 
(such as an amine or HOSu), so no further investigation of mixed anhydride couplings of 
malonyl residues was undertaken.
In summary, a selection of coupling procedures successfully yielded the desired 
PMRI tetrapeptide, 104 [the simplest (blocked) representative of the target compound 
class], the best of these being the HOSu active ester procedure described in section 
2.1.1(d)(iii)(2), which gave a 53% yield.
§ The same overall reaction of a carboxylic acid and a chloroformate to yield the carboxylate ester is fairly
general but requires the agency of DMAP.25^
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This yield is, however, rather moderate, though within the range of those achieved 
by Martinez and co-workers in their acylations using H2N-mPhe-OSu [51-79%, over both 
an amino terminal deprotection (or gem-diaminoalkyl residue synthesis) and coupling 
step],124’174 and close to that of Pallai et al. in their coupling of MeO-mPhe-OSu and 
Thr(Bul) (60%), from which they also recovered free acid, MeO-mPhe.253 What causes 
this moderate yield [and the general low yields experienced in Boc-Glyi|>(NHCO)Gly- 
Glyi|)(NHCO)Gly-OEt, 104, synthesis] is not obvious. Many side reactions of the acid 
component, 103, in the presence of carbodiimide reagents may be suspected: not only the 
classic side reactions such as A-acylurea formation (which should, however, be 
suppressed by the auxiliary nucleophile) ,100 but also side reactions involving ketene 
formation [as encountered in attempted mixed anhydride procedures, see sections 
\.5A(a)(i)(l), 2.1.1 (dXH) and (iiiX3)]^ although such a species could itself act as an 
acylating agent.258
However, the successful synthesis of the active ester, 106, implies that the 
problems are not attributable to DCC. Ketene formation from 106, in the presence of 
triethylamine during the coupling step is a possibility and it is not obvious where such a 
side reaction would lead.
Decomposition of the amino component, 101, during (or prior to) the coupling 
reactions is likely. According to Loudon and co-workers' study [section 1.5.1(a)(i)(5)] the 
(ultimate) products of this decomposition are ammonia, ethyl malonamate, 118, and 
formaldehyde [as discussed in section 2.1.1 (b)(i)]. Therefore a possible by-product of the 
coupling reactions is Boc-Glyxp(NHCO)Gly-NH2, resulting from ammonolysis of the 
acylating species (ammonia being a better nucleophile than a gem-diaminoalkyl residue). 
However, neither Boc-Glyt|>(NHCO)Gly-NH2 nor ethyl malonamate, 118, were isolated 
from any of the coupling reactions. *
5 The action of DCC / triethylamine on suitable carboxylic acids yields ketenes 257
* Indeed, no by-products whatsoever were isolated, though TLC indicated their presence and identified 103 
(which may merely be that carried through) in the HOSu active ester procedure.
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Other than the studies of the mixed anhydride procedure [see sections
1.5.1 (a)(i)(l) and 2.1.1(iii)(3)], no investigation of side reactions during PMRI peptide 
coupling reactions has been undertaken. Nonetheless it seems reasonable to conclude that 
the moderate yields of these reactions are caused by gem-diaminoalkyl residue 
decomposition and difficult isolation and purification of the product, 104, due to its poor 
solubility properties.
The low solubility of 104 necessitated NMR studies at low concentration (ca. 13 
mM) in DMSOd6- These conditions make conformational studies, the second aspect of 
this project, difficult. Therefore two other PMRI tetrapeptides [rather than Boc- 
Alaip(NHCO)Gly-Alaip(NHCO)Gly-OEt] with lipophilic side chains, were targeted, in 
order to produce members of the target compound class with higher solubility in organic 
solvents.
2.1.2 Synthesis ofBoc-Valq(NHCO)Gly-Valq(NHCO)Gly-OEt, 122.
Valine, with its zso-propyl side chain, is more lipophilic than glycine or alanine. 
In addition its side chain is ^-branched, a property which contributes to p-sheet 
stabilisation. 13’187’204’259*260 Therefore valine replaced alanine, the original second 
choice, as a side chain bearing gem-diamino re si due. t Thus, the PMRI tetrapeptide Boc- 
Vahi)(NHCO)Gly-Vah[>(NHCO)Gly-OEt, 122, was regarded as an appropriate target 
because it was expected to be more soluble in organic solvents than 104 and the side 
chains are in specified positions (i.e. on every other residue and not on the 
configurationally labile malonyl residues) appropriate to stabilise p-sheet formation (in 
this or subsequent, elongated PMRI peptides),204 a property of interest in this project.
The same approach to Boc-Vah|)(NHCO)Gly-Vah|>(NHCO)Gly-OEt, 122, as to 
Boc-Glyi|)(NHCO)Gly-Glyi|>(NHCO)Gly-OEt, 104, was used, Le. the coupling of two 
protected Valip(NHCO)Gly moieties.
t  Alanine has a conformational preference for a-helices rather than p-sheets.13*187’204’259’260
(a) Synthesis o f Boc- Valijj(NHCO)Gly-OEt, 116(a)
(i) The Goldschmidt and Wick type procedure
The Goldschmidt and Wick type procedure provided Boc-Valr|i(NHCO)Gly-OEt, 
116(a), in 48% yield from Boc-valine, 113(a): scheme 52.
Scheme 52: Goldschmidt and Wick type synthesis of Boc-Vah|>(NHCO)Gly-OEt, 116(a) 
and Boc-Pheip(NHCO)Gly-OEt, 116(b).
Analogous to the Boc-Gly'ip(NHCO)Gly-OEt, 99, case, Boc-valine, 113(a), 
monoethyl malonate, 98, and the urea, 117(a), were identified as by-products (by TLC or 
NMR spectroscopy), although purification of Boc-Valip(NHCO)Gly-OEt, 116(a) was 
less difficult. In order to depress regeneration of Boc-valine, 113(a), by hydrolysis during 
aqueous sodium azide addition, alternative solvents were employed. However, both 
addition of sodium azide suspended in DMF or dissolved in acetone / water resulted in 
decreased yields of Boc-Val‘ip(NHCO)Gly-OEt, 116(a) (29% and 45% respectively).
As described in section \.S.\(a)(i)(l), DPPA may be used in the synthesis of gem- 
diaminoalkyl residues. A Goldschmidt and Wick type synthesis of Boc- 
Vah|i(NHCO)Gly-OEt, 116(a), employing DPPA (based upon the procedures of 
Goodman and Chorev90 and Verdini and co-workers112) using IR spectroscopy to monitor 
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monoethyl malonate, 98, (analogous to our normal procedure, see experimental chapter) 
failed. The IR spectroscopy did indicate consumption of DPPA, some accumulation of 
isocyanate 115(a), and its subsequent disappearance after monoethyl malonate, 98, 
addition, but little product, 116(a), was isolated (<5% crude yield): scheme 53.
Pr* O O
X X X
BocN N s>* ^ O E t  
H H
116(a), <5%
Scheme 53: Attempted synthesis of Boc-Valip(NHCO)Gly-OEt, 116(a), using DPPA.
It is noteworthy that DPPA is more frequently used to generate isocyanates (or acyl azides 
for that matter) in situ rather than in isolation.110’111’261 Presumably a slow 
decomposition of these species occurs in the presence of DPPA (or its by-products) and 
the absence of a trapping nucleophile. No identifiable products were isolated from these 
reactions to enable elucidation of the reaction pathway.
Thus no improvements on the usual Goldschmidt and Wick type synthesis of Boc- 
Vah|)(NHCO)Gly-OEt, 116(a), were made.
(b) N-Terminal deprotection o f Boc-Vahp(NHCO)Gly-OEt, 116(a)
(i) Deprotection using hydrogen chloride
Treatment of Boc-Vah|>(NHCO)Gly-OEt, 116(a), with hydrogen chloride in 
ethanol or 1,4-dioxane effected Boc removal and partial decomposition. Attempts to 
obtain pure HCl.Valxp(NHCO)Gly-OEt from the resultant mixture of products {by ether 
trituration, ethyl acetate extraction of an aqueous solution, ion-exchange chromatography 
[Amberlite IR 120(+)], crystallisation or HPLC} failed. However, column 
chromatography did provide a sample of decomposition product. This isolated material 
turned out to be a mixture of ethyl malonamate, 118, and ethyl malonyl- 
Vahl>(NHCO)Gly-OEt [bis-(A^-ethylmalonyl)-l,l-diamino-2-methylpropane], 120, as 
indicated by NMR spectroscopy, 13C NMR spectroscopy and m.s. The sample of




mixed by-products was insufficient to permit separation, therefore their independent 
synthesis was undertaken, in order to confirm their identity.
(1) Synthesis o f ethyl malonamate, 118
The literature synthesis of ethyl malonamate, 118, is that due to Pinner, from ethyl 
cyanoacetate: scheme 54.
O EtO O Q Q
, J i EtOH, H C I ^  T J ] A, - EtCI ,  J l
0°C, 4h H C I .H g N ^ ^ ^ O E t
118
Scheme 54: Pinner's synthesis of ethyl malonamate, 118 262
However, having monoethyl malonate, 98, in hand, a simple EDC / HOSu 
mediated coupling with aq. ammonia was carried out, which provided ethyl malonamate,
118, in 59% yield: scheme 55.
Q Q (i) EDC.HCI, HOSu, MeCN, r.t., 75  m °  °JLA (i) NH3 /H 2 Q, r.t., O/N__________________  JL A
H O ^ ^ ' T E t  (jjj) EDC.HCI, r.t., O/N, 59% H2 N/ V ^ ^ O E t
98 118
Scheme 55: Coupling of monoethyl malonate, 98, and ammonia.
(2) Synthesis o f ethyl malonyl- Val ip(NHCO)Gly-OEt, 120
In addition to the desire to confirm the above by-products' identity, ethyl malonyl- 
Vahp(NHCO)Gly-OEt, 120, was deemed inherently interesting as a truncated member of 
the target compound class, as illustrated by the formula EtO-mGly-gVal-mGly-OEt. EDC 
/ HOSu mediated coupling of monoethyl malonate, 98, and TFA.Vali[>(NHCO)Gly-OEt,
119, provided ethyl malonyl-Valxp(NHCO)Gly-OEt, 120, in 28% yield: scheme 56.
Pr* O O 98, EDC.HCI (1.1 eq), 0  0  Pr* O O
1 1 1  HOSu, NEt3 (2  eq), L i l l i
TFA.H2N N / ^ s / / ^ O E t  THF, -10°C, 4 h, r.t., EtO'/ ^ ^ v N x ^ N >^ ^ ' ^ O E t  
H 2  days, 28% H H
119 120
Scheme 56: Coupling of monoethyl malonate, 98, and TFA.Vah|)(NHCO)Gly-OEt, 119.
The low yield resulted due to difficult isolation of ethyl malonyl-Valtp(NHCO)Gly-OEt,
120, from ethyl malonamate, 118 (either carried through with, or formed by in situ 
decomposition of TFA.Val'ip(NHCO)Gly-OEt, 119). Use of DCC instead of EDC gave a 
lower yield (18% crude).
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NMR spectroscopy, 13C NMR spectroscopy, TLC and m.s. confirmed that 
ethyl malonamate, 118, and ethyl malonyl-Vah|>(NHCO)Gly-OEt, 120, were indeed the 
by-products isolated during HCl.Vah|)(NHCO)Gly-OEt formation.
Thus we may conclude that TV-terminal deprotection of Boc-Valip(NHCO)Gly- 
OEt, 116(a), with hydrogen chloride solutions results in some decomposition to yield a 
mixture of the desired compound, plus ethyl malonamate, 118, and ethyl malonyl- 
Vah|)(NHCO)Gly-OEt, 120. The ethyl malonamate, 118, presumably derives from 
HCl.Vah|>(NHCO)Gly-OEt, according to the mechanism determined by Loudon and co- 
workers {scheme 19, section 1.5.1 (a)(i)(5) [for HCl.Valtp(NHCO)Gly-OEt: R1 = 
EtC>2CCH2, R2 = Pri and R3 = H] *}.116 However, this does not account for the formation 
of ethyl malonyl-Valip(NHCO)Gly-OEt, 120, which most probably arises from a 
transamidation reaction between HC1.Valip(NHCO)Gly-OEt and ethyl malonamate, 118 
[or a second molecule of HCl.Vahp(NHCO)Gly-OEt], under the acidic conditions: scheme
H H 
120
Scheme 57: Transamidation reaction leading to ethyl malonyl-Valip(NHCO)Gly-OEt, 
120.
(ii) Deprotection using TFA
TV-Terminal deprotection of Boc-Val'ip(NHCO)Gly-OEt, 116(a), using TFA (with 
or without TES) furnished TFA.Valt|)(NHCO)Gly-OEt, 119, in 84% crude yield (in all 
cases): scheme 58.
$ Note that the stereochemistry of HCl.Vali|)(NHCO)Gly-OEt is opposite to that depicted in scheme 19.
57.
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Scheme 58: N-Terminal deprotection of Boc-Vali|)(NHCO)Gly-OEt, 116(a), with TFA (/ 
TES).
The preferred method required no TES and utilised an alternative work-up procedure 
employing petrol to aid TFA removal and therefore prevent excessive dissolution of 
TFA.Valip(NHCO)Gly-OEt, 119, during ether trituration (see experimental chapter).263 
Some decomposition occurred under these conditions (as indicated by TLC), but the 
resultant product was sufficiently pure for use in the subsequent coupling step (as shown 
by *H NMR spectroscopy).
Thus, as in the Boc-Glyip(NHCO)Gly-OEt, 99, case, TFA is superior to hydrogen 
chloride solutions for N-Boc deprotection of Boc-Vali|)(NHCO)Gly-OEt, 116(a). 
Presumably decomposition is a greater problem during the A-deprotection of Boc- 
Vahp(NHCO)Gly-OEt, 116(a), than of Boc-Glyif)(NHCO)Gly-OEt, 99, due to the iso- 
propyl group in 116(a) stabilising the resultant iminium species [see section 
l.S.l(a)(i)(5)l
(c) C-Terminal deprotection o f Boc- Val ip(NHCO )Gly-OEt, 116(a)
Saponification of Boc-Vahj)(NHCO)Gly-OEt, 116(a), gave the free acid, Boc- 
Vahf>(NHCO)Gly, 121, in 99% yield.
(d) Coupling o f Boc- Valip( NHCO )Gly, 121, and TFA. Val ip( NHCO )Gly-OEt, 119
(i) Carbodiimide reagent mediated coupling
(l)DCCfHOBt
U nlike Boc-Gly^(NHCO)Gly-Glyil>(NHCO)Gly-OEt, 104, B oc- 
Vahp(NHCO)Gly-Valty(NHCO)Gly-OEt, 122, was expected to be sufficiently soluble in 
organic solvents to permit its efficient extraction during the standard work-up of a DCC / 
HOSu mediated coupling procedure.
Thus Boc-Vali[)(NHCO)Gly, 121, and TFA.Valip(NHCO)Gly-OEt, 119, were 
coupled under the usual conditions {i.e. as scheme 44). However, little crude Boc-
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Vahp(NHCO)Gly-Vah|>(NHCO)Gly-OEt, 122, was isolated on standard work-up,242 
indicating that it is not very soluble in organic solvents after all.
(2) EDC I HOSu
Given the disappointingly poor solubility of Boc-Vahj>(NHCO)Gly- 
Vali[>(NHCO)Gly-OEt, 122, the methods developed for Boc-Glyip(NHCO)Gly- 
Glyi[>(NHCO)Gly-OEt, 104, were applied. So Boc-Valip(NHCO)Gly, 121, and 
TFA.Vali|>(NHCO)Gly-OEt, 119, were coupled using EDC / HOSu, scheme 59, and the 
product recovered by evaporation of solvent, washing the residue with water and 
chromatography of the resultant precipitate to yield Boc-Vahl>(NHCO)Gly- 
V ahp (NHCO)Gly-OEt, 122(27%).
Scheme 59: EDC / HOSu mediated coupling of Boc-Valip(NHCO)Gly, 121, and 
TFA.Vali|)(NHCO)Gly-OEt, 119.
Although better than the corresponding synthesis of Boc-Glyi|>(NHCO)Gly- 
Gly,il)(NHCO)Gly-OEt, 104, this yield was poor, presumably for similar reasons, i.e. 
TFA.Val xp(NHCO)Gly-OEt, 119, decomposition, difficult product isolation and possibly 
other inherent complications [c.f. sections 2.1.1(d)(i)(3) and (d)(iii)(3)]. Again, no 
indicative by-products were identified, other than Boc-Vali^(NHCO)Gly, 121.
(ii) Formation and coupling o f the HOSu active ester, Boc-Valip(NHCO)Gly-OSu, 123
The HOSu active ester procedure was the method of choice for the synthesis of 
Boc-Glyip(NHCO)Gly-Glyi|>(NHCO)Gly-OEt, 104, therefore this procedure was applied 
to the synthesis of Boc-Valip(NHCO)Gly-Vahp(NHCO)Gly-OEt, 122.
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(1) HOSu / DCC
Boc-Valii)(NHCO)Gly-OSu, 123, was prepared in 87% crude yield using 
essentially the same procedure as for Boc-Glyi|>(NHCO)Gly-OSu, 106 [section
2.1.1 (d)(iii)(2)]. The resultant active ester, 123, contaminated by traces of DCU and 
HOSu (as indicated by *H NMR spectroscopy), was employed without purification in a 
coupling reaction with TFA.Vali|>(NHCO)Gly-OEt, 119, under the usual conditions: 
scheme 60.
Pr* O O Pr1 o  O Pr* Q O
B ocN ^ N ^ ^ ^ ^ O S u  I!9 ^ B o c N ^ N ^ ^ ^ N ^ N ^ ^ ^ O E tH H r.t., 3  days, 12% H H H H
123 122
Scheme 60: Acylation of TFA.Val^(NHCO)Gly-OEt, 119, with Boc-Vah|>(NHCO)Gly-
OSu, 123.
Boc-Valip(NHCO)Gly-Vah|>(NHCO)Gly-OEt, 122, was thus obtained in only 12% yield 
[over the two steps from Boc-Vali|)(NHCO)Gly, 121].
(2) DSC
In an attempt to increase this low yield, a different synthesis of Boc- 
Vah|)(NHCO)Gly-OSu, 123, was undertaken. Ogura and co-workers have developed a 
number of reagents which convert A-protected amino acids and peptides to HOSu active 
e s te rs  [i.e. A,A-disuccinimidyl carbonate (DSC ) ,264 A-succinimidyl 
diphenylphosphate,265 and A^A-disuccinimidyl oxalate266]. Thus, the reaction of DSC (3 
eq, added in 3 batches during the course of the reaction) and Boc-Vala|>(NHCO)Gly, 121, 
provided Boc-Vahp(NHCO)Gly-OSu, 123, in quantitative crude yield: scheme 61.
Pr' O O /?  °  \
B o c N ^ N ^ ^ ^ O H  + 7 —ys»
1 2 1  O DSC O
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Scheme 61: Synthesis of Boc-Valip(NHCO)Gly-OSu, 123, using DSC.
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TLC and NMR spectroscopy indicated that the resultant active ester, 123, was of 
higher purity than that obtained using DCC, contaminated only by traces of impurities 
(probably including the free acid, 121). The subsequent coupling reaction [under 
essentially the same conditions as before (scheme 60)] of the active ester, 123 (used 
without purification), with TFA.Val\|>(NHCO)Gly-OEt, 119, provided a reasonably pure 
sample of Boc-Vah])(NHCO)Gly-Vahj)(NHCO)Gly-OEt, 122, in 27% yield, without the 
need for chromatography [122 was isolated by evaporating the reaction mixture to 
dryness, washing the resultant off-white solid with water and drying under high vacuum 
over phosphorus pentoxide {i.e. the usual work-up)]. This procedure was not thoroughly 
investigated but holds promise for future development.
In summary, Boc-Valt|j(NHCO)Gly-Valilj(NHCO)Gly-OEt, 122, may be 
synthesised via the active ester, 123 (generated in situ with EDC / HOSu or in isolation 
with DSC) in moderate yield. Presumably difficulties similar to those encountered with 
the synthesis of Boc-Glyi|j(NHCO)Gly-Glyi|j(NHCC))Gly-OEt, 104 [section 2.1.1 (d)\ 
augmented by problems associated with the wo-propyl group [i.e. additional steric 
hindrance and greater decomposition of TFA.Vali|)(NHCC))Gly-OEt, 119], account for the 
low yield.
2.1.3 Synthesis ofBoc-Pheil)(NHCO)Gly-Pheip(NHCO)Gly-OEt, 126$
Phenylalanine is highly lipophilic, so the synthesis of Boc-Phei|)(NHCO)Gly- 
Phei|>(NHCO)Gly-OEt, 126, was undertaken (following the established route) with the 
expectation that it would be more soluble in organic solvents than the PMRI tetrapeptides 
104 and 122, described above. Furthermore, phenylalanine has a high p-sheet forming 
tendency.13’187’204*259
(a) Synthesis ofBoc-Pheip(NHCO)Gly-OEt, 116(b)
The Goldschmidt and Wick type procedure provided Boc-Phei|)(NHCO)Gly-OEt, 
116(b), in 20% yield from Boc-phenylalanine, 113(b): scheme 52. Again Boc-
§ The work described in this section was performed in conjunction with three final year undergraduate 
project students.2^7"2^9
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phenylalanine, 113(b), monoethyl malonate, 98, and the urea, 117(b), were identified as 
by-products (by TLC or NMR spectroscopy). An additional by-product, jV-(Boc)-1- 
amino-trans-styrene [A-(Boc)-2-phenyl-trans-ethenamine], 24(b), was isolated in this 
case, presumably formed by the mechanism proposed by Chorev, Goodman and 
MacDonald [scheme 5, section l£.l(a)(i)( 1 )].105 No significant procedural changes were 
attempted [as none of those tested on the synthesis of Boc-Valx|j(NHCO)Gly-OEt, 116(a), 
proved worthwhile: see section 2.1.2(a)] and therefore no improvement on this low yield 
was attained. The unusually low yield in this case is attributed, at least in part, to the ease 
with which the Curtius rearrangement of acyl azide 114(b) occurred (during its isolation 
effervescence was observed on standing at r.t.) thus increasing the opportunity for side 
reactions prior to product, 116(b), formation.
(b) N-Terminal deprotection of Boc-Phety(NHCO)Gly-OEt, 116(b)
(i) Deprotection using hydrogen chloride
In view of the by-product formation experienced during A-Boc deprotection of 
Boc-Glyi|>(NHCO)Gly-OEt, 99, and Boc-Valip(NHCO)Gly-OEt, 116(a), using ethanolic 
hydrogen chloride [section 2.1.1 (bXi) and 2.1.2(bXi)] it was not surprising when the same 
procedure caused substantial decomposition of Boc-Pheip(NHCO)Gly-OEt, 116(b): no 
products were isolated.
(ii) Deprotection using TFA
N-Boc deprotection of Boc-Pheip(NHCO)Gly-OEt, 116(b), using TFA (with or
without TES) furnished TFA.Pheip(NHCO)Gly-OEt, 124: scheme 62.
Bn O O Bn O O
1 1 1  TFA, TES (0  or 2 .5  eq), J L .  J L
BOCN N r ♦ on m 0/_ T F A . H , N ^ N ^ s '" ''X > E t
116(b) 124
Scheme 62: /V-Terminal deprotection of Boc-Phei|>(NHCO)Gly-OEt, 116(b), with TFA (/
TES).
The highest yield obtained was in the presence of TES (61% vs 43% in its absence). In 
both cases significant product isolation difficulties occurred due to dissolution of the
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product, 124, in ether in the presence of residual TFA. However, in the absence of TES a 
pure sample of Boc-Pheip(NHCO)Gly-OEt, 124, resulted after crystallisation.
Thus TFA again proved superior to hydrogen chloride solutions for A-Boc 
deprotection. However the yields were rather unsatisfactory in this case: presumably the
decomposition [see scheme 19, section 1.5.1(a)(i)(5)\y though no by-products were 
isolated to support this supposition.
(c) C-Terminal deprotection ofBoc-Phe xpfNHCO)Gly-OEt, 116(b)
Saponification of Boc-Phei[>(NHCO)Gly-OEt, 116(b), gave the free acid, Boc- 
Pheip(NHCO)Gly, 124, in 88% yield.
(d) Coupling o f Boc-Phexp(NHCO)Gly, 125, and TFA.Phe ip(NHCO)Gly-OEt, 124
(i) DCCI HOSu
Boc-Phei|>(NHCO)Gly, 125, and TFA.Pheip(NHCO)Gly-OEt, 124, were coupled 
following the standard procedure to provide Boc-Phetp(NHCO)Gly-Phexp(NHCO)Gly- 
OEt, 126, in 55% crude yield (contaminated by DCU), scheme 63; in this case the product 
was isolated by extraction (with ethyl acetate).
Bn O O Bn O O
Scheme 63: DCC / HOSu mediated coupling of Boc-PheT^(NHCO)Gly, 125, and 
TFA.Pheip(NHCO)Gly-OEt, 124.
(ii) EDC/HOSu
In order to procure the target PMRI tetrapeptide, 126, free from DCU, the coupling 
reagent was changed to EDC, scheme 64, which furnished pure Boc-Pheip(NHCO)Gly- 
Pheip(NHCO)Gly-OEt, 126, in 21% yield, after isolation by extraction and 
chromatography.
benzyl side chain provides additional stabilisation for the iminium species formed during
H H H
DCC, HOSu, NEt3, THF, 
-10°C, 1 h, r.t., 2 days r
125 124
Bn O O Bn O O




124 (1.1 eg), EDC.HCI (1.1 eq), HOSu, NEt3 (2.2 eq), 
>OH THF, -10°C, 3 0  m, r.t., 7  days, 21%
125
Bn O O Bn O O
BocN
H H H H
126
Scheme 64: EDC / HOSu mediated coupling of Boc-Pheip(NHCO)Gly, 125, and 
TFA.Pheip(NHCO)Gly-OEt, 124.
Thus Boc-Phei[>(NHCO)Gly-Phei|>(NHCO)Gly-OEt, 126, was synthesised in poor 
yield, again attributed to decomposition of TFA.Phetj^NHCC^Gly-OEt, 124. In both 
coupling reactions the only by-product identified was the free acid, 125. Although it was 
possible to isolate Boc-Phe\p(NHCO)Gly-Phex|)(NHCO)Gly-OEt, 126, by extraction, it 
nevertheless displayed low solubility in organic solvents and NMR experiments still had 
to be performed in DMSOd6-
Due to the particularly low yields suffered in the synthesis of Boc- 
Pheip(NHCO)Gly-OEt, 116(b) and its TV-Boc deprotection, no further work was carried 
out on this Phe series.
2.1.4 Solubilisation. " '
In order to aid chain extension of the PMRI tetrapeptides 104 and 122 in solution, 
an investigation of possible solubilisation strategies was undertaken.
(a) Solvents and additives
(i) Polar solvents
Toniolo and co-workers established by extensive studies (using quantitative IR 
absorption titrations) that the major cause of insolubility of blocked peptides is 
intermolecular self-association, often with formation of a regular p-structure.270 Their 
results show that increasing peptide chain length (from dipeptide through to hexapeptide) 
leads to increasing self-association, whereas further extension (hexapeptide through to 
decapeptide) reverses this trend.270 If these results obtained with natural peptides (C- 
terminal segments of porcine secretin)270 apply to PMRI peptides then they imply that
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some solubilisation strategy is essential, for the solubility of elongated PMRI peptides is 
expected to decline before it increases. This is a reasonable assumption because solubility 
in organic solvents decreases markedly through the PMRI dipeptide to tetrapeptide series: 
116(a) > 120 > 122; however further extension may not eventually lead to increasing 
solubility because this phenomenon for natural peptides is thought to result from a p-sheet 
to helix conformational transition.271*272 This is unlikely to occur with our target 
structural motif [see section l.S.3(bXH) and (iii)]. Toniolo and co-workers assessed the p- 
structure disruption potential displayed by numerous polar solvents.270*273 They 
concluded that DMSO destabilises self-association more effectively than DMF or 
hexamethyl phosphoramide (HMPA).270 The fluorinated alcohols 2,2,2-trifluoroethanol 
(TFE) and l,l,l,333-hexafluoro-2-propanol (HF1P) also strongly disrupt self-association, 
but a direct relationship between peptide solubility and coupling reaction yields does not 
exist.273
Narita and co-workers performed comprehensive investigations (also using 
quantitative IR absorption titrations plus solubility classification) of the p-structure 
stability of protected peptides.271*274-277 They classified organic solvents based upon 
their solvating potential for protected peptides and related this classification to the 
solvents' electron-acceptor and -donor numbers (AN and DN).275*278 In general, 
increasing the solvent AN or DN increases the solvating potential.275 Narita and co- 
workers divided the solvents they investigated into six groups.275 The fifth group [py, 
DMF, A-methyl-2-pyrrolidinone (NMP), DMSO and tributylphosphine oxide] displayed 
high solvating potential for blocked peptides up to heptapeptides, but poorer solvating 
potential for longer peptides.275 The sixth group (acetic acid, TFE, phenol, HFIP) 
displayed high solvating potential even for blocked peptides longer than an 
octapeptide.275
Qualitative tests on the solubility of Boc-Gly'ip(NHCO)Gly-Glyxp(NHCO)Gly- 
OEt, 104, in a range of solvents were performed. In ethyl acetate, ethanol, water, THF 
and dichloromethane (members of Narita and co-workers' second, third and forth 
groups)275 it is sparingly soluble. Whereas it is fairly soluble in DMF and DMSO and 
soluble in TFE and HFIP. Therefore elongation reactions may be performed in DMF,
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which is preferred over DMSO due to greater ease of removal (although DMSO may be 
necessary for further elongations as it reduces self-association better than DMF).270 DMF 
is favoured over TFE and HFIP. The latter has been described as unsuitable for 
carbodiimide mediated couplings,279 which suggests that TFE may also be unsuitable. 
Both these fluoroalcohols can form their respective esters (which are weak acylating 
agents) during coupling reactions.277*280^ However, given that TFE or HFIP and 
dichloromethane mixtures are reportedly as, or more effective than the pure fluoroalcohols 
for dissolving peptides of low solubility,274’277 a result affirmed by the dissolution of 
Boc-Glyip(NHCO)Gly-Glytp(NHCO)Gly-OEt, 104, in a mixture of HFIP and 
dichloromethane, such mixtures may be useful for elongation reactions if DMF or DMSO 
prove unsuccessful.
(ii) Additives: chaotropic salts and lithium salts
Chaotropic salts are substances that destroy the order of water when dissolved in it 
and thereby raise the solubility of hydrophobic substances in the solution. They have 
proved useful in tackling the problem of "difficult sequences" in SPS (e.g. potassium 
thiocyanate or sodium perchlorate in DMF / dichloromethane).283
Seebach and co-workers discovered that lithium halides and peptides co-solubilise 
each other in THF.288 * The effect is reversed (i.e. precipitation occurs) upon addition of 
water.288 The effect is caused by an interaction between lithium ions and (amide)
5 TFE and more so HFIP have proved useful as resin swelling solvents during SPS of so-called "difficult 
sequences",279’28* which are the SPS manifestation of solution phase insolubility. "Difficult sequences" 
are caused by incomplete solvation and thus self-association of resin bound peptides, again often with 
formation of p-structure.274’282'284 However carbodiimide mediated coupling reactions are rarely carried 
out in the presence of fluoroalcohols, except under extreme circumstances.273’28^’28^ These 
fluoroalcohols have been successfully used as (components of) chromatographic eluents during the 
purification of peptides of low solubility.28^’287
* These authors investigated various inorganic salts, of which lithium chloride, lithium bromide, lithium 
iodide, lithium perchlorate, lithium tetrafluoroborate, titanium(IV) ethoxide and titanium(IV) iyo-propoxide 
were most effective.288 The effect is also observed, to a greater or lesser extent, in other solvents: dioxane, 
dimethoxyethane, polyethylene glycol 200, acetonitrile, DMF, NMP, 3,4,5,6-tetrahydro-l,3- 
dimethylpyrimidin-2( 1 H)-one (DMPU), and water (for proteins).288-290
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carbonyl oxygens that prevents the oxygens from participating in hydrogen bonds and 
lowers the barrier to rotation about the CO-N bond.291 Seebach and co-workers further 
developed conditions for the exploitation of this co-solubilisation during coupling 
reactions in solution and SPS.290*292 Lansbury and co-workers utilised this co­
solubilisation in their work on the notoriously insoluble amyloid (5-plaque peptides. They 
found that lithium bromide in THF was an efficient solvent in this context (whereas TFE 
and 6 M aq. guanidinium thiocyanate were less successful) and applied it to coupling and 
deprotection reactions and as a solvent in gel permeation purifications.4’293’294
Boc-Glyil)(NHCO)Gly-Glyrl>(NHCO)Gly-OEt, 104, readily dissolves in 1 M 
lithium chloride in THF, but the addition of water causes precipitation. The *H NMR 
spectrum of Boc-Glyi[>(NHCO)Gly-Gly'ip(NHCO)Gly-OEt, 104, in lithium chloride / 
THFds [figure A3(b)] differs from that taken in DMS0^6 [figure A3(a)]. These changes 
are similar to those described by Seebach and co-workers for a normal peptide, i.e. the NH 
signals are shifted downfield.288 Thus, the interactions between Boc-GlyiKNHCO)Gly- 
Glyili(NHCO)Gly-OEt, 104, and lithium chloride are similar to those between the salt and 
normal peptides. Hence lithium chloride / THF provides another possible choice of 
solvent for coupling reactions leading to elongation of the PMRI tetrapeptides 104 and 
122.
(b) Complexes
Complex formation by peptides is rather common, e.g. Schneider and Kelly 
synthesised a modified peptide that adopts a p-sheet structure upon coordination of 
copper(II).295 1,3-Dicarbonyl compounds also readily form complexes with transition 
metals. Since the results with lithium chloride (described above) demonstrated the ability 
of the carbonyl groups in Boc-Glyxp(NHCO)Gly-Glyxi)(NHCO)Gly-OEt, 104, to interact 
with lithium ions, an investigation of complex formation between 104 and copper(II) and 
nickel(II) was undertaken, with the view that chelation of a metal ion by 104 could result 
in its disaggregation and thus solubilisation.
In our hands all attempts to form a copper(II) complex of Boc-Glyip(NHCO)Gly- 
Glyip(NHCO)Gly-OEt, 104, failed: stirring at r.t. with copper(II) chloride or copper(II)
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tetrafluoroborate in DMF (with or without sodium hydroxide) merely produced a physical 
mixture (indicated by an unchanged IR spectrum after removal of DMF). t
Overnight stirring at r.t. of a mixture of Boc-Glyip(NHCO)Gly-Glyip(NHCO)Gly- 
OEt, 104, and nickel(II) chloride hexahydrate in DMF, followed by evaporation produced 
a blue film that gave an altered IR spectrum with respect to that of 104 itself. However, 
further attempts to characterise this material were inconclusive and no firm statement 
regarding its nature (complex or physical mixture) can be made. Addition of water to this 
material followed by freeze-drying caused it to separate into a mixture of white and blue 
precipitates: the IR spectrum of the white portion was identical to that of Boc- 
Glyip(NHCO)Gly-Gly,i|)(NHCO)Gly-OEt, 104. Addition of THF to the blue film 
produced a mixture of white and green precipitates. Therefore it seems that even if this 
blue film was a complex formed between nickel(II) and Boc-Glyip(NHCO)Glyr 
Gly,ip(NHCO)Gly-OEt, 104, it would not be useful for solubilisation or extraction 
purposes. The investigations of complex formation ceased here.
(c) Protecting groups
The solubilising influence of terminal protecting groups on all but the shortest 
peptides is rather limited, even for macromolecular protecting groups.272 Therefore no 
investigation of alternative terminal protecting groups was undertaken [except for SPS: 
see section 2.2.2].*
Temporary blocking of backbone amide bonds of peptides deters aggregation 
through hydrogen bonding. However, as Greene and Wuts state: "Protection of the amide 
-NH is an area of protective group chemistry that has received little attention, and as a 
consequence few methods exist for amide -NH protection."296 Furthermore, most of the 
effort directed towards the development of amide protecting groups for use in peptides has 
focused on protection of the asparagine and glutamine side chains.297 Nevertheless a
* NB: 2,4-Pentanedione did form a copper(II) complex on stirring at r.t. with copper(II) chloride in DMF.
* The simplest possible TV-terminal protecting group change, from Boc to Z, was expected to aggravate the 
solubility problems.27^
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number of protecting groups suitable for temporary protection of backbone amide bonds 
have been developed, interest in this area having been revitalised by the preponderance of 
"difficult sequences" in SPS. The successful, solubilising, temporary, backbone amide 
protecting groups are: 2-hydroxy-4-methoxybenzyl (Hmb),298-300 2-hydroxybenzyl 
(Hbz),3014-methoxybenzyl (pMB),302 2,4-dimethoxybenzyl (Dm or Dmob),302-307 2,4,6- 
trimethoxybenzyl (Tmob) ,305’307 4-methoxy-2,3-dihydroxybenzyl (DHMB),308 
ferrocenylmethyl (Fern),309’310 cyclohexadienyliumiron(O) tricarbonyl (Fed),311 
Boc,312*313 Bn,302’314-316 and Bartl et al.'s range of groups derived from Mannich 
reactions (of general structure R-X-CH2-, e.g. R-X = methyloxy or phenylthio).317 
However, most of these protecting groups ( i.e. all except Boc, Bn, and those of Bartl et 
al.) are introduced by reaction at the amino terminus followed by a peptide coupling 
reaction that is greatly decelerated by the steric hindrance they present. Even the Hmb 
group, designed to aid the approach of the acylating species, suffers from slow 
couplings.298’299’301
Therefore, given the slow couplings and connected problems due to side reactions 
suffered en route to the PMRI tetrapeptides 104, 122 and 126, any measure expected to 
further impede rapid coupling was deemed unwise.
(i) Exhaustive tert-butoxycarbonylation of Boc- Val ip( NHCO)Gly-OEt, 116(a)
Ragnarsson and co-workers' method of terf-butoxycarbonylation permits 
protection at the amide itself, rather than via reductive amination and subsequent 
amidation.312’313 Thus, a suitable solubilisation strategy is available that does not 
necessitate an excessively hindered coupling step. Therefore the synthesis of Boc2- 
Xaai|j[N(Boc)CO]Yaa-OEt and its subsequent carboxy terminal deprotection and 
extension [by coupling to Xaaip(NHCO)Yaa-OEt, etc. as usual] was planned.^ This level 
of backbone amide protection is expected to be sufficient to prevent aggregation as 
previous studies indicate that blocking ca. 1 in 6 backbone amides is adequate.298’300*305
§ The Boc groups may ultimately be removed with TFA312 The free acid may be obtained by 
saponification of Boc2-Xaaxp[N(Boc)CO]Yaa-OEt,3 18 though alternative carboxy protection strategies 
might have proved necessary.3 13
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Thus Boc-Vah|>(NHCO)Gly-OEt, 116(a), was employed as a model substrate in an 
exhaustive terf-butoxycarbonylation reaction under Ragnarsson and co-workers' 
conditions,312 i.e. an attempted synthesis of Boc2-Vah|>[N(Boc)CO]Gly-OEt, 127: 
scheme 65.
Scheme 65: Exhaustive terJ-butoxycarbonylation of Boc-Valip(NHCO)Gly-OEt, 116(a).
However, this reaction effected not the expected N-acylation, but rather C- 
acylation, to produce ethyl Af-[(.S')-l-(W-Boc-amino)-2-methylpropyl]-(/?,.S,)-2-Boc- 
malonamate, 128, in 56% yield, plus 9% recovered starting material, 116(a). Whether the 
C-acylated product, 128, might have proved useful in preventing aggregation is open to 
conjecture: no further investigation was performed as it gradually reverted to starting 
material, 116(a), during characterisation. No further attempts at exhaustive tert- 
butoxycarbonylation were made because the results of Ragnarsson and co-workers 
indicated that C-acylation of malonates under these conditions is general and subsequent 
iV-acylation is very sluggish.319
This result suggested that the conditions required for benzylation (strong base / 
benzyl bromide) 314 and for Bartl et al.'s protection method (paraformaldehyde / R-X-H / 
A)317 would also result in undesired C-derivatisation, so they were not investigated.
(ii) TBDMS "protection" o f Boc-Glyip(NHCO)Gly-OEt, 99
Instead of N-protection, an attempt to derivatise the malonyl residue(s) was 
undertaken: since the malonyl residues of PMRI peptides readily enolise [see section 
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carbonyl oxygen from participating in hydrogen bonding and thus prevent aggregation. 
Thus Boc-Glyty(NHCO)Gly-OEt, 99, as a model substrate, was treated with TBDMSOTf 
and triethylamine in dichloromethane.320’321 It was unclear where silylation might occur 
(the amide oxygen seeming most probable, but the ester carbonyl oxygen or the nitrogens 
were possibilities);320 nor whether A-Boc deprotection might occur.322 The reaction was 
monitored by TLC (mixture A). After 30 m at 0°C TLC indicated a mixture of starting 
material, 99, (Rp = 0.41) and a higher running product (Rp = 0.68). The reaction was 
allowed to warm to r.t. and after a further 30 minutes TLC showed another product spot 
(Rp = 0.50). No further change occurred after another hour at r.t. so the reaction was 
worked up following the standard procedure {i.e. diluted with dichloromethane, washed 
with cold sat. sodium bicarbonate, the organic layer dried over sodium sulfate, evaporated, 
the residue taken up in ether, filtered and evaporated).320’321 Column chromatography of 
the resultant material [on silica, eluting with ethyl acetate / petrol / triethylamine 
(49:49:2)] only isolated the original product (16%, assuming monosilylated) and starting 
material, 99 (43%). Subsequent NMR spectroscopy (CDCI3) indicated that the 
isolated product had decomposed, but confirmed the presence of the TBDMS group in the 
sample (by a series of signals below 6h = lppm). TLC confirmed the presence of starting 
material, 99, in the recovered NMR sample. Thus this isolated product remains 
unidentified, but is assumed to be a silylated derivative of Boc-Glyip(NHCO)Gly-OEt, 99, 
due to its reversion thereto and the accompanying silicon compound musty smell. So it is 
not clear which of the possible products was formed and / or isolated. Due to the 
instability of the product, and the low yield, this approach to solubilisation was not 
pursued.
(d) The influence o f amino acid composition
Despite the failure of (most of) the attempted strategies, the fact that the desired 
chain extension involves incorporation of proline may weigh in favour of solubilisation. 
Proline has a very low propensity for incorporation into p-sheets,187*204’271*276 and has 
been shown to break up the p-structure of otherwise troublesome peptide 
sequences.272’286’323 Thus, the incorporation of proline during the elongation of the
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PMRI tetrapeptides 104 and 122 was expected to at least stem the tide of decreasing 
solubility, and, in conjunction with the use of polar solvents, enable further studies in 
solution.
2.2 Elongation o f the PMRI Tetrapeptides, Boc-Xaa ip(NHCO)Gly-Xaa ip(NHCO)Gly-OEt, 
104 and 122.-
Formal chain extension of PMRI tetrapeptides 104 and 122 was examined 
concurrently by solution phase synthesis and SPS, the ultimate targets being PG1- 
Xaaip(NHCO)Gly-Xaaip(NHCO)Gly-Pro-Gly-Xaailj(NHCO)Gly-Xaail)(NHCO)Gly-PG2, 
where PG1 = Boc and PG2 = OEt (e.g. 140, Xaa = Gly) or PG1 = Ac and PG2 = NH2 (e-g- 
146, Xaa = Gly), respectively.
In addition, the synthesis of truncated products, Boc-Xaaip(NHCO)Gly-Pro-Gly- 
Xaa,i|)(NHCO)Gly-OEt, 132 (Xaa = Gly) and 1 (Xaa = Val), was undertaken by solution 
phase methods only. These PMRI hexapeptides, 132 and 1, were targeted because they 
retain the key pattern of peptide bond reversal found in the ultimate targets, i.e. every 
other peptide bond is reversed, except for the Pro-Gly bond in the turn region. So, the 
PMRI hexapeptides, 132 and 1, have their first and fifth peptide bonds reversed, whereas 
the ultimate targets (e.g. 140) have their first, third, seventh, and ninth peptide bonds 
reversed. The PMRI hexapeptides, 132 and 1, are simply truncated versions of the 
ultimate target PMRI decapeptides, and as such are able to fold up in a similar fashion. 
Thus, the PMRI hexapeptides, 132 and 1, represent pertinent targets for two reasons: (1) 
they are interesting molecules in their own right and for comparison with ultimate target 
PMRI decapeptides (e.g. 140); and (2) they are synthetic intermediates on an alternative 
route to the ultimate target PMRI decapeptides (e.g. 140), which may delay the onset of 
insolubility and the resultant problems thereof.
2.2.1 Solution phase synthesis.
(a) The truncated targets, 132 and 1
The strategy for the synthesis of the truncated products, 132 and 1, was to 
minimise the number of steps that included the relatively inaccessible Xaaip(NHCO)Gly 
units. Thus, a fragment synthesis approach was adopted: the three fragments being 2 x
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[Xaaip(NHCO)Gly] and the readily accessible Pro-Gly. The order of fragment coupling 
was designed to allow the use of a mixed anhydride coupling for the last step, thereby 
furnishing the desired products, 132 and 1, relatively free from by-products and thus 
easing their purification.
(i) Synthesis o f HCLPro-Gly-OEt, 129
A standard DCC / HOBt mediated coupling of Boc-Pro and HCl.Gly-OEt provided 
Boc-Pro-Gly-OEt in ca. 75% yield. A-Terminal deprotection with ethanolic hydrogen 
chloride yielded HCl.Pro-Gly-OEt, 129 (91%).
(ii) Synthesis ofBoc-Gly ip(NHCO)Gly-Pro-Gly-Gly\p(NHCO)Gly-OEt, 132
(1) Coupling ofBoc-Glyip(NHCO)Gly, 103, and HCl.Pro-Gly-OEt, 129
Boc-Glyip(NHCO)Gly, 103, and HCl.Pro-Gly-OEt, 129, were coupled under 
standard DCC / HOSu conditions to yield Boc-Gly‘ip(NHCO)Gly-Pro-Gly-OEt, 130, 
which was isolated by extraction with dichloromethane: scheme 66. Use of DMF, rather 
than THF, as solvent gave a better yield (58% vs 37%), due to improved dissolution of 
HCl.Pro-Gly-OEt, 129.
DCC, HOSu, NEt3, DMF,
BocN N
Scheme 66: Coupling of Boc-Glyi|)(NHCO)Gly, 103, and HCl.Pro-Gly-OEt, 129.
(2) C-Terminal deprotection and elongation of Boc-Glyip(NHCO)Gly-Pro-Gly-OEt, 130 
Saponification of Boc-Glyip(NHCO)Gly-Pro-Gly-OEt, 130, gave the free acid, 
131, in 88% yield, scheme 67. For the final coupling to TFA.Glyip(NHCO)Gly-OEt, 102, 
a mixed anhydride procedure was employed without fear of the previously experienced 
side reaction [see sections 2.1,l(d)(ii) and (iiiX3)] because here the C-terminal residue 
was not wGly but plain Gly and therefore not susceptible. Thus, an /50-butyl carbonate 
mixed anhydride coupling of Boc-Glyip(NHCO)Gly-Pro-Gly, 131, and
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TFA.Glyi[>(NHCO)Gly-OEt, 102, under standard conditions,242*251 provided Boc- 
Gly,ip(NHCO)Gly-Pro-Gly-Gly'ip(NHCO)Gly-OEt, 132: scheme 67.
O
H T1 NaOH, H2Q, EtOH,
" ^ " S s E t  r.t., O/N, 8 8 % ^
O
H JJ (a) Bu'COCI, NMM, DMF, -15°C, 3 0  m
(b) 102 (1.1 eq), NEt3 (1.1 eq), DMF, *
-15°C, 30  m, r.t., O/N, 35%
H H II H H
132 0
S c h e m e  6 7 :  C-Terminal deprotection and elongation of Boc-Glyty(NHCO)Gly-Pro-Gly- 
OEt, 130.
The product, 132, proved to be insufficiently soluble in dichloromethane for its efficient 
extraction, despite the inclusion of proline in the middle of its sequence [c.f. section 
2.1.4(d)], Therefore it was isolated using a work-up procedure similar to that developed 
for Boc-Gly'ip(NHCO)Gly-Glytl>(NHCO)Gly-OEt, 104 (see experimental chapter). 
Column chromatography of the resultant crude product provided pure Boc- 
Gly^(NHCO)Gly-Pro-Gly-Glyil)(NHCO)Gly-OEt, 132, in 35% yield.
It is interesting that the yield of this coupling reaction was less than that of the 
HOSu active ester route to Boc-Gly'i|j(NHCO)Gly-Glyi|>(NHCO)Gly-OEt, 104 [see 
section 2.1.1 (d)(iii)(2)]. In the present case none of the previously discussed side 
reactions involving DCC [see section 2.1.1(d)] are possible, only those that stem from 
decomposition of the amino component, 102. This suggests that the moderate yields 
obtained in couplings to gem-diamino residues are primarily due to decomposition [a 
problem exacerbated by inherently slow couplings to malonyl residues: see section 
l.S.l(a)(i)(l)]. This problem is augmented by difficult isolation and purification for most 
of the products investigated in this project. No side reactions were observed (c.f. 
reference 100) and the only by-product identified was unreacted Boc-Gly^(NHCO)Gly- 
Pro-Gly, 131 (by TLC).





(iii) Synthesis o f Boc-Vahp(NHCO)Gly-Pro-Gly-Vahp(NHCO)Gly-OEt, 1
Much the same approach furnished Boc-Vahp(NHCO)Gly-Pro-Gly- 
Vahp(NHCO)Gly-OEt, 1: scheme 68.
Pr» O 0  / S j  0
j N ^ N ^ ^ ^ O H  + H C I.H N ^Sf'N>s^ vC 
H H II
DCC, HOSu, NEt3, DMF, 
"0 H  +H C I.H N — J  'O E t -io°C , 4 h , r.t., 6 days, 22% ;
121 129 °
Pr» o  o  o
JL X X\ jL N X NaOH, H20 , EtOH,
i f  " ^ 0 E t r.t., O/N, 78% ’
133
Pr* O O / X  u  O
|  II II \  7  f?| II (a) Bu'COCI, NMM, DMF, -15°C, 3 0  m
v ^ s"OH (b) 119 (1.1 eq), NEt3 (1 .1 eq ), DMF, ^
H H -15°C, 30  m, r.t., O/N, 18%
134 °
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N ^ - N ^ ABocN N
H H II H H
1 0
Scheme 68: Synthesis of Boc-Valtp(NHCO)Gly-Pro-Gly-Vah|KNHCO)Gly-OEt, 1.
As in the corresponding Gly series, the PMRI tetrapeptide, 133 (but not the PMRI 
hexapeptide, 1), was readily isolated by extraction with dichloromethane.
The lower coupling yields, with respect to those leading to 130 and 132, are not 
surprising in light of the previous experiences en route to Boc-Vahp(NHCO)Gly- 
Vali|>(NHCO)Gly-OEt, 122 [see section 2.1.2(d)], Indeed, ethyl malonamate, 118, was 
isolated in 19% yield from the coupling reaction of Boc-Valty(NHCO)Gly-Pro-Gly, 134, 
and TFA.Vah|>(NHCO)Gly-OEt, 119, confirming that decomposition of 119 is at least 
partially accountable for the low yield of this step. No other by-products were identified 
in this sequence of reactions, except for unreacted starting materials, 121 and 134 (by 
TLC), in their respective coupling steps.
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(b) A ttem pted synthesis o f  Boc-Glyip(NHCO)Gly-Glyip(NHCO)Gly-Pro-Gly- 
Glyip( NHCO )Gly-Gly ip(NHCO )Gly-OEt, 140
Solution phase synthesis of the ultimate targets was only attempted for Xaa = Gly,
140.
Given that the truncated product Boc-Glyip(NHCO)Gly-Pro-Gly- 
Glyi|i(NHCO)Gly-OEt, 132, did not display high solubility, it was not used as an 
intermediate en route to PMRI decapeptide, 140. Rather, a fragment coupling strategy, 
with the minimum number of coupling steps, was adopted. Thus the strategy was to 
couple two Glyi|>(NHCO)Gly-Glyi|>(NHCO)Gly fragments to Pro-Gly, rather than extend 
132 at its carboxy and amino termini (i.e. three coupling steps featuring Glyij)(NHCO)Gly 
moieties rather than four). The coupling to the A-terminus of the Pro-Gly fragment was 
expected to be sterically hindered and was therefore tackled first.
(i) C-Terminal deprotection ofBoc-Gly ip(NHCO)Gly-Gly ip(NHCO)Gly-OEt, 104
Saponification of Boc-Glyty(NHCO)Gly-Glyi|j(NHCO)Gly-OEt, 104, gave the 
free acid, 135 scheme 69, though not without a minor complication. Acidification of the 
reaction mixture with 1 M potassium hydrogen sulfate, as used in the syntheses of acids 
103, 131, etc, lead to precipitation. Attempts to isolate and wash this precipitate (with 
water or dilute acetic acid) merely resulted in its dissolution. Therefore the desired acid, 
135, was isolated by freeze-drying the aqueous reaction mixture followed by column 
chromatography [with chloroform / methanol / acetic acid (70:28:2) as eluent] of the 
resultant colourless solid.5 This procedure was unsatisfactory. Therefore an alternative 
acidification protocol was adopted. Acidification of the reaction mixture using the ion 
exchange resin Amberlite IR 120(+), decantation of the supernatant liquid (along with the 
suspended solid) and freeze-drying, provided acid 135 in 89% yield without resorting to 
chromatography.
5 Given that Boc-GlyTp(NHCO)Gly-Glyi|>(NHCO)Gly-OEt, 104, was only sparingly soluble in 
dichloromethane, an organic extraction (as used for acids 103,131, etc.) was expected and found to fail.
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(ii) Synthesis ofBoc-Gly ip(NHCO)Gly-Gly ip(NHCO)Gly-Pro-Gly-OEt, 136
In contrast to the synthesis of Boc-Glyi|>(NHCO)Gly-Gly'ip(NHCO)Gly-OEt, 104, 
there is no advantage to be gained by isolation of an active ester en route to Boc- 
Glyx|>(NHCO)Gly-Glyt|>(NHCO)Gly-Pro-Gly-OEt, 136; for its precursor, 135, already 
exhibits poor solubility. Nevertheless, the lessons learned during the synthesis of Boc- 
Glytl)(NHCO)Gly-Glytl)(NHCO)Gly-OEt, 104 [c.f. section 2.1.1 (d)], were useful and 
prompted the choice of EDC / HOSu as the coupling procedure: scheme 69.
Scheme 69: Synthesis of Boc-Glyip(NHCO)Gly-Glyip(NHCO)Gly-Pro-Gly-OEt, 136.
Boc-Glyo|)(NHCO)Gly-Gly'i|)(NHCO)Gly-Pro-Gly-OEt, 136, like its sequential 
isomer, Boc-Glyip(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly-OEt, 132, proved to be
(3-structure disrupting potential of proline [see section 2.1.4(d)]. Neither was it possible to 
follow the protocol developed for isolation of Boc-Glyip(NHCO)Gly-Glyi[)(NHCO)Gly- 
OEt, 104: very little precipitation occurred upon addition of water to the evaporated 
reaction mixture. Therefore PMRI hexapeptide 136, was isolated by column 
chromatography without any prior clean-up. Thus, PMRI hexapeptide 136, was obtained 
in 20% yield.
This yield was rather disappointing in comparison with the analogous coupling 
leading to Boc-Glyip(NHCO)Gly-Pro-Gly-OEt, 130 [58%: see section 2.2.1(a)(ii)(l)]. No 
by-products were identified, other than Boc-Glyip(NHCO)Gly-Glyt])(NHCO)Gly, 135 (by 
TLC). Presumably the characteristically poor coupling of malonyl residues [see sections 
1.5.1(a)(/)(7), 2.1.1(d) and 2.1.2(d)], augmented by isolation and purification difficulties,
(a) NaOH, H2Q, EtOH, r.t., O/N 
OEt (b) H+, 89%
Boc
129 ( 2  eq), EDC.HCI ( 2  eq), HOSu, 
‘OH NEt3 (4 eq). DMF, -10°C, 4  h, r.t.,
4  days, 20%
BocN
H
O O  O O  / S *  O
 H H H M
136 O
insufficiently soluble in dichloromethane to permit its isolation by extraction, despite the
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are to blame. Additionally, the fact that the coupling was to sterically hindered proline 
probably contributed to the low yield: side reactions such as ring opening of the 
intermediate HOSu ester, Pro-Gly diketopiperazine formation or A-acyl urea formation 
are known under these circumstances,100 although there is no direct evidence that these 
side-reactions occurred in this case [or in any of the couplings to HCl.Pro-Gly-OEt, 129 
undertaken].
Saponification of Boc-Glyip(NHCO)Gly-Glyxl)(NHCO)Gly-Pro-Gly-OEt, 136, 
followed by acidification with Amberlite IR 120(+), provided Boc-Glyip(NHCO)Gly- 
Glyip(NHCO)Gly-Pro-Gly, 138, in 84% yield, scheme 71.
(iii) N-Terminal deprotection ofBoc-Gly ip(NHCO)Gly-Gly ip(NHCO)Gly-OEt, 104
(1) Deprotection using hydrogen chloride
A-Terminal deprotection of Boc-Glyip(NHCO)Gly-Gly,il)(NHCO)Gly-OEt, 104, 
was initially performed using ethanolic hydrogen chloride and produced 
HCl.Gly,ilJ(NHCO)Gly-Glyi|)(NHCO)Gly-OEt, 139, in quantitative crude yield, but with 
some decomposition (indicated by *H NMR spectroscopy).
(2) Deprotection using TFA
In view of the decomposition problems generally experienced during N-Boc 
deprotection using hydrogen chloride [sections 2.1.1 (bXi)> 2.1.2(bXi) and 2.13(b)(i)], 
TFA was used in preference for the N-Boc deprotection of Boc-Glyip(NHCO)Gly- 
GlyxKNHCO)Gly-OEt, 104. Thus TFA.Glyip(NHCO)Gly-Glytl)(NHCO)Gly-OB. 137 of 
reasonable purity was obtained in 77% yield: scheme 70.
0 0 O O
BocN ' ^ N ' ^ ^ N ' ^ N ^ A o E, TFA, PCM, r.t., 4 h, 77%^
H H H H
104
0 0 o o
TFA.H2N ^ N  ' ^ Ss^ KOEt
H H H
137
Scheme 70: A-Terminal deprotection of Boc-Glyip(NHCO)Gly-Glyiji(NHCO)Gly-OEt, 
104, with TFA.
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(iv) Attempted coupling o f Boc-Glytp(NHCO)Gly-Glyip(NHCO)Gly-Pro-Gly, 138, and 
HA.Glyip( NHCO )Gly-Gly ip( NHCO )Gly-OEt
Two procedures that had previously proved useful in comparable coupling 
reactions were attempted for this step: EDC / HOSu and /so-butyl carbonic anhydride 
couplings. The desired reaction is depicted in scheme 71, but neither coupling procedure 
yielded any PMRI decapeptide, Boc-Glyip(NHCO)Gly-Glyil)(NHCO)Gly-Pro-Gly- 
Glyil)(NHCO)Gly-Glyip(NHCO)Gly-OEt, 140.
NaOH, H20 ,  EtOH, r.t., 
BocjST ' N '  'O Et O /N .84%
136
O O 0  0  / N *  u O
H H H H II
138
0 0 o  o
tx j L ^ K X
ii)
HA.H2N N v  N N —  OEt2 H H H
139: HA = HCI 
137: HA = TFA
140
Scheme 71: C-Terminal deprotection of Boc-Glyij)(NHCO)Gly-Glyip(NHCO)Gly-Pro- 
Gly-OEt, 136, and attempted elongation of the resultant free acid, 138. (i) 139, EDC.HC1, 
HOSu, NEt3 (2 eq), DMF, -5°C, 4 h, r.t., 9 days, (ii) (a) BuiOCOCI, NMM, DMF, -15°C, 
30 m; (b) 137 (1.1 eq), NEt3, DMF, -15°C, 30 m, r.t., O/N.
In both cases investigation of the reactions' progress by TLC provided little 
information [even with chloroform / methanol / TFE / acetic acid (85:10:3:2) as eluent]. 
In the former case, scheme 71 step (i), product isolation following the protocol developed 
for Boc-Gly'i|)(NHCO)Gly-Gly,i|j(NHCO)Gly-OEt, 104 (i.e. evaporation of the reaction 
mixture, addition of water and collection of the resultant precipitate), followed by column 
chromatography [on silica, with chloroform / methanol / acetic acid (95:3:2 increasing to
125
75:20:5 and ultimately 0:90:10)] failed to isolate any of the desired PMRI decapeptide, 
140. In the latter case, scheme 71 step (ii), the residue from evaporation of the reaction 
mixture was chromatographed on Sephadex G25, with 1 M lithium chloride in THF as 
eluent,293 but again none of the desired PMRI decapeptide, 140, was isolated. 
Furthermore in both cases no identifiable material whatsoever was isolated.
It is thus unclear whether any of the desired PMRI decapeptide, 140, was formed. 
In view of the experience with its precursors, Boc-Glyty (NHCO)Gly-Glyi^(NHCO)Gly - 
Pro-Gly-Glyti>(NHCO)Gly-Gly'ilKNHCO)Gly-OEt, 140, was certainly expected to be 
highly insoluble and thus difficult to isolate, but any further analysis of the failure of these 
abortive couplings would be merely speculative.
2.2.2 Solid phase synthesis.
(a) Strategy
The guiding principles in our choice of a SPS strategy were: (1) to use, as much as 
possible, the knowledge and methods arrived at during the solution phase synthesis; and
(2) to use the expertise and facilities within the department. Therefore, rather than form 
the gem-diamino residues on the solid support [i.e. by use of IBTFA, see section 
l.S.l(bXi)], the plan was to incorporate them within PMRI dipeptide building blocks 
(hereafter referred to as the monomers).
This decision posed the question of A-terminal protecting group choice, the 
options being Boc, Fmoc or MNP. Fmoc was chosen because it was for this protecting 
group that the in-house expertise and facilities were available. Furthermore, use of the 
Fmoc group, in conjunction with a dye, under continuous flow SPS conditions, permits 
monitoring of the progress of deprotection and acylation steps using post- and pre-column 
UV absorption measurement respectively.324-326
Previous studies of the SPS of PMRI peptides [see section 1.5.1 (b)] and our 
solution phase synthesis results suggested three areas of potential difficulty, which we 
planned to tackle as follows.
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(i) Troublesome anchorage ofmalonyl residues [see section 7.5.1(b)(iii) ]
As a free carboxy-terminus in the target PMRI decapeptide was not required, this 
potential problem could be avoided by use of the PAL-PEG-PS support.327 PAL anchors 
the (PMRI) peptide to the solid support through an amide bond and was thus expected not 
to suffer from the difficulties encountered by Verdini and co-workers with their anchorage 
by malonyl residue esterification.165 On ultimate cleavage from the resin, the PAL handle 
yields a (PMRI) peptide amide,327 which is a suitable form of C-terminal blocking for the 
purposes of this study.
(ii) Slow couplings
Slow couplings, especially between malonyl and gem-diamino residues, were 
expected from previous results, therefore we planned to manually prolong these steps until 
the UV monitoring indicated their completion. The coupling procedure chosen was 
DIPCDI / HOBt, which is frequently employed in Fmoc continuous flow SPS. This 
method was chosen because carbodiimide couplings were successful in the solution phase 
studies and the nature of SPS makes those previously experienced isolation and 
purification difficulties specific to carbodiimides [see section 2.1.1(d)(7)] irrelevant.
Standard incorporation of Gly6 and Pro5 as their Fmoc-Xaa-OPfp derivatives was 
anticipated to proceed without complications.
(iii) Decomposition o f free gem-diamino residues
In order to minimise the opportunity for decomposition of the deprotected gem- 
diamino residues [c.f section 1.5.1(a)(i)(5)], the automated, shortened, "diketopiperazine 
deprotection protocol" was selected.
(iv) A "difficult sequence"?
Given the aggregation problems experienced during solution phase synthesis, there 
was the possibility that the SPS would become that of a "difficult sequence". UV 
monitoring of the V-Fmoc deprotection peak profiles would enable assessment of this 
situation and thus permit extension of deprotection and subsequent coupling times if 
necessary.282*324
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If this problem was to become too grave then one of the previously investigated 
solubilisation strategies could be employed, e.g. resin swelling using TFE, HFIP or a 
lithium chloride solution [see section 2.1.4(a)\
(b) Synthesis o f the monomers, Fmoc-Xaa ip(NHCO )Gly, 143 (Xaa = Gly) and 144 (Xaa = 
Val)
The Fmoc group was designed to be cleaved under mild basic conditions.325’328 It 
is therefore highly unlikely that the required A-Fmoc SPS monomers, 143 and 144, could 
be synthesised from Fmoc-Xaa using our Goldschmidt and Wick type procedure (schemes 
40 and 52). The alternative is to transform Boc-Xaaa|j(NHCC))Gly into Fmoc- 
Xaai|>(NHCO)Gly. Although simple reaction sequences (and even one-pot 
transformations) exist for A-Boc to N-Z 322 N-Z to A-Boc,329»330 N-Fmoc to N-Z 331 and 
jV-Fmoc to A-Boc 332 there is no such procedure for iV-Boc to A-Fmoc. It was therefore 
necessary to effect this transformation in two steps.
(i) C-Terminal deprotection o f Boc-Xaa ip(NHCO)Gly, 103 (Xaa = Gly) and 121 (Xaa = 
Val), and subsequent introduction o f Fmoc
Treatment of Boc-Xaaip(NHCO)Gly, 103 and 121, with TFA / dichloromethane 
followed by the previously developed work-up procedure (see experimental chapter) 
yielded the corresponding fully deprotected PMRI dipeptides, 141 and 142: scheme 72. 
Neither of these products, 141 and 142, showed any trace of ammonium trifluoroacetate 
(by lH NMR spectroscopy), although TFA.Vahp(NHCO)Gly, 142, was contaminated by 
traces of by-products [one of which could be malonamic acid (as indicated by !H and 13C 
NMR spectroscopy)]. An attempt to purify TFA.Vah|>(NHCO)Gly, 142, by crystallisation 
from ethanol was unsuccessful. It is not obvious why Boc-Xaaip(NHCO)Gly, 103 and 
121, should suffer less decomposition during A-Boc deprotection than the corresponding 
ethyl esters, 99 and 116(a) [cf. sections 2.1.1 (bXii) and 2A.2(b)(ii)\
There is a selection of commercially available reagents that introduce the Fmoc 
group: Fmoc-Cl, Fmoc-N3 and Fmoc-OSu.325 Fmoc-OSu is reputedly the best reagent 
with regard to product purity 325 so it was employed, according to Paquet's procedure,333 
to prepare Fmoc-Xaa'ip(NHCO)Gly, 143 and 144: scheme 72.
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Ft °  O R O O
A .  J L  TFA, DCM, r.t., 4 0 - 1 5 0 m ..... .. ................
BocN N OH  :---------------------------------► TFA. H2N N v  OH
H H H
103: R = H 141: R = H, quantitative
121: R = Pr1 142: R = Pr1, 82%
(a) N aH C 03, H20 ,  acetone, r.t.
(b) Fmoc-OSu, r.t., O/N
(c) HCI, H20  ^
O R O O
a n a n j ^
H H
143: R = H, 92%
144: R = Pr*, 31% 145: R = H, 0%; R = Pr<, 17%
Scheme 72: Preparation of the SPS monomers, 143 and 144.
For Fmoc-Gly,il)(NHCO)Gly, 143, this synthesis was very successful, despite the 
failure of the literature work-up procedures333’334 because the product was insoluble in 
chloroform (or dichloromethane or ethyl acetate) precluding its extraction. Instead, Fmoc- 
Glyil)(NHCO)Gly, 143, was isolated by washing the precipitated crude product with 
water, and purified by column chromatography. The resultant material was contaminated 
with traces of HOSu,* but used without further purification as HOSu would not interfere 
with the SPS.
Similarly the literature work-up procedures333*334 failed for Fmoc- 
VahJj(NHCO)Gly, 144, so the method developed for the isolation and purification of 
Fmoc-Glyip(NHCO)Gly, 143 was applied. After column chromatography Fmoc- 
Vahp(NHCO)Gly, 144 was again contaminated with HOSu (crude yield 50%), which was 
removed by crystallisation from acetone / water to provide Fmoc-Vali|>(NHCO)Gly, 144, 
in 31% yield. Also isolated from the synthesis of Fmoc-Vahl)(NHCO)Gly, 144 was 9- 
fluorenylmethyl carbamate (F1110C-NH2), 145, which derives from the decomposition of
* NMR spectroscopy indicated that the ratio of Fmoc-GlyT|)(NHCO)Gly, 143 to HOSu was 94:6; 
therefore the corrected yield of Fmoc-Glyip(NHCO)Gly, 143 is 90%. Crystallisation from ethanol gave 
pure Fmoc-Glyip(NHCO)Gly, 143 containing retained ethanol, which certainly would interfere with the 
SPS.
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TFA.Valip(NHCO)Gly, 142 under (or prior to) the conditions of the Fmoc introduction. 
There was no sign of this by-product in the synthesis of Fmoc-Glyil>(NHCC))Gly, 143, 
presumably because the absence of a side chain makes TFA.Gly'ip(NHCO)Gly, 141 more 
resistant to decomposition [the zso-propyl side chain of TFA.Vali|)(NHCC))Gly, 142 
stabilises the intermediate iminium species on the decomposition pathway: c.f. sections
1.5.1 (a)(i)(5) and 2.1.2(bXi)]- Alternative methods of Fmoc introduction325 might 
improve the yield of Fmoc-Vah|j(NHCO)Gly, 144, but none were attempted. 
Furthermore, the low yield of this reaction meant that there was insufficient Fmoc- 
VahJ)(NHCO)Gly, 144 to proceed with the SPS of Boc-Valip(NHCO)Gly- 
V alty (NHCO)Gly-Pro-Gly-V alip (NHCO)Gly-V ah|>(NHCO)Gly-OEt.
( c ) SPS o f  Ac-Glyip(NHCO)Gly-Glyxp(NHCO)Gly-Pro-Gly-Glytp(NHCO)Gly-
Glytp(NHCO )Gly-NH2, 146
As planned, the SPS of Ac-Glyil)(NHCO)Gly-Glyil)(NHCO)Gly-Pro-Gly- 
Glyip(NHCO)Gly-Glyip(NHCO)Gly-NH2, 146 was performed on a PAL-PEG-PS327 
support (on a 0.1 mmol scale using a fourfold excess of coupling reagents). The coupling 
steps were monitored by following the displacement of a dye (acid violet 17) from the 
resin by the acylating species (by measuring the pre-column UV absorption; this 
technique is called counterion distribution monitoring).326 The couplings to malonyl 
residues [i.e. steps (ii), (iv), (x) and (xii), scheme 73] were prolonged manually until the 
pre-column detector recorded a steady maximum, indicating no further acylation. These 
steps typically took ca. 24 h. except for the last coupling [step (xii), scheme 73], which 
was slower. Gly6 and Pro5 were successfully incorporated, under automatic control, as 
their commercially available Fmoc-Xaa-OPfp derivatives [steps (vi) and (viii), scheme 
73], requiring coupling times of 3 h and 1 h respectively. No problems associated with 
















(v), (vi), (vii), (viii)
Fmoc-Pro-Gly-Glyip(NHCO)Gly-Glyv(NHCO)Gly-PAL-PEG-PS




Scheme 73: SPS of Ac-Glyip(NHCO)Gly-Gly^(NHCO)Gly-Pro-Gly-Glyxp(NHCO)Gly- 
Glyxp(NHCO)Gly-NH2, 146. (i) Pip, DMF. (ii) 143, DIPCDI, HOBt, DMF. (iii) As (i).
(iv) As (ii). (v) As (i). (vi) Fmoc-Gly-OPfp, HOBt, DMF. (vii) As (i). (viii) Fmoc-Pro- 
OPfp, HOBt, DMF. (ix) As (i). (x) As (ii). (xi) As (i). (xii) As (ii). (xiii) As (i). (xiv) 





The Fmoc deprotection steps [(i), (iii), (v), (vii), (ix), (xi) and (xiii), scheme 73] 
were also monitored (by measuring the post-column UV absorption). The resultant 
deprotection profiles [those for steps (i) and (xiii), scheme 73 are depicted in figures A4(a) 
and (b)] indicated successful incorporation of each preceding residue {e.g. the existence 
of a deprotection profile for step (xiii), scheme 73 [figure A4(b)], indicated that 
Gly 1ip(NHCO)Gly2 was successfully incorporated}.324’325 Moreover, none of the 
deprotection profiles displayed the distortion observed during the SPS of "difficult 
sequences", i.e. a flattening and broadening, indicating slowing of the deprotection 
rate.282’324 As shown in figure A4, the first and last deprotection steps proceeded 
normally, despite the fact that the last coupling step [(xii), scheme 73] needed 48 h to 
reach its steady maximum pre-column detector reading.
Therefore the monitoring of both acylation and deprotection during the SPS 
indicated that each step proceeded satisfactorily, i.e. the resin bound PMRI decapeptide, 
146 was successfully synthesised.
The PMRI decapeptide, 146 was cleaved from the resin using TFA / water (95:5), 
step (xv), scheme 73. No additional scavengers were included in the "cleavage cocktail" 
(c./. reference 327) because no alkylation was expected as no temporary protecting groups 
were present that could give rise to alkylating species during the cleavage. Additionally 
no alkylation was observed during N-Boc deprotections using (scavenger free) TFA 
solutions, in the course of the solution phase synthesis [sections 2.1.1 (bXH) and
2.2.1 (b)(iii)(2)], indicating that such PMRI peptides are not overly susceptible to 
alkylation during acidoyltic deprotection. Furthermore, if any PMRI decapeptide, 146 
were alkylated by the resin bound PAL-derived carbonium ion it would remain resin 
bound and thus not contaminate the product^ We were keen to avoid additional 
scavengers in order to circumvent the potentially difficult removal thereof.
The resultant crude PMRI decapeptide, 146 was insufficiently soluble in the 
standard HPLC solvent system to permit its analysis or purification. Therefore a portion
t  A test cleavage yielded crude PMRI decapeptide, 146, without any sign of unforeseen complications, so 
the bulk of the material was cleaved in the same fashion.
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of the material was flash column chromatographed on silica, eluting with chloroform / 
methanol / TFE / acetic acid (85:10:3:2).* However no PMRI decapeptide, 146 was 
recovered. The remaining crude material was successively washed and centrifuged, which 
effected some purification, although the low density of the material (a result of freeze- 
drying) caused low recovery.
Evidence for the successful SPS of Ac-Glyip(NHCO)Gly-Glyx|)(NHCO)Gly-Pro- 
Gly-Glyijj(NHCO)Gly-Glyt|j(NHCC>)Gly-NH2, 146 (in addition to that given by the UV 
monitoring during the assembly) is provided by an electrospray mass spectrum of the 
crude material (obtained despite solubility difficulties), which contains a (M+Na)+ and 
(M+H)+ peak. The mass spectrum's fragmentation pattern contains only one other 
assignable peak, but there are no peaks that correspond to deletion sequences {i.e. [146 - a 
Glytp(NHCO)Gly moiety + H]+ = 556}. Neither are there any peaks appropriate for 
decomposition PMRI peptides [i.e. terminated due to gem-diamino residue decomposition 
resulting in, e.g. H2N-mGly-Pro-Gly-Gly'i|>(NHCO)Gly-Glyi|>(NHCO)Gly-NH2; all the 
possible (M+H)+ ions from this process (599, 485, 216 and 103) are absent]. *H NMR 
spectroscopy furnishes additional evidence. NMR spectra of the crude and washed 
material, accumulated in DMSOd6, are consistent with the desired PMRI decapeptide, 146 
(see experimental chapter). An attempt to accumulate NMR spectra in TFE / 
methanol d4 (95:5), having applied the solubilising pretreatment of Tanner and co-workers 
(i.e. dissolution in TFA, followed by cycles of dilution with TFE and concentration)335 
failed. Although this NMR sample solution was initially clear it clouded on standing and 
the resultant spectrum was very poor. Spectra accumulated in lithium chloride / THFds 
were similarly useless: the crude PMRI decapeptide, 146 did not dissolve well in this 
mixture, possibly due to retained water.
* A similar solvent system was successfully used to purify thymosin a j  fragments. 2&5 Given that both a 
chloroform / methanol / acetic acid eluent with silica as the stationary phase and chromatography on 
Sephadex G25 with 1 M lithium chloride in THF as eluent failed for purification of Boc-Gly»l>(NHCO)Gly- 
Glyil>(NHCO)Gly-F>ro-Gly-Glyil)(NHCO)Gly-Glyil)(NHCO)Gly-OEt, 140, these approaches were not 
attempted for Ac-GlyTl)(NHCO)Gly-Gly'iJ)(NHCO)Gly-Pro-Gly-Gly'il)(NHCO)Gly-Glyt|)(NHCO)Gly-NH2, 
146.
133
In summary, PMRI decapeptide, 146 was successfully synthesised by solid phase 
methods, but its low solubility thwarted effective purification and thus thorough 
characterisation and analysis.
2.3 Conformational Studies.-
Our initial plan was to study the conformations of our PMRI peptides principally 
using NMR techniques,336-340 supplemented by X-ray crystallography185’341’342 and, 
where applicable, CD spectroscopy.187’343-345 However, the solubility difficulties that 
complicated the syntheses also caused problems in our conformational studies. As a result 
it was necessary to perform all the NMR studies on the PMRI peptides of interest (Le. 
PMRI tripeptides and above) in DMSOd6- As DMSO is a strong hydrogen bond 
accepting solvent it is likely to disrupt both intermolecular hydrogen bonding [hence 
effecting dissolution: c.f section 2.\A(a)(i)] and intramolecular hydrogen bonding (hence 
disrupting secondary structure).§ Furthermore the solubility difficulties meant that we 
were unable to obtain any data from X-ray crystallography.5
Limited NMR studies were undertaken and are described below, along with a 
measurement of CD spectra of Boc-Glyil>(NHCO)Gly-Pro-Gly-Gly'i|j(NHCO)Gly-OEt, 
132. Phase sensitive COSY and NOESY experiments were performed on the PMRI 
peptides with structure of interest. Results from these studies allowed the assignment of 
the NMR resonances of the PMRI peptides. In addition, VT NMR spectra were 
recorded and analysed to study the changes in the chemical shifts of the amide H- 
resonances. This was undertaken in order to assess hydrogen bonding within the PMRI 
peptides.338 For all the PMRI peptides studied [except HCl.Gly4>(NHCO)Gly-OEt, 101: 
see section 2,l.l(bXi)] no decomposition was observed during the VT experiments. This 
was confirmed by recording a final NMR spectrum on cooling the sample to r.t. after
§ However some (modified) peptides have been shown to form (3-sheet type structures in DMSO, e.g. 
references 13,28,216346 and 347.
5 Of the PMRI peptides larger than dipeptides, only ethylmalonyl-ValTj)(NHCO)Gly-OEt, 120, was 
crystalline, but crystals of sufficient quality for X-ray crystallography were not obtained.
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the VT experiment was complete. The discussion below is arranged in order of PMRI 
peptide length.
In theory IR spectroscopy could also have been employed. Indeed the peptide or 
protein p-sheet conformation exhibits a characteristic IR absorption pattern in the amide I 
region: a strong absorption at ca. 1625 cm-1, with a shoulder at ca. 1695 cm-1 for the 
antiparallel p-sheet, and a single strong absorption at ca. 1635 cm-1 for the parallel p- 
sheet. 187345348349 These absorption bands may be observed in solution or the solid 
state.
None of our PMRI peptides that might adopt P-sheet structure exhibited such 
absorptions in their IR spectra (see experimental chapter). However, it is by no means 
clear whether the p-sheet absorption bands exhibited by peptides and proteins should be 
displayed by PMRI peptides,* and furthermore Narita and co-workers demonstrated that 
the application of shear stress (as occurs during the preparation of Nujol mull samples) 
can disrupt p-sheet structure.350’351 Therefore no conclusions concerning the existence of 
p-sheet structure can be drawn from the Nujol mull IR spectra of our PMRI peptides, and 
their low solubility precluded additional studies in solution.
2.3.1 The PMRI tripeptide ethyl malonyl- Val ty(NHCO)Gly-OEt, 120.
The NOESY spectrum of ethyl malonyl-Vahp(NHCO)Gly-OEt, 120 contains only 
the cross peaks expected from its primary structure, figure 19, and none corresponding to 
a folded conformation. This is consistent with the expected extended structure of 120, but 
the absence of NOEs cannot be taken as a positive indication of any particular 
structure.352
The scalar coupling constants (Js) observed in the JH NMR spectrum of ethyl 
malonyl-Val'il>(NHCO)Gly-OEt, 120, similarly provide only ambiguous information. 
Literature precedent suggests that the usual Karplus-type equation P^HNCaH = 
Acos2((j>±60) - Bcos(<jht60) + C (+ for L-amino acids, - for D-amino acids) or
* The only IR spectroscopic studies carried out on PMRI peptides are those of Gellman and co-workers [see 
section l.S3(bXiv)(2)] and those of Marraud and co-workers [see section 1 .S3(bXi)], which were 
performed in solution and required individual absorption assignment and / or suitable reference compounds.
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2! (3*^ HNCaH2) = -Acos2(|) - Bcos<|> + C for glycine]336*3^  use(j for amino acids and 
peptides is applicable to PMRI peptide gem-diaminoalkyl residues (the D-amino acid 
version being used with 37hc aipNH to determine ip). 172354355,t p0r ethyl malonyl- 
Vahp(NHCO)Gly-OEt, 120, the value of 37 h n c« H  (8.4 Hz) is indicative of = (- 
150°, 150°), (-90°,90°), or (40°, -40°) to (80°,-80°), using Bystrov's Karplus cu rv e .* ^  
This data therefore permits no firm deductions regarding the conformation of ethyl 
malony 1-Valty(NHCO)Gly-OEt, 120, especially considering the proximity of the observed 
value of 37 h n c « h  to the average value for a freely rotating bond (7.5 Hz),338’356 and the 
similar value recorded for Boc-Val xp(NHCO)Gly-OEt, 116(a).
Figure 19: NOEs observed for ethyl malonyl-Vah|>(NHCO)Gly-OEt, 120; NOEs 
observed between multiple symmetrically identical protons are only indicated once (in 
this and subsequent figures).
Measurement of the variation of the NH chemical shifts with temperature for 
PMRI tripeptide 120, produced a linear relationship (over the range 20-100°C) with 
gradient -5x1 O'3 ppm/K, indicative of a solvent exposed NH, confirming the absence of 
intramolecular hydrogen bonding.338
Therefore all these NMR experiments on ethyl malonyl-Val'i|j(NHCO)Gly-OEt, 
120 provided no strong evidence for any particular secondary structure, but conversely, 
provided no evidence inconsistent with the expected extended structure.
t  Use of 2JHcaH to determine the (<j>,i|>) of wGly residues is, conversely, unprecedented. By comparison 
with native peptides a relationship is expected,338,353 but it is unclear what form it might take in PMRI 
peptides and therefore no attempt has been made to utilise it in this study.




(a) Boc-Xaa ip(NHCO)Gly-Xaa NHCO)Gly-OEt, 104 (Xaa = Gly) and 122 (Xaa = Val) 
The NOESY spectra of 104 and 122 contain only cross peaks indicative of primary 
structure: figures 20 and 21.
Figure 20: NOEs observed for Boc-Glyi|>(NHCO)Gly-Glyip(NHCO)Gly-OEt, 104.
Figure 21: NOEs observed for Boc-Valx|>(NHCO)Gly-Vahp(NHCO)Gly-OEt, 122.
For Boc-Glyi|>(NHCO)Gly-Glyip(NHCO)Gly-OEt, 104, the values of 
2 (37hnc«H2) indicate the ambiguous set of values shown in table 3.
Table 3:
2 (3iHNC«H2) <t>/° 2(3-/H2C<*iDNH> 4)/°
Gly1 11.6 ±130, ±50 12.0 ±120, ±60
Gly3 11.0 ±120, ±60 12.0 ±120, ±60
For Boc-Val ip(NHCO)Gly-Vah|>(NHCO)Gly-OEt, 122, the values of 3/hnc«H2 
indicate the ambiguous set of (<t>,i|>) values shown in table 4.
Table 4:
37hnc«h / Hz 4>/° 3^ HC«iDNH/Hz ip/ °
Val1 9.0 -130, -90,50 to 70 8.4 150,90,-40 to -80
Val3 8.1 -150, -90,40 to 80 8.5 150,90, -40 to -80
So, for both PMRI tetrapeptides 104 and 122, as for PMRI tripeptide 120, the 
NMR data does not indicate a folded structure and is consistent with, yet insufficient to 
prove, the expected extended (or any other rigid) structure.
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(b) Boc-Xaaip(NHCO)Gly-Pro-Gly-OEt, 130 (Xaa = Gly) and 133 (Xaa = Val)
No detailed study of these two PMRI tetrapeptides was undertaken, but brief 
comparisons between them (plus Boc-Glyip(NHCO)Gly-Pro-Gly, 131) and longer PMRI 
peptides are made below.
2.3.3 PMRI hexapeptides.
(a) Boc-Gly NHCO )Gly-Gly itf NHCO)Gly-Pro-Gly-OEt, 136
(i) Conformers
As is apparent from the NMR spectra of 136 (see experimental chapter), the 
incorporation of proline in its sequence gives rise to a major and minor conformer in 
DMSO solution. Indeed, this phenomenon was observed for all the PMRI peptides 
synthesised in this project that contain proline, i.e. 130, 131, 132, 133, 134, 1, 136 and 
138. This is a common observation for proline containing peptides: the two conformers 
differ in the configuration of the Xaa-Pro bond (cis vs trans), and equilibrate slowly on 
the NMR time scale.338’357 The two conformers may be distinguished using the chemical 
shift difference between the proline CP and CY resonances in the 13C NMR spectrum: a 
larger difference is observed for the cw-conformer.338’357-360 Furthermore, the relative 
heights of the proline CP and CY peaks in the 13C NMR spectrum may be used to 
determine the cis : trans ratio;357 although in these investigations appropriate !H NMR 
integrals are employed to this end.
The relative intensities of the proline CP and CY 13C NMR resonances (and / or the 
chemical shifts thereof) for all the proline containing PMRI peptides described herein 
indicate that the £r<ms-conformer is the major form.
For Boc-Glyty(NHCO)Gly-Glyx|)(NHCO)Gly-Pro-Gly-OEt, 136 the cis : trans 
ratio is ca. 30:70, c.f. ca. 36:64 for Boc-Glyip(NHCO)Gly-Pro-Gly, 131. In the former 
case, acquisition of the lH NMR spectrum at 50°C did not lead to coalescence of the 
signals corresponding to the major and minor conformers. In the latter case a more 
extensive VT lH NMR study was carried out, and by 100°C, the major and minor signals
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of both the BocNH and GlyhpNHS had coalesced, but those of Gly4NH§, Gly2CaH2 and 
Pro3CaH had not: presumably, therefore, rapid equilibration of the two conformers did 
not occur, even at 100°C. Figure 22 displays the variation observed in the NH chemical 
shifts with temperature for Boc-Glyt|i(NHCO)Gly-Pro-Gly, 131. The temperature 
gradients for the NH chemical shifts are presented in table 5.
b B o c N H  
bGlyl^NH 
6 G l y 4 N H  
b B o c N H  m i n 
S G l y i t p N H  min 
d G l y 4 N H  min
Figure 22: Variation of NH chemical shifts with temperature for Boc-Glyip(NHCO)Gly- 
Pro-Gly, 131; min refers to the minor conformer.
Table 5:
BocNH G ly^N H Gly4NH
^  / -10-3 ppm/K 8(8) 5(4?) 4(5)
The figures in brackets refer to the minor conformer. 
? Significant deviation from linearity.













All these values are indicative of solvent exposed NHs, except that for Gly4NH (major 
conformer), which is intermediate in value and thus inconclusive.338’*
(ii) Boc-Gly ip(NHCO)Gly-Gly ip(NHCO)Gly-Pro-Gly-OEt, 136 NOESY and J analysis
The NOESY spectrum of 136, in common with those described above, contains 
only (weak) cross peaks (observed for the major conformer only) corresponding to its 
primary structure: figure 23.
Figure 23: NOEs observed for Boc-Glyip(NHCO)Gly-Glyip(NHCO)Gly-Pro-Gly-OEt, 
136.
The values of 2 ( 3/HNCaH2) anc* 2*/hc«H for Boc-Glyip(NHCO)Gly- 
Glyx[)(NHCO)Gly-Pro-Gly-OEt, 136, and the ambiguous set of (<t>,i|>) values they indicate 
are shown in table 6.
Table 6:
SX^HNOTfe) 1 Hz <J>/° 2 (3^ H2CaiDNH) / Hz ip /°
Gly1 12.0 ±120, ±60 br
Gly3 12.2 ±120, ±60 12.0(12.0) ±120, ±60
Gly6 11.4(11.0) ±130, ±50 17.4t 0 to ±30, ±150 to 
±180
The figures in brackets correspond to the minor conformer.
These (<j>,ip) values for the PMRI portion of 136 (i.e. Gly1 and Gly3) are very similar to 
those of 104, again indicating no rigid secondary structure. Moreover, none of this NMR 
data is indicative of any (unexpected) folded structure.
* For comparison, the values for Boc-GlyTj>(NHCO)Gly-OEt, 99 (recorded in DMSOd6) were: BocNH, 
-8xl0"3 ppm/K and Gly ^ N H , -6x1 O'3 ppm/K.
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(b) Boc-Glyip(NHCO)Gly-Pro-Gly-Glytp(NHCO)Gly-OEt, 132
Unlike the preceding cases, PMRI hexapeptides 132 and 1 were expected to adopt 
(or at least populate) a rigid, folded (p-hairpin type) secondary structure.
(i) Conformers and VT NMR spectroscopy
As described above [section 2.3.3(aXi)]> PMRI hexapeptide 132 exists in cis and 
trans-conformers at -raGly2-Pro3-: its cis : trans ratio, given by JH NMR spectroscopy, is 
ca. 34:66, much the same as that for PMRI peptides 131 and 136. Therefore the desired 
P-hairpin type structure, if adopted, does not favour one conformer at the expense of the 
other. A p-hairpin type structure is only expected to be possible with a trans -mGly2- 
Pro3- bond (in order to permit p-tum formation across residues -raGly 2-Pro3-Gly4-gGly5- 
). Hence, this invariance of cis : trans ratio suggests that a p-hairpin type structure for 
PMRI hexapeptide 132 is either not significantly populated at all, or does not substantially 
stabilise the trans -conformer with respect to the cis.
The VT *H NMR study of PMRI hexapeptide 132 brought about only partial 
coalescence of the major and minor signals, as was the case for PMRI tetrapeptide 131 
[see section 2.3.3(aX*)L so rapid equilibration of the two conformers did not occur. 
Assignment of both the major and minor NH signals was possible using the COSY and 
NOESY results. The variation of the NH chemical shifts of PMRI hexapeptide 132 with 
temperature is plotted in figure 24, and the gradients shown in table 7. These values 
indicate exposure to solvent for BocNH, Gly hpNH, Gly5NH, and Gly^ipNH, whereas the 
value for Glj^NH is ambiguous.338 A p-hairpin type structure would result in solvent 
shielding for Gly5NH, and Gly^ipNH (due to hydrogen bonds between Gly2CO and 
Gly5NH, and G ly^CO  and Gly^ipNH, c.f. figure 26), and exposure to solvent for the 
other NHs. Thus the VT *H NMR results do not indicate formation of a P-hairpin type 
structure by Boc-Glyip(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly-OEt, 132. In contrast the 
9-membered hydrogen bonded ring conformation characterised by Gellman and co- 
workers [see section 1.5.3(6)(/v)(2)] would result in solvent shielding of only Gly4NH: the 
above VT results (and those for PMRI tetrapeptide 131) may be consistent with such a 
structure, but the value of the NH chemical shift temperature gradient is ambiguous.
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Figure 24: Variation of NH chemical shifts with temperature for Boc-Glyty(NHCO)Gly-
Pro-Gly-Gly^(NHCO)Gly-OEt, 132.
Table 7:
BocNH Gly 'tpNH Gly4NH Gly5NH GlySipNH
—  / -10"3 ppm/K 8 5(4*) 4(4) 5(5) 6(6*)
The figures in brackets refer to the minor conformer. 
$ Significant deviation from linearity.
(ii) NOESY and J analysis
The weak NOEs observed in the NOESY spectrum of PMRI hexapeptide 132, for 
the major conformer, are depicted in figure 25.
Observation of the NOEs depicted in figure 26 would establish the adoption of a 
p-hairpin type conformation by Boc-Glyi|>(NHCO)Gly-Pro-Gly-Glyx|i(NHCO)Gly-OEt, 
132 .28336344352
142
= obscured by noise.
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Figure 26: NOEs expected if Boc-GlyiKNHCO)Gly-Pro-Gly-Glyaj)(NHCO)Gly-OEt, 132 
adopted a (5-hairpin type conformation.
None of these characteristic NOEs were observed. Rather, only NOEs indicative of 
primary structure were detected, except for a possible NOE between Gly2CaH2 and 
Gly5CaH2, but it is not clear whether this signal was an artefact or a real NOE.
The values of 2 ( 3^ HNCaH2) anc* 2^ HC«H for PMRI hexapeptide 132, and the 
ambiguous values of (<J>,i|>) they imply are presented in table 8.
Table 8:
2 (3/hNC«H2) 1 H z 4>/° 2 (3^ H2C«Ti>NH) / Hz t|>/°
Gly1 br 12.8 ±120, ±60
Gly4 12.0(12.0) ±130, ±60 16.75 0 to ±40, ±140 to 
±180
Gly5 12.0 ±130, ±60 12.0(11.6) ±130, ±60
The figures in brackets correspond to the minor conformer.
These values are much the same as those observed for PMRI peptides 104, 131 and 136, 
which suggests that no significant structural change occurred within this set of PMRI 
peptides. If PMRI hexapeptide 132 adopted a p-tum across residues -/wGly2-Pro3-Gly4-
§ Very few cross peaks were conclusively observed for the minor conformer.
gGly5-, then the values of 3^ HNCaH2 f°r Gly4 might be expected to reflect this, e.g. one 
large and one small value is often seen.203 No such evidence was observed, although <(>4 = 
±60° is accordant with, but does not rigorously establish, the presence of a p-tum (type III 
or III').187’203
So the NMR studies performed on PMRI hexapeptide 132, in common with the 
other PMRI peptides described above, gave no firm indication of a preference for any 
rigid structure.
(Hi) CD spectra*
The CD spectra of PMRI hexapeptide 132 were recorded in four different solvent 
environments (water, SDS above critical micelle concentration, and TFE, with and 
without 57 mM sodium hydroxide) t: figure A5.
For (pseudo)peptides without aromatic residues and disulfide bonds, the CD arises 
from the orientation in space of the peptide bonds. In PMRI hexapeptide 132, only the 
proline residue is chiral and therefore the CD is primarily due to the orientation of the 
prolyl tertiary amide chromophore relative to the Gly4 secondary amide chromophore, i.e. 
the -mGly2(tertiary amide)Pro3(secondary amide)Gly4- fragment. The other amide bonds 
in the pendent PMRI peptide chains are expected to make little, if any, CD contribution.
Therefore the CD spectrum characteristic of a P-sheet structure187’343’345’361 is 
not expected, even if PMRI hexapeptide 132 adopts a P-hairpin conformation under these 
conditions, because the p-sheet portion would contain no chiral centres and so make a 
negligible CD contribution. Rather, we might expect to observe a CD spectrum indicative 
of a p-tum.343’361 The CD spectra recorded (figure A5) may be interpreted as follows, 
assuming negligible contributions from proline cis / trans isomerism (which is not usually
* The CD spectra of Boc-Glyip(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly-OEt, 132 were recorded and 
interpreted by Dr. Giuliano Siligari at the EPSRC National Chiroptical Laboratory, Birkbeck College, 
London.
t  Measurement was possible in these solvents because the sensitivity of CD spectroscopy permits use of low 
concentration solution [0.5 mM in this case ( i.e. ca. 0.3 mg/mL)]. DMSO is not a suitable solvent for CD 
spectroscopy.
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observed at such concentrations), and referring only to the -mGly2-Pro3-Gly4- portion. In 
water the structure was irregular without preferred orientations of the two amide 
chromophores. At supramicellar SDS concentration, the positive CD band below 195 nm 
is indicative of a more defined orientation between the two amide chromophores. The 
conformation appeared to be even more defined in TFE, but the addition of 57 mM 
sodium hydroxide caused substantial conformational disruption. The CD spectrum in 
TFE resembles that of a type II p-tum conformation (or a p-sheet, the two CD spectra are 
similar),343*361 but it is not possible to conclusively state that a P-tum is adopted.
(iv) /5-Turn detection by IR spectroscopy
An amide I absorption band near or below 1640 cm-1 in peptide or protein IR 
spectra (solution or solid state) may be correlated with the acceptor carbonyl of a strong i 
... i+3 intramolecular hydrogen bond, such as usually exists in a p-tum.348*362
The Nujol mull IR spectrum of PMRI hexapeptide 132 (but not Boc- 
Vah|)(NHCO)Gly-Pro-Gly-Vah|)(NHCO)Gly-OEt, 1) displayed a very strong band at 
1635cm-1, which may, therefore, be indicative of p~tum formation. However such an 
absorption band was also found in the IR spectrum of Boc-Glyip(NHCO)Gly- 
Glyi|>(NHCO)Gly-Pro-Gly-OEt, 136, which cannot form a p-tum. Thus the observation 
of the 1635cm-1 absorption for these PMRI hexapeptide is inconclusive.
(c) Boc- Val xp( NHCO )Gly-Pro-Gly- Valty( NHCO)Gly-OEt, 1
The quantity of pure PMRI hexapeptide 1 obtained was insufficient to permit 
thorough conformational investigations. The studies that were carried out are described 
below.
(i) Conformers
As noted in section 2.3.3(a)(7), PMRI hexapeptide 1 exists in cis and trans-
conformers at -mGly2-Pro3-: its cis : trans ratio, measured by NMR spectroscopy, is
ca. 30:70 (the same as that for PMRI tetrapeptide 133). This suggests that if the desired p- 
hairpin type structure is adopted by PMRI hexapeptide 1, it does not lead one conformer
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to be favoured at the expense of the other [as discussed for PMRI hexapeptide 132, see 
section 2.3.3(bXi)\
(ii) NOESY and J analysis
The NOESY spectrum of Boc-Valip(NHCO)Gly-Pro-Gly-Val'ip(NHCO)Gly-OEt, 
1 was very noisy (this was not such a problem with the COSY): only an NOE between the 
methylene and methyl protons of the ethyl ester was detected with any certainty.$ 
Consequently unambiguous assignment of the *H NMR NH resonances was not possible 
in this case.
The substantial overlap of the NH resonances in the *H NMR spectrum of PMRI 
hexapeptide 1 makes the usual J  analysis impossible. Neither is it possible to extract J  
values from the CaH resonances. No attempt was made to extricate the J  values from the 
COSY spectrum.
Thus no conclusions may be drawn on the conformation of Boc-Valip(NHCO)Gly- 
Pro-Gly-Valip(NHCO)Gly-OEt, 1, other than the existence of cis / trans-isomers at the 
-mGly2-Pro3- amide bond, and the absence of any detectable, rigid, defined structure.
2.3.4 Summary o f the conformational investigations.
NMR studies in DMSOd6 failed to detect any defined secondary structure for 
PMRI peptides 120, 104, 122,131, 136, 132, or 1. In no case was evidence found for a 
folded structure, which was as expected for all but PMRI hexapeptides 132 and 1. For 
these two PMRI hexapeptides we had hoped to detect a p-hairpin type structure, but as 
with the other PMRI peptides mentioned, all the NMR evidence merely pointed towards 
conformational averaging, i.e. a range of rapidly interconverting conformational states 
(often misleadingly called a ’’random coil"340’344). Only the proline containing PMRI 
peptides (131, 136, 132, and 1) deviated from this behaviour in that they .displayed slow 
cis / trans -mGlyi-Proi+1- isomerism.
$ The tumbling rate of (modified) peptides of about this size is often such as to result in very weak, hence 
unobservable, NOEs 340352
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Nevertheless, no evidence against the expected structures was observed. Thus the 
|3-hairpin type structure may be adopted / occupied by Boc-Xaai|)(NHCO)Gly-Pro-Gly- 
Xaaty(NHCO)Gly-OEt, 132 (Xaa = Gly) and / or 1 (Xaa = Val), but if so, it is not a 
sufficiently rigid and / or energetically favoured arrangement in DMSO to permit its 
detection.
The CD spectra of Boc-Glytp(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly-OEt, 132 
suggested the existence of some defined secondary structure of the -mGly2-Pro3-Gly4- 
sequence in TFE, possibly the adoption of a type II p-tum.
The combination of CD and NMR studies under suitable conditions could prove 
useful for future studies of the conformational behaviour of such PMRI peptides, if 
solubility problems can be surmounted (see section 2.5.2).
2.4 Conclusions.-
2.4.1 Synthesis and protecting group manipulations o f PMRI dipeptides.
The Goldschmidt and Wick type synthesis of PMRI dipeptides Boc- 
Xaail>(NHCO)Gly-OEt, 99 (Xaa = Gly), 116(a) (Xaa = Val), and 116(b) (Xaa = Phe) from 
the corresponding Boc-amino acids [95, 113(a) and 113(b) respectively], sodium azide 
and monoethyl malonate, 98, has been demonstrated to proceed in moderate yield (20- 
48%). Variations in the method of formation of the intermediate a-(Boc-amino)acyl azide 
did not improve the original procedure.
C-Terminal deprotection of these PMRI dipeptides was trivially accomplished, in 
near quantitative yields, by saponification.
V-Terminal deprotection using hydrogen chloride solutions was problematic: 
decomposition of the products occurred, as noted by Loudon and co-workers for 
monoacyl gem-diamino compounds generally [section yielding ammonium
chloride, an aldehyde and ethyl malonamate, 118. The extent of decomposition increased 
across the series 99 < 116(a) < 116(b), due to stabilisation of the intermediate iminium 
species by the side chains. Ethyl malonamate, 118, and ethyl malonyl-Val'ijj(NHCO)Gly- 
OEt, 120 were identified as by-products from the deprotection of Boc-Val ip(NHCO)Gly- 
OEt, 116(a) with ethanolic hydrogen chloride.
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Satisfactory N-Boc deprotection was achieved using TFA, and an appropriate 
work-up procedure was developed. Thus, TFA.Glyx|>(NHCO)Gly-OEt, 102 was obtained 
in 86% yield; TFA.Valt|>(NHCO)Gly-OEt, 119, in 84% yield ; and 
TFA.Pherp(NHCO)Gly-OEt, 124, in 43-61% yield (decomposition is obviously still 
significant in this case at least).
Therefore we have demonstrated that V-Boc deprotection of PMRI dipeptides may 
be achieved quite satisfactorily, provided the side chain of the gem-diamino residue 
bearing the Boc group does not greatly stabilise the iminium intermediate on the 
decomposition pathway (-gPhe- was particularly problematic in this project).
PMRI dipeptides Fmoc-Xaaip(NHCO)Gly, 143 (Xaa = Gly), and 144 (Xaa = Val), 
for use in SPS, were obtained by reprotection of the corresponding fully deprotected 
PMRI dipeptides, 141 and 142, using Fmoc-OSu. Fmoc-Glyip(NHCO)Gly, 143, was 
obtained in 92% yield from Boc-Glyi|)(NHCO)Gly, 103. In contrast, Fmoc- 
Vahp(NHCO)Gly, 144 was obtained in only 25% yield from Boc-Val,»l)(NHCO)Gly, 121, 
and a by-product, Fmoc-NH2, 145 [derived from TFA.Valtp(NHCO)Gly, 142 
decomposition] was also isolated in this case (in 17% yield). To the best of our 
knowledge, these are the first examples of W-Fmoc PMRI dipeptides.
2.4.2 Elongation o f the PMRI dipeptides: PMRI tripeptides and beyond.
The syntheses of Boc-Glyi|>(NHCO)Gly-Glyi|>(NHCO)Gly-OEt, 104, and Boc- 
Valip(NHCO)Gly-Vah|>(NHCO)Gly-OEt, 122, were used as test-beds for various peptide 
coupling procedures. Carbodiimide mediated couplings, in the presence of the auxiliary 
nucleophiles, HOSu and HOBt, gave moderate yields of the desired PMRI tetrapeptides, 
but profound purification difficulties resulted due to the low solubility of the products. 
Thus, the only satisfactory carbodiimide procedure to yield the PMRI tri- and 
tetrapeptides 120,104,122 and 126 used EDC / HOSu, and owed its success to the water 
solubility of the by-products. Indeed EDC / HOSu was the method of choice for the 
couplings to PMRI tri- and tetrapeptides 120,122 and 126.
The method of choice for the synthesis of Boc-Glyi|>(NHCO)Gly- 
Glyxp(NHCO)Gly-OEt, 104 was isolation of the active ester, Boc-Glyip(NHCO)Gly-OSu,
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106 (generated using DCC), and subsequent coupling. Formation of the active ester, Boc- 
Vahp(NHCO)Gly-OSu, 123 using DSC, showed promise, but was not thoroughly 
investigated [section 2.1.2(d)(ii)(2)\
Carbonate mixed anhydride couplings were only successful between gem-diamino 
residues and non-malonyl residues [e.g. the syntheses of Boc-Xaa'i|>(NHCO)Gly-Pro-Gly- 
Xaaip(NHCO)Gly-OEt, 132 (Xaa = Gly) and 1 (Xaa = Val)]. Attempted carbonate mixed 
anhydride couplings to malonyl residues merely yielded the corresponding esters, as 
previously observed by Goodman and co-workers and Gutman and Boltanski [see sections 
lS.l(a)(i)(l)and 2AA(d)(iii)(3)].
All the couplings investigated between gem-diamino and malonyl residues were 
rather slow, which is a finding general to PMRI peptide synthesis [see section 
lSA(a)(i)(l)l
The moderate coupling yields generally experienced are attributed to gem-diamino 
residue decomposition during the long reactions. A further detrimental factor was 
difficult product isolation and purification due to the low solubility encountered in most of 
the elongated PMRI peptides.
Thus, judicious use of the above mentioned coupling procedures [and the 
deprotection procedures developed for the PMRI dipeptides, 99, 116(a) and 116(b)] 
provided access to the initial target PMRI tetrapeptides, 104, 122 and 126, and the 
truncated target PMRI hexapeptides, 132 and 1; but failed to furnish the ultimate target 
PMRI decapeptide 140. Poor solubility of all PMRI peptides containing our target motif, 
and of the truncated targets, irrespective of the presence of proline or the nature of the side 
chains, dogged the syntheses and could only be tackled by the use of highly polar 
solvents; solubilisation by chemical modification was investigated to no avail.
SPS of PMRI peptides was demonstrated to be possible under somewhat modified 
Fmoc continuous flow conditions, but insolubility prohibited purification of the SPS 
product, 146. Nonetheless the PAL handle was shown to be a suitable anchor for malonyl 
residues (ultimately yielding the C-terminal amide) and prolonged couplings (DIPCDI / 
HOBt) and shortened deprotections allowed incorporation of the PMRI dipepitde SPS 
monomers, 143, as indicated by the Fmoc deprotection profiles (figure A4).
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2.4.3 Conformational studies.
The aforementioned solubility problems necessitated the use of DMSOd6 as 
solvent for the NMR studies. Under these conditions we were unable to detect any 
secondary structure formation. Thus we must conclude that our PMRI peptides do not 
adopt any rigid conformation(s), but rather, are in rapid equilibrium between many 
conformers under these conditions. This finding does not preclude the occupation of the 
expected P-hairpin structures (twisted or otherwise), but provides no evidence thereof.
The CD spectrum of Boc-Glyil)(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly-OEt, 132 
in TFE suggested some defined secondary structure of the -wGly2-Pro3-Gly4- sequence, 
possibly a type II p-tum, which would be consistent with a p-hairpin structure.
Weak evidence suggesting a p-sheet forming tendency of our structural motif is 
provided by the low solubility of the PMRI peptides that featured it, since p-structure 
formation by blocked peptides and intermolecular association, leading to insolubility are 
causally linked. The fact that solvent systems used to disrupt peptide p-structure [i.e. 
DMSO, TFE, lithium chloride / THF, etc: see section 2.1.4(a)] were effective against the 
insolubility of PMRI peptides in this study further supports the view that our PMRI 
peptides exhibit a p-structure forming tendency. However there is no suggestion of well- 
defined secondary structure formation by our PMRI peptides.
It is possible that the insolubility observed for our PMRI peptides (tetra- and 
above) was merely due to unfortunate sequence choice, rather than an inherent property of 
the target motif, for the PMRI peptides were designed to include side chains with a high 
p-sheet forming propensity. Only further investigation with alternative side chains can 
shed light upon this. However, comparison with blocked natural peptides of analogous 
sequence indicates that, in the glycine case, the onset of aggregation / insolubility / p- 
sheet formation does not occur until at least the pentapeptide.363-365
In summary, we have developed synthetic methodology that permits access to 
PMRI peptides containing the structural motif [Xaaxp(NHCO)Gly] n, n ^  2, using solution 
or SPS. This motif was expected to be predisposed towards p-sheet formation but we 
have been unable to produce evidence to that effect, due to difficulties caused by low
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solubility (which may itself be weak evidence thereof). Thus we are unable to support or 
refute the conflicting conformational predictions of Dauber-Osguthorpe and co-workers 
and Aleman, Puiggalf and co-workers, based upon molecular modelling [section 1.5.3(b)], 




As mentioned above, couplings between gem-diamino and malonyl residues are 
slow, a factor that contributes to their inefficiency. Hence further investigation of 
alternative coupling procedures is warranted.
(a) New coupling reagents
In view of Verdini and co-workers' successful anchorage of a malonyl residue to a 
solid support using carbonyl bis(A-methylimidazolium) dichloride, 89 [section 
1.5.1(b)(m)], this reagent may also prove useful for solution phase synthesis. The 
application of the related coupling reagent, carbonyldiimidazole (and other variants 
thereof) 100 is also worthy of investigation, for it is yet to find widespread use in PMRI 
peptide synthesis.
The literature abounds with new peptide coupling reagents, the popularity of 
which waxes and wanes with their (low-cost) commercial availability. Two recent 
examples that may prove useful in the PMRI peptide context are bis{[4-(2,2-dimethyl-13- 
dioxolyl)]methyl}carbodiimide, which gives rise to a urea that is readily removed with 
water,366 and the amidation catalyst 3,4,5-trifluorobenzeneboronic acid.367
(b) Non-carbonate mixed anhydrides
Following Goodman and co-workers' report of failed mixed anhydride couplings 
[see section 1.5.1(a)(/)(7)] there has been little evaluation of their utility in PMRI peptide 
synthesis. However, in the light of the mechanism of malonyl residue esterification 
during attempted carbonate mixed anhydride couplings [see section 2.1.1 (d)(iii)(3)], a re- 
investigation thereof is justified. The use of a non-carbonate mixed anhydride would
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preclude undesired ester formation (although generation of the proposed ketene 
intermediate is still possible) and may thus enable the desired coupling, either with an 
amine [c.f. section 2.1.1(dXH)] or an auxiliary nucleophile, generating an active ester [c.f. 
section 2.1.1 (d)(iii)(3)]. Appropriate reagents are pivaloyl chloride or zso-propenyl 
chloroformate (although this yields a carbonate mixed anhydride, subsequent elimination 
or nucleophilic displacement generates acetone, not an alkoxide or alcohol, so is unlikely 
to lead to ester formation).368
The influence of the C2 allyl protecting group [see section 1.5.1(a)(ii)(l)] upon the 
course of attempted mixed anhydride coupling to malonyl residues is, as yet, untested.
(c) Active esters
Further examination of malonyl residue active ester formation using DSC, 
following up that described herein [section 2,1.2(d)(ii)(2)], is merited.
(d) SPS
Although our synthesis of Fmoc-Gly'i[)(NHCO)Gly, 143 was successful, the 
introduction of Fmoc leading to Fmoc-Vali|)(NHCO)Gly, 144, was unsatisfactory. Other 
reagents, such as Fmoc-Cl and Fmoc-N3 may improve this synthesis.
Use of an alternative resin (e.g. the Kaiser oxime resin, with which anchorage may 
be more difficult) would permit the SPS of a PMRI peptide blocked at the C-terminus 
with a group other than a primary amide 294 Following the rationale of Kemp,216 such a 
reduction in the number of hydrogen bond donors not satisfied by intermolecular 
hydrogen bonding could result in less aggregation and thus facilitate purification and 
further study of PMRI peptides analogous to 146.
(e) Solvents
In this project, couplings leading to and involving PMRI peptides of low solubility 
were generally carried out in DMF. In our investigation of solubilisation [section 2.1.4] 
we found that DMSO, TFE, HFIP and lithium chloride / THF dissolved Boc- 
Glyiji(NHCO)Gly-Gly'i|)(NHCO)Gly-OEt, 104. Therefore couplings in these solvents 
(during solution or SPS) could prove efficient, although the isolation and purification
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problems we encountered would not be alleviated. TFE and / or HFIP have been 
employed with natural peptides, diluted with dichloromethane [see section 2AA(a)(i)\. 
such a solvent system may also be useful in PMRI peptide synthesis. However, with these 
fluoroalcohols there is the possibility of ester formation and thus rather slow or 
incomplete reactions [see section 2.1 A(a)(i)].
2.5.2 The target motif: [Xaa\\)(NHCO)Yaa]n, n ^ 2 .
Although the results of Gardner and Gellman demonstrate that our target motif 
may not lead to p-structure any more stable than that of the corresponding natural peptides 
[see section 1.5.3(b)(iv)(2)), there is still the question of what secondary structure, if any, 
such PMRI peptides favour. Furthermore, the motif remains an interesting category of 
structure [c.f. section l.S.3(b)(iv)(l)], worthy of additional experimental investigation. 
Thus, various avenues for redesign are outlined below, with the caveat that too much 
constraint may lead to secondary structure formation influenced more by the constraints 
than any inherent tendency of the motif.
(a) Alternative residues
Alternative choices of Xaa and Yaa permit solubility to be designed into our target 
motif. Attempts, in this study, to thereby effect solubility in organic solvents failed. But 
conversely, Xaa = Lys could result in aqueous solubility.
(b) Templates
Mutter’s "template-assembled synthetic protein" concept,369 and Nowick and co- 
workers’ oligourea "molecular scaffold"370 permit secondary structure formation by 
peptide chains attached to a "template" or "scaffold". Thus, PMRI peptide chains, 
featuring our target motif, could be attached to such a template with the potential result 
that intramolecular p-sheet formation could occur without intermolecular aggregation.
(c) Alternative turns
Rather than the -Pro-Gly- sequence employed in this study, another turn forming 
unit could be employed. Use of a less flexible P-tum mimic, e.g. those of Kelly and co­
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workers,371 Feigel,372 or Kemp and L i ,373374 c o u l d  favour p-hairpin formation between 
the pendant PMRI peptide chains.
(d) Extra constraints
More forcing constraints could be applied to the target motif, e.g. cyclisation using 
a second (natural or peptidomimetic) turn unit,375 or by the incorporation of cystine.347 
Alternatively, those amide hydrogen bond donors not involved in the desired p-hairpin 
formation [i.e. those that point outwards in figure 14(a)] could be blocked (e.g. by 
methylation). This course of action would serve the dual purpose of disfavouring 
undesired conformations stabilised by hydrogen bonds involving those donors, and 
diminishing intermolecular hydrogen bonding and thus aggregation. However, further 




3.1 General Methods, Equipment, and Materials.-
3.1.1 General Methods.
Glassware used for moisture sensitive reactions was dried by washing with acetone 
before heating in an oven at ca. 120°C overnight, then allowed to cool in a desiccator over 
calcium chloride / silica gel.
Reactions requiring an inert atmosphere were performed under nitrogen or argon; 
those in a dry atmosphere were initially flushed with nitrogen or argon and kept dry using 
a calcium chloride / silica gel guard tube.
Reactions carried out at -10 or -15°C were cooled using an ice-salt bath; the 
temperature refers to that of the bath.
Solvents were removed using a rotary evaporator with a water condenser or dry- 
ice / acetone cold finger and under water or oil pump vacuum, as required.
3.1.2 Solvents.
Ether, which refers to diethyl ether, and THF were pre-dried over sodium wire and 
then distilled from sodium / benzophenone ketyl in an inert atmosphere, prior to use.
Toluene was pre-dried over sodium wire and then distilled from sodium under an 
inert atmosphere, prior to use.
Chloroform was washed with water, dried over calcium chloride, distilled from 
calcium chloride, and stored in dark bottles in an inert atmosphere.
Petrol, which refers to petroleum b.p. 60-80°C, was distilled; as were acetone and 
ethyl acetate.
Dichloromethane was distilled from phosphorus pentoxide.
Ethanol was dried by the Lund and Bjerrum method.376
DMF was fractionally distilled under water pump vacuum, with a nitrogen bleed; 
the initial wet fore-run was discarded and dry DMF collected at ca. 50°C and stored over 
activated 4 A molecular sieves, in dark bottles, in an inert atmosphere.
Acetonitrile was distilled from calcium hydride.
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All other solvents were used as supplied.
Solvent A refers to water containing 0.1% TFA. Solvent B refers to commercial 
acetonitrile / water (90:10) containing 0.1% TFA.
3.1.3 Reagents.
Amberlite IR 120(+) ion-exchange resin was soaked overnight in 2 M 
hydrochloric acid, the resin filtered off and washed with water until the washings were 
neutral.
Ethyl chloroformate was fractionally distilled at atmospheric pressure, collecting 
the fraction with b.p. 91-92°C.
HCl.Gly-OEt was crystallised from ethanol.
5 to 6 M HC1 in ethanol was prepared by bubbling HC1 through ethanol to produce 
a saturated solution. An aliquot of this solution was titrated against 2 M sodium 
hydroxide (phenolphthalein indicator) and the remainder diluted with the determined 
volume of ethanol to produce a 5 to 6 M solution (precise molarity as stated in 
procedures).
NMM and pyridine were distilled from calcium hydride.
Triethylamine was distilled from lithium aluminium hydride.
Lithium chloride was dried at 150°C, over phosphorus pentoxide, under vacuum
for 5 h.
All solutions mentioned were aq. unless otherwise stated. Brine refers to a sat. 
solution of sodium chloride.
3.1.4 Chromatography.
TLC on Whatman aluminium backed UV254 silica gel plates, was routinely used 
as a qualitative guide to the progress of reactions, and the purity of compounds. The 
following solvent systems were used for TLC: mixture A [ethyl acetate / petrol (70:30)], 
mixture B [ethyl acetate / petrol (60:40)], mixture C [ethyl acetate / petrol (50:50)], 
mixture D [chloroform / methanol / acetic acid (80:18:2)], mixture E [chloroform / 
methanol / acetic acid (90:8:2)], and mixture F [chloroform / methanol / acetic acid
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(95:3:2)]. The chromatograms were viewed under UV light and visualised using a 
ninhydrin dip solution (0 .2% ninhydrin in absolute ethanol) followed by heating.
Flash column chromatography was carried out under medium pressure on Amicon 
60A 35-70 mesh silica gel, following the guidelines of Still et. al.377 The columns were 
packed with a slurry of silica in the initial eluent. The substrates were applied to the 
columns either preabsorbed onto silica from a suitable solvent, or as a solution or slurry in 
the initial eluent, as noted. Moderate pressure was applied to the columns using hand 
bellows. When acetic acid was used as a component of the eluent, toluene was added to 
the pooled fractions in order to aid the evaporation of the acetic acid by azeotrope 
formation; some samples retained toluene, in those cases the toluene was removed by 
washing with petrol.
Analytical HPLC was performed on a LKB Bromma twin-pump HPLC 
instrument, with a Vydak C is wide pore reverse phase column, a high-pressure gradient 
manager and a diode-array detector, using a gradient of solvent B in solvent A.
3.1.5 Analysis and Spectroscopy.
Melting points were recorded on an Electrothermal apparatus and are uncorrected.
Elemental analyses were recorded on a Carlo Erba 1106 Elemental Analyser.
Optical rotations were recorded on a Perkin-Elmer 141 Polarimeter, with [a]D 
values quoted in 10_1 deg cm2 g_1, and concentration (c) quoted in g /100 mL.
IR spectra (Nujol mull, sodium chloride plates, unless otherwise stated) were 
recorded on a Perkin Elmer 1600 Series FTIR instrument, or a Perkin-Elmer 1310 Infrared 
Spectrophotometer.
UV spectra were recorded on a Perkin-Elmer Lambda 3 UV/VIS 
Spectrophotometer.
JH NMR spectra were recorded at 270 MHz and 13C NMR spectra at 67.8 MHz 
on a Jeol JNM-GX270 instrument, or at 400 MHz and 100.4 MHz on a Jeol-EX400 
instrument, as indicated. All spectra were recorded at room temperature (ca. 21°C), 
unless otherwise stated. Chemical shifts (6) are quoted in ppm with TMS as standard 
[spectra were referenced to internal TMS or to solvent (DMSOd6 at 2.50 ppm and 39.6
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ppm, and chloroform at 7.26 ppm and 77.0 ppm, for *H and 13C spectra respectively) as 
noted]. Coupling constants (,J) are given in Hz. The assignment of 13C NMR spectra was 
assisted by DEPT experiments. The assignment of !H spectra was assisted by D2O 
exchange experiments where appropriate. It should be noted that, for all NMR spectra 
run in DMSOd6 there is a broad water peak at ca. 3.3 ppm which somewhat obscures 
other resonances in that vicinity. Suppression of this signal was not carried out in order to 
avoid saturation transfer to exchangeable protons, suppression of signals of interest, and / 
or distortion of the spectra.241 With some samples, immediate accumulation after the 
addition of D2O enabled the obscured resonances to be observed. All integrals are quoted 
to the nearest integer, except when two (or more) species are present: in such cases well 
resolved signals due to each species are integrated to one decimal place. All variable 
temperature experiments and 2D spectra were recorded on the Jeol-EX400 instrument. 
Variable temperature experiments were performed by heating the sample with a stream of 
dry air, the data was accumulated once the sample was held at the desired temperature for 
ca. 3 m and the temperature was stable to within ± 0.6°C. Plots of 6nh against 
temperature were produced using CA - Cricket Graph III (Macintosh version 1.0) and 
gradients measured using linear curve fitting.
Mass spectra were recorded on a VG Autospec, a VG Analytical 7070E, a VG 
Masslab Model 12-253 quadrupole, or a Kratos MS80 instrument. All mass spectra 
presented are positive FAB spectra, with NBA used as the matrix, unless otherwise stated. 
Electron impact (E.I.) spectra were recorded with an ionising potential of 70 eV. 
Chemical ionisation (C.I.) spectra were recorded using wo-butane as the reagent gas. The 
electrospray spectrum was recorded at 2 kV in methanol / water / acetic acid 
(49.9:49.9:0.2) and has an expected calibration error of at least 0.4 Da. In the mass 
spectra of salts, M+ refers to the cation of the salt concerned. Negative ion (FAB) mass 
spectra are presented only for salts. The work of De Angelis et al. proved helpful in the 
assignment of PMRI peptide mass spectrometric fragments. 179.180
CD spectra were recorded with a nitrogen flushed JASCO spectropolarimeter 
J720, using 4 s time constant, 10 nm / minute scan speed, spectral bandwidth of 1 nm and 




(a) tert- Butoxycarbonyl protection o f glycine242^ ’™
A solution of glycine (10.0 g, 0.13 mol) in 1,4-dioxane / water (2:1, 400 mL) was 
cooled to 0°C and 1 M sodium hydroxide (133 mL, 0.13 mol) added with stirring. Di- 
tert-butyl dicarbonate (31.9 g, 0.15 mol) was added and the solution stirred at 0°C for 5 m. 
After stirring for a further 30 m at r.t. the solution was concentrated in vacuo to ca. 250 
mL. The resultant aq. solution was cooled to 0°C and an equal volume of ethyl acetate 
added. The mixture was stirred and acidified to pH 2 / 3 with 1 M potassium hydrogen 
sulfate. The mixture was extracted twice with ethyl acetate (2 x 150 mL), the extracts 
combined, dried over sodium sulfate and evaporated to produce a colourless solid. 
Recrystallisation from ethyl acetate / hexane yielded Boc-glycine, 95, as a colourless 
crystalline solid (13.1 g, 75 mmol, 56%), m.p. 85-88°C (lit.: 86.5-8^ C 242, 93-94°C379, 
85-89°C380) (Found: C, 48.5; H, 7.2; N, 7.65. Calculated for C7H 13NO4: C, 48.0; H, 7.5; 
N, 8.0%); Vmax/cm-1 3405m (NH), 3340m (NH), 3100br,s (OH), 1750vs (carboxylic 
acid), 1670vs (Boc carbonyl), 1535vs (amide II), 1410vs, 1335w, 1300m, 1280s, 1255m, 
1215vs, 1200vs, 1165vs, 1055m, 1030w, 960s, 885w and 860s; 6H(270 MHz; DMSOd6) 
1.34 (0.7 H, s, Boc minor conformer), 1.37 (8.3 H, s, Boc major conformer), 3.52 (0.3 H, 
br d, 77.5, CaH2 minor conformer), 3.56 (1.7 H, d, 76.2, CaH2 major conformer), 6.68 
(0.1 H, br t, NH minor conformer), 7.06 (0.9 H, t, 76.2, NH major conformer) and 12.50 
(br s, C 0 2H); 6h(270 MHz; CDCI3; TMS) 1.46 (9 H, s, Boc), 3.90 (0.7 H, br d, 7 4.5, 
CaH2 minor conformer), 3.97 (1.3 H, d, 75.7, CaH2 major conformer), 5.17 (0.6 H, br s, 
NH major conformer), 6.83 (0.4 H, br s, NH minor conformer) and 9.55 (1 H, br s, CO2H) 
[lit.,38! (90 MHz; CDCI3; TMS; -30°C) 1.47 (Boc), 3.95 (C«H2), 5.15 (0.1 H, t, 7 5.5, 
NH), 7.68 (0.9 H, t, 74.1, NH) and 12.5 (C02H)]; m/z (C.I.) 176 [(M+H)+, 12%], 120 
[100, (M+H) - CH2CMe2], 102 (13,120 - H20 ) and 76 (26, 120 - C 0 2).
(b) Coupling ofBoc-Pro and HCl.Gly-OEt
A solution of HCl.Gly-OEt (2.9 g, 21 mmol) and Boc-Pro (4.5 g, 21 mmol) in 
THF (50 mL) was cooled to -10°C. Triethylamine (2.9 mL, 2.1 g, 21 mmol), HOBt
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hydrate (3.2 g, 21 mmol) and DCC (4.4 g, 21 mmol) were successively added at -10°C, 
with stirring. The mixture was stirred in a dry atmosphere, at -10°C for 4 h, and then at 
r.t. for a further 5 days. The colourless precipitate was filtered off and washed with ethyl 
acetate (100 mL). The filtrate was washed successively with 5% citric acid (100 mL), 5% 
sodium hydrogen carbonate (100 mL) and water (100 mL plus 10 mL brine) and 
separated. Each aq. layer was back extracted with ethyl acetate (3 x 33 mL) and the 
combined organic extracts dried over sodium sulfate, evaporated, and dried under high 
vacuum. Column chromatography of the resultant yellow oil (preabsorbed onto silica 
from ethyl acetate solution) with ethyl acetate / petrol (70:30) as eluent yielded Boc-Pro- 
Gly-OEt as a colourless gum which retained solvent [4.7 g, ca. 75% (prior to analysis the 
gum was subjected to a few dissolution / evaporation cycles with deuterochloroform as 
solvent, in order to ensure that deuterochloroform was the only solvent retained)], (Found: 
C, 54.1; H, 7.85; N, 9.15. Calculated for C14H24N2O5.0.1CDCl3: C, 54.2; H, 7.8; N, 
8.95%); [a]^  - 58.1 (c 1.98 in ethanol*) [lit.,382 -58.0 (c 7.8 in ethanol)]; vmax /cm-1 
(neat) 3530br,w (NH), 3310br,m (NH), 3085w (NH), 2980s (CH), 2955m (CH), 2885m 
(CH), 1755s (ester carbonyl), 1695vs (Boc carbonyl), 1665br,vs (amide carbonyl), 
1535br,s (amide II), 1470m (CH), 1455m (CH), 1395br,vs, 1365s, 1250s, 1195vs, 1165vs, 
1125s, 1095m, 1025m, 975w, 920w, 890w, 850w, 775w and 730m; 6^210  MHz; CDC13; 
TMS) 1.28 (3 H, t, 7 7.1, OCH2C//3), 1.47 (9 H, s, Boc), 1.83-2.40 (4 H, br m, ProCPH2 
and CVH2)t, 3.29-3.57 (2 H, br m, ProC6H2)*, 4.00 (1 H, br dd, J  6.0 and 18.0, 
GlyC«H2)§, 4.06 (1 H, dd, 7 6.0 and 18.0, GlyC«H2), 4.21 (2 H, q, 77.1, OC//2CH3), 
4.33 (1 H br s, ProC«H)§, 6.60 (0.5 H, br s, NHp and 7.28 (0.5 H, br s, NH)5; 6C(100.4
* Concentration corrected for deuterchloroform content of 9 mole %, as indicated by elemental analysis.
t  On warming to 50°C, there was only a small change in the appearance of this multiplet.
$ At r.t this signal consisted of two overlapping broad singlets: major, 6h 3.47 and minor 6h 3.37. At 50°C: 
6n3.45(brs).
§ Sharpened at 50°C.
5 At 50°C these two signals virtually coalesced: 6h 6.86.
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MHz; CDCI3) 14.1 (OCH2CH3), 23.6 (br, ProCYH2 minor conformer), 24.4 (br, ProCYH2 
major conformer), 28.3 [(CH3)3C], 30.9 (br, ProCPH2), 41.2 (GlyC«H2), 47.0 (ProC6H2),
59.9 (br, ProC«H), 61.3 (br, OCH2CH3), 80.5 [(CH3)3C], 154.6 (br, Boc CO minor 
conformer), 155.7 (br, Boc CO major conformer), 169.6 (GlyCO), 172.3 (br, ProCO 
major conformer) and 172.9 (br, ProCO minor conformer); m/z (E.I.)* 300 (M+, 
300.1706, C14H24N2O5 requires 300.1685, 1%), 244 (3, M - CH2CMe2), 227 (3, 244 - 
OH), 199 (7, 244 - C02H), 170 {19, BocN[CH2]3CH+}, 114 (79, 170 - CH2CMe2), 70 
{100, HN[CH2]3CH+}, 57 (62, But+), 41 (14) and 30 (10).
(c) N-Terminal deprotection o f Boc-Pro-Gly-OEt with ethanolic hydrogen chloride
Boc-Pro-Gly-OEt (2.3 g, ca. 7.5 mmol) was dissolved in 6 M HC1 in ethanol (50 
mL) and stirred at r.t., in a dry atmosphere for 2 h. The solution was evaporated to 
dryness to provide a yellow oil. The oil was dissolved in water and freeze dried to yield 
HCl.Pro-Gly-OEt, 129 (1.7 g, 95%), as a hygroscopic, glassy, yellow syrup; [a ] |f  - 41.2 
(c 0.61 in ethanol); vmax /cm"1 3650-2400br,m (NH2+ and H20), 3325br,m (NH), 
3210br,m (NH), 2725m (NH2+), 1740s (ester carbonyl), 1680vs (amide carbonyl), 
1555br,m (amide II and NH2+), 1300m, 1210vs, 1115w, 1025m, 975w, 940w, 865w and 
720m; 6^270 MHz; DMSOd6) 1.19 (3 H, t, 7 7.0, OCH2C//3), 1.79-1.96 (3 H, m, 
ProCPH2 and CYH2), 2.23-2.40 (1 H, m, ProCPH2 and CYH2), 3.19 (2 H, br s, ProC6H2), 
3.77-4.09 (2 H, m, GlyC«H2), 4.10 (2 H, q, 7 7.1, OC//2CH3), 4.23 (1 H br s, ProC«H),
8.56 (1 H, br s, P r o N H 2+ ) t ,  8.99 (0.2 H, t, 75.3, GlyNH minor conformer), 9.13 (0.8 H, t, 
7 5.9, GlyNH major conformer) and 10.23 (1 H, br s, ProNH2+)t; 6^(100.4 MHz; 
DMSOd6) 14.2 (OCH2CH3), 23.6 (ProCYH2), 29.8 (ProCPH2), 40.9 (GlyC«H2), 45.6 
(ProC6H2), 58.7 (ProC«H), 60.7 (OCH2CH3), 168.7 (GlyCO minor conformer), 168.9 
(GlyCO major conformer), 169.3 (ProCO major conformer) and 170.6 (ProCO minor 
conformer); m/z 401 [(2M-H)+, 14%], 201 (100, M+) and 173 (10, M - C2H4); m/z (-ve) 
275 [(M+237C1)-, 3%], 273 [21, (M+37C1+35C1)1, 271 [33, (M+235C1)-], 245 (6 , 273 -
* The mass spectrum also contained the following peaks, due to deuterochloroform: 88 (3, DC37Q 2+), 86 
(19, DC35a 37a +) and 84 (29, DC35C12+).
t At 80°C these two signals coalesced: 6h 9.62.
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C2H4), 243 (13, 271 - C2H4), 237 [7, (M-H+^ci)-], 235 [27, (M-H+35C1)-], 209 (10,237 
- C2H4), 207 (30,235 - C2H4), 190 [34, (37C1+NBA)'], 188 [100, (35C1+NBA)-] and 171 
[21, (M-2H) - C2H4],
(d) Hydrogenolysis o f benzyl ethyl malonate
A solution of benzyl ethyl malonate (Aldrich, 85% tech.*, 13.8 g, 62 mmol) in 
absolute ethanol (250 mL) was hydrogenolysed over 10% palladium on carbon (1.4 g), 
under atmospheric pressure, at r.t. for 5 h. The solution was filtered through Celite, and 
the ethanol removed by evaporation. Fractional distillation of the residual oil under 
vacuum yielded monoethyl malonate, 98, (5.3 g, 65%), b.p. 89°C, 0.2 mmHg (lit.,383 77- 
78°C, 0.15 mmHg) (Found: C, 44.9; H, 6.35. Calculated for C5H8O4: C, 45.45; H, 6.1%); 
Vmax (liquid Film)/cm_1 3500-2500br,m (CO2H), 2985s (CH), 1730br,vs (carbonyls), 
1395m, 1375s, 1325vs, 1205s, 1160vs and 1030s (C-O); 6h (400 MHz, CDCI3, TMS) 130 
(3 H, t, J  7.1, CH2C//3), 3.45 (2 H, s, COCH2CO), 4.24 (2 H, q, 77.2, C //2CH3) and
10.45 (1 H, br s, CO2H) [lit.,384 1.27 (3 H, t, 7 7, CH2CT3), 3.40 (2 H, s, COCH2CO),
4.22 (2 H, q, 77, CH2CH3) and 8.63 (1 H, s, C 02H)]; m/z (E.I.) 133 [(M+H)+, 6%], 115 
[10, (M+H) - H20], 105 [12, (M+H) - CH2CH2], 87 (23, 105 -H20), 70 (9), 61 (15), 43 
(100, CH2COH+) and 29 (28, CHO+).
3.2.2 Gly series.
(a) Preparation o f Boc-Gly ip(NHCO)Gly-OEt, 99
(i) Original procedure
Boc-glycine, 95 (5.9 g, 33 mmol) was dissolved in THF (67 mL) and cooled to 
0°C in an inert atmosphere. Tri-«-butyl amine (6.2 g, 8.0 mL, 34 mmol) followed by 
ethyl chloroformate (3.7 g, 3.3 mL, 34 mmol) were added slowly, with stirring and the 
temperature maintained at 0°C. Stirring was continued at 0°C for 30 m. An ice cold
* Use of benzyl ethyl malonate supplied by Fluka (">97% HPLC"), yielded crude monoethyl malonate, 98, 
which required two distillations to obtain pure monoethyl malonate, 98, in a consistantly lower yield (50%) 
than that obtained from the Aldrich benzyl ethyl malonate.
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solution of sodium azide § (4.4 g, 67 mmol) in the minimum volume of water (20 mL) was 
added and stirring continued for 1 h at 0°C. Ice cold portions of ethyl acetate (335 mL) 
and sat. sodium hydrogen carbonate (335 mL) were added and the mixture shaken and 
separated. The organic portion was washed with ice cold brine (335 mL), dried over 
magnesium sulfate and evaporated at <25°C.5 The resultant yellow oil was dissolved in 
toluene (67 mL) and heated to 70°C in an inert atmosphere, with stirring, for ca. 1 h 
(during which vigorous effervescence occurred), until IR analysis indicated all the acyl 
azide, 96, [vmax(tol) 2140 cm-1] had converted to the isocyanate, 97, [vmax(tol) 2245 cm' 
1]. The solution was maintained at 70°C and monoethyl malonate, 98 (5.3 g, 40 mmol) 
was added. Stirring was continued at 70°C for ca. 45 m (during which further 
effervescence occurred), until IR analysis indicated all the isocyanate, 97, was consumed; 
after which the solution was cooled to r.t. and evaporated. The resultant yellow residue 
was redissolved in the minimum volume of toluene (30 mL) and petrol (100 mL) added. 
The resultant precipitate was filtered off, washed with toluene / petrol (2:1) and dried 
under vacuum. Further crude Boc-Glyxp(NHCO)Gly-OEt, 99, was obtained from the 
filtrate by addition of ethyl acetate (50 mL) and successive washes with 5% sodium 
hydrogen carbonate (50 mL), 5% citric acid (50 mL) and water (50 mL). The organic 
portion was dried over sodium sulfate, evaporated and dried under high vacuum. Column 
chromatography (sample preabsorbed from ethyl acetate solution) with ethyl acetate / 
petrol (70:30) as eluent, followed by recrystallisation from toluene / petrol yielded Boc- 
Glyxp(NHCO)Gly-OEt, 99 (2.2 g, 25%)*, as colourless needles, m.p. 86-87°C (Found: C,
§ This reaction has been performed safely using up to 10 g of sodium azide.
5 When the flask was removed from the rotary evaporator, air was readmitted via a calcium chloride / silica 
gel drying tube.
* The column chromatography also yielded crude /V,/V-bis(/V-Boc-aminomethyl)-urea, 100, as a colourless 
solid. This material was very difficult to purify, but a relatively pure sample was obtained by exhaustive 
washing with ethyl acetate; 6^ (270 MHz; DMSOd6) 1-37 (9 H, s, Boc), 4.21 (2 H, t, J  6.0, NHC//2NH),
6.58 (1 H, br m, BocNH) and 7.35 (1 H, br m, NH); m/z (C.I.) 391 (2%), 319 [3, (M+H)+], 263 [10, (M+H) 
- CH2CMe2], 207 [20, (M+H) - CH2CMe2], 202 (20, 263 - H20 , CO, NH), 183 (11), 146 (100, 202 -
163
50.7; H, 7.8; N, 10.75. Cj 1H2oN20 5 requires C, 50.75; H, 7.75; N, 10.75%); vmax /cm' 1 
3345vs (NH), 1745vs (ester carbonyl), 1690vs (Boc carbonyl), 1665vs (amide carbonyl), 
1545s (amide II), 1525vs (amide II), 1415w, 1390m, 1340m, 1320s, 1280vs, 1255s, 
1225m, 1170m, 1150vs, 1120s, 1045m, 965w, 945w and 900m; 6^(270 MHz; CDCI3; 
TMS) 1.29 (3 H, t, 77.1, OCH2C//3), 1.44 (9 H, s, Boc), 3.31 (2 H, s, COCH2CO), 4.20 
(2 H, q, 77.2, OCH2CH3\  4.55 (2 H t, 76.4, HNC//2NH), 5.70 (1 H, br s, BocNH) and 
7.84 (1 H, br s, NH); 6C(67.8 MHz; CDC13) 13.9 (OCH2CH3), 28.2 [(CH3)3C], 41.6 
(COCH2CO), 46.0 (HNCH2NH), 61.5 (OCH2CH3), 80.0 [(CH3)3C], 155.9 (Boc CO),
166.4 (CO) and 168.2 (CO); m/z 261 [(M+H)+, 35%], 205 [100, (M+H) - CH2CMe2], 144 
(39,205 - H20 , CO, NH) and 132 [31, (M+H) - BocNCH2].
(ii) Modified procedure
Boc-glycine 95 (13.5 g, 77 mmol) was dissolved in THF (150 mL) and cooled to 
0°C in an inert atmosphere. Tri-n-butyl amine (14.3 g, 18.3 mL, 77 mmol) followed by 
ethyl chloroformate (8.5 g, 7.5 mL, 78 mmol) were added slowly, with stirring and the 
temperature maintained at 0°C. Stirring was continued at 0°C for 30 m. An ice cold 
solution of sodium azide (10.0 g, 154 mmol) in the minimum volume of water (37 mL) 
was added and stirring continued for 1 h at 0°C. Ice cold portions of ethyl acetate (750 
mL) and sat. sodium hydrogen carbonate (750 mL) were added and the mixture shaken 
and separated. The organic portion was washed with ice cold brine (750 mL), dried over 
magnesium sulfate and evaporated at <25°C7 The resultant yellow oil was dissolved in 
toluene (150 mL) and heated to 70°C in an inert atmosphere, with stirring, for ca. 1 h 
(during which vigorous effervescence occurred), until IR analysis indicated all the acyl 
azide, 96, [vmax(tol) 2140 cm-1] had converted to the isocyanate, 97, [vmax(tol) 2250 cm-
1]. The solution was maintained at 70°C and monoethyl malonate, 98 (10.2 g, 77 mmol) 
added. Stirring was continued at 70°C for ca. 5 m (during which further effervescence
CH2CMe2), 134 (47), 130 (31, H2CNHBoc+), 118 (28), 102 (24), 85 (23,146 - H20 , CO, NH), 74 (34), 73 
(57, H2NCONHCH2+), 62 (59) and 61 (48).
T When the flask was removed from the rotary evaporator, air was readmitted via a calcium chloride / silica 
gel drying tube.
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occurred), until IR analysis indicated all the isocyanate, 97, was consumed. The solution 
was cooled to r.t., diluted with ethyl acetate (750 mL) and washed with water (750 mL). 
The organic portion was dried over sodium sulfate and evaporated. Column 
chromatography (sample preabsorbed from ethyl acetate solution) with ethyl acetate / 
petrol (70:30) as eluent, followed by recrystallisation from toluene / petrol yielded Boc- 
Gly,ip(NHCO)Gly-OEt, 99 (8.4 g, 42%), as colourless needle crystals, identical to the 
above.
(b) Reaction o f Boc-Glytl>(NHCO)Gly-OEt, 99, with  tert-Butyldimethylsilyl 
trifluoromethanesulfonate32°321
Boc-Glyip(NHCO)Gly-OEt, 99 (105 mg, 0.40 mmol) was dissolved in 
dichloromethane (1.5 mL) and the solution cooled to 0°C in an inert atmosphere. 
Triethylamine (56 pL, 41 mg. 0.40 mmol) and tert-butyldimethylsilyl 
trifluoromethanesulfonate (93 pL, 107 mg, 0.40 mmol) were successively added, and 
stirring continued at 0°C for 30 m. After this time TLC (mixture A) indicated the 
formation of a new compound (Rp 0.7), the presence of residual starting material, 99 (Rp 
0.4), and a base-line spot. The reaction mixture was allowed to warm to r.t. and stirring 
continued. After a further 90 m, TLC indicated the formation of a second new compound 
(Rp 0.5) in addition to that formed initially, residual starting material, 99, and the base­
line spot. The reaction mixture was diluted with dichloromethane (13.5 mL) and washed 
with ice-cold sat. sodium hydrogen carbonate (10 mL). The organic layer was dried over 
sodium sulfate and evaporated. The resultant residue was taken up in ether and filtered (to 
remove triethylammonium trifluoromethanesulfonate)321. The filtrate was evaporated to 
dryness. Column chromatography of the residue (applied as a solution in the initial 
eluent), with ethyl acetate / petrol / triethylamine (49:49:2 then 98:0:2) as eluent, yielded: 
a colourless oil [24 mg, 16% (assuming mono silylated), Rp 0.7 (mixture A)] which 
decomposed prior to analysis NMR (CDCI3) indicated a mixture of compounds and 
TLC (mixture A) indicated three components with Rps 0.8 (UV active), 0.7, and 0.4 (Boc- 
Glyip(NHCO)Gly-OEt, 99)};
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and Boc-Glyip(NHCO)Gly-OEt, 99, as a colourless solid (66 mg, 62%), identified by 
NMR and TLC (mixture A).
(c) N-Terminal deprotection of Boc-Gly ip(NHCO)Gly-OEt, 99, with ethanolic hydrogen 
chloride
Boc-Glyip(NHCO)Gly-OEt, 99 (100 mg, 0.38 mmol) was dissolved in 5 M HC1 in 
ethanol (2.0 mL) and stirred at r.t., in a dry atmosphere for 2 h. The solution was diluted 
with ethanol and evaporated to dryness to provide a yellow solid. Water was added to the 
solid and the resultant cloudy solution freeze dried to yield crude HCl.Glyop(NHCO)Gly- 
OEt, 101, as a hygroscopic yellow solid (91 mg, quantitative), m.p. 105-110°C; vmax /cm' 
1 3500-2500s (NH3+ and H20), 3255s (NH), 2000w (NH3+), 1735vs (ester carbonyl), 
1680vs (amide carbonyl), 1545m (NH3+), 1535s (amide II), 1505m (NH3+), 1400m, 
1345m, 1260m, 1195s, 1030m (C-O) and 950w; 6^270 MHz; DMSOd6)* 1.19 (3 H, t, J  
7.2, OCH2Ctf3), 3.36 (2 H, s, COCH2CO), 4.08 (2 H, q, 77.1, OC//2CH3), 4.22 (2 H, br 
d, +H3NC//2NH), 8.35 (3 H, br s, +H3N) and 9.24 (1 H, t, 7 6.4, NH); 6C(67.8 MHz; 
DMSOd6) 14.3 (OCH2CH3), 42.3 (COCH2CO), 44.7 (+H3NCH2NH), 61.2 (OCH2CH3),
167.4 (CO) and 167.6 (CO); m/z 321 [(2M-H)+, 21%], 161 (100, M+, 161.0927, 
C6Hi3N20 3 requires 161.0926) and 132 (90, M - HNCH2); m/z (-ve) 343 [(37C1+2NBA)', 
11%], 341 [34, (35C1+2NBA)'], 190 [34, (37C1+NBA)"] and 188 [100, (35C1+NBA)-]. 
Crystallisation of crude HCl.Glyi|>(NHCO)Gly-OEt, 101, from ethanol / ether, provided 
the pure compound as a colourless solid (28 mg, 0.14 mmol, 37%); 6^(270 MHz; 
DMSOd6) 1.19 (3 H, t, 77.0, OCH2C/73), 3.33 (2 H, s, COCH2CO), 4.08 (2 H, q, 77.2, 
OC//2CH3), 4.22 (2 H, d, 76.6, +H3NC//2NH), 8.33 (3 H, br s, +H3N) and 9.22 (1 H, t, 7 
6.4, NH).
(d) N-Terminal deprotection o f Boc-Gly ip(NHCO)Gly-OEt, 99, with TFA (in the presence 
oftriethylsilane)243
TFA (0.38 mL, 0.57 g, 5.0 mmol) and triethylsilane (0.15 mL, 112 mg, 0.96 
mmol) were added to a solution of Boc-Glyxp(NHCO)Gly-OEt, 99 (100 mg, 0.38 mmol)
$ The crude material's NMR spectrum also contained a signal due to NHf": 7.37 (0.5 H, t, Jh ,N 50.8).
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in dichloromethane (0.8 mL). The mixture was stirred at r.t. in a dry atmosphere for 90 m, 
after which time TLC (mixture A) indicated all the starting material, 99, was consumed. 
The mixture was evaporated to dryness and the residue triturated with ether. The resultant 
suspension was filtered, the precipitate washed with ether, dissolved in ethanol, 
evaporated and dried under high vacuum. The filtrate was evaporated, dried under high 
vacuum and further product obtained from the resultant residue by retrituration with ether, 
as before. The combined product, a colourless oil, was dissolved in water and freeze dried 
to yield TFA.Gly^NHCC^Gly-OEt, 102, as a colourless oil which solidified on standing 
in a refrigerator to produce a hygroscopic colourless glassy solid (89 mg, 86%), m.p. 64- 
67°C (Found: C, 34.3; H, 4.75; N, 9.9. C s H b I N ^ C ^ .^ O  requires C: 34.3, H: 4.9, N: 
10.0%); vmax /cm-1 3310s (NH), 3060br,s (NH3+), 2130w (NH3+), 1735vs (ester 
carbonyl), 1695vs (carboxylate), 1680vs (amide carbonyl), 1625s (NH3+), 1570s (NH3+), 
1525s (amide II), 1430m, 1410m, 1340vs, 1310m, 1195br,vs (C-F and C-O), 1125vs (C-F 
or C-O), 1080w, 1025m, 965w, 950w, 875w, 840m, 800m, 725m (C-F), 685w (C-F) and 
593m; 6^400 MHz; DMSOd6) 1.19 (3 H, t, 77.2, OCH2C//3), 3.35 (2 H, s, COCH2CO),
4.09 (2 H, q, 77.1, OC//2CH3), 4.25 (2 H, d, 7 6.4, +H3NC//2NH), 8.19 (3 H, br s, +H3N) 
and 9.16 (1 H, br s, NH); 6C(67.8 MHz; DMSOd6) 14.2 (OCH2CH3), 42.3 (COCH2CO),
44.7 (+H3NCH2NH), 61.1 (OCH2CH3), 167.3 (CO) and 167.5 (CO); m/z 321 [(2M-H)+, 
44%], 183 [15, (M-H+Na)+], 161 (56, M+), 144 (20, M - NH3) and 132 (100, M - 
HNCH2); m/z (-ve) 341 [(3CF3C 02+2H)-, 15%], 266 [11, (CF3C 02+NBA)-], 249 [17, 
(2CF3C 02+Na)-], 227 [69, (2CF3C 02+H)-] and 113 (100, CF3C 02 ).
(e) C-Terminal deprotection ofBoc-Gly ip(NHCO)Gly-OEt, 99, by saponification
2 M Sodium hydroxide (15 mL) was added to a solution of Boc-Glyip(NHCO)Gly- 
OEt, 99 (4.5 g, 17 mmol) in ethanol (90 mL). The mixture was stirred at r.t. overnight, 
then diluted with water and acidified to pH 2/3 by careful addition of 1 M potassium 
hydrogen sulfate. Brine (300 mL) was added and the solution extracted with ethyl acetate 
(5 x 200 mL). The organic extract was dried over sodium sulfate, evaporated and dried 
under high vacuum to yield Boc-Glyi|>(NHCO)Gly, 103, as a colourless solid (4.0 g, 
99%), m.p. 121-126°C (Found: C, 46.4; H, 6.95; N, 11.9. C9Hi6N2C>5 requires C, 46.55;
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H, 6.95; N, 12.05%); vmax /cn r1* 3355m (NH), 3320m (NH), 3100-2500br,w (C02H), 
1720s (acid carbonyl), 1685m (Boc carbonyl), 1650vs (amide carbonyl), 1555w (amide
II), 1535s (amide II), 1370w, 1275m, 1235m, 1160m, 1120m and 1050w; 6^270 MHz, 
DMSOd6) 1.38 (9 H, s, Boc), 3.13 (2 H, s, COCH2CO), 4.29 (2 H, t, 76.1, HNC//2NH),
7.45 (1 H, t, 76.1, BocNH), 8.52 (1 H, br s, NH) and 12.49 (1 H, br s, C 02H); 6C(67.8 
MHz, DMSOd6) 28.3 [(CH3)3C], 42.4 (COCH2CO), 45.3 (HNCH2NH), 78.3 [(CH3)3C],
155.7 (Boc CO), 166.0 (amide CO) and 169.5 (acid CO); m/z 233 [(M+H)+, 233.1143, 
C9Hi7N20 5 requires 233.1137, 37%], 177 [100, (M+H) - CH2CMe2], 116 (34, 177 - 
H20 , CO, NH) and 104 [19, (M+H) - BocNCHJ.
(f) Preparation ofBoc-Gly ip(NHCO)Gly-OSu, 106142
A solution of Boc-Glytp(NHCO)Gly, 103 (84 mg, 0.36 mmol) and N- 
hydroxysuccinimide (42 mg, 0.36 mmol) in THF (8 mL) was cooled to 0°C. DCC (75 
mg, 0.36 mmol) was added and the mixture stirred in a dry atmosphere at 0°C for 4 h, and 
then at r.t. overnight. The precipitated DCU was filtered off and washed with THF. The 
filtrate was evaporated and dried under high vacuum to yield crude Boc- 
Glyip(NHCO)Gly-OSu, 106, as a colourless solid (129 mg, quantitative). TLC (mixture 
F) of the crude material revealed the presence of starting materials and DCU. 
Recrystallisation of crude Boc-Glyip(NHCO)Gly-OSu, 106, from THF / petrol provided 
Boc-Glyi|)(NHCO)Gly-OSu, 106, as colourless crystals (29 mg, 24%); 6^(270 MHz, 
CDC13, TMS)5 1.44 (9 H, s, Boc), 2.87 (4 H, s, succinimide H), 3.63 (2 H, s, COCH2CO),
4.57 (2 H, t, 76.2, HNCf/2NH), 5.59 (1 H, br s, BocNH) and 7.62 (1 H, br s, NH); m/z 
330 [(M+H)+, 49%], 274 [100, (M+H) - CH2CMe2], 225 [32, (DCU+H)+], 213 (49, 274 -
§ Nujol mull IR spectra of Boc-Glyip(NHCO)Gly, 103, showed great variation, particularly in the NH and 
CO absorptions, pressumably indicating the presence of more than one conformer and / or different 
hydrogen bonded species in varying ratios. Boc-GlyTj>(NHCO)Gly, 103, was insufficiently soluble in 
appropriate solvents (chloroform, dichloromethane and carbon disulfide) for the measurement of its solution 
phase IR spectra. Thus the V j^  values quoted are merely representative.
5 The recrystallised material's NMR spectrum also contained the following signals, due to impurities: 
1.00-1.40 (3 H, m, DCU Hax), 1.50-2.00 (3 H, m, DCU Hgq) and 2.73 (0.5 H, s, HOSu CH2).
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H20 , CO, NH), 201 [64, (M+H) - BocNCH2], 177 (19), 138 (19), 116 [15, (HOSu+H)+] 
and 83 (30, 201 - HOSu).
(g) Coupling ofBoc-Gly rp(NHCO)Gly-OSu, 106, and HCLGlyty(NHCO)Gly-OEt, 101
A solution of crude Boc-Glyip(NHCO)Gly-OSu, 106 (290 mg, ca. 0.65 mmol*) in 
THF (20 mL) was added by decantation (leaving behind residual DCU) to crude 
HCl.Glyil>(NHCO)Gly-OEt, 101 (128 mg, ca. 0.65 mmol). Triethylamine (91 pL, 66 mg, 
0.65 mmol) was added and the mixture stirred at r.t., in an inert atmosphere, for 5 days, 
after which time TLC (mixture E) indicated consumption of the Boc-Glyi|)(NHCO)Gly- 
OSu, 106, was complete. The cloudy solution was filtered, the colourless precipitate 
washed with water and collected. The filtrate was evaporated to dryness and the resultant 
yellow residue washed with water and the colourless precipitate collected. The combined 
precipitates were dried under high vacuum over phosphorus pentoxide. Column 
chromatography of the combined precipitates (preabsorbed onto silica from a suspension 
in ethyl acetate), eluting with chloroform / methanol / acetic acid (90:8:2) yielded Boc- 
Glyip(NHCO)Gly-Gly4)(NHCO)Gly-OEt, 104, as a colourless solid [181 mg, 53% over 
the two steps from Boc-Glyi|j(NHCO)Gly, 103], m.p. 178-181°C (Found: C, 48.4; H, 7.1; 
N, 14.8. C15H26N4O7 requires C, 48.1; H, 7.0; N, 14.95%); vmax / cm' 1 3320vs (NH), 
1740m (ester carbonyl), 1690m (Boc carbonyl), 1675vs (amide carbonyl), 1650s (amide 
carbonyl), 1535s (amide II), 1530s (amide II), 1350w, 1280m, 1250w, 1230w. 1165w, 
1150m, 1115m and 1035w; 6^400 MHz, DMSOd6) 1.17(3 H, t,77.2, OCH2C//3). 138 
(9 H, s, Boc), 3.05 (2 H, s, Gly2C«H2), 3.22 (2 H, s, Gly4^ ^ ) ,  4.06 (2 H, q. 7 7.1, 
OC//2CH3), 4.29 (2 H, t, 7 6.0, Gly ^ " H ^ ,  4.38 (2 H, t, 7 6.1, Gly3C«H2), 7.43 (1 H, br 
t, 7 5.8, BocNH), 8.44 (1 H, br t, 76.0, Gly HpNH), 8.63 (1 H, br t, 7 5.5, Gly3NH) and 
8.73 (1 H, br t, 7 6.0, Gly3xpNH); 6C( 100.4 MHz, DMSOd6) 14.1 (OCH2CH3), 28.3 
[(CH3)3C], 42.2 (COCH2CO), 42.9 (COCH2CO), 43.5 (HNCH2NH), 45.2 (HNCH2NH),
60.5 (OCH2CH3), 78.2 [(CH3)3C], 155.7 (Boc CO), 165.8 (CO), 166.7 (CO), 167.3 (CO) 
and 167.7 (CO); m/z 375 [(M+H)+, 23%], 319 [34, (M+H) - CH2CMe2], 258 (39, 319 -
* Estimated from 1H NMR.
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H20 , CO, NH), 246 [31, (M+H) - BocNCHJ, 188 (25), 176 (28), 153 (25), 144 (20, 
CH2NHCOCH2CO2Et+), 132 [27, H2NC(0H)CH2C 02Et+], 127 (38), 115 (100, 
C0CH2C 02Et+), 107 (75), 103 (49) and 91 (51).
(h) Coupling ofBoc-Gly ip(NHCO)Gly, 103, and HCLPro-Gly-OEt, 129
A solution of Boc-Glyip(NHCO)Gly, 103 (0.40 g, 1.7 mmol), HCl.Pro-Gly-OEt, 
129 (0.45 g, 1.9 mmol) and A-hydroxysuccinimide (0.20 g, 1.7 mmol) in DMF (5 mL) 
was cooled to -10°C in a dry atmosphere. DCC (0.36 g, 1.7 mmol) and triethylamine 
(0.26 mL, 0.19 g, 1.9 mmol) were successively added at -10°C, with stirring. The mixture 
was stirred at -10°C for 4 h, and then at r.t. for a further 5 days. The precipitated DCU 
was filtered off and washed with dichloromethane (30 mL). The filtrate was evaporated to 
produce a brown residue which was dissolved in dichloromethane (100 mL) and the 
solution washed with 5% citric acid (50 mL) and water (50 mL plus a few drops of brine). 
The aq. layers were back-extracted with dichloromethane (50 mL), the combined organic 
extracts dried over sodium sulfate and evaporated. Column chromatography of the 
resultant solid (preabsorbed from dichloromethane solution), with chloroform / methanol 
(95:5) as the eluent, yielded Boc-Glyty(NHCO)Gly-Pro-Gly-OEt, 130, as a colourless 
solid (0.41 g, 58%); m.p. 122-124°C (Found: C, 52.1; H, 7.25; N, 13.4. C 18H3oN407 
requires C, 52.15; H, 7.3; N, 13.5%); [ajjj6 - 62.5 (c 1.95 in dichloromethane); vmax /cm-1 
3325s (NH), 1755w (ester carbonyl), 1730m (ester carbonyl), 1690s (Boc carbonyl), 
1655vs (amide carbonyl), 1650vs (amide carbonyl), 1545s (amide II), 1520s (amide II), 
1340w, 1305w, 1275w, 1255m, 1230w, 1195m, 1165m, 1115w, 1035w, 965w, 900w, 
865w and 730w; 6^210  MHz, CDCI3) 1.25 (3 H, t, 77.1, OCH2C//3), 1.41 (9 H, s, Boc), 
1.87-2.36 (4 H, m, Pro3CPH2 and CYH2), 3.32 (1 H, d, 7 16.3, Gly2C«H2), 3.39 (1 H, d, 7 
16.3, Gly2C«H2), 3.47-3.76 (2 H, m, Pro3C6H2), 3.92 (1 H, dd, 7 5.4 and 18.0, 
Gly4CaH2), 4.05 (1 H, dd, 75.8 and 18.0, G l y ^ H ^ ,  4.17 (2 H, q, 77.1, OC//2CH3), 
4.51 (2 H, br t, 76.4, Gly ^ “H ^, 4.61 (1 H, br dd, 7 2.2 and 7.7, Pro3C«H), 5.67 (0.8 H, 
br t, 76.0, BocNH major conformer), 5.78 (0.2 H, br t, 76.0, BocNH minor conformer), 
7.32 (0.2 H, br s, NH minor conformer), 7.48 (0.8 H, br s, NH major conformer), 8.12 (0.7 
H, br s, NH major conformer) and 8.24 (0.3 H, br s, NH minor conformer); 6^(100.4
170
MHz; CDCI3) 14.1 (OCH2CH3), 22.6 (Pro3CYH2 minor conformer), 24.6 (Pro3CYH2 
major conformer), 28.2 [(CT^^C], 28.5 (Pro3CPH2 major conformer), 32.0 (Pro3CPH2 
minor conformer), 41.2 ( G ly ^ H ^ ,  42.1 (Gly2C«H2), 46.1 (Gly1CaH2), 47.2 (Pro3C6H2 
minor conformer), 47.9 (Pro3C6H2 major conformer), 59.9 (Pro3CaH major conformer),
61.1 (PnPO H  minor conformer), 61.3 (OCH2CH3 major conformer), 61.7 (OCH2CH3 
minor conformer), 79.9 [(CH3)3C], 155.7 (Boc CO), 167.3 (amide CO), 167.4 (amide 
CO), 169.9 (Gly4C02Et) and 171.3 (Pro3CO); m/z 415 [(M+H)+, 40%], 359 [24, (M+H) - 
CH2CMe2], 298 (46,359 - H20 , CO, NH), 286 [100, (M+H) - BocNCH2], 269 (22, 298 - 
H2CNH), 228 (13), 201 [16, (Pro-Gly-OEt+H)+], 199 (23), 183 (17), 112 (10) and 73 
(13).
(i) C-Terminal deprotection o f Boc-Glytp(NHCO)Gly-Pro-Gly-OEt, 130, by 
saponification
2 M Sodium hydroxide (0.9 mL) was added to a solution of Boc- 
Gly,ip(NHCO)Gly-Pro-Gly-OEt, 130 (373 mg, 0.90 mmol) in ethanol (5 mL). The 
mixture was stirred at r.t. overnight, then diluted with water and acidified to pH 2/3 by 
careful addition of 1 M potassium hydrogen sulfate. Brine (20 mL) was added and the 
solution extracted with dichloromethane (10 x 20 mL). The combined organic extracts 
were dried over sodium sulfate, evaporated and dried under high vacuum. The resultant 
colourless solid was dissolved in water and freeze-dried to yield Boc-Glyip(NHCO)Gly- 
Pro-Gly, 131, as a colourless solid (304 mg, 88%), m.p. 142-148°C (change in appearance 
noted at 45-65°C); [a ]^0 - 78.5 (c 0.11 in water); vmax /cm-13330vs (NH), 3200-2500br,w 
(C02H), 1725m (acid carbonyl), 1680m (Boc carbonyl), 1660s (amide carbonyl), 1650vs 
(amide carbonyl), 1620vs (amide carbonyl), 1550m (amide II), 1535m (amide II), 1525m 
(amide II), 1340m, 1325m, 1285m, 1255m, 1220m, 1150s, 1115m, 1030w, 970w, 900w, 
865w, 800w, 775w, 725w, 680w and 650w; 6^(270 MHz, DMSO^) 1*38 (9 H, s, Boc),
1.70-2.23 (4 H, m, Pro3CPH2 and CYH2), 3.00 (0.3 H, d, /  15.4, Gly2C«H2 minor 
conformer), 3.17 (0.5 H, d, J  15.4, Gly2CaH2 minor conformer), 3.26 (1.2 H, s,
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Gly2C«H2 major conformer), 3.29-3.60 (3 H*, m, Pro3C6H2), 3.66 (1 H, dd, 7 5.9 and 
17.6, G ly^H ;*), 3.75 (1 H, dd, 75.7 and 17.4, Gly4C«H2), 4.30 (2.7 H, m, Gly1C«H2 
and PkPOTO major conformer), 4.53 (0.3 H, dd, 7 3.0 and 6.2, Pro3CaH minor 
conformer), 7.45 (1 H, m, BocNH)§, 8.16 (0.6 H, t, 75.9, NH major conformer), 8.44 (0.3 
H, t, 7 6.0, NH minor conformer), 8.51 (0.4 H, t, 7 6.0, NH minor conformed, 8.59 (0.7 
H, t, 7 5.3, NH major conform ed and 12.55 (0.4 H, br s, C 02H); 6C(100.4 MHz; 
DMSOd6) 22.4 (Pro3CYH2 minor conformer), 23.9 (Pro3CYH2 major conformer), 28.3 
[(CH3 )3 C], 29.7 (Pro3CPH2 major conformer), 31.6 (Pro3CPH2 minor conformer), 40.6 
(Gly4C(XH2 major conformer), 40.9 (Gly4CaH2 minor conformer), 42.0 (Gly2CaH2 minor 
conformer), 42.5 (Gly2CaH2 major conformer), 45.3 (Gly1CaH2), 46.5 (Pro3C6H2 minor 
conformer), 47.3 (Pro3CsH2 major conformer), 59.5 (PrcPOH major conformer), 60.2 
(Pro3CaH minor conformer), 78.3 [(C ^ ^C ], 155.7 (Boc CO), 166.4 (amide CO major 
conformer), 166.5 (amide CO minor conformer), 166.5 (amide CO minor conformer),
166.8 (amide CO major conformer), 171.2 (Gly4C 02H minor conformer), 171.2 
(Gly^C^H major conformer), 171.9 (PrcPCO major conformer) and 172.2 (Pro3CO 
minor conformer); m/z (FAB, glycerol) 387 [(M+H)+, 387.1860, Ci6H27N407 requires 
387.1880, 32%], 331 [11, (M+H) - CH2CMe2], 270 (18, 331 - H20 , CO, NH), 258 [34, 
(M+H) - BocNCH2], 239 (12), 155{15, H2NCOCH2CON[CH2]3CH+}, 147 (17), 91 (19), 
70 (42), 61 (14), 57 (36, But+), 45 (63), 43 (29), 31 (58, CH2OH+) and 29 (100, CHO+).
(j) Coupling ofBoc-Gly ip(NHCO)Gly-Pro-Gly, 131, and TFA.Gly ip(NHCO)Gly-OEt, 102 
A solution of TFA.Glyip(NHCO)Gly-OEt, 102 (92 mg, 0.34 mmol) in DMF (2.0 
mL) was prepared. A solution of Boc-Glyi|>(NHCO)Gly-Pro-Gly, 131 (115 mg, 0.30 
mmol) in DMF (1.0 mL) was cooled to -15°C in an inert atmosphere. N- 
Methylmorpholine (33 pL, 30 mg, 0.30 mmol) and /50-butylchloroformate (39 pL, 41 mg,
$ Due to presence of water signal.
§ At 400 MHz this signal appeared to be two overlapping triplets: 6h7.40 (75.9) and 7.44 (J 5.9).
5 At 100°C these two signals virtually coalesced.
0.30 mmol) were successively added and stirring continued at -15°C, in an inert 
atmosphere, for 30 m.
Triethylamine (47 pL, 34 mg, 0.34 mmol) was added to the solution of 
TFA.Glyip(NHCO)Gly-OEt, 102, and the resultant mixture immediately added to the 
solution of Boc-Glyip(NHCO)Gly-Pro-Gly, 131, N-methylmorpholine and iso- 
butylchloroformate. Stirring was continued at -15°C for 30 m, and then at r.t. overnight, 
in an inert atmosphere. The solution was evaporated to produce an off-white residue, to 
which water (10 mL) was added. The resultant colourless precipitate was collected, 
washed with water (10 mL) and dried under high vacuum over phosphorus pentoxide. 
The filtrate was freeze-dried and further crude product recovered from the resultant 
colourless solid by the addition of dichloromethane (20 mL) and water (30 mL); the 
layers were separated and the aq. phase back-extracted with dichloromethane (4 x 20 mL). 
The combined organic extracts were dried over sodium sulfate and evaporated. The two 
portions of crude product were combined and column chromatography (sample applied as 
a slurry in the initial eluent), with chloroform / methanol / acetic acid (95:3:2 then 90:8:2) 
as the eluent, yielded Boc-Gly'i|>(NHCO)Gly-Pro-Gly-Gly'ip(NHCO)Gly-OEt, 132, as a 
colourless solid (55 mg, 35%); m.p. 172-177°C; [a ]/f  - 20.6 (c 0.76 in TFE); vmax /cm-1 
3315s (NH), 3075w (NH), 1750m (ester carbonyl), 1690s (Boc carbonyl), 1655vs (amide 
carbonyl), 1650vs (amide carbonyl), 1635vs (amide carbonyl), 1545s (amide II), 1525s 
(amide II), 1345w, 1280m, 1230m, 1165m, 1120m, 1040w, 970w, 900w and 720w; 
6h(270 MHz, DMSOd6; TMS) 1.17 (3 H, t, 7 7.1, OCH2OT3), 138 (9 H, s, Boc), 1.70- 
2.20 (4 H, m, Pro3CPH2 and CYH2), 3.00-3.31 (4 H, m, Gly2C«H2 and GljftM fe), 3.39- 
3.59 (2 H, m, Pro3C6H2), 3.56-3.75 (2 H, m, G ly ^ H ^ * , 4.06 (2 H, q, 77.1, OC//2CH3), 
4.23-4.36 (2.5 H, m, Gly1CaH2 and Pro3CaH major conformer), 4.40 (2 H, t, 7 6.0, 
Gly5C«H2), 4.52 (0.5 H, br d, 78.4, Pro3C«H minor conformer), 7.44 (1 H, m, BocNH), 
8.16 (0.7 H, t, 7 6.0, Gl^NH major conformer), 8.29 (0.3 H, t, 7 6.0, Glj^NH minor 
conformer), 8.36 (0.7 H, t, 7 6.0, Gly5NH major conformer), 8.52 (0.3 H, t, 7 6.4,
* This signal appeared to be two doublets of doublets [6h  3.62 (dd, J  6.0 and 16.7) and 3.69 (dd, J  5.9 and 
16.7)] due to the major conformer, superimposed on a multiplet due to the minor conformer.
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Gly^N H  minor conformer), 8.59 (0.9 H, m, G ly^N H  major conformer and Gly5NH 
minor conformer), 8.68 (0.7 H, t, J  6.0, Gly^ipNH major conformer) and 8.74 (0.3 H, t, J  
5.8, G ly^N H  minor conformer); 6C( 100.4 MHz; DMSOd6) 14.1 (OCH2CH3), 22.4 
(Pro3CYH2 minor conformer), 24.1 (Pro3CYH2 major conformer), 28.3 [(CH3)3C], 29.5 
(Pto3CPH2 major conformer), 31.6 (Pro3CPH2 minor conformer), 41.7 (Gly4CaH2 minor 
conformer), 41.8 (Gly4CaH2 major conformer), 42.2 (COCH2CO), 42.5 (COCH2CO),
43.4 (HNCH2NH minor conformer), 43.5 (HNCH2NH major conformer), 45.3 
(HNCH2NH), 46.5 (Pro3C6H2 minor conformer), 47.4 (Pro3C6H2 major conformer), 59.8 
(Pro3CaH major conformer), 60.3 (P n^O H  minor conformer), 60.5 (OCH2CH3), 78.3 
[(CH3)3C], 155.7 (Boc CO), 165.8 (CO), 165.8 (CO minor conformer), 166.6 (CO),
166.8 (CO), 167.8 (CO), 169.4 (G ly^O ), 171.8 (Pro3CO major conformer) and 172.1 
(Pro3CO minor conformer); m/z 551 [(M+Na)+, 68%], 529 [100, (M+H)+, 529.2632, 
C22H37N6O9 requires 529.2622], 473 [9, (M+H) - CH2CMe2], 412 (19, 473 - H20 , CO, 
NH), 400 [46, (M+H) - BocNCH2], 313 (19), 269 (17, H2NCOCH2CO-Pro-Gly- 
NHCH2+), 257 [36, H2NCOCH2CO-Pro-NHCH2C(OH)NH2+], 240 (46, H2NCOCH2CO- 
Pro-NHCH2CO+) and 183 {23, H2NCOCH2C O N [C ^C H C O +}.
(k) N-Terminal deprotection o f Boc-Glyip(NHCO)Gly-Glyip(NHCO)Gly-OEt, 104, with 
ethanolic hydrogen chloride
Boc-Glyi[j(NHCO)Gly-Glyip(NHCO)Gly-OEt, 104 (61 mg, 0.16 mmol) was 
dissolved in 5 M HC1 in ethanol (5.0 mL) and stirred at r.t., in a dry atmosphere for 4 h. 
The solution was diluted with ethanol and evaporated to dryness to provide an off-white 
residue. Water was added to the residue and the resultant cloudy solution freeze dried to 
yield crude HCl.Glyip(NHCO)Gly-Glyi|j(NHCO)Gly-OEt, 139, as a hygroscopic off- 
white solid (56 mg, quantitative); 6^(270 MHz; DMSOd6)t 1.17 (3 H, t, J  7.0, 
OCH2CH3), 3.18 (2 H, s, COCH2CO), 3.24 (2 H, s, COCH2CO), 4.06 (2 H, q, 77.1, 
OCH2CH3), 4.21 (2 H, br m, +H3NCf/2NH), 4.40 (2 H, t, HNC//2NH), 8.26 (3 H, br s, 
+H3N), 8.76 (2 H, m, 2xNH) and 9.04 (1 H, t, J  6.0, NH).
t The crude material's NMR spectrum also contained the following signals, due to impurities: 3.15 (1 H, 
s) and 7.32 (1 H, t, 7H,N 50.7, NH4+).
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(I) N-Terminal deprotection o f Boc-Glyip(NHCO)Gly-Gly ip(NHCO)Gly-OEt, 104, with 
TFA
TFA (0.13 mL, 192 mg, 1.7 mmol) was added to a suspension of Boc- 
Gly'ii)(NHCO)Gly-Glyip(NHCO)Gly-OEt, 104 (50 mg, 0.13 mmol) in dichloromethane 
(0.2 mL). The mixture was stirred at r.t. in a dry atmosphere for 4 h, after which time 
TLC (mixture D) indicated all the starting material, 104, was consumed. The mixture was 
evaporated to dryness, petrol (2 mL) added and the mixture slowly stirred overnight. The 
petrol was decanted off and the process repeated with a further aliquot of petrol (2 mL). 
The resultant off-white residue was triturated with ether. The ether was decanted off and 
the process repeated with a further aliquot of ether. The resultant residue was dried under 
high vacuum to yield TFA.Glyip(NHCO)Gly-Gly'i|>(NHCO)Gly-OEt, 137, as a 
hygroscopic beige solid (40 mg, 77%), m.p. 121-127°C dec; vmax /cm-1 3600-2400br,m 
(NH3+ and H20), 3295vs (NH), 1965br,w (NH3+), 1740br,s (ester carbonyl), 1730s (ester 
carbonyl), 1715m, 1705w, 1700s, 1695s (carboxylate), 1680s (amide carbonyl), 1675w 
(amide carbonyl), 1665m (amide carbonyl), 1660m (amide carbonyl), 1650vs (amide 
carbonyl), 1645vs (amide carbonyl), 1635s (amide carbonyl), 1620w (NH3+), 1615w 
(NH3+), 1575w (amide II), 1565w (amide II), 1555s (amide II), 1540s (amide II), 1115m, 
975br,m, 840br,m, 725vs (C-F) and 665vs (C-F); 6^400 MHz; DMSOd6; TMS) 1.18 (3 
H, t, J  7.0, OCH2CH3), 3.19 (2 H, s, COCH2CO), 3.24 (2 H, s, COCH2CO), 4.07 (2 H, q, 
J 7.0, OC//2CH3), 4.22 (2 H, d, J  6.1, +H3NC//2NH), 4.41 (2 H, br t, 75.5, HNC//2NH),
8.23 (3 H, br s, +H3N), 8.76 (2 H, m, 2xNH) and 9.02 (1 H, br t, 76.0, NH); ^(100.4 
MHz; DMSOd6) 14.1 (OCH2CH3), 42.2 (COCH2CO), 42.8 (COCH2CO), 43.6 
(HNCH2NH), 44.6 (HNCH2NH), 60.5 (OCH2CH3), 165.9 (CO), 166.8 (CO), 167.7 (CO) 
and 168.2 (CO); m/z 549 [(2M-H)+, 12%], 393 (17), 322 (15), 297 [10, (M-H+Na)+], 275 
(100, 275.1340, C 10H19N4O5 requires 275.1355, M+), 258 (23, M - NH3), 246 (47, M - 
HNCH2), 176 (12), 144 (12, H2CNHC0CH2C 02Et+), 132 (15), 127 (13) and 103 [17, 
H2NCOCH2C(OH)NH2+].
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(m) C-Terminal deprotection o f Boc-Gly\p(NHCO)Gly-Gly\p(NHCO)Gly-OEt, 104, by 
saponification
2 M Sodium hydroxide (0.6 mL) was added to a suspension of Boc- 
Gly'ip(NHCO)Gly-Glyii>(NHCO)Gly-OEt, 104 (232 mg, 0.62 mmol) in ethanol (8 mL). 
The mixture was stirred at r.t. overnight, then diluted with water and the cloudy solution 
acidified to pH 2/3 by careful addition of Amberlite IR 120(+). The supernatant liquid 
(and the suspended colourless solid) was decanted off (leaving behind the ion-exchange 
resin) and freeze-dried to yield Boc-Glyip(NHCO)Gly-Glyt|)(NHCO)Gly, 135, as a 
colourless solid (191 mg, 89%), m.p. 128-140°C dec; vmax /cm-1 3355m (NH), 3300s 
(NH), 3150-2500br,w (CO2H), 1720m (acid carbonyl), 1695s (Boc carbonyl), 1655vs 
(amide carbonyl), 1650vs (amide carbonyl), 1640vs (amide carbonyl), 1545s (amide II), 
1530s (amide II), 1345w, 1320w, 1280m, 1255w, 1235m, 1170m, 1120m and 740w; 
6h(270 MHz, DMSOd6) 1.38 (9 H, s, Boc), 3.05 (2 H, s, COCH2CO), 3.13 (2 H, s, 
COCH2CO), 4.29 (2 H, t, 75.7, HNC//2NH), 4.38 (2 H, t, 75.9, HNC//2NH), 7.44 (1 H, 
br t, 76.0, BocNH), 8.45 (1 H, br t, 76.0, NH), 8.63 (1 H, br t, 76.0, NH), 8.70 (1 H, br t, 
75.5, NH) and 12.45 (1 H, br s, C 0 2H); 6^100.4 MHz, DMSOd6) 28.3 [(CH3)3C], 42.4 
(COCH2CO), 42.9 (COCH2CO), 43.5 (HNCH2NH), 45.2 (HNCH2NH), 78.3 [(CH3)3C],
155.7 (Boc CO), 166.4 (amide CO), 166.7 (amide CO), 167.3 (amide CO) and 169.3 (acid 
CO); m/z (FAB, glycerol) 439 [(M+H+glycerol)+, 11%], 347 [100, 347.1594, 
C13H23N4O7 requires 347.1567, (M+H)+], 291 [60, (M+H) - CH2CMe2], 230 (31, 291 - 
H20 , CO, NH), 218 [57, (M+H) - BocNCHJ, 188 (31), 176 (49), 147 (12), 127 (17), 115 
(29, H2NCOCH2CONHCH2+), 103 [23, H2NCOCH2C(OH)NH2+], 91 (15), 86 (12), 57 
(35, But+) and 30 (19, H2NCH2+).
(n) Coupling ofBoc-Gly \p(NHCO)Gly-Gly \p(NHCO)Gly, 135, and HCl.Pro-Gly-OEt, 129
A solution of Boc-Glyip(NHCO)Gly-Glyip(NHCO)Gly, 135 (178 mg, 0.52 mmol) 
and HCl.Pro-Gly-OEt, 129 (246 mg, 1.0 mmol) in DMF (4 mL) was cooled to -10°C in a 
dry atmosphere. A-Hydroxysuccinimide (60 mg, 0.5 mmol), EDC.HC1 (199 mg, 1.0 
mmol) and triethylamine (290 pL, 210 mg, 2.1 mmol) were successively added at -10°C, 
with stirring. The mixture was stirred at -10°C for 4 h, and then at r.t. for a further 4 days.
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The solution was evaporated to dryness and water (10 mL) added to the resultant yellow 
residue: very little product precipitated, so the mixture was freeze-dried. Column 
chromatography [sample applied as a slurry in chloroform / methanol / acetic acid 
(95:3:2)], with chloroform / methanol / acetic acid (90:8:2) as the eluent, followed by 
washing of the collected product with petrol and drying under high vacuum, yielded Boc- 
Glyi|>(NHCC))Gly-Glyi|>(NHCO)Gly-Pro-Gly-OEt, 136, as a colourless solid (55 mg, 
20%); m.p. 176-179°C dec; [ a f ,0 - 58.5 (c 0.96 in TFE); vmax /cm-1 3340br,s (NH), 
3310br,s (NH), 1730m (ester carbonyl), 1695s (Boc carbonyl), 1650vs (amide carbonyl), 
1635vs (amide carbonyl), 1555m (amide II), 1540s (amide II), 1520s (amide II), 1505s 
(amide II), 1340m, 1295br,m, 1230m, 1165m, 1115m, 1030m, 1005m, 960w, 940w and 
720w; 6h(400 MHz, DMSOd6)* 1.18 (3 H, br t, 7 7.1, OCH2C//3), 1.38 (9 H, s, Boc), 
1.74-2.26 (5 H§, br m, Pro5C0H2 and CyH2), 2.97-3.29 (5 PP, m, Gly2C«H2 and 
Gly4CaH2), 3.40-3.60 (2 H, m, Pro5C6H2), 3.71-3.87 (2 H, m, Gly6C«H2)*, 4.08 (2 H, m, 
OC/^CH^t, 4.29 (2.7 H, m, Gly1CaH2 and Pro5CctH major conformer), 4.40 (2 H, m, 
Gly3C«H2), 4.52 (0.3 H, dd, 73.0 and 8.0, P r o ^ H  minor conformer), 7.42 (1 H, t, 76.0, 
BocNH), 8.25 (0.7 H, t, 7 5.7, Gly6NH major conformer), 8.44 (1 H, br s, Gly^NH), 8.54 
(0.3 H, t, 7 5.5, Gly6NH minor conformer), 8.61 (1 H, t, 76.1, Gly3NH), 8.68 (0.2 H, t, 7 
6.0, Gly3i|>NH minor conformer) and 8.74 (0.5 H, t, 7 6.0, Gly3i|)NH major conformer); 
6C( 100.4 MHz; DMSOd6) 14.1 (OCH2CH3), 22.2 (Pro5CYH2 minor conformer), 23.9 
(Pro5CYH2 major conformer), 28.3 [(CH3)3C], 29.7 (Pro5CPH2 major conformer), 31.6 
(Pto5CPH2 minor conformer), 40.7 (Gly6CaH2 major conformer), 40.9 (Gly6CaH2 minor
t  Accumulation at 50°C resulted in little change in the spectrum.
§ There is no obvious source of the extra proton.
5 Extra proton due to overlap with the water signal.
* This signal appeared to be two doublets of doublets: 8h 3.75 (dd 76.0  and 17.5) and 3.83 (dd, 76.0  and 
17.2); with an overlapping multiplet, presumably due to the minor conformer.
t  This signal consisted of two overlapping quartets: 6h 4.07 (q, 7  7.1, major conformer) and 4.08 (q, 77.0, 
minor conformer).
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conformer), 41.9 (COCH2CO minor conformer), 42.4 (COCH2CO major conformer),
42.9 (COCH2CO), 43.5 (HNCH2NH), 45.2 (HNCH2NH), 46.5 (Pto?& H 2 minor 
conformer), 47.3 (Pro5C6H2 major conformer), 59.4 (Pn>5CaH major conformer), 60.4 
(Pro5CaH minor conformer), 60.5 (OCH2CH3 major conformer), 60.6 (OCH2CH3 minor 
conformer), 78.3 [(CH3)3C], 155.7 (Boc CO), 166.2 (amide CO), 166.7 (amide CO),
167.3 (amide CO), 167.3 (amide CO), 169.8 (Gly6C 02Et), 172.1 (P ro ^ O  major 
conformer) and 172.4 (Pro5CO minor conformer); m/z 1057 [(2M+H)+, 18%], 652 (16), 
551 [54, (M+Na)+], 529 [95, (M+H)+, 529.2627, C22H37N6O9 requires 529.2622], 412 
[35, (M+H) - CH2CMe2, H20 , CO, NH], 400 [95, (M+H) - BocNCH2], 298 (72, 
H2CNHCOCH2CO-Pro-Gly-OEt+), 286 [100, H2NC(OH)CH2CO-Pro-Gly-OEt+], 269 
(42, OCCH2CO-Pro-Gly-OEt+), 201 [27, (Pro-Gly-OEt+H)+], 199 (21) and 182 (23).
(o) C-Terminal deprotection o f Boc-Glyip(NHCO)Gly-Gly'ip(NHCO)Gly-Pro-Gly-OEt, 
136, by saponification
2 M Sodium hydroxide (0.1 mL) was added to a suspension of Boc- 
Glyip(NHCO)Gly-Gly^(NHCO)Gly-Pro-Gly-OEt, 136 (18.6 mg, 0.035 mmol) in ethanol 
(2 mL). The mixture was stirred at r.t. overnight, then diluted with water and the cloudy 
solution acidified to pH 2/3 by careful addition of Amberlite IR 120(+). The supernatant 
liquid (and the suspended colourless solid) was decanted off (leaving behind the ion- 
exchange resin) and freeze-dried to yield Boc-Glyip(NHCO)Gly-Gly'i[)(NHCO)Gly-Pro- 
Gly, 138, as an off-white solid (14.7 mg, 84%), m.p. 133-182°C dec (change in 
appearance noted at 102-110°C); [a ]^1 - 53.0 (c 0.41 in TEE); vmax /cm-13305br,m (NH), 
1730w (acid carbonyl), 1690m (Boc carbonyl), 1665s (amide carbonyl), 1655s (amide 
carbonyl), 1650vs (amide carbonyl), 1645vs (amide carbonyl), 1535m (amide II), 1525m 
(amide II), 1170m, 1120m and 720s; 6^(270 MHz, DMSO^g; TMS) 1.39 (9 H, s, Boc),
1.71-2.08 (4 H, m, Pro5CPH2 and CYH2), 2.92-3.29 (4 H, m, Gly2C«H2 and Gly4C«H2), 
3.43-3.61 (2 H, m, Pro5C6H2), 3.68 (1 H, dd, J  6.0 and 18.0, Gly6^ ^ ) ,  3.76 (1 H, dd, J  
6.0 and 16.5, Gly6CaH2), 4.29 (2.7 H, m, Gly1CaH2 and Pro5CaH major conformer), 
4.40 (2 H, t, J 5.3, Gly3C«H2), 4.51 (0.3 H, dd, 73.0 and 9.0, Pro5C«H minor conformer), 
7.44 (1 H, t, 7 6.0, BocNH), 8.16 (1 H, t, 76.0, NH), 8.46 (1 H, br m, NH), 8.63 (1 H, m,
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NH), 8.75 (1 H, t, J  6 .0, NH) and 12.40 (1 H, br s, C02H); 6C( 100.4 MHz; DMSOd6) 22.7 
(Pro5O H 2 minor conformer), 23.9 (Pro5CYH2 major conformer), 28.3 [(CH3)3C], 29.7 
(Pro5CPH2 major conformer), 31.9 (Pro5CPH2 minor conformer), 40.7 (Gly6CaH2 major 
conformer), 40.9 (G l^C01^  minor conformer), 42.2 (COCH2CO minor conformer), 42.4 
(COCH2CO major conformer), 42.9 (COCH2CO), 43.5 (HNCH2NH), 45.2 (HNCH2NH),
46.5 (Pro5CsH2 minor conformer), 47.3 (Pro5C6H2 major conformer), 59.5 (Pro5CaH 
major conformer), 60.2 (Pro5CaH minor conformer), 78.3 [(CH3)3C], 156.0 (Boc CO),
166.2 (amide CO), 167.1 (br, amide CO), 167.3 (amide CO), 167.3 (amide CO), 171.2 
(Gly6C 02H), 171.9 (Pro5CO major conformer) and 172.1 (Pro5CO minor conformer); 
m/z 523 [(M+Na)+, 71%], 501 [56, 501.2291, C20H33N6O9 requires 501.2309, (M+H)+], 
392 (40), 384 [26, (M+H) - CH2CMe2, H20 , CO, NH], 372 [69, (M+H) - BocNCH2], 322
(24), 270 (81, H2CNHCOCH2CO-Pro-Gly+), 258 [100, H2NC(OH)CH2CO-Pro-Gly+], 
241 (24, OCCH2CO-Pro-Gly+), 214(13), 199(16), 195(13), 188(18), 183(11), 176(35), 
173 [26, (Pro-Gly+H)+], 171 (21), 127(34), 115(80, H2NCOCH2CONHCH2+), 113 (46), 
105 (33), 103 [23, H2NCOCH2C(OH)NH2+], 91 (49) and 86 (27).
(p) N-Terminal deprotection ofBoc-Gly ip(NHCO)Gly, 103, with TFA
TFA (3.2 mL, 4.7 g, 42 mmol) was added to a solution of Boc-Glyi|)(NHCO)Gly, 
103 (734 mg, 3.2 mmol) in dichloromethane (5.3 mL). The mixture was stirred at r.t. in a 
dry atmosphere for 150 m, after which time TLC (mixture E) indicated all the starting 
material, 103, was consumed. The solution was evaporated to dryness, petrol (30 mL) 
added to the residue and the resultant mixture slowly stirred overnight. The petrol was 
decanted off and the process repeated with a further aliquot of petrol (30 mL). The 
resultant colourless residue was dissolved in ethanol, evaporated and dried under high 
vacuum to yield TFA.Glyip(NHCO)Gly, 141, as a colourless solid (787 mg, quantitative), 
m.p. 120-125°C dec (Found: C, 29.2; H, 3.55; N, 11.1. C6H9N205F3 requires C: 29.3, H:
3.7, N: 11.4%); vm3LX/crn-1 3300m (NH), 3060br,m (C 02H and NH3+), 2690br,w (C02H 
and NH3+), 2570br,w (C 02H and NH3+), 1720s (acid carbonyl), 1680vs (carboxylate), 
1660vs (amide carbonyl), 1595m (NH3+), 1550s (amide II), 1500w (NH3+), 1430w, 
1410w, 1330s, 1305w, 1220s (C-F and / or C-O), 1200vs (C-F and / or C-O), 1140s (C-F
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and / or C-O), 1130m (C-F and / or C-O), 1085w, lOOOw, 950w, 930w, 910w, 855w, 
845m, 805w, 785w and 725m (C-F); 6^270 MHz; DMSOd6) 3.25 (2 H, s, COCH2CO), 
4.25 (2 H, d, J  6.2, +H3NC//2NH), 8.20 (3 H, br s, +H3N), 9.11 (1 H, t, J  6.4, NH) and 
12.83 (1 H, br s, CO2H); 6C(67.8 MHz; DMSOd6) 42.4 (COCH2CO), 44.8 
(+H3NCH2NH), 167.4 (amide CO) and 168.4 (acid CO); m/z 286 [(M+NBA)+, 27%], 133 
(100, M+), 116 (14, M - NH3) and 94 (12); m/z (-ve) 266 [(CF3CO2+NBA)-, 72%] and 
113(100, CF3C 02-).
(q) N-Terminal protection ofTFA.Glyip(NHCO)Gly, 141, with Fmoc333
TFA.Glyil)(NHCO)Gly, 141 (703 mg, 2.9 mmol) and sodium hydrogen carbonate 
(480 mg, 5.7 mmol) were dissolved in a mixture of water (9 mL) and acetone (9 mL) with 
a concomitant evolution of gas. 9-Fluorenylmethyloxycarbonyl succinimide (963 mg, 2.9 
mmol) was added and the cloudy mixture stirred overnight at r.t., after which time TLC 
(mixture E) indicated complete consumption of the 9-fluorenylmethyloxycarbonyl 
succinimide. The mixture was diluted with acetone and acidified to pH 2 with 2 M 
hydrochloric acid. The solution was concentrated in vacuo, the precipitate collected, 
washed with water (100 mL) and dried under high vacuum over phosphorus pentoxide. 
Column chromatography (sample applied as a slurry in the initial eluent) with chloroform 
/ methanol / acetic acid (95:3:2 then 90:8:2) yielded crude Fmoc-Glyip(NHCO)Gly, 143, 
as a colourless solid (928 mg, 92%) [crystallisation from ethanol yielded Fmoc- 
Glyip(NHCO)Gly, 143, free from impurities, but with retained ethanol, which would 
cause problems during the SPS; therefore Fmoc-Glyty(NHCO)Gly, 143, was largely 
characterised without crystallisation], m.p. 182-185°C (from ethanol) (Found: C, 63.0; H, 
5.6; N, 7.1. C i9H18N2O5.0.8EtOH requires C: 63.25, H: 5.85, N: 7.15%); vmax /cm-1 
3315vs (NH), 3000-2500br,w (C02H), 1725s (acid carbonyl), 1700s (Fmoc CO), 1660vs 
(amide carbonyl), 1545m (amide II), 1530s (amide II), 1340w, 1315m, 1265s, 1230m, 
1170w, 1120m, 1050w, 985m, 900w, 785w, 760m and 740m; 6^(400 MHz; DMSOdg;
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TMS)t 3.16 (2 H, s, COCH2CO), 4.19-4.29 (3 H, m, Fmoc CH and CH2), 4.38 (2 H, t, 7 
5.9, HNC//2NH), 7.33 (2 H, t, 7 7.3, Fmoc Ar CH), 7.42 (2 H, t, 7 1 3 , Fmoc Ar CH), 7.72 
(2 H, d, 7 7.3, Fmoc Ar CH), 7.89 (2 H, d, 7 7.3, Fmoc Ar CH), 8.09 (1 H, t, 7 6.0, 
FmocNH), 8.64 (1 H, br t, 7 6.0, NH) and 12.49 (1 H, br s, C 0 2H); 6C( 100.4 MHz; 
DMSOd6)t 42.5 (COCH2CO), 45.5 (HNCH2NH), 46.7 (Fmoc CH), 65.8 (Fmoc CH2),
120.2 (Fmoc Ar CH), 125.4 (Fmoc Ar CH), 127.2 (Fmoc Ar CH), 127.8 (Fmoc Ar CH),
140.8 (Fmoc Ar C), 143.9 (Fmoc Ar C), 156.4 (Fmoc CO), 166.1 (amide CO) and 169.4 
(acid CO); m/z 355 [(M+H)+, 355.1299, Ci9Hi9N20 5 requires 355.1294,74%], 252 (13, 
FmocNHCH2+), 191 (13), 179 (97, 9-fluorenylmethyl cation), 178 (100, dibenzofulvene 
radical cation), 116 (22, H2CNHC0CH2C 02H+) and 94 (14).
(r) Solid Phase Synthesis o f  Ac-Glyty(NHCO)Gly-Glyty(NHCO)Gly-Pro-Gly-
Glyip(NHCO)Gly-Glyip(NHCO)Gly-NH2, 146
The SPS was performed under continuous flow conditions on a MilliGen 9050 
PepSynthesizer. The synthesis was carried out on a 0.1 mmol scale, using a fourfold 
excess of reagents, on a PAL-PEG-PS327 support (Millipore, 0.17 mEqg-1, 590 mg). 
Freshly distilled DMF was used throughout. The resin was swollen in DMF before 
loading into the synthesizer. The standard HOBt solution [HOBt hydrate (5 g), acid violet 
17 (25 mg) and DIPEA (67 pL) per 100 mL of DMF] was used as solvent during the 
coupling steps. The Fmoc deprotection steps were achieved with 20% piperidine in DMF 
and were carried out automatically, using the shortened "diketopiperidine deprotection 
protocol" for Fmoc-Glyip(NHCO)Gly- residues and monitoring the deprotection profiles 
with the post-column detector (360 nm). The coupling steps which incorporated Fmoc-
t The crude material's NMR spectrum also contained the following signals, due to impurities: 1.92 (0.1 
H, s, acetic acid Me), 2.30 (0.4 H, s, toluene Me), 2.60 (0.3 H, s, HOSu CH2), and 7.12-7.28 (0.4 H, m, 
toluene Ar CHs).
$ The crude material's 13C NMR spectrum also contained the following signals, due to impurities: 21.1 
(toluene Me), 25.3 (HOSu CH2), 128.3 (toluene Ar CH), 129.0 (toluene Ar CH) and 172.9 (HOSu CO).
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Glyxp(NHCO)Gly, 143 [four aliquots of (144 mg, ca. 0.40 mmol§)], used DIPCDI [four 
aliquots of (63 pL, 50 mg, 0.40 mmol)] as the coupling reagent, added manually to 0.2 M 
Fmoc-Glyip(NHCO)Gly, 143, in the HOBt solution.^ These coupling steps were 
prolonged manually until the pre-column detector reading (546 nm) reached a steady 
maximum. Gly6 and Pro5 were incorporated as their Fmoc-Xaa-OPfp derivatives (186 mg 
and 202 mg respectively, 0.40 mmol) at 0.3 M in the HOBt solution, under automatic 
control. A-Terminal capping with acetic anhydride (41 mg, 0.40 mmol) at 0.3 M in the 
HOBt solution, was performed automatically. Thus the coupling times were: 
Gly 9i|>(NHCO)Gly10, 22 h; Gly7ip(NHCO)Gly8, 24 h; Gly6, 3 h; Pro5, 1 h; 
Gly3^(NHCO)Gly4, 24 h; Gly1ip(NHCO)Gly2, 48 h; and Ac, 40 m. After the assembly, 
the resin was removed from the synthesizer and washed successively with 20 mL aliquots 
of dichloromethane, methanol and ether, then dried under a stream of nitrogen.
The product, Ac-Glyip(NHCO)Gly-Glyt[)(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly- 
Glyx|)(NHCO)Gly-NH2, 146, was cleaved from the resin by standing in TFA / water (95:5, 
15 mL) for 2 h. The resin was removed by filtration and washed with TFA (25 mL). The 
filtrate was evaporated, water (20 mL) added to the resultant green residue and the 
suspension freeze-dried to yield crude Ac-Glyip(NHCO)Gly-Glyip(NHCO)Gly-Pro-Gly- 
Gly'i[)(NHCO)Gly-Gly,i[)(NHCO)Gly-NH2, 146, as a pale green solid (50 mg, 75%); m/z 
(electrospray) 692.9 [(M+Na)+, C25H39N nO nN a requires 692.3, 100%], 670.7 [41, 
(M+H)+, C25H40N 11O11 requires 670.3], 641.3 (34), 578.3 (38), 555.7 (32), 514.0 (44),
486.3 (32), 442.1 {27, [Ac-GlyiKNHCO)Gly-GlyiKNHCO)Gly-Pro-Gly-NH2+H]+},
400.1 (34), 355.4 (35), 299.4 (22) and 278.4 (34).
A portion of the crude PMRI decapeptide, 146 (40 mg), was purified by 
successively washing with 10 mL aliquots of: solvent A plus B (50:50); water; ethanol; 
and ether. The respective solvent was added to the crude pseudopeptide, the suspension
§ Corrected for HOSu content, as judged by *H NMR. Before use Fmoc-Glyty(NHCO)Gly, 143 was dried 
under high vacuum over sodium hydroxide to remove all traces of acetic acid.
5 Prior to embarking on this SPS a solubility test on the monomer, Fmoc-Gly x|>(NHCO)Gly, 143, indicated 
that it was necessary to perform its coupling steps at 0.2 M rather than the usual 0.3 M.
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centrifuged (3000 rpm, 2 m) and the solvent decanted off. The resultant precipitate was 
dried under high vacuum to yield Ac-Gly,ip(NHCO)Gly-Gly,i|>(NHCO)Gly-Pro-Gly- 
Glyii>(NHCO)Gly-Glyi|>(NHCO)Gly-NH2, 146, as an off-white solid (8.7 mg); 6h(400 
MHz, DMSOd6)* 1.74-2.18 (4 H, m, Pro5CPH2 and CYH2), 1.80 (3 H, s, Ac), 3.00-3.30 
(12 H, m, Gly2C«H2, G ly^H ;* , Gly8C«H2 and Gly10C«H2)t, 3.45-3.58 (2 H, m, 
Pro5C6H2), 3.58-3.73 (2 H, m, G ly ^ H ^ ,  4.24-4.52 (9 H, m, Gly1C«H2, Gly3C«H2, 
Gly7C«H2, Gly9C«H2 and Pro5CaH)*, 7.05 (1 H, br s, NH2), 7.41 (1 H, br s, NH2), 8.16 
(0.8 H, t, 7 5.5, NH major conformer), 8.27 (0.3 H, t, 76.1, NH minor conformer), 8.32 
(0.8 H, t, 7 5.9, NH major conformer), 8.48-8.64 (6.6 H, m, NHs) and 8.74 (0.6 H, t, 75.3, 
NH major conformer).
3.2.3 Val series.
(a) Preparation o f Boc- Vafy(NHCO)Gly-OEt, 116(a) 157
Boc-valine 113(a) (1.1 g, 5.0 mmol) was dissolved in THF (10 mL) and cooled to 
0°C in an inert atmosphere. Tri-w-butyl amine (0.93 g, 1.2 mL, 5.0 mmol) followed by 
ethyl chloroformate (0.56 g, 0.49 mL, 5.1 mmol) were added slowly, with stirring and the 
temperature maintained at 0°C. Stirring was continued at 0°C for 30 m. An ice cold 
solution of sodium azide (0.66 g, 10.2 mmol) in the minimum volume of water (2.2 mL) 
was added and stirring continued for 1 h at 0°C. Ice cold portions of ethyl acetate (50 
mL) and sat. sodium hydrogen carbonate (50 mL) were added and the mixture shaken and 
separated. The organic portion was washed with ice cold brine (50 mL), dried over
* The *H NMR spectrum also contained the following signals due to impurities: 0.84-0.90 (2 H, m), 1.03- 
1.11 [3 H, two overlapping t, 1.05 (77.1, ethanol) and 1.09 (7 7.2, ether)], 1.21-1.39 (3 H, m), 4.11-4.15 
(m), 7.65-7.73 (0.6 H, m) and 8.64-8.70 (0.6 H, m). The *H NMR spectrum of the crude material before 
washing was identical except for the presence of 5^3.50 (7 H,s) and the absense of 6jj 1.03-1.11 (m).
t  It is unclear which (if any) of the signals in this region are due to impurities, nor how much the water 
signal contributes to the integral.
■f- This signal consisted of 6pj4.26 (dd, 72.9 and 8.3, Pro^Ca H major conformer) and 4.33-4.52 (m).
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magnesium sulfate and evaporated at <25°C.§ The resultant yellow oil, which 
effervesced slowly at r.t., was dissolved in toluene (10 mL): IR analysis at this stage 
indicated a mixture of acyl azide, 114(a), [vmax(tol) 2140 cm-1] and isocyanate, 115(a), 
[vmax(tol) 2250 cm-1]. The solution was heated to 70°C in an inert atmosphere, with 
stirring, for ca. 15 m (during which vigorous effervescence occurred), until IR analysis 
indicated all the acyl azide, 114(a), [vmax(tol) 2140 cm-1] had converted to the isocyanate, 
115(a), [vmax(tol) 2250 cm-1]. The solution was maintained at 70°C and monoethyl 
malonate, 98 (0.80 g, 6.1 mmol) added. Stirring was continued at 70°C for ca. 5 m 
(during which further effervescence occurred), after which time IR analysis indicated all 
the isocyanate, 115(a), was consumed. The solution was cooled to r.t. and petrol (boiling 
range 40-60°C, 50 mL) was added. The resultant colourless precipitate was collected and 
dried under high vacuum. Column chromatography (sample preabsorbed from ethyl 
acetate solution) with ethyl acetate / petrol (50:50) as eluent, followed by recrystallisation 
from toluene / petrol yielded Boc-Valip(NHCO)Gly-OEt, 116(a), as colourless needles 
(0.72 g, 48%)5, m.p. 144-146°C (Found: C, 55.8; H, 8.85; N, 935. C14H26N20 5 requires 
C, 55.6; H, 8.65; N, 9.25%); [a] ^ + 8.0 (c 1.05 in ethyl acetate); vmax /cm-1 3295s (NH), 
1740s (ester carbonyl), 1685vs (Boc carbonyl), 1655vs (amide carbonyl), 1560m (amide 
II), 1510vs (amide II), 1410w, 1390w, 1300w, 1285w, 1250m, 1215w, 1175m, 1145s, 
1125w, 1 lOOw, 1080w, 1040m and 1020m; 6^270 MHz; DMSOd6; TMS) 0.84 [3 H, d, 7
6.8 , CH(Cf/3)2], 0.85 [3 H, br d, 7 6 .6 , CH(CH3)2l  1.17 (3 H, t, 7 7.1, OCH2C//3), 1.38 
(9 H, s, Boc), 1.81 (1 H, br m, CH{CH3)2l, 3.19 (1 H, d, 7 15.0, COCH2CO), 3.27 (1 H, d, 
7 15.2, COCH2CO), 4.06 (2 H, q, 7 7.1, OC//2CH3), 4.94 [1 H, q, 78.3, HNtC/ZPrONH],
7.08 (1 H, br d, 77.5, BocNH) and 8.09 (1 H, d, 78.4, NH); 6C(67.8 MHz; CDC13; TMS)
§ When the flask was removed from the rotary evaporator, air was readmitted via a calcium chloride / silica 
gel drying tube.
5 The column chromatography also yielded a gummy colourless solid with *H NMR consistent with crude 
NyV,-bis[(S)-l-(W-Boc-amino)-2-methylpropyl]-urea, 117(a). This material was not further purified;
(400 MHz; DMSOd6; TMS) 0.81-0.88 [14 H, m, CH(CH3)2 plus impurity], 1.24-1.34 (11 H, impurity), 1.37 
(10 H, s, Boc plus impurity), 1.80 (1 H, br s, C//(CH3)2], 2.32 (4 H, t, J  7.1, impurity), 4.77 [1 H, q, J  7.8, 
HN(CHR-i)NH], 6.19 (1 H, br s, BocNH) and 6.98 (1 H, br s, NH).
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14.1 (OCH2CH3), 18.5 [CH(CH3)2], 28.3 [(CH3)3C], 31.8 [CH(CH3)2], 41.6 
(COCH2CO), 61.6 (OCH2CH3), 63.8 [HN(CHPri)NH], 79.9 [(CH3)3C], 155.1 (Boc CO),
164.8 (CO) and 169.2 (CO); m/z (C.I.) 303 [(M+H)+, 4%], 259 (9), 247 [30, (M+H) - 
CH2CMe2], 203 (26, 247 - C 02), 186 (100, 203 - NH3), 172 (19), 159 (17), 132 [38, 
(M+H) - BocNCHPri], 116 (18) and 72 (45, PriCHNH^).
(b) Exhaustive tert-Butoxycarbonylation o f Boc-Vaty(NHCO)Gly-OEt, 116(ap12
DMAP (46 mg, 0.37 mmol) and di-ter/-butyl dicarbonate (81 mg, 0.37 mmol) 
were added to a solution of Boc-Valip(NHCO)Gly-OEt, 116(a) (51 mg, 0.17 mmol) in 
acetonitrile (1.0 mL) and the mixture stirred at r.t., in a dry atmosphere, for 22 h. After 
this time TLC (mixture C) indicated the presence of unreacted starting material, 116(a), 
therefore further di-terf-butyl dicarbonate (30 mg, 0.14 mmol) was added. Stirring was 
continued for an additional 24 h, after which time TLC indicated further, but incomplete, 
consumption of starting material, 116(a). The yellow reaction mixture was evaporated, 
the resultant yellow solid dissolved in ethyl acetate (50 mL) and the solution successively 
washed with 1 M potassium hydrogen sulfate (2 x 20 mL) and brine (20 mL). The 
organic layer was dried over sodium sulfate and evaporated. Column chromatography of 
the resultant yellow solid (preabsorbed from ethyl acetate solution), with ethyl acetate / 
petrol (30:70) as eluent, yielded:
ethyl /V-[(S)-l-(/V'-Boc-amino)-2-methylpropyl]-(/?,S)-2-Boc-malonamate, 128, as a 
colourless solid (38 mg, 56%) [which slowly reverted to starting material (as shown by 
TLC) during analysis (the order of the analysis, and thus the order of increasing impurity, 
was: *H NMR, 13C NMR and m.s.)]; 6h(270 MHz; CDC13; TMS) 0.96 [6 H, d, 7 6 .6 , 
CH(Cfl3)2], 0.97 [6 H, d, 76.8, CH(C/£)2], 1.29 (3 H, t, 77.1, OCH2CJ73), 1.30 (3 H, t, 7 
7.1,0CH2O /3), 1.44 (18 H, s, NBoc), 1.47 (9 H, s, Boc), 1.48 (9 H, s, Boc), 1.90 (1.2 H, 
br s, impurity or C//(CH3)2 minor conformer], 2.22 (1.4 H, br s, Cf/(CH3)2], 4.21 [2 H, s, 
COC//(Boc)CO], 4.24 (2 H, q, 7 7.1, OC//2CH3), 4.25 (2 H, m, OCT2CH3)*, 4.92 [2 H, 
br s, HN(C//Pri)NH], 5.33 (2 H, br s, BocNH) and 7.76 (2 H, br s, NH); 6C(100.4 MHz;
* This signal consisted of two closely overlapping quartets, 77.1.
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CDCl3)t 13.9 (OCH2CH3), 18.4 [CH(CH3)2], 18.5 [CH(CH3)2], 27.7 [(CH3)3C], 28.2 
[(CH3)3C], 31.7 [CH(CH3)2], 31.9 [CH(CH3)2], 60.3 [COCH(Boc)CO], 62.3 
(OCH2CH3), 63.9 [br, HN(CHPr*)NH], 79.7 [br, (CH3)3COCONH], 83.7 
[(CH3)3COCOCH], 83.8 [(CH3)3COCOCH], 154.9 (NBoc CO), 155.0 (NBoc CO), 162.2 
(br, Boc CO), 164.4 (CO), 164.6 (CO), 165.6 (CO) and 165.8 (CO); m/z 425 [(M+Na)+, 
16%), 403 [23, (M+H)+], 347 [7, (M+H) - CH2CMe2], 303 {9, 347 - C 0 2 and / or 
[116(a)+H]+]} 286 (21, 347 - H20 , CO, NH), 247 (14, 303 - CH2CMe2), 230 (51, 286 - 
CH2CMe2), 186 (33, 230 - C 0 2), 176 (16), 132 [14, H2NC(0H)CH2C 02Et+], 116 (26) 
and72(100,PriCHNH2+);
and Boc-Val'ip(NHCO)Gly-OEt, 116(a) (4.4 mg, 9%); confirmed by TLC.
(c) N-Terminal deprotection o f Boc-Valip(NHCO)Gly-OEt, 116(a), with TFA
(i) In the presence o f triethylsilane24^
TFA (30 mg, 0.2 mL, 2.6 mmol) and tri ethyl si lane (55 mg, 76 pL, 0.48 mmol) 
were added to a solution of Boc-Valii)(NHCO)Gly-OEt, 116(a) (58 mg, 0.19 mmol) in 
dichloromethane (0.3 mL). The mixture was stirred at r.t. in a dry atmosphere for 2 h, after 
which time TLC (mixture C) indicated all the starting material, 116(a), was consumed. 
The mixture was evaporated to dryness and the residue triturated with ether. The ether 
was decanted off and the colourless residue collected by dissolving in ethanol, evaporation 
and drying under high vacuum. Evaporation of the ether and additional trituration / 
decantation / evaporation cycles yielded further product.* The resultant colourless oil was 
dissolved in water and freeze dried to yield crude TFA.Valip(NHCO)Gly-OEt, 119, as a 
hygroscopic, cloudy, colourless gum (50 mg, 84%); [a{f + 12.1 ( c 0.57 in ethanol); vmax 
/cm-1 3420s (NH), 3200s (NH), 3050s (NH3+), 1735vs (ester carbonyl), 1675br,vs 
(carboxylate and amide carbonyl), 1535s (amide II), 1430s, 1325m, 1200vs (C-F and / or 
C-O), 1135vs (C-F and / C-O), 1030s, 1000m, 835m, 800m, 765m and 720m (C-F);
* The 13C NMR spectrum also contained the following signals, due to impurities: 14.0 [116(a) OCH2CH3], 
31.2 [CH(CH3)2],41.5 [116 (a) COCH2CO] and 61.5 [116 (a)OCH2CH3].
* The total number of such cycles necessary to achieve good recovery of the product varied between 1 and 5 
from experiment to experiment.
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6h(270 MHz; DMSOd6)* 0.94 [6 H, d, 7 7.0, CH(C//3)2], 1.19 (3 H, t, 77.2, OCH2C//3), 
1.99 (1 H, octet, 77.0, CH{CH3)2], 3.30 (1 H, d, 7 15.4, C0CH2C0), 3.38 (1 H, d, 7 15.2, 
COCHoCO), 4.09 (2 H, q, 77.1, OC//2CH3), 4.70 [1 H, t, 7 8 .1, HN(C/H¥)NH], 8.26 (3 
H, br s, +H3N) and 8.90 (1 H, d, 78.4, NH); 6C(100.4 MHz; DMSOd6) 14.1 (OCH2CH3), 
17.0 [CH(CH3)2], 18.1 [CH(CH3)2], 30.4 [CH(CH3)2], 42.3 (COCH2CO), 60.7 
(OCH2CH3), 61.6 [HN(CHPri)NH], 158.4 (q, 7 31, CF3C 02 ), 166.4 (CO) and 167.4 
(CO); m/z 405 [(2M-H)+, 23%], 257 (12), 203 (33, M+, 203.1384, C9H i9N20 3 requires 
203.1396), 186 (100, M - NH3) and 72 (87, PriCHNH^); m/z (-ve) 341 [(3CF3C 02+2H)-, 
16%], 287 (14), 227 [100, (2CF3C 02+H)-] and 113 (71, CF3C 02 ).
(ii) In the absence oftriethylsilane
TFA (1.2 g, 0.8 mL, 10 mmol) was added to a solution of Boc-Vali|>(NHCO)Gly- 
OEt, 116(a) (237 mg, 0.78 mmol) in dichloromethane (1.3 mL). The mixture was stirred 
at r.t. in a dry atmosphere for 135 m, after which time TLC (mixture C) indicated all the 
starting material, 116(a), was consumed. The mixture was evaporated to dryness, petrol 
(8 mL) added and the mixture slowly stirred for a few hours.263 The petrol was decanted 
off and the process repeated with a further aliquot of petrol (8 mL). The resultant residue 
was triturated with ether. The ether was decanted off and the colourless residue collected 
by dissolving in ethanol, evaporation and drying under high vacuum. Evaporation of the 
ether and additional trituration / decantation / evaporation cycles yielded further product. § 
Thus crude TFA.Vahl>(NHCO)Gly-OEt, 119, was obtained as a hygroscopic, cloudy, 
colourless gum (207 mg, 84%), identical to the above.
* The crude material's NMR spectrum also contained the following signals, due to impurities: 6h 0.84
(0.4 H, d J 6.6), 0.90 (0.1 H, s), 2.88 (0.1 H, t, J  6.0), 3.18 (0.3 H, d, 7 10.3) and 7.18 (0.8 H, t, JH,N 51.8,
NH4+).
§ The total number of such cycles necessary to achieve good recovery of the prodcut varied between 3 and 5 
from experiment to experiment.
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(d) N-Terminal deprotection o f Boc-Valip(NHCO)Gly-OEt, 116(a), with ethanolic 
hydrogen chloride
Boc-Vali|j(NHCC))Gly-OEt, 116(a) (200 mg, 0.66 mmol) was dissolved in 5 M 
HC1 in ethanol (3.3 mL) and stirred at r.t., in a dry atmosphere for 3 h. The solution was 
diluted with ethanol, evaporated and dried under high vacuum to provide a yellow residue. 
*H NMR (DMSOd6) and TLC (mixture A) revealed that this residue was a mixture of 
compounds, probably including the desired HCl.Valii)(NHCO)Gly-OEt. In order to 
identify the impurities, the mixture was column chromatographed (sample applied as a 
slurry in the initial eluent) with ethyl acetate / petrol (50:50 then 100:0), as eluent. The 
pooled fractions yielded a colourless solid (23 mg), which was subsequently revealed to 
be a mixture of ethyl malonamate, 118, and ethylmalonyl-Valrp(NHCO)Gly-OEt, 120, in 
a molar ratio of 63:37; Rp 0.4 (ethyl acetate), 0.4 and 0.5 (mixture E) and 0.1 (ether); 
&h(270 MHz, DMSOd6) 0.86 [6 H, d, J  6 .6 , CH(C//3)2], 1.18 (11.4 H, m, OCH2C//3)5, 
1.91 [1 H, octet, 7 7.0, C//(CH3)2], 3.17 (3.2 H, s, COCH2CO), 3.18 (2 H, d, J  15.4, 
COCH2CO), 3.28 (2.6 H*, d, J  15.0, COCH2CO), 4.06 (7.5 H, m, OC//2CH3)t, 5.17 [1 H, 
q, J 8.1, HN(Cflft*)NH], 7.10 (1.5 H, br s, NH2), 7.52 (1.5 H, br s, NH2) and 8.26 (2 H, d, 
J  8.4, NH); 6C( 100.4 MHz; DMSOd6) 14.1 (OCH2CH3), 18.2 [CH(CH3)2], 31.7 
[CH(CH3)2], 42.5 (C0CH2C0), 60.4 [HN(CHI¥)NH and OCH2CH3], 60.5 (OCH2CH3), 
164.6 (CO), 167.3 (CO), 167.9 (CO) and 168.0 (CO); m/z 317 [(120+H)+, 36%], 186 
(100, PriCHNHC0CH2C 02Et+) and 132 [46, (118+H)+].
(e) Coupling o f monoethyl malonate, 98, and ammonia
A-Hydroxy succinimide (453 mg, 3.9 mmol) and EDC.HC1 (754 mg, 3.9 mmol) 
were added to a solution of monoethyl malonate, 98 (520 mg, 3.9 mmol) in acetonitrile (5
A
mL) and the mixture stirred in a dry atmosphere, at r.t. for 75 m. Aq. ammonia {ca. 33% 
w/w, 0.23 mL, 3.9 mmol NH3) was added to the reaction mixture, and the cloudy solution
5 This signal consisted of two overlapping triplets: 8h 1.17 (t, J 7.0) and 1.18 (t, J7.1).
* Due to overlap with the water signal.
This signal consisted of two overlapping quartets: 6h 4.06 (q, J7.0) and 4.06 (t, 77.0).
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stirred at r.t. overnight. After this time, TLC (mixture E) indicated incomplete 
consumption of the monoethyl malonate, 98, so further EDC.HC1 (377 mg, 2.0 mmol) was 
added and stirring continued. After an additional 6 h, unreacted monoethyl malonate, 98, 
still remained (as indicated by TLC), so further EDC.HC1 (377 mg, 2.0 mmol) was added 
and stirring continued overnight. TLC then indicated complete consumption of the 
monoethyl malonate, 98, so the solution was concentrated in vacuo and dichloromethane 
(70 mL) added to the residual solution. The mixture was washed with brine (15 mL), and 
the brine back-extracted with dichloromethane (70 mL). The combined organic extracts 
were dried over sodium sulfate, evaporated and dried under high vacuum. Column 
chromatography (sample preabsorbed from ethyl acetate solution), with ethyl acetate as 
the eluent, yielded ethyl malonamate, 118, as a colourless oil, which crystallised as 
colourless needles on standing in the refridgerator (306 mg, 59%); m.p. 39-42°C (from 
ether) (lit.,262 42°C) (Found: C, 45.6; H, 7.0; N, 10.6. Calculated for C5H9NO3: C, 45.8; 
H, 6.9; N, 10.7); Rp 0.4 (ethyl acetate), 0.4 (mixture E) and 0.1 (ether); v max / cm-13390s 
(NH), 3325m (NH), 3310s (NH), 1720br,vs (ester carbonyl), 1665br,vs (amide carbonyl), 
1625s (amide II), 1425s, 1315s, 1285s, 1170s, 1130m, 1115m, 1030s, 965w, 880m and 
850m; 6H(270 MHz, DMSOd6; TMS) 1.18 (3 H, t, 7 7.1, OCH2C//3), 3.18 (2 H, s, 
COCH2CO), 4.07 (2 H, q, 77.1, OC//2CH3), 7.10 (1 H, br s, NH2) and 7.52 (1 H, br s, 
NH2); 6c (67.8 MHz; DMSOd6) 14.1 (OCH2CH3), 42.5 (COCH2CO), 60.4 (OCH2CH3),
167.3 (CO) and 168.0 (CO); m/z (C.I.) 132 [(M+H)+, 100%], 115 [5, (M+H) - NH3], 104 
[3, (M+H) - C2H4] and 86 (4, 104 - H20).
(f) Coupling o f monoethyl malonate, 98, and TFA.Valip(NHCO)Gly-OEt, 119
Monoethyl malonate, 98 (108 mg, 0.82 mmol), crude TFA.Valip(NHCO)Gly-OEt, 
119 (258 mg, ca. 0.82 mmol) and A-hydroxysuccinimide (94 mg, 0.82 mmol) in THF (10 
mL) were cooled to -10°C, in a dry atmosphere. EDC.HC1 (170 mg, 0.89 mmol) and 
triethylamine (227 pL, 165 mg, 1.6 mmol) were added and the mixture stirred in a dry 
atmosphere, at -10°C for 4 h, and then at r.t. for 2 days. The solution was evaporated to 
dryness. The resultant off-white residue was dissolved in dichloromethane (100 mL), the 
solution washed with 5% citric acid (50 mL) and separated. The aq. layer was back-
189
extracted with dichloromethane (50 mL), the combined organic extracts were washed with 
water (50 mL plus a few drops of brine), dried over sodium sulfate, evaporated and dried 
under high vacuum. Column chromatography (sample applied as a solution in the eluent), 
with chloroform / methanol / acetic acid (95:3:2) as the eluent, yielded ethylmalonyl- 
Vah|)(NHCO)Gly-OEt [bi s-(A-ethylmalonyl)-1,1 -diamino-2-methylpropane], 120, as a 
colourless solid. Crystallisation from ethyl acetate yielded ethylmalonyl- 
Vah|>(NHCO)Gly-OEt, 120, as colourless needles (73 mg, 28%); m.p. 150-151°C (change 
in appearance noted at 99-105°C and 139-143°C) (Found: C, 53.1; H, 7.6; N, 8.85. 
C14H24N2O6 requires C, 53.15; H, 7.65; N, 8.85); Rp 0.4 (ethyl acetate), 0.5 (mixture E) 
and 0.1 (ether); vmax / cm’1 3255s (NH), 3140m (NH), 3050w (NH), 1740s (ester 
carbonyl), 1730s (ester carbonyl), 1660vs (amide carbonyl), 1585w (amide II), 1540m 
(amide II), 1420w, 1330s, 1205s, 1180m, 1130w, 1080m, 1035w, 865w, 800w, 725w and 
625w; 6h(270 MHz, DMSOd6; TMS) 0.87 [6 H, d, 7 6.6, CH(C/fc)2], 1.17 (6 H, t, 7 7.1, 
OCH2C//3), 1.90 [1 H, octet, 77.1, C//(CH3)2], 3.19 (2 H, d, 715.2, COCH2CO), 3.28 (2 
H, d, 7 15.0, COCH2CO), 4.06 (4 H, q, 7 7.1, OC//2CH3), 5.17 [1 H, q, 7 8.2, 
HN(C//Pri)NH] and 8.27 (2 H, d, 7 8.4, NH); 6C( 100.4 MHz; DMSOd6) 14.1 
(OCH2CH3), 18.2 [CH(CH3)2], 31.7 [CH(CH3)2], 42.5 (COCH2CO), 60.4 
[HN(CHPri)NH], 60.5 (OCH2CH3), 164.6 (CO) and 167.9 (CO); m/z (FAB, glycerol) 317 
[(M+H)+, 317.1716, C14H25N2O6 requires 317.1713, 63%], 172 (15), 158 (15), 140 (15) 
and 72 (100, PriCHNH2+).
(g) C-Terminal deprotection o f Boc-Valty(NHCO)Gly-OEt, 116(a), by saponification
2 M Sodium hydroxide (14 mL) was added to a solution of Boc-Valip(NHCO)Gly- 
OEt, 116(a) (3.6 g, 12 mmol) in ethanol (65 mL). The mixture was stirred at r.t. overnight 
and acidified to pH 2/3 by careful addition of 1 M potassium hydrogen sulfate. Brine 
(250 mL) was added and the solution extracted with ethyl acetate (5 x 250 mL). The 
organic extract was dried over sodium sulfate, evaporated and dried under high vacuum to 
yield Boc-Vahl>(NHCO)Gly, 121, as a colourless solid (3.3 g, 99%), m.p. 118-121°C 
(Found: C, 52.5; H, 8.1; N, 10.0. C12H22N2O5 requires C, 52.55; H, 8.1; N, 10.2%); 
[a]k9 + 12.0 (c 1.16 in ethanol); vmax /cm"1 3325s (NH), 3 100-2500br,w (C02H), 1725s
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(acid carbonyl), 1690vs (Boc carbonyl), 1655m (amide carbonyl), 1560m (amide II), 
1515s (amide II), 1315w, 1290w, 1250w, 1215w, 1175m, 1150m, 1070w, 1045w and 
1025w; 6h(270 MHz, DMSOd6) 0.83 [3 H, d, 7 6 .6 , CH(Ctf3)2], 0.84 [3 H, br d, 7 6 .6 , 
CH(C//3)2], 1.37 (9 H, s, Boc), 1.81 (1 H, m, CH(CH3)2], 3.11 (1 H, d, 7 15.4, 
COCH2CO), 3.18 (1 H, d, 7 15.4, COCH2CO), 4.94 [1 H, q, 7 8.3, HN(tt/I¥)NH], 7.05 
(1 H, d, 77.7, BocNH), 8.05 (1 H, d, 78.4, NH) and 12.47 (1 H, br s, C 0 2H); 6C(67.8 
MHz; DMSOd6) 18.2 [CH(CH3)2], 18.3 [CH(CH3)2], 28.2 [(CH3)3C], 32.0 [CH(CH3)2],
42.5 (COCH2CO), 61.9 [HN(CHI¥)NH], 78.2 [(CH3)3C], 154.6 (Boc CO), 164.9 (amide 
CO) and 169.5 (acid CO); m/z 275 [(M+H)+, 56%), 219 [59, (M+H) - CH2CMe2], 158 
(100, 219 - H20 , CO, NH), 116 [30, CH2NHC0CH2C 02H+], 104 [23, (M+H) - 
BocNCHPd] and 89 (14).
(h) Coupling o f Boc- Valip(NHCO)Gly, 121,andTFA.Val\l>(NHCO)Gly-OEt, 119
A solution of crude TFA.Val,ijj(NHCO)Gly-OEt, 119 (125.6 mg, ca. 0.40 mmol), 
Boc-Val^(NHCO)Gly, 121 (109 mg, 0.40 mmol), EDC.HC1 (77 mg, 0.40 mmol) and N- 
hydroxysuccinimide (46 mg, 0.40 mmol) in THF (2.5 mL) was cooled to -10°C in a dry 
atmosphere and triethylamine (0.11 mL, 80 mg, 0.79 mmol) added. The mixture was 
stirred at -10°C for 4 h, and then at r.t. for a further 2 days. The solution was evaporated 
to dryness, the resultant residue washed with water, the colourless precipitate collected 
and dried under high vacuum over phosphorus pentoxide. Column chromatography of the 
precipitate (applied as a slurry in the eluent), with chloroform / methanol (95:5) as eluent, 
yielded crude Boc-Vah|>(NHCO)Gly-Valx|>(NHCO)Gly-OEt, 122. This material was 
further purified by dissolving in hot ethanol and collecting the colourless solid which 
precipitated on cooling, to yield Boc-Valtp(NHCO)Gly-Val'ip(NHCO)Gly-OEt, 122, as a 
colourless solid (49 mg, 27%); m.p. 224-227°C; [a]J)9 + 3.8 (c 0.21 in DMSO); vmax / cm" 
1 3295s (NH), 3260s (NH), 3110w (NH), 1745s (ester carbonyl), 1715m (ester carbonyl), 
1695s (Boc carbonyl), 1670br,vs (amide carbonyl), 1650s (amide carbonyl), 1565s (amide 
II), 1555s (amide II), 1520s (amide II), 1390m, 1310m, 1255m, 1175m, 1160m, 1145s, 
1075m, 1045m, 1025m, 960m, 880w and 725m; 6^(270 MHz, DMSOd<5, TMS) 0.80-0.87 
[12 H, m, CH(C#3)2], 1.17 (3 H, t, 77.2, OCH2C//3), 1.37 (9 H, s, Boc), 1.71-1.94 [2 H,
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m, C «C H 3)2], 3.06 (1 H, d, 7 15.0, Gly2C«H2), 3.11 (1 H, d, 7 15.0, Gly2C“H2), 3.17 (1 
H, d, 7 15.0, G l y ^ H ^ ,  3.27 (1 H, d, 7 15.0, Gly^CTHb), 4.06 (2 H, q, 77.1, OC//2CH3), 
4.97 [1 H q, 78.4, V a l^ H ] ,  5.22 [1 H q, 78.1, VaPC“H], 7.07 (1 H, br d, 79.0, 
BocNH), 8.04 (1 H, d, 7 8.4, ValtyNH), 8.23 (1 H, d, 7 8.1, VaPNH) and 8.28 (1 H, d, 7
8.5, ValfyNH); 6C(100.4 MHz; DMSOd6) 14.1 (OCH2CH3), 18.1 [CH(CH3)2], 18.1 
[ 0 1 ( 0 ^ ] ,  183 [CH(CH3)2], 18.3 [CH(CH3)2], 28.3 [(CH3)3C],31.8[CH(CH3)2],32.2 
[CH(CH3)2], 42.5 (COCH2CO), 42.8 (COCH2CO), 60.1 (OCH2CH3), 60.5 
[HN(CHPr')NH], 61.7 [HN(CHPri)NH], 77.9 [(CH3)3C], 154.7 (Boc CO), 164.5 (CO),
166.0 (CO), 166.3 (CO) and 167.9 (CO); m/z 459 [(M+H)+, 459.2808, C2iH39N40 7 
requires 459.2819,14%), 342 [36, (M+H) - CH2CMe2, H20 , CO, NH], 288 [24, (M+H) - 
BocNCHPri], 272 (7), 211 (38, Pr>CHNHCOCH2CONCHPri+), 186 (56,
Pr'CHNHCOCH2C 02Et+), 157 (90, H2NCOCH2CONHOfl¥+), 72 (100, Pr'CHNH2+) 
and 57 (22, Bu,+).
(/) Preparation ofBoc-Valip(NHCO)Gly-OSu, 123
(i) DCC Method2*1
A solution of Boc-Vahj>(NHCO)Gly, 121 (0.99 g, 3.6 mmol) and N- 
hydroxysuccinimide (0.46 g, 4.0 mmol) in THF (20 mL) was cooled to -10°C. DCC (0.82 
g, 4.0 mmol) was added and the mixture stirred in a dry atmosphere at -10°C for 4 h, and 
then at r.t. overnight. The precipitated DCU was filtered off and washed with ethyl 
acetate. The filtrate was evaporated and dried under high vacuum to yield crude Boc- 
Vahp(NHCO)Gly-OSu, 123, as a colourless solid (1.2 g, 87%); 6^270 MHz, CDC13, 
TMS)* 0.87 [3 H, d, 77.0, CH(C//3)2], 0.89 [3 H, d, 77.0, CH(C//3)2], 137 (9 H, s, Boc), 
2.11 (1 H, br s, C//(CH3)2], 2.81 (4 H, s, succinimide CH2), 3.56 (2 H, s, COCH2CO),
4.89 [1 H, br s, HN(C/fl¥)NH], 5.22 (1 H, br s, BocNH) and 7.19 (1 H, br s, NH); m/z 
7433 [(2M+H)+, 10%], 394.2 [12, (M+Na)+], 372.2 [72, (M+H)+], 316.2 [46, (M+H) - 
CH2CMe2], 255.1 (100, 316.2 - H2Q, CO, NH), 225.2 [39, (DCU+H)+], 201.1 [12,
* The crude material's *H NMR spectrum also contained the following signals, due to impurities: 0.90-1.32 
(3 H, m, DCU Hax), 1.42-2.00 (5.3 H, m, DCU Hjq + unknown), 2.76 (0.5 H, s, HOSu CH2) and 3.40 (0.5 
H, m, DCUCH).
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(M+H) - BocNCHPr1], 172.1 (12), 116.1 [26, (HOSu+H)+], 99.1 (13), 86.1 (16) and 72
(83, PriCHNH2+).
(ii) DSC Method264
To a solution of Boc-Vahp(NHCO)Gly, 121 (109 mg, 0.40 mmol) in acetonitrile 
(2 mL), pyridine (32 pL, 31 mg, 0.40 mmol) and DSC (102 mg, 0.40 mmol) were 
successively added and the resultant suspension stirred in a dry atmosphere at r.t.. After 
50 m the solution was yellow and homogeneous, and stirring was continued. After 4 days 
TLC (mixture E) indicated that some Boc-Vahp(NHCO)Gly, 121, remained unreacted, 
therefore additional DSC (102 mg, 0.40 mmol) was added, and stirring continued. After a 
further 2 days TLC still indicated incomplete reaction, therefore additional DSC (102 mg, 
0.40 mmol) was added, and stirring continued. After a further day, although TLC 
indicated traces of Boc-Valtp(NHCO)Gly, 121, remaining, the reaction was worked-up as 
follows. The solution was evaporated, the resultant cloudy yellow residue dissolved in 
dichloromethane (50 mL) and washed successively with 5% citric acid (25 mL) and water 
(25 mL). The organic layer was dried over sodium sulfate, evaporated and dried under 
high vacuum to yield crude Boc-Valil)(NHCO)Gly-OSu, 123, as a colourless solid [147 
mg, quantitative; TLC (mixture E) of the crude material revealed the presence of traces of 
Boc-Valip(NHCO)Gly, 121], m.p. 154-159°C; [af7  + 1.5 (c0.20 in dichloromethane); 
vmax /cm_13340s (NH), 3315s (NH), 1820m (succinimide carbonyl), 1790m (succinimide 
carbonyl), 1740vs (ester carbonyl), 1690vs (Boc carbonyl), 1660m (amide carbonyl), 
1655m (amide carbonyl), 1545m (amide II), 1505m (amide II), 1285s, 1245m, 1195s, 
1165w, 1140m, 1085m, 1055m, 1020m, 1000m, 970w, 945m, 835m and 705vs; 6^(270 
MHz, CDC13, TMS)§ 0.86 [3 H, d, J 7.0, CH(C//3)2], 0.87 [3 H, d, J  6.6 , CH(CH3)2l  135 
(9 H, s, Boc), 2.09 (1 H, br s, Cfl(CH3)2], 2.80 (4 H, s, succinimide CH2), 3.55 (2 H, s, 
COCH2CO), 4.87 [1 H, br s, HN(CtfPri)NH], 5.26 (1 H, br s, BocNH) and 7.19 (1 H, br s, 
NH); m/z 372 [(M+H)+, 372.1807, Ci6H26N30 7 requires 372.1771, 77%], 316 [45, 
(M+H) - CH2CMe2], 272 (12), 255 (100, 316 - H20 , CO, NH), 201 [12, (M+H) -
§ The crude material's *H NMR spectrum also contained the following signals, due to impurities: 1.68-1.93 
(0.6 H, br s), 2.64 (0.1 H, s) and 3.03 (0.4 H, s).
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BocNCHPr*], 172 (16), 163 (12), 147 (10), 141 (13), 116 [29, (HOSu+H)+], 99 (19), 86
(22) and 72 (90, PriCHNH2+).
(j) Coupling o f Boc- Val ty(NHCO)Gly-OSu, 123, and TFA.Valip(NHCO)Gly-OEt, 119
A solution of crude Boc-Valty(NHCO)Gly-OSu, 123 (1.17 g, ca. 3.1 mmol, 
synthesised by the DCC method) in THF (100 mL) was added by decantation (leaving 
behind residual DCU) to crude TFA.Vah|>(NHCO)Gly-OEt, 119 (995 mg, ca. 3.1 mmol). 
Triethylamine (440 pL, 318 mg, 3.1 mmol) was added and the mixture stirred at r.t., in a 
dry atmosphere, for 3 days, after which time TLC (mixture E) indicated consumption of 
the Boc-Vahp(NHCO)Gly-OSu, 123, was complete. The solution was evaporated to 
dryness, the resultant off-white solid washed with water and the colourless precipitate 
collected. The precipitate was dried under high vacuum over phosphorus pentoxide. 
Column chromatography of the precipitate (applied as a slurry in the eluent), with 
chloroform / methanol (95:5) as eluent, yielded crude Boc-Val'ip(NHCO)Gly- 
Vahp(NHCO)Gly-OEt, 122. This material was further purified by dissolving in hot 
ethanol and collecting the colourless solid which precipitated on cooling, to yield Boc- 
Vahjj(NHCO)Gly-Vah|>(NHCO)Gly-OEt, 122, as a colourless solid [191 mg, 12% over 
the two steps from Boc-Valty(NHCO)Gly, 121], identical to the above.
(k) Coupling o f Boc- Val y(NHCO )Gly, 121, and HCl.Pro-Gly-OEt, 129
A solution of Boc-Vali|>(NHCO)Gly, 121 (529 mg, 1.9 mmol), HCl.Pro-Gly-OEt, 
129 (503 mg, 2.1 mmol) and A-hydroxysuccinimide (396 mg, 1.9 mmol) in DMF (6 mL) 
was cooled to -10°C in a dry atmosphere. DCC (398 mg, 1.9 mmol) and triethylamine 
(270 pL, 195 mg, 1.9 mmol) were successively added at -10°C, with stirring. The mixture 
was stirred at -10°C for 4 h, and then at r.t. for a further 6 days. The precipitated DCU 
was filtered off and washed with dichloromethane (40 mL). The filtrate was evaporated to 
produce a cloudy yellow residue which was dissolved in dichloromethane (150 mL) and 
the solution successively washed with 5% citric acid (60 mL plus a few drops of brine) 
and water (50 mL). The aq. layers were back-extracted with dichloromethane (2 x 50 
mL), the combined organic extracts dried over sodium sulfate and evaporated. Column 
chromatography of the resultant off-white solid (applied as a solution in the eluent), with
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chloroform / methanol (95:5) as eluent, furnished crude Boc-Val xp(NHCO)Gly-Pro-Gly - 
OEt, 133, which was crystallised from ethanol to yield pure Boc-Vahj)(NHCO)Gly-Pro- 
Gly-OEt, 133, as a colourless solid (196 mg, 22%); m.p. 160-162°C (Found: C, 55.25; H, 
8.05; N, 12.25. C2iH36N407  requires C, 55,25; H, 7.95; N, 12.25%); [a] g  - 47.8 (c 0.26 
in ethanol); vmax /cm-1 3335s (NH), 3300vs (NH), 3080w (NH), 1730s (ester carbonyl), 
1690vs (Boc carbonyl), 1660vs (amide carbonyl), 1650vs (amide carbonyl), 1645vs 
(amide carbonyl), 1555s (amide II), 1550s (amide II), 1515s (amide II), 1335s, 1290s, 
1250s, 1230s, 1175s, 1150s, llOOw, 1075w, 1040m, 1020m, 965w, 915w, 875w, 855w, 
780w and 720w; 6^210  MHz, DMSOd6; TMS) 0.80-0.87 [6 H, br m, CH(C//3)2], 1.15- 
1.21 (3 H, m, OCH2C/73)5, 1.37 (9 H, s, Boc), 1.69-2.27 (5 H, m, C//(CH3)2, Pro3CPH2 
and O H 2), 2.99-3.33 (2 H, m, Gly2C«H2), 3.37-3.63 (2 H, m, Prc^C6^ ) ,  3.75 (0.8 H, dd, 
J  6.0 and 17.4, G ly ^ 01^  major conformer), 3.80-3.88 (1.2 H, m, Gly4^ * ^  both 
conformers)*, 4.04-4.12 (2 H, m, OCtf2CH3)t, 4.31 (0.7 H, br dd, J  1.8 and 7.5, Pro3C«H 
major conformer), 4.55 (0.3 H, dd, J  2.7 and 8.9, PkPO^H minor conformer), 4.98 (1 H, 
q, 78.3, VaHCTI), 7.06 (1 H, br t, J 9.0, BocNH), 8.16 (1 H, t, J  9.2, ValtyNH), 8.27 
(0.7 H, t, J  5.9, Gly4NH major conformer) and 8.56 (0.3 H, t, J  6.3, Gly4NH minor 
conformer); 6C(100.4 MHz; DMSOd6; TMS) 13.9 (OCH2CH3), 18.0 [CH(CH3)2 minor 
conformer], 18.1 [CH(CH3)2], 18.2 [CH(CH3)2], 22.2 (Pro3CYH2 minor conformer), 23.7 
(Pro3CYH2 major conformer), 28.1 [(CH3)3C], 29.5 (Pro3CPH2 major conformer), 31.5 
(Pro3CPH2 minor conformer), 31.9 [CH(CH3)2 major conformer], 32.1 [CH(CH3)2 minor 
conformer], 40.5 (Gly4CotH2 major conformer), 40.7 (Gly4CctH2 minor conformer), 41.7 
(Gly2CaH2 minor conformer), 42.2 (Gly2CaH2 major conformer), 46.3 (Pro3C6H2 minor 
conformer), 47.0 (Pro3C6H2 major conformer), 59.2 (PrcPC^H major conformer), 60.0
5 This signal consisted of two overlapping triplets: 6h 1.18 (t, J  7.2, minor conformer) and 1.18 (t, 77.1, 
major conformer).
* This signal consisted of a doublet of doublets, 8h 3.82 (dd, J  6.2 and 17.3) due to the major conformer, 
overlaping a multiplet due to the minor conformer.
t  This signal consisted of two overlapping quartets: 6h4.08 (t, J7.1, major conformer) and 4.09 (t, J 7.2, 
minor conformer).
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(Pro3CaH minor conformer), 60.3 (OCH2CH3 major conformer), 60.4 (OCH2CH3 minor 
conformer), 61.6 (br, Val minor conformer), 61.7 (Val major conformer), 77.7 
[(CH3)3C], 154.5 (Boc CO), 165.2 (amide CO minor conformer), 165.6 (amide CO major 
conformer), 166.4 (amide CO major conformer), 166.6 (amide CO minor conformer),
169.5 (Gly4C0 2 Et), 171.9 (Pro3CO major conformer) and 172.2 (PnPCO minor 
conformer); m/z 457 [(M+H)+, 15%], 340 [100, (M+H) - CH2CMe2, H20 , CO, NH], 286 
[70, (M+H) - BocNCHPri], 155 {50, H2NCOCH2CON[CH2]3CH+}, 72 (31, H2NCHPri+), 
70 {50, HN[CH2]3CH+}, and 57 (37, But+).
(/) C-Terminal deprotection o f Boc-Valip(NHCO)Gly-Pro-Gly-OEt, 133, by saponification 
2 M Sodium hydroxide (0.4 mL) was added to a solution of Boc- 
Vahp(NHCO)Gly-Pro-Gly-OEt, 133 (156 mg, 0.34 mmol) in ethanol (2.5 mL). The 
mixture was stirred at r.t. overnight, then diluted with water (5 mL) and acidified to pH 
2/3 by careful addition of 1 M potassium hydrogen sulfate. Brine (7 mL) was added and 
the solution extracted with dichloromethane (5 x 15 mL). The combined organic extracts 
were dried over sodium sulfate, evaporated and dried under high vacuum to yield Boc- 
Vah|>(NHCO)Gly-Pro-Gly, 134, as a colourless solid (114 mg, 78%), m.p. 149-153°C 
(change in appearance noted at 135-145°C) (Found: C, 53.3; H, 7.65; N, 12.7. 
C19H32N4O7 requires C, 53.25; H, 7.55; N, 13.1%); [a] J7 - 45.7 (c 0.99 in ethanol); vmax 
/cm'1 3305br,m (NH), 3050-2500br,w (CO2H), 1755m (acid carbonyl), 1720m (acid 
carbonyl), 1690s (Boc carbonyl), 1650vs (amide carbonyl), 1625s (amide carbonyl), 
1555m (amide II), 1510s (amide II), 1290w, 1250m, 1175m, 1045w, lOOOw, 850w and 
720m; 6h(400 MHz, DMSOd6) 0.81-0.86 [6 H, m, CH(CH3)2l  1.37 (9 H, s. Boc), 1.75- 
2.20 (5 H, m, C//(CH3)2, Pro3CPH2 and CYH2), 3.02 (0.4 H, d, J  15.6, Gly2C«H2 minor 
conformer), 3.16 (0.4 H, d, J  15.6, Gly2CaH2 minor conformer), 3.24 (0.9 HL d, J  16.1, 
Gly2CaH2 major conformer), 3.29 (1.1 H, s§ Gly2CaH2 major conformer), 3.40-3.60 (2 
H, m, Pro3C6H2), 3.67 (0.7 H, dd, 75.9 and 17.6, Gly4C«H2 major conformer), 3.72-3.79 
(1.1 H, m, Gly4CaH2 both conformers), 4.31 (0.7 H, dd, 72.5 and 6.4, Pro3CaH major
t Some overlap with the water signal.
§ Pressumably a doublet partially obscured by the water signal.
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conformer), 4.53 (0.3 H, dd, J  2.5 and 8.3, Pro3CaH minor conformer), 4.97 (1 H, q, J
8.3, Va^C^H), 6.98-7.09 (1 H, m, BocNH), 8.10-8.17 (1.6 H, m, Val tyNH and Gly4NH), 
8.43 (0.3 H, t, J  5.9, NH minor conformer) and 12.53 (1 H, br s, CO2H); 6^(100.4 MHz; 
DMSOd6) 18.2 [CH(CH3)2 minor conformer], 18.3 [CH(CH3)2], 18.4 [CH(CH3)2], 22.4 
(Pro3CYH2 minor conformer), 23.9 (Pro3CYH2 major conformer), 28.3 [(CT^^C], 29.7 
(Pto3CPH2 major conformer), 31.6 (Pro3CPH2 minor conformer), 32.1 [CH(CH3)2 major 
conformer], 32.2 [CH(CH3)2 minor conformer], 40.6 (Gly4CaH2 major conformer), 40.8 
(Gly4CaH2 minor conformer), 41.9 (Gly2CaH2 minor conformer), 42.4 (Gly2CaH2 major 
conformer), 46.6 (Pro3C6H2 minor conformer), 47.2 (Pro3C6H2 major conformer), 59.4 
(Pro3CaH major conformer), 60.1 (Pro3CaH minor conformer), 61.9 (br, Val !CaH), 77.9 
[(CH3)3C], 154.7 (Boc CO), 165.4 (amide CO minor conformer), 165.7 (amide CO major 
conformer), 166.5 (amide CO major conformer), 166.8 (amide CO minor conformer),
171.2 (Gly4C0 2 H), 171.9 (Pn^CO major conformer) and 172.2 (PnPCO minor 
conformer); m/z 429 [(M+H)+, 429.2360, C i9H33N40 7 requires 429.2349, 24%], 393 
(22), 322 (18), 312 [56, (M+H) - CH2CMe2, H20 , CO, NH], 281 (13), 258 [36, (M+H) - 
BocNCHPr*], 221 (16), 207 (14), 147 (42), 99 (22) and 73 (100).
(m) Coupling o f Boc-Valip(NHCO)Gly-Pro-Gly, 134t and TFA.Valtl>(NHCO)Gly-OEt, 
119242
A solution of TFA.Vahp(NHCO)Gly-OEt, 119 (81 mg, 0.25 mmol) in DMF (1.5 
mL) was prepared. A solution of Boc-Val'ip(NHCO)Gly-Pro-Gly, 134 (99 mg, 0.23 
mmol) in DMF (1.0 mL) was cooled to -15°C in an inert atmosphere. N- 
Methylmorpholine (25 pL, 23 mg, 0.23 mmol) and /sobutylchloroformate (30 pL, 32 mg, 
0.23 mmol) were successively added and stirring continued at -15°C, in an inert 
atmosphere, for 30 m.
Triethylamine (36 pL, 26 mg, 0.25 mmol) was added to the solution of 
TFA.Valip(NHCO)Gly-OEt, 119, and the resultant mixture immediately added to the 
solution of Boc-Val4>(NHCO)Gly-Pro-Gly, 134, V-methylmorpholine and iso- 
butylchloroformate. Stirring was continued at -15°C for 30 m, and then at r.t. overnight, 
in an inert atmosphere. The solution was evaporated to produce a yellow oil, to which
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water (7.5 mL) was added. The resultant off-white precipitate was collected, washed with 
water (4 mL) and dried under high vacuum over phosphorus pentoxide. Further crude 
product was recovered from the filtrate by extraction with dichloromethane (4 x15  mL). 
The combined organic extracts were dried over sodium sulfate and evaporated. The two 
portions of crude product were combined and column chromatography (sample applied as 
a solution in the initial eluent), with chloroform / methanol / acetic acid (95:3:2 then 
90:8:2) as the eluent, yielded:
ethyl malonamate, 118, as a colourless oil (6.3 mg, 19%), identified by *H NMR; 
and Boc-Vah|)(NHCO)Gly-Pro-Gly-Valxp(NHCO)Gly-OEt, 1 (26.0 mg, 18%). This 
material was further purified by dissolving in hot ethanol and collecting the colourless 
solid which precipitated on cooling, to yield Boc-Vahp(NHCO)Gly-Pro-Gly- 
Vahjj(NHCO)Gly-OEt, 1 (7.7 mg, 5%); m.p. 203-207°C dec; [a ]^ 9 - 10.6 (c 0.51 in TFE); 
v max /cm_13295br,m (NH), 1745m (ester carbonyl), 1735w (ester carbonyl), 1715w (ester 
carbonyl), 1695vs (Boc carbonyl), 1660vs (amide carbonyl), 1650vs (amide carbonyl), 
1560s (amide II), 1540m (amide II), 1515br,m (amide II), 1505m (amide II), 1290w, 
1245m, 1225m, 1170m, 1150m, 1075w, 1035w, 1015w, 965w, 865w and 720m; 6^(400 
MHz, DMSOd6) 0.77-0.87 [12 H, m, CH(C//3)2], 1.17 (3 H, t, 7 7.2, OCH2C//3), 1.37 (9 
H, s, Boc), 1.69-2.20 (6 H, m, C//(CH3)2, Pro3CPH2 and O H 2), 3.04-3.33 (4 H, m, 
Gly2C«H2 and Gly6C«H2), 3.37-3.58 (3 H5, m, Pro3C6H2), 3.58-3.86 (2 H, m, 
Gly^CaH2), 4.06 (2 H, q, 77.1, OC//2CH3), 4.26 (0.7 H, br dd, 73.7 and 8.3, Pro3C«H 
major conformer), 4.49 (0.3 H, br dd, 73.0 and 9.0, Pro3CaH minor conformer), 4.91-
5.01 (1 H, m, Val lC«H), 5.17-5.28 (1 H, m, Val5C«H), 6.97-7.10 (1 H, m, BocNH), 7.66- 
7.73 (0.7 H, m, Val5NH* major conformer), 8.09-8.19 (1.7 H, m, VaPipNH and Val5NH*) 
and 8.24-8.33 (1.3 H, m, Gly4NH and Val5NH* minor conformer); 6^(100.4 MHz; 
DMSOd6) 14.1 (OCH2OH3), 17.9 [CH(CH3)2 minor conformer], 18.1 [CH(CH3)2 minor 
conformer], 18.3 [CH(CH3)2], 18.4 [CH(CH3)2], 24.3 (Pro3CYH2 major conformer), 28.3
5 Due to overlap with the water signal.
* Unambiguous assignment of Val^NH and Val^tpNH was not possible, therefore in the above *H NMR 
data," Val^NH" means Val^NH and / or Val5ij>NH.
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[(CH3)3C], 29.4 (Pro3CPH2 major conformer), 31.8 [CH(CH3)2], 32.0 [CH(CH3)2], 42.1 
(Gly4CaH2), 42.5 (Gly2CaH2 and Gly6CaH2), 47.3 (Pro3C6H2 major conformer), 59.9 
(Pro3CaH major conformer), 60.2 (ValCaH major conformer), 60.3 (Pro3CaH minor 
conformer), 60.3 (ValCaH minor conformer), 60.5 (OCH2CH3), 61.9 (ValCaH minor 
conformer), 78.0 [(CH3)3C], 154.7 (Boc CO), 164.6 (CO), 165.8 (CO), 166.9 (CO), 167.9 
(CO), 168.0 (CO), 172.0 (Pn^CO major conformer) and 172.2 (PnPCO minor 
conformer); m/z 1247 [(2M+Na)+, 12%], 635 [100, (M+Na)+], 613 [11, (M+H)+, 
613.3523, C28H49N6O9 requires 613.3561], 496 [23, (M+H) - CH2CMe2, H20 , CO, NH], 
464 [19, (M+Na) - BocNCHPr1], 442 [11, (M+H) - BocNCHPr*], 393 (29), 365 [17,496 - 
HNC(0H)CH2C 02Et], 333 (14), 322 (30), 311 (42, 496 - PriCHNC0CH2C 02Et], 294 
(27), 257 [25, 442 - PriCHNC0 CH2C0 2Et], 240 (30, H2NCOCH2CO-Pro-NHCH2CO+), 
186 [12, PriCHNHC0CH2C 02Et+], 183 (17), 116 (10) and 72 (75, H2NCHPri+).
(n) N-Terminal deprotection o f Boc-Valip(NHCO)Gly, 121, with TFA.
TFA (2.6 mL, 3.8 g, 34 mmol) was added to a solution of Boc-Vahp(NHCO)Gly, 
121 (704 mg, 2.6 mmol) in dichloromethane (43 mL). The mixture was stirred at r.t. in a 
dry atmosphere for 40 m, after which time TLC (mixture E) indicated all the starting 
material, 121, was consumed. The solution was evaporated to dryness, petrol (25 mL) 
added to the residue and the resultant mixture slowly stirred overnight. The petrol was 
decanted off and the process repeated with a further aliquot of petrol (25 mL). Ether (25 
mL) was added to the residue and the resultant off-white suspension slowly stirred 
overnight. The off-white precipitate was collected by filtration in an inert atmosphere, 
dissolved in ethanol and evaporated to furnish a yellow solid. Addition of ether (2 x 20 
mL) to the solid, followed by evaporation and drying under high vacuum yielded crude 
TFA.Valxp(NHCO)Gly, 142, as a colourless solid (604 mg, 82%), m.p. 94-100°C dec; 
[a]g> + 24.2 (c 2.89 in ethanol); vmax /cm’1 3500-2500br,vs (C02H and NH3+), 3285s 
(NH), 1720s (acid carbonyl), 1665br,vs (carboxylate and amide carbonyl), 1545s (amide 
II), 1520s (NH bend), 1315m, 1195br,vs (C-F and / or C-O), 1145br,vs (C-F and / or C- 
O), 1065m, 985w, 950m, 915w, 865m, 840s, 800s, 720s (C-F), 660m (C-F) and 600w;
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6h(270 MHz; DMSOd6; TMS)t 0.94 [6 H, d, 7 6 .6, CH(C//3)2], 2.01 [1 H, octet, 7 6 .8 , 
C//(CH3)2], 3.19 (1 H, d, 7 15.4, COCH2CO), 3.30 (1 H, d, 7 15.4, COCH2CO), 4.71 [1 
H, t, 77.9, HNCCT/PrONH], 8.07 (4 H, br s, +H3N and C 02H) and 9.01 (1 H, d, 7 8.4, 
NH); 6^(100.4 MHz; DMSOd6)* 17.0 [CH(CH3)2], 18.1 [CH(CH3)2], 30.5 [CH(CH3)2],
42.6 (COCH2CO), 61.6 [HN(CHPr*)NH], 117.2 (q, 7 300, CF3C 02 ), 158.5 (q, 7 31, 
CF3C 02-), 167.0 (amide CO) and 169.2 (acid CO); m/z 349 [(2M-H)+, 15%], 175 (76, 
M+, 175.1071, C7H i5N20 3 requires 175.1083), 158 (100, M - NH3, 158.0814, CtH^NC^ 
requires 158.0817), 131 (24, M - C 02), 110 (10) and 72 (84, PriCHNH2+); m/z (-ve) 340 
[(173+matrix)", 33%], 266 [59, (CF3C0 2+NBA)], 173 [41, H2N(CHPri)NHC0 CH2C0 2 -] 
and 113(100, CF3C 02-).
(o) N-Terminal protection of TFA .Valip(NHC O )Gly, 142, with Fmoc333
TFA.Val4>(NHCO)Gly, 142, (516 mg, 1.8 mmol) and sodium hydrogen carbonate 
(300 mg, 3.6 mmol) were dissolved in a mixture of water (5.5 mL) and acetone (5.5 mL) 
with a concomitant evolution of gas. 9-Fluorenylmethyloxycarbonyl succinimide (604 
mg, 1.8 mmol) was added and the cloudy mixture stirred overnight at r.t., after which time 
TLC (mixture E) indicated complete consumption of the 9-fluorenylmethyloxycarbonyl 
succinimide. The mixture was diluted with acetone and acidified to pH 2 with 2 M 
hydrochloric acid. The solution was concentrated in vacuo, the precipitate collected, 
washed with water (65 mL) and dried under high vacuum over phosphorus pentoxide. 
Column chromatography (sample applied as a slurry in the eluent), with chloroform / 
methanol / acetic acid (95:3:2) as eluent yielded:
9-fluorenylmethyl carbamate (Fmoc-NH2), 145, as a colourless solid (75 mg, 17%), m.p. 
195-199°C (lit., 192-195° C327, 200-201°C385); vmax /cnr1 3430m (NH), 3320w (NH), 
3260w (NH), 3205w (NH), 1685vs (Fmoc CO), 1615s (amide II), 1425s, 1335s, 1105m, 
1090m, 1055s, 800w, 760s and 740s; 6^270 MHz; DMSOd6) 4.17-4.28 (3 H, m, CH and
t  The crude material's *H NMR spectrum also contained the following weak signals, due to impurities: 6jj 
3.09 (0.3 H, s), 7.10 (br s), 7.19 (br s), 7.57 (br m) and 7.71 (br s).
t  The crude material's 13C NMR spectrum also contained the following weak signals, due to impurities: 6c  
15.3, 19.2,42.5,65.0 and 169.6.
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CH2), 6.54 (1 H, br s, NH2), 6.75 (1 H, br s, NH2), 7.33 (2 H, t, 7 7.1, Ar CH), 7.41 (2 H, 
t, 77.3, Ar CH), 7.69 (2 H, d, 7 7.3, Ar CH) and 7.89 (2 H, d, 77.3, Ar CH) [lit.,327 4.25 
(3 H, apparent s), 6.6 (2 H, br, NH2), 7.34 (2 H, t, 77.3), 7.43 (2 H, t, 7 7.2), 7.70 (2 H, d, 
77.0) and 7.90 (2 H, d, 76.8)]; m/z (C.I.) 257 [(M+NH4)+, 2%], 240 [2, (M+H)+], 239 (1, 
M*+), 196 (14,9-fluorenylmethanol radical cation), 180 (22), 179 (100,9-fluorenylmethyl 
cation), 178 (42, dibenzofulvene radical cation), 166 (10), 165 (14), 71 (12), 69 (19) and 
67 (16) [lit.,327 m/z (E.I., source 200°C, solid probe 175°C, 20 eV) 239 [(M#+, 2%], 196 
(15, M - HNCO), 178 (100, M - C 02, NH3), 166 (37) and 165 (43)]; 
and crude Fmoc-Val'ij)(NHCO)Gly, 144, contaminated with A-hydroxysuccinimide (353 
mg); crystallisation from acetone / water yielded Fmoc-Vahp(NHCO)Gly, 144, as a 
colourless solid (217 mg, 31%), m.p. 207-210°C; [af^  + 10.7 (c 0.61 in DMSO); vmax 
/cm-1 3290s (NH), 1730m (acid carbonyl), 1715m (acid carbonyl), 1695br,vs (Fmoc CO), 
1650s (amide carbonyl), 1635w (Ar CH), 1625w (Ar CH), 1565m (Ar CH), 1560m 
(amide II), 1540w (amide II), 1520s (amide II), 1505m (Ar CH), 1280w, 1255s, 1145w, 
1125w, 1085w, 1080w, 1030s, 965w, 795w, 760w and 740m; 6h(400 MHz; DMSOd6) 
0.86 [6 H, d, 76.6, CH(C/fj)2], 1.82-1.93 [1 H, m, CH(CH3)2], 3.10 (1 H, d, 7 15.4, 
COCH2CO), 3.20 (1 H, d, 7 15.4, COCH2CO), 4.19-4.33 (3 H, m, Fmoc CH and CH2),
5.00 [1 H, br q, 78.1, HN(Cf/Pri)NH], 7.30-7.35 (2 H, m, Fmoc Ar CH), 7.41 (2 H, t, 7
7.5, Fmoc Ar CH), 7.64 (1 H, br d, 7 8.4, FmocNH), 7.71 (2 H, br d, 76.6, Fmoc Ar CH),
7.89 (2 H, d, 77.3, Fmoc Ar CH), 8.20 (1 H, br d, 77.7, NH) and 12.50 (br s, C 0 2H); 
6C( 100.4 MHz; DMSOd6) 18.4 [CH(CH3)2], 18.5 [CH(CH3)2], 32.0 [CH(CH3)2], 42.6 
(COCH2CO), 46.8 (Fmoc CH), 62.4 [HN(CHPri)NH], 65.4 (Fmoc CH2), 120.2 (Fmoc Ar 
CH), 125.4 (Fmoc Ar CH), 127.1 (Fmoc Ar CH), 127.7 (Fmoc Ar CH), 140.8 (Fmoc Ar 
C), 143.9 (br, Fmoc Ar C), 155.3 (Fmoc CO), 165.2 (amide CO) and 169.6 (acid CO); m/z 
410 (13%), 397 [48, (M+H)+, 397.1759, C22H25N20 5 requires 397.1763], 368 (53), 294 
(22, FmocNHCHPri+), 191 (62), 179 (100, 9-fluorenylmethyl cation), 178 (96, 
dibenzofulvene radical cation), 158 (79, PriCHNHCOCH2C 02H+), 147 (37), 133 (29), 
117 (23), 94 (29) and 73 (65).
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3.2.4 Phe series.
(a) Preparation of Boc-Pheip(NHCO)Gly-OEt, 116(b)
Boc-phenylalanine 113(b) (2.0 g, 7.5 mmol) was dissolved in THF (15 mL) and 
cooled to 0°C in an inert atmosphere. Tri-n-butyl amine (1.4 g, 1.8 mL, 7.5 mmol) 
followed by ethyl chloroformate (0.82 g, 0.72 mL, 7.6 mmol) were added slowly, with 
stirring and the temperature maintained at 0°C. Stirring was continued at 0°C for 30 m. 
An ice cold solution of sodium azide (0.98 g, 15 mmol) in the minimum volume of water 
(2.4 mL) was added and stirring continued for 1 h at 0°C. Ice cold portions of ethyl 
acetate (50 mL) and sat. sodium hydrogen carbonate (50 mL) were added and the mixture 
shaken and separated. The organic portion was washed with ice cold brine (50 mL), dried 
over magnesium sulfate and evaporated at <25°C.§ The resultant colourless solid was 
dissolved in toluene (15 mL): IR analysis at this stage indicated a mixture of acyl azide, 
114(b), [vmax(tol) 2140 cm-1] and isocyanate, 115(b), [vmax(tol) 2250 cm-1]. The 
solution was heated to 70°C in an inert atmosphere, with stirring, for ca. 40 m (during 
which vigorous effervescence occurred), until IR analysis indicated all the acyl azide, 
114(b), [vmax(tol) 2140 cm-1] had converted to the isocyanate, 115(b), [vmax(tol) 2250 
cm'1]. The solution was maintained at 70°C and monoethyl malonate, 98 (1.2 g, 9.1 
mmol) added. Stirring was continued at 70°C for ca. 10 m (during which further 
effervescence occurred), after which time IR analysis indicated all the isocyanate, 115(b), 
was consumed. The solution was cooled to r.t. and petrol (50 mL) added. The resultant 
colourless precipitate was filtered off and dried under high vacuum.^ Column
§ When the flask was removed from the rotary evaporator, air was readmitted via a calcium chloride / silica 
gel drying tube.
5 The first time this reaction was attempted, the addition of petrol produced very little precipitate, therefore 
the reaction mixture was evaporated to dryness. The resultant yellow oil was purified by column 
chromatography (sample preabsorbed from ethyl acetate solution) with ethyl acetate / petrol (10:90) as 
eluent and yielded /V-(Boc)-l-amino-/ra/is-styrene [/V-(Boc)-2-phenyl-tra/is-ethenamine], 24(b), as a 
colourless solid, in 1% yield, m.p. 133-139°C; vm^  /cm'1 3300s (NH), 1680vs (Boc carbonyl), 1655vs
(alkene), 1510s (amide II), 1480s (Ph), 1330w, 1315s, 1300s, 1280s, 1240s, 1160vs, 1050m, 1020w, 950m, 
850m, 740m and 680m; 6H (270 MHz; DMSOd6) 1.45 (9 H, s, Boc), 5.98 (1 H, d, J  14.7,CHCtfPh), 6.99- 
7.31 (6 H, m, Ph and BocNHCH) and 9.54 (1 H, br d, J  13.3, BocNH); 6C (100.4 MHz; CDC13) 28.2
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chromatography (sample preabsorbed from ethyl acetate solution*), with ethyl acetate / 
petrol (50:50) as eluent yielded Boc-Pheip(NHCO)Gly-OEt, 116(b), as a colourless 
crystalline solid (0.52 g, 20%), m.p. 115-117°C (from toluene / petrol) (Found: C, 61.5; H, 
7.5; N, 8.15. C18H26N205  requires C, 61.7; H, 7.5; N, 8.0%); [a]g> + 7.6 (c 1.18 in 
deuterochloroform); vmax /cm-1 3335s (NH), 1745s (ester carbonyl), 1695vs (Boc 
carbonyl), 1650m (amide carbonyl), 1540m (amide II), 1510s (amide II), 1400w, 1340w, 
1290w, 1270m, 1250m, 1225w, 1200w, 1170m, 1140m, 1065w, 1050m, 1015m, 950w, 
940w, 880w and 855w; 6h(270 MHz; DMSOd6) 1.17 (3 H, t, 7 7.2, OCH2C//3), 1.32 (9 
H, s, Boc), 2.88 [2 H, br d, 77.5, HN(CHCH2Ph)NH], 3.20 (2 H, s, COCH2CO), 4.05 (2 
H, q, 77.1, OC//2CH3), 5.25 [1 H, quintet, 7 7.5, HN(C//CH2Ph)NH], 7.19-7.30 (6 H, m, 
Ph and BocNH) and 8.39 (1 H, d, 7 7.5, NH); 6C(100.4 MHz; CDC13; TMS) 14.0 
(OCH2CH3), 28.3 [(CH3)3C], 39.8 [HN(CHCH2Ph)NH], 41.6 (COCH2CO), 59.7 
[HN(CHCH2Ph)NH], 61.6 (OCH2CH3), 80.1 [(CH3)3C], 126.9 (Ph C-4), 128.6 (Ph C-3
[(CH3>5C], 80.9 [(CH3>5C], 109.6 (CHCHPh), 124.2 (Ph C-4), 125.1 (Ph C-3 or 2), 126.0 (BocNHCH), 
128.6 (Ph C-2 or 3), 136.5 (Ph C-l) and 152.7 (Boc CO); m/z (E l.) 219 (M+, 219.12742, C 13H17NO2 
requires 219.12593, 9%), 163 (59, M - CH2CMe2), 145 (10), 119 (58, 163 - CO2), 118 (30), 91 (16), 59
(23), 57 (100, But+), 41 (37) and 29 (17, CHO+). N-(Boc)~ 1 -amino-trans-styrene, 24(b), was identified by 
TLC as a by-product in subsequent, more successful, syntheses of Boc-Phety(NHCO)Gly-OEt, 116(b).
* The material which would not dissolve in ethyl acetate was filtered off and yielded crude 
(/V-Boc-amino)-2-phenylethyl]-urea, 117(b), as a colourless solid. This material was very difficult to purify, 
but a relatively pure sample was obtained by exhaustive washing with methanol; vmax /cm 'l 3340m (NH),
3215s (NH), 3065br,s (NH), 1780m, 1755m, 1710vs (Boc carbonyl), 1695vs (Boc carbonyl), 1650m (urea 
carbonyl), 1565w (amide II), 1530w (amide II), 1500w (Ph), 1420s, 1400s, 1305w, 1265w, 1240w, 1225w, 
1170m, 1050m, 1025w, 850w, 790w and 750w; 6^270 MHz; DMSOd6) 132 (9 H, s, Boc), 2.84 [2 H, br d,
J  7.5, HN(CHCH2Ph)NH], 5.08 [1 H, quintet, J  7.5, HN(CHCH2Ph)NH], 6.41 (1 H, br d, J  7.5, BocNH) 
7.15-7.30 (6 H, m, Ph and NH) and 10.91 (3 H, br s, impurity acid H); fi^(67.8 MHz; DMSOd6) 28.2 
[(CH3)3C], 41.0 [HN(CHCH2Ph)NH], 59.5 [HN(CHCH2Ph)NH], 77.8 [(C T ^ C ], 126.2 (Ph C-4), 128.1
(Ph C-3 or 2), 129.0 (impurity), 129.2 (Hi C-2 or 3), 138.0 (Ph C-l), 150.0 (impurity), 154.5 (CO) and 155.6 
(CO); m/z 499 [(M+H)+, 18%), 382 [21, (M+H) - CH2CMe2, H20 , CO, NH], 326 (10, 382 - CH2CMe2), 
280 [17, (M+H) - BocNCHCH2Ph], 265 (38, 326 - H20 , CO, NH), 224 (11, 280 - CH2CMe2), 220 (18, 
BocNHCHCH2Ph+), 186 (100), 164 (28, 220 - CH2CMe2), 163 (33, H2NCONHCHCH2Ph+) and 120 (90, 
PhCH2CHNH2+). This urea, 117(b), is thought to be responsible for the turbidity which sometimes 
developed in the toluene solution of the acyl azide, 114(b) / isocyanate, 115(b), prior to the addition of 
monoethyl malonate, 98.
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or 2), 129.4 (Ph C-2 or 3), 136.6 (Ph C-l), 154.8 (Boc CO), 164.8 (CO) and 168.8 (CO); 
m/z 351 [(M+H)+, 22%], 295 [19, (M+H) - CH2CMe2], 234 (79, 295 - H20 , CO, NH), 
203 (13), 164 (20), 132 [23, (M+H) - BocNCHCH2Ph] and 120 (100, PhCH2CHNH2+).
(b) N-Terminal deprotection o f Boc-Phexp(NHCO)Gly-OEt, 116(b), with TFA (in the 
absence of triethylsilane)
TFA (0.47 mL, 0.70 g, 6.1 mmol) was added to a solution of Boc- 
Phe4)(NHCO)Gly-OEt, 116(b) (163 mg, 0.47 mmol) in dichloromethane (1.1 mL). The 
mixture was stirred at r.t. in a dry atmosphere for 90 m, after which time TLC (mixture B) 
indicated all the starting material, 116(b), was consumed. The mixture was evaporated to 
dryness and the resultant residue was triturated with ether. The resultant suspension was 
filtered, the precipitate washed with ether and dried under high vacuum. The filtrate was 
evaporated to dryness and further product obtained from the resultant residue by 
retrituration with ether, prolonged cooling (2 days) in a refridgerator, and filtration as 
before. Thus TFA.PheT|>(NHCO)Gly-OEt, 124, (73 mg, 43%) was obtained as a 
hygroscopic, colourless solid, m.p. 91-94°C (Found: C, 49.4; H, 5.3; N, 8.0. 
Ci5Hi9N205F3 requires C, 49.45; H, 5.25; N,7.7%); vmax /cm-1 3300m (NH), 3110br,s 
(NH), 2760s (NH3+), 2155br,w (NH3+), 1735vs (ester carbonyl), 1660br,vs (carboxylate 
and amide carbonyl), 1525s (amide II), 1500w (Ph), 1340s, 1210br,vs (C-F and / or C-O), 
1185br,vs (C-F and / C-O), 1155vs (C-F and / C-O), 1080w, 1015m, 840w, 800m, 735m, 
720s and 695m; 6^270 MHz; DMSOd6) 1.13 (3 H, t, 77.2, OCH2C//3), 2.99 [1 H, dd, 
7gem 13.5, 37hh 10.5, HN(CHC//2Ph)NH], 3.06 [1 H, dd, 7gem 13.5, 37hh 4.5, 
HN(CHC//2Ph)NH], 3.25 (2 H, s, COCH2CO), 4.02 (2 H, q, 7 7.2, OC//2CH3), 5.09 [1 H, 
m, HN(C//CH2Ph)NH], 7.13-7.38 (5 H, m, Ph), 8.41 (3 H, br s, NH3+), and 9.12 (1 H, d,
78.3, NH); 6C(67.8 MHz; DMSOd6) 14.0 (OCH2CH3), 37.5 [HN(CHCH2Ph)NH], 42.2 
(COCH2CO), 58.1 [HN(CHCH2Ph)NH], 60.6 (OCH2CH3), 127.1 (Ph C-4), 128.5 (Ph C- 
3 or 2), 129.2 (Ph C-2 or 3), 135.2 ( Ph C-l), 166.3 (CO) and 166.9 (CO); m/z 501 [(2M- 
H)+, 14%], 251 (26, M+), 234 (96, M - NH3), 159 (10), 120 (100, PhCH2CHNH2+) and 
91 (10, PhCH2+); m/z (-ve) 266 [(CF3C02+NBA)-, 19%], 227 [49, (2CF3C 02+H)-] and 
113(100, CF3C 02-).
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(c) C-Terminal deprotection o f Boc-Pheip(NHCO)Gly-OEt, 116(b) , by saponification
2 M Sodium hydroxide (0.13 mL) was added to a solution of Boc- 
Pheip(NHCO)Gly-OEt, 116(b) (50 mg, 0.14 mmol) in ethanol (1.5 mL). The mixture was 
stirred at r.t. overnight, then diluted with water (10 mL) and concentrated in vacuo. Water 
(10 mL) was added and the solution washed with ethyl acetate (15 mL). The aq. portion 
was acidified to pH 2/3 by careful addition of 1 M potassium hydrogen sulfate. Brine (2 
mL) was added and the solution extracted with ethyl acetate (4 x 10 mL). The organic 
extract was dried over sodium sulfate, evaporated and dried under high vacuum to yield 
Boc-Pheil)(NHCO)Gly, 125, as a colourless solid (40 mg, 88%), m.p. 150-151 °C (Found: 
C, 59.6; H, 6.95; N, 8.55. C16H22N2O5 requires C, 59.6; H, 6.9; N, 8.7%); [a^9 + 1.4 (c 
0.43 in ethanol); Vm^/cnr13335vs (NH), 3200-2500br,w (CO2H), 1725s (acid carbonyl), 
1690vs (Boc carbonyl), 1655m (amide carbonyl), 1555m (amide II), 1510m (amide II), 
1380w, 1300m, 1270w, 1250m, 1230w, 1205m, 1175w, 1155m, 1065m, 1025m, 1000m, 
940w, 915m, 865w and 835m; 6^270 MHz, DMSOd6) 1.31 (9 H, s, Boc), 2.85 [2 H, br d, 
7 7.5, HN(CHC//2Ph)NH], 3.12 (2 H, s, COCH2CO), 5.26 [1 H, quintet, 7 7.5, 
HN(C//CH2Ph)NH], 7.18-7.27 (6 H, m, Ph and BocNH), 8.38 (1 H, d, 7 7.5, NH); 
6C(67.8 MHz; DMSOd6) 28.3 [(CH3)3C], 40.1 [HN(CHCH2Ph)NH], 42.5 (COCH2CO), 
58.9 [HN(CHCH2Ph)NH], 78.1 [(CH3)3C], 1263 (Ph C-4), 128.2 (Ph C-3 or 2), 129.3 
(Ph C-2 or 3), 137.7 ( Ph C-l), 154.4 (Boc CO), 165.1 (amide CO) and 169.6 (acid CO); 
m/z 667 [(2M+Na)+, 5%], 645 [6, (2M+H)+], 393 (13), 345 [20, (M+Na)+], 323 [90, 
(M+H)+], 267 [55, (M+H) - CH2CMe2], 231 (20), 206 (100, 267 - H20 , CO, NH), 175
(25), 164 (22), 147 (12), 131 (17) and 73 (33).
(d) Coupling ofBoc-Phexp(NHCO)Gly, 125, and TFA.Phexp(NHCO)Gly-OEt, 124
A solution of TFA.Pheip(NHCO)Gly-OEt, 124 (40 mg, 0.11 mmol), Boc- 
Phei|)(NHCC))Gly, 125 (33 mg, 0.10 mmol) and A-hydroxysuccinimide (12 mg, 0.10 
mmol) in THF (1.0 mL) was cooled to -10°C in a dry atmosphere. EDC.HC1 (21 mg, 0.11 
mmol) and triethylamine (31 pL, 23 mg, 0.22 mmol) were successively added at -10°C, 
with stirring. The mixture was stirred at -10°C for 30 m, and then at r.t. for a further 7 
days. The solution was evaporated to dryness and the resultant yellow residue dissolved
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in dichloromethane (25 mL). The dichloromethane solution was washed successively 
with 5% citric acid (25 mL) and water (25 mL plus a few drops of brine). The 
dichloromethane layer was separated, dried over sodium sulfate, evaporated and dried 
under high vacuum. Column chromatography of the resultant orange residue 
(preabsorbed onto silica from a solution in dichloromethane), with chloroform / methanol 
/ acetic acid (95:3:2) as eluent, followed by washing of the collected product with petrol 
and drying under high vacuum, yielded Boc-Pheip(NHCO)Gly-Pheil)(NHCO)Gly-OEt, 
126, as a colourless solid (12 mg, 21%); m.p. 99-120°C dec; [a]^ + 5.5 (c 0.72 in 
DMSO); vmax / cm-1 3285s (NH), 1735w (ester carbonyl), 1725m (ester carbonyl), 
1690vs (Boc carbonyl), 1680vs (amide carbonyl), 1565m (amide II), 1550m (amide II), 
1530m (amide II), 1510s, 1500s (Ph), 1250w, 1170m, 1090w, 1045w and 1025w; 6H(270 
MHz, DMSOd6) 1.15 (3 H, t, 7 7.2, OCH2C//3), 1.31 (9 H, s, Boc), 2.84 (2 H, br d, 7 7.5, 
Phe^fofe), 2.89 (2 H, d, 7 6.6, Phe3CPH2), 3.01 (2 H, s, GlyC«H2), 3.18 (2 H, s, 
GlyC«H2), 4.04 (2 H, q, 77.2, OC//2CH3), 5.30 (1 H, quintet, 7 7.5, P h e ^ H ) ,  5.49 (1 
H, quintet, 7 7.5, Phe3C«H), 7.12-7.40 (11 H, m, Ph and BocNH), 8.40 (1 H, m, 
Phe^NH) and 8.63 (2 H, m, Phe3NH and Phe3ipNH); 6C(100.4 MHz; DMSOd6) 14.1 
(OCH2CH3), 28.2 [(CH3)3C], 40.9 [HN(CHCH2Ph)NH], 41.0 [HN(CHCH2Ph)NH], 42.4 
(COCH2CO), 42.6 (COCH2CO), 57.4 [HN(CHCH2Ph)NH], 58.9 [HN(CHCH2Ph)NH],
60.5 (OCH2CH3), 77.9 [(CH3)3C], 126.3 (Ph C-4), 126.4 (Ph C-4), 128.2 (Ph C-3 or 2),
128.3 (Ph C-3 or 2), 129.3 (Ph C-2 or 3), 137.3 (Ph C-l), 137.6 (Ph C-l), 154.6 (Boc CO),
164.6 (CO), 165.9 (CO), 166.2 (CO) and 167.7 (CO); m/z 577 [(M+Na)+, 100%], 555 [16, 
(M+H)+, 555.2801, Q 9H39N4O7 requires 555.2819], 438 [23, (M+H) - CH2CMe2, H20, 
CO, NH], 393 (21), 358 [19, (M+Na) - BocNCHCH2Ph], 336 [16, (M+H) - 
BocNCHCH2Ph], 322 [23, BocNH(CHCH2Ph)NHCOCH2C(OH)NH2+], 234 (44, 
PhCH2CHNHCOCH2CO2Et+), 205 (66, H2NCOCH2CONHCHCH2Ph+), 176 (26), 164 
(24), 132 [17, H2NC(0H)CH2C 02Et+] and 103 (17).
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Figure A5: CD spectra of Boc-Glyi^(NHCO)Gly-Pro-Gly-Glyip(NHCO)Gly-OEt, 132 as 
a function of solvent environment. Water: solid line. Supramicellar SDS 25 mM: dashed 
line. TFE: dashed-dot line. TFE / sodium hydroxide (57 mM): dotted line.
234
